U.S. patent application number 16/617025 was filed with the patent office on 2022-03-24 for aggrecan binding immunoglobulins.
This patent application is currently assigned to Ablynx N.V.. The applicant listed for this patent is Ablynx N.V., Merck Patent GmbH. Invention is credited to Gerald Beste, Hans Guhring, Guy Hermans, Christoph Ladel, Soren Steffensen, Lars Toleikis.
Application Number | 20220089703 16/617025 |
Document ID | / |
Family ID | 1000006193864 |
Filed Date | 2022-03-24 |
United States Patent
Application |
20220089703 |
Kind Code |
A9 |
Steffensen; Soren ; et
al. |
March 24, 2022 |
AGGRECAN BINDING IMMUNOGLOBULINS
Abstract
The present invention relates to immunoglobulins that
specifically bind Aggrecan and more in particular to polypeptides,
nucleic acids encoding such polypeptides; to methods for preparing
such polypeptides; to compositions and in particular to
pharmaceutical compositions that comprise such polypeptides, for
prophylactic, therapeutic or diagnostic purposes. In particular,
the immunoglobulins of the present invention inhibit the activity
of Aggrecan.
Inventors: |
Steffensen; Soren;
(Etterbeek, BE) ; Beste; Gerald; (Gent, BE)
; Hermans; Guy; (Merelbeke, BE) ; Guhring;
Hans; (Geisenheim, DE) ; Ladel; Christoph;
(Darmstadt, DE) ; Toleikis; Lars;
(Kleinniedesheim, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ablynx N.V.
Merck Patent GmbH |
Ghent-Zwijnaarde
Darmstadt |
|
BE
DE |
|
|
Assignee: |
Ablynx N.V.
Ghent-Zwijnaarde
BE
Merck Patent GmbH
Darmstadt
DE
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20200140532 A1 |
|
|
US 20210115117 A9 |
April 22, 2021 |
|
|
Family ID: |
1000006193864 |
Appl. No.: |
16/617025 |
Filed: |
June 4, 2018 |
PCT Filed: |
June 4, 2018 |
PCT NO: |
PCT/EP2018/064608 PCKC 00 |
371 Date: |
November 26, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62514180 |
Jun 2, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/33 20130101;
C07K 16/18 20130101; C07K 2317/94 20130101; A61P 19/02 20180101;
C07K 2317/569 20130101; C07K 2317/31 20130101; C07K 16/40 20130101;
C07K 2319/00 20130101; C07K 2317/92 20130101; C07K 2317/22
20130101; C07K 2317/24 20130101 |
International
Class: |
C07K 16/18 20060101
C07K016/18; A61P 19/02 20060101 A61P019/02; C07K 16/40 20060101
C07K016/40 |
Claims
1. An immunoglobulin single variable domain (ISV) that specifically
binds to Aggrecan.
2. The ISV of claim 1, wherein said ISV specifically binds to human
Aggrecan [SEQ ID NO: 125].
3. The ISV of claim 1 or 2, wherein said ISV specifically binds to
dog Aggrecan (SEQ ID NO: 126), bovine Aggrecan (SEQ ID NO: 127),
rat Aggrecan (SEQ ID NO: 128); pig (core) Aggrecan (SEQ ID NO:
129); mouse Aggrecan (SEQ ID NO: 130), rabbit Aggrecan (SEQ ID NO:
131); cynomolgus Aggrecan (SEQ ID NO: 132) and/or rhesus Aggrecan
(SEQ ID NO: 133).
4. The ISV according to any one of claims 1-3, wherein said ISV
does not bind substantially to Neurocan (SEQ ID NO: 134) and/or
Brevican (SEQ ID NO: 135).
5. The ISV according to any one of claims 1 to 3, wherein the ISV
has more than 10 fold, more than 100 fold, preferably more than
1000 fold selectivity over Neurocan and/or Brevican for binding to
Aggrecan.
6. The ISV according to any one of claims 1-4, wherein said ISV
preferably binds to cartilaginous tissue such as cartilage and/or
meniscus.
7. The ISV according to any one of claims 1-5, wherein said ISV has
a stability of at least 7 days, such as 14 days, 21 days, 1 month,
2 months or even 3 months in synovial fluid (SF) at 37.degree.
C.
8. The ISV according to any one of claims 1-6, wherein said ISV has
a cartilage retention of at least 2, such as at least, 3, 4, 5 or 6
RU in a cartilage retention assay.
9. The ISV of any one of claims 1-8, wherein said ISV penetrates
into the cartilage by at least 5 .mu.m, such as at least 10 .mu.m,
20 .mu.m, 30 .mu.m, 40 .mu.m, 50 .mu.m or even more.
10. The ISV according to any one of claims 1 to 9, wherein said ISV
essentially consists of a domain antibody, an immunoglobulin that
is suitable for use as a domain antibody, a single domain antibody,
an immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation.
11. The ISV according to any one of claims 1 to 10, that
essentially consists of 4 framework regions (FR1 to FR4,
respectively) and 3 complementarity determining regions (CDR1 to
CDR3, respectively), in which: CDR1 is chosen from the group
consisting of SEQ ID NOs: 24, 20, 21, 22, 23, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37 and 109; CDR2 is chosen from the
group consisting of SEQ ID NOs: 42, 38, 39, 40, 41, 43, 44, 45, 46,
47, 48, 49, 50, 51, 52, 53, 54, 55 and 110; and CDR3 is chosen from
the group consisting of SEQ ID NOs: 60, 56, 57, 58, 59, 61, 62, 63,
64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 and 111.
12. The ISV according to any one of claims 1 to 11, wherein said
ISV binds to the G1 domain of Aggrecan.
13. The ISV according to claim 12, wherein said ISV has a pI of
more than 8.
14. The ISV according to any one of claims 12-13, wherein said ISV
has a Koff of less than 2*10.sup.-2 s.sup.-1.
15. The ISV according to any one of claims 12-14, wherein said ISV
has an EC.sub.50 of less than 1*10.sup.-6M.
16. The ISV according to any one of claims 1-15, that essentially
consists of 4 framework regions (FR1 to FR4, respectively) and 3
complementarity determining regions (CDR1 to CDR3, respectively),
in which: i) CDR1 is chosen from the group consisting of: a) SEQ ID
NOs: 24, 20, or 21; or b) amino acid sequences that have 5, 4, 3,
2, or 1 amino acid(s) difference with the amino acid sequence of
SEQ ID NO: 24, wherein at position 2 the S has been changed into R,
F, I, or T; at position 3 the T has been changed into I; at
position 5 the I has been changed into S; at position 6 the I has
been changed into S, T, or M; at position 7 the N has been changed
into Y, or R; at position 8 the V has been changed into A, Y, T, or
G; at position 9 the V has been changed into M; and/or at position
10 the R has been changed into G, K, or A; and/or ii) CDR2 is
chosen from the group consisting of: c) SEQ ID NOs: 42, 38, or 39;
or d) amino acid sequences that have 5, 4, 3, 2, or 1 amino acid(s)
difference with the amino acid sequence of SEQ ID NO: 42, wherein
at position 1 the T has been changed into A, or G; an S or N is
inserted between position 3 and position 4 (position 2a Table 1.3
B); at position 3 the S has been changed into R, W, N, or T; at
position 4 the S has been changed into T or G; at position 5 the G
has been changed into S; at position 6 the G has been changed into
S, or R; at position 7 the N has been changed into S, T, or R; at
position 8 the A has been changed into T; and/or at position 9 the
N has been changed into D or Y; and/or iii) CDR3 is chosen from the
group consisting of: e) SEQ ID NO: 60, 56 or 57; or f) amino acid
sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference with
the amino acid sequence of SEQ ID NO: 60, wherein at position 1 the
P has been changed into G, R, D, or E, or is absent; at position 2
the T has been changed into R, L, P, or V, or is absent; at
position 3 the T has been changed into M, S, or R, or is absent; at
position 4 the H has been changed into D, Y, G, or T; at position 5
the Y has been changed into F, V, T or G; at position 6 the G has
been changed into L, D, S, Y, or W; an R, T, Y or V is inserted
between position 6 and position 7 (position 6a Table 1.3C); at
position 7 the G has been changed into P, or S; at position 8 the V
has been changed into G, T, H, R, L, or Y; at position 9 the Y has
been changed into R, A, S, D or G; at position 10 the Y has been
changed into N, E, G, W, or S; a W is inserted between position 10
and position 11 (position 10a Table 1.3C); at position 11 the G has
been changed into S, K, or Y; at position 12 the P has been changed
into E, or D, or is absent; and/or at position 13 the Y has been
changed into L, or is absent.
17. The ISV according to any one of claims 1 to 16, wherein said
ISV is chosen from the group of ISVs, wherein: CDR1 is chosen from
the group consisting of SEQ ID NOs: 24, 20, 21, 25, 27, 29, 31, 34,
35, 36, 37 and 109; CDR2 is chosen from the group consisting of SEQ
ID NOs: 42, 38, 39, 43, 45, 47, 49, 50, 53, 54, 55, and 110; and
CDR3 is chosen from the group consisting of SEQ ID NOs: 60, 56, 57,
61, 63, 65, 67, 71, 72, 73, 74, and 111.
18. The ISV according to claim 17, wherein said ISV is chosen from
the group of ISVs, wherein: CDR1 is SEQ ID NO: 24, CDR2 is SEQ ID
NO: 42, and CDR3 is SEQ ID NO: 60; CDR1 is SEQ ID NO: 20, CDR2 is
SEQ ID NO: 38, and CDR3 is SEQ ID NO: 56; CDR1 is SEQ ID NO: 21,
CDR2 is SEQ ID NO: 39, and CDR3 is SEQ ID NO: 57; CDR1 is SEQ ID
NO: 25, CDR2 is SEQ ID NO: 43, and CDR3 is SEQ ID NO: 61; CDR1 is
SEQ ID NO: 27, CDR2 is SEQ ID NO: 45, and CDR3 is SEQ ID NO: 63;
CDR1 is SEQ ID NO: 29, CDR2 is SEQ ID NO: 47, and CDR3 is SEQ ID
NO: 65; CDR1 is SEQ ID NO: 31, CDR2 is SEQ ID NO: 49, and CDR3 is
SEQ ID NO: 67; CDR1 is SEQ ID NO: 34, CDR2 is SEQ ID NO: 50, and
CDR3 is SEQ ID NO: 71; CDR1 is SEQ ID NO: 35, CDR2 is SEQ ID NO:
53, and CDR3 is SEQ ID NO: 72; CDR1 is SEQ ID NO: 36, CDR2 is SEQ
ID NO: 54, and CDR3 is SEQ ID NO: 73; and CDR1 is SEQ ID NO: 37,
CDR2 is SEQ ID NO: 55, and CDR3 is SEQ ID NO: 74.
19. The ISV according to any one of claims 1-16, that essentially
consists of 4 framework regions (FR1 to FR4, respectively) and 3
complementarity determining regions (CDR1 to CDR3, respectively),
in which: i) CDR1 is chosen from the group consisting of: a) SEQ ID
NO: 24 and 109; or b) amino acid sequences that have 2, or 1 amino
acid(s) difference with the amino acid sequence of SEQ ID NO: 24,
wherein at position 7 the N has been changed into S; and/or at
position 9 the V has been changed into M; and/or ii) CDR2 is chosen
from the group consisting of: c) SEQ ID NO: 42 and 110; or d) amino
acid sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 42, wherein at position
1 the T has been changed into A; at position 3 the S has been
changed into R; at position 4 the S has been changed into T; at
position 8 the A has been changed into T; and/or at position 9 the
N has been changed into D; and/or iii) CDR3 is chosen from the
group consisting of: e) SEQ ID NO: 60 and 111; or f) amino acid
sequences that have 2, or 1 amino acid(s) difference with the amino
acid sequence of SEQ ID NO: 60, wherein at position 4 the H has
been changed into R; and/or at position 8 the V has been changed
into D.
20. The ISV according to any one of claims 1 to 16, wherein said
ISV is chosen from the group of ISVs, wherein: CDR1 is chosen from
the group consisting of SEQ ID NOs: 24 and 109; CDR2 is chosen from
the group consisting of SEQ ID NOs: 42 and 110; and CDR3 is chosen
from the group consisting of SEQ ID NOs: 60 and 111.
21. The ISV according to any one of claims 12-20, wherein said ISV
belongs to epitope bin 1 or epitope bin 4.
22. The ISV according to claim 21, that essentially consists of 4
framework regions (FR1 to FR4, respectively) and 3 complementarity
determining regions (CDR1 to CDR3, respectively), in which: i) CDR1
is chosen from the group consisting of: a) SEQ ID NO: 36; and b)
amino acid sequences that have 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 36, wherein at position
3 the T has been changed into S; at position 6 the T has been
changed into S; at position 8 the T has been changed into A; and/or
at position 9 the M has been changed into V; and/or ii) CDR2 is
chosen from the group consisting of: c) SEQ ID NO: 54; and d) amino
acid sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 54, wherein at position
1 the A has been changed into I; at position 4 the W has been
changed into R; at position 7 the G has been changed into R; and/or
at position 8 the T has been changed into S; and/or iii) CDR3 is
chosen from the group consisting of: e) SEQ ID NO: 73; and f) amino
acid sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 73, wherein at position
1 the R has been changed into G; at position 2 the P has been
changed into R or L; at position 3 the R has been changed into L or
S; at position 5 the Y has been changed into R; at position 6 the Y
has been changed into S or A; at position 7 the Y has been changed
into T, or is absent; at position 8 the S has been changed into P;
at position 9 the L has been changed into H or R; at position 10
the Y has been changed into P or A; at position 11 the S has been
changed into A or Y; at position 12 the Y has been changed into D;
at position 13 the D has been changed into F; at position 14 the Y
has been changed into G, or is absent; and/or after position 14 an
S is inserted.
23. The ISV according to claim 22, wherein said ISV is chosen from
the group of ISVs, wherein: CDR1 is chosen from the group
consisting of SEQ ID NOs: 20, 29, and 36; CDR2 is chosen from the
group consisting of SEQ ID NOs: 38, 47, and 54; and CDR3 is chosen
from the group consisting of SEQ ID NOs: 56, 65, and 73.
24. The ISV according to any one of claims 22-23, wherein said ISV
cross-blocks the binding of domain antibody, an immunoglobulin that
is suitable for use as a domain antibody, a single domain antibody,
an immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation, to the G1 domain of Aggrecan.
25. An ISV, a domain antibody, an immunoglobulin that is suitable
for use as a domain antibody, a single domain antibody, an
immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation that binds to epitope bin 1 of the G1-domain of
Aggrecan, and which competes for binding to the G1 domain of
Aggrecan with the ISV according to any one of claims 22-23.
26. The ISV according to claim 21, that essentially consists of 4
framework regions (FR1 to FR4, respectively) and 3 complementarity
determining regions (CDR1 to CDR3, respectively), in which: i) CDR1
is chosen from the group consisting of: a) SEQ ID NO: 24; and b)
amino acid sequences that have 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 24, wherein at position
2 the S has been changed into I or F; at position 5 the I has been
changed into S; at position 6 the I has been changed into S or M;
at position 7 the N has been changed into R or Y; at position 8 the
V has been changed into A or Y; at position 9 the V has been
changed into M; and/or at position 10 the R has been changed into
K; and/or ii) CDR2 is chosen from the group consisting of: c) SEQ
ID NO: 42; and d) amino acid sequences that have 5, 4, 3, 2, or 1
amino acid(s) difference with the amino acid sequence of SEQ ID NO:
42, wherein at position 1 the T has been changed into A or G; an N
is inserted between position 2 and position 3 (position 2a Table
2.3B); at position 7 the N has been changed into R; at position 8
the A has been changed into T; and/or at position 9 the N has been
changed into D; and/or iii) CDR3 is chosen from the group
consisting of: e) SEQ ID NO: 60; and f) amino acid sequences that
have 5, 4, 3, 2, or 1 amino acid(s) difference with the amino acid
sequence of SEQ ID NO: 60, wherein at position 1 the P is absent;
at position 2 the T has been changed into R or is absent; at
position 3 the T has been changed into M or is absent; at position
4 the H has been changed into D or Y; at position 5 the Y has been
changed into F or V; at position 6 the G has been changed into L or
D; at position 8 the V has been changed into G or T; at position 9
the Y has been changed into R; at position 10 the Y has been
changed into N or E; at position 11 the G has been changed into S
or K; at position 12 the P has been changed into E or is absent;
and/or at position 13 the Y has been changed into L or is
absent.
27. The ISV according to claim 26, wherein said ISV is chosen from
the group of ISVs, wherein: CDR1 is chosen from the group
consisting of SEQ ID NOs: 24, 25, and 27; CDR2 is chosen from the
group consisting of SEQ ID NOs: 42, 43, and 45; and CDR3 is chosen
from the group consisting of SEQ ID NOs: 60, 61, and 63.
28. The ISV according to any one of claims 26-27, wherein said ISV
cross-blocks the binding of domain antibody, an immunoglobulin that
is suitable for use as a domain antibody, a single domain antibody,
an immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation, to the G1 domain of Aggrecan.
29. An ISV, domain antibody, an immunoglobulin that is suitable for
use as a domain antibody, a single domain antibody, an
immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation that binds to epitope bin 4 of the G1-domain of
aggrecan, and which competes for binding to the G1 domain of
Aggrecan with the ISV according to any one of claims 26-27.
30. The ISV according to any one of claims 1 to 29, wherein said
ISV is chosen from the group consisting of ISVs with SEQ ID NOs: 5,
1, 2, 6, 8, 10, 12, 16, 17, 18, and 19, and ISVs which have more
than 80%, such as 90% or 95% sequence identity with any one of SEQ
ID NOs: 5, 1, 2, 6, 8, 10, 12, 16, 17, 18, and 19.
31. The ISV according to any one of claims 1 to 11, wherein said
ISV binds to the G1-IGD-G2 domain of Aggrecan.
32. The ISV according to claim 31, wherein said ISV has a pI of
more than 8.
33. The ISV according to any one of claims 31-32, wherein said ISV
has a Koff of less than 2*10.sup.-2 s.sup.-1.
34. The ISV according to any one of claims 31-33, wherein said ISV
has an EC50 of less than 1*10.sup.-6M.
35. The ISV according to any one of claims 31-34, in which: i) CDR1
is chosen from the group consisting of: a) SEQ ID NO: 32, 30 and
23; and b) amino acid sequences that have 3, 2, or 1 amino acid(s)
difference with the amino acid sequence of SEQ ID NO: 32, wherein
at position 2 the R has been changed into L; at position 6 the S
has been changed into T; and/or at position 8 the T has been
changed into A; and/or ii) CDR2 is chosen from the group consisting
of: c) SEQ ID NO: 50, 41, 48 and 51; and d) amino acid sequences
that have 2, or 1 amino acid(s) difference with the amino acid
sequence of SEQ ID NO: 50, wherein at position 7 the G has been
changed into S or R; and/or at position 8 the R has been changed
into T; and/or iii) CDR3 is chosen from the group consisting of: e)
SEQ ID NO: 68, 59, 66 and 69; and f) amino acid sequences that have
5, 4, 3, 2, or 1 amino acid(s) difference with the amino acid
sequence of SEQ ID NO: 68, wherein at position 4 the R has been
changed into V, or P; at position 6 the A has been changed into Y;
at position 7 the S has been changed into T; at position 8 the S is
absent; at position 9 the N has been changed into P; at position 10
the R has been changed into T or L; at position 11 the G has been
changed into E; and/or at position 12 the L has been changed into T
or V.
36. The ISV according to any one of claims 31-35, wherein said ISV
is chosen from the group of ISVs, wherein: CDR1 is chosen from the
group consisting of SEQ ID NOs: 32, 30 and 23; CDR2 is chosen from
the group consisting of SEQ ID NOs: 50, 41, 48 and 51; and CDR3 is
chosen from the group consisting of SEQ ID NOs: 68, 59, 66 and
69.
37. The ISV according to claim 36, wherein said ISV is chosen from
the group of ISVs, wherein: CDR1 is SEQ ID NO: 32, CDR2 is SEQ ID
NO: 50, and CDR3 is SEQ ID NO: 68; CDR1 is SEQ ID NO: 32, CDR2 is
SEQ ID NO: 51, and CDR3 is SEQ ID NO: 69; CDR1 is SEQ ID NO: 30,
CDR2 is SEQ ID NO: 48, and CDR3 is SEQ ID NO: 66; and CDR1 is SEQ
ID NO: 23, CDR2 is SEQ ID NO: 41, and CDR3 is SEQ ID NO: 59.
38. The ISV according to any one of claims 31-37, wherein said ISV
is chosen from the group consisting of ISVs with SEQ ID NOs: 13, 4,
11 and 14, and ISVs which have more than 80%, such as 90% or 95%
sequence identity with any one of SEQ ID NOs: 13, 4, 11 and 14.
39. The ISV according to any one of claims 31-38, wherein said ISV
cross-blocks the binding of domain antibody, an immunoglobulin that
is suitable for use as a domain antibody, a single domain antibody,
an immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation, to the G1-IGD-G2 domain of Aggrecan.
40. An ISV, a domain antibody, an immunoglobulin that is suitable
for use as a domain antibody, a single domain antibody, an
immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation that binds to the G1-IGD-G2 domain of Aggrecan,
and which competes for binding to the G1-IGD-G2 domain of Aggrecan
with the ISV according to any one of claims 31-38.
41. The ISV according to any one of claims 1 to 11, wherein said
ISV binds to the G2 domain of Aggrecan.
42. The ISV according to claim 41, wherein said ISV has a pI of
more than 8.
43. The ISV according to any one of claims 41-42, wherein said ISV
has a Koff of less than 2*10.sup.-2 s.sup.-1.
44. The ISV according to any one of claims 41-43, wherein said ISV
has an EC50 of less than 1*10.sup.-6M
45. The ISV according to any one of claims 41-44, in which: i) CDR1
is chosen from the group consisting of: a) SEQ ID NO: 28; and b)
amino acid sequences that have 5, 4, 3, 2, or 1 amino acid(s)
difference with the amino acid sequence of SEQ ID NO: 28, wherein
at position 1 the G has been changed into R; at position 2 the P
has been changed into S or R; at position 3 the T has been changed
into I; at position 5 the S has been changed into N; at position 6
the R has been changed into N, M, or S; at position 7 the Y has
been changed into R or is absent; at position 8 the A has been
changed into F or is absent; and/or at position 10 the G has been
changed into Y; and/or ii) CDR2 is chosen from the group consisting
of: c) SEQ ID NO: 46; and d) amino acid sequences that have 5, 4,
3, 2, or 1 amino acid(s) difference with the amino acid sequence of
SEQ ID NO: 46, wherein at position 1 the A has been changed into S,
or Y; at position 4 the W has been changed into L; at position 5
the S has been changed into N; at position 6 the S is absent; at
position 7 the G is absent; at position 8 the G has been changed
into A; at position 9 the R has been changed into S, D, or T;
and/or at position 11 the Y has been changed into N or R; and/or
iii) CDR3 is chosen from the group consisting of: e) SEQ ID NO: 64;
and f) amino acid sequences that have 5, 4, 3, 2, or 1 amino
acid(s) difference with the amino acid sequence of SEQ ID NO: 64,
wherein at position 1 the A has been changed into R, or F; at
position 2 the R has been changed into I, or L; at position 3 the I
has been changed into H, or Q; at position 4 the P has been changed
into G, or N; at position 5 the V has been changed into S; at
position 6 the R has been changed into G, N, or F; at position 7
the T has been changed into R, W, or Y; at position 8 the Y has
been changed into R, or S, or is absent; at position 9 the T has
been changed into S, or is absent; at position 10 the S has been
changed into E, K or is absent; at position 11 the E has been
changed into N, A, or is absent; at position 12 the W has been
changed into D, or is absent; at position 13 the N has been changed
into D, or is absent; at position 14 the Y is absent; and/or D
and/or N are added after position 14 of SEQ ID NO: 64.
46. The ISV according to any one of claims 41 to 45, wherein said
ISV is chosen from the group of ISVs, wherein: CDR1 is chosen from
the group consisting of SEQ ID NOs: 28, 22, 26, and 33; CDR2 is
chosen from the group consisting of SEQ ID NOs: 46, 40, 44, and 52;
and CDR3 is chosen from the group consisting of SEQ ID NOs: 64, 58,
62, and 70.
47. The ISV according to claim 46, wherein said ISV is chosen from
the group of ISVs, wherein: CDR1 is SEQ ID NO: 28, CDR2 is SEQ ID
NO: 46, and CDR3 is SEQ ID NO: 64; CDR1 is SEQ ID NO: 22, CDR2 is
SEQ ID NO: 40, and CDR3 is SEQ ID NO: 58; CDR1 is SEQ ID NO: 26,
CDR2 is SEQ ID NO: 44, and CDR3 is SEQ ID NO: 62; and CDR1 is SEQ
ID NO: 33, CDR2 is SEQ ID NO: 52, and CDR3 is SEQ ID NO: 70.
48. The ISV according to any one of claims 41 to 47, wherein said
ISV is chosen from the group consisting of ISVs with SEQ ID NOs: 9,
3, 7 and 15, and ISVs which have more than 80%, such as 90% or 95%
sequence identity with any one of SEQ ID NOs: 9, 3, 7 and 15.
49. The ISV according to any one of claims 41-48, wherein said ISV
cross-blocks the binding of domain antibody, an immunoglobulin that
is suitable for use as a domain antibody, a single domain antibody,
an immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation, to the G2 domain of Aggrecan.
50. An ISV domain antibody, an immunoglobulin that is suitable for
use as a domain antibody, a single domain antibody, an
immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation that binds to the G2-domain of Aggrecan, and
which competes for binding to the G2 domain of Aggrecan with the
ISV according to any one of claims 41-48.
51. The ISV according to any of the preceding claims, wherein said
ISV is chosen from the group consisting of SEQ ID NO:s 1-19 and
114-118 and ISVs which have more than 80%, such as 90% or 95%
sequence identity with any one of SEQ ID NOs: 1-19 and 114-118.
52. A polypeptide comprising at least one ISV according to any one
of claims 1-51, and possibly a second ISV, possibly a third ISV,
and possibly a fourth ISV.
53. The polypeptide according to claim 52, that comprises at least
two ISVs according to any one of claims 1 to 51, and possibly a
third ISV, and possibly a fourth ISV.
54. The polypeptide according to claim 53, wherein said at least
two ISVs can be the same or different.
55. The polypeptide according to claim 54, wherein said at least
two ISVs are independently chosen from the group consisting of SEQ
ID NOs: 1-19 and 114-118.
56. The polypeptide according to claim 55, wherein said at least
two ISVs are chosen from the group consisting of SEQ ID NOs: 5, 6,
8 and 114-117.
57. The polypeptide according to claim 55, wherein said at least
two ISVs are chosen from the group consisting of SEQ ID NOs: 13 and
118.
58. The polypeptide according to any one of claims 52-57,
comprising at least one further ISV.
59. The polypeptide according to claim 58, wherein said at least
one further ISV binds to a member of the serine protease family,
cathepsins, matrix metalloproteinases (MMPs)/Matrixins or A
Disintegrin and Metalloproteinase with Thrombospondin motifs
(ADAMTS), preferably MMP8, MMP13, MMP19, MMP20, ADAMTS5
(Aggrecanase-2), ADAMTS4 (Aggrecanase-1) and/or ADAMTS11.
60. The polypeptide according to claim 58 or 59, wherein said at
least one further ISV retains activity.
61. The polypeptide according to any one of claims 58-60, wherein
said at least one further ISV inhibits an activity of a member of
the serine protease family, cathepsins, matrix metalloproteinases
(MMPs)/Matrixins or A Disintegrin and Metalloproteinase with
Thrombospondin motifs (ADAMTS), preferably MMP8, MMP13, MMP19,
MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4 (Aggrecanase-1) and/or
ADAMTS11.
62. The polypeptide according to any one of claims 52-61, wherein
said polypeptide has a stability of at least 7 days, such as at
least 14 days, 21 days, 1 month, 2 months or even 3 months in
synovial fluid (SF) at 37.degree. C.
63. The polypeptide according to any one of claims 52-62, wherein
said polypeptide has a cartilage retention of at least 2, such as
at least, 3, 4, 5 or 6 RU in a cartilage retention assay.
64. The polypeptide according to any one of claims 52-63, wherein
said polypeptide penetrates into the cartilage by at least 5 .mu.m,
such as at least 10 .mu.m, 20 .mu.m, 30 .mu.m, 40 .mu.m, 50 .mu.m
or even more.
65. The polypeptide according to any one of claims 52-64, wherein
said polypeptide further comprising a serum protein binding moiety
or a serum protein.
66. The polypeptide according to claim 65, wherein said serum
protein binding moiety binds serum albumin.
67. The polypeptide according to claim 65 or 66, wherein said serum
protein binding moiety is an ISV binding serum albumin.
68. The polypeptide according to claim 67, wherein said ISV binding
serum albumin essentially consists of 4 framework regions (FR1 to
FR4, respectively) and 3 complementarity determining regions (CDR1
to CDR3 respectively), in which CDR1 is SFGMS, CDR2 is
SISGSGSDTLYADSVKG and CDR3 is GGSLSR.
69. The polypeptide according to claim 68, wherein said ISV binding
serum albumin comprises Alb8, Alb23, Alb129, Alb132, Alb135, Alb11,
Alb11 (S112K)-A, Alb82, Alb82-A, Alb82-AA, Alb82-AAA, Alb82-G,
Alb82-GG, Alb82-GGG.
70. The polypeptide according to claim 65 or 66, wherein said serum
protein binding moiety is a non-antibody based polypeptide.
71. The polypeptide according to any of the claims 52-64, further
comprising PEG.
72. The polypeptide according to any one of the preceding claims,
wherein said ISVs are directly linked to each other or are linked
via a linker.
73. The polypeptide according to any one of the claims 52-69,
wherein a first ISV and/or a second ISV and/or possibly a third ISV
and/or possibly fourth ISV and/or possibly said ISV binding serum
albumin are linked via a linker(s).
74. The polypeptide according to claim 72 or 73, wherein said
linker is chosen from the group consisting of linkers of 5GS, 7GS,
9GS, 10GS, 15GS, 18GS, 20GS, 25GS, 30GS and 35GS.
75. The polypeptide according to any one of claims 52-74, wherein
said polypeptide is chosen from the group of polypeptides and/or
constructs comprising an ISV binding a target as indicated and one
or two ISVs binding Aggrecan as indicated in Table E-1 and Table
E-2, respectively.
76. A construct that comprises or essentially consists of an ISV
according to any one of claims 1 to 51 or a polypeptide according
to any one of claims 52-75, and which optionally further comprises
one or more other groups, residues, moieties or binding units,
optionally linked via one or more peptidic linkers.
77. The construct according to claim 76, in which said one or more
other groups, residues, moieties or binding units is chosen from
the group consisting of a polyethylene glycol molecule, serum
proteins or fragments thereof, binding units that can bind to serum
proteins, an Fc portion, and small proteins or peptides that can
bind to serum proteins.
78. A nucleic acid encoding an ISV according to any one of claims 1
to 51, a polypeptide according to any one of claims 52-75, or a
construct according to any one of claims 76-77.
79. An expression vector comprising a nucleic acid according to
claim 78.
80. A host or host cell comprising a nucleic acid according to
claim 78, or an expression vector according to claim 79.
81. A method for producing an ISV according to any one of claims 1
to 51 or a polypeptide according to any one of claims 52-75, said
method at least comprising the steps of: a) expressing, in a
suitable host cell or host organism or in another suitable
expression system, a nucleic acid according to claim 78; optionally
followed by: b) isolating and/or purifying the ISV according to any
one of claims 1 to 51, or the polypeptide according to any one of
claims 52-75.
82. A composition comprising at least one ISV according to any one
of claims 1 to 51, a polypeptide according to any one of claims
52-75, a construct according to any one of claims 76-77, or a
nucleic acid according to claim 78.
83. The composition according to claim 82, which is a
pharmaceutical composition.
84. The composition according to claim 83, which further comprises
at least one pharmaceutically acceptable carrier, diluent or
excipient and/or adjuvant, and optionally comprises one or more
further pharmaceutically active polypeptides and/or compounds.
85. The composition according to any one of claims 82-84, the ISV
according to any one of claims 1 to 51, the polypeptide according
to any one of claims 52-75, the construct according to any one of
claims 76-77 for use as a medicament.
86. The composition, the ISV, the polypeptide, or the construct
according to claim 85, for use in preventing or treating
arthropathies and chondrodystrophies, arthritic disease, such as
osteoarthritis, rheumatoid arthritis, gouty arthritis, psoriatic
arthritis, traumatic rupture or detachment, achondroplasia,
costo-chondritis, Spondyloepimetaphyseal dysplasia, spinal disc
herniation, lumbar disk degeneration disease, degenerative joint
disease, and relapsing polychondritis.
87. A method for preventing or treating arthropathies and
chondrodystrophies, arthritic disease, such as osteoarthritis,
rheumatoid arthritis, gouty arthritis, psoriatic arthritis,
traumatic rupture or detachment, achondroplasia, costo-chondritis,
Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar
disk degeneration disease, degenerative joint disease, and
relapsing polychondritis, wherein said method comprises
administering, to a subject in need thereof, a pharmaceutically
active amount of at least a composition, the ISV, the polypeptide,
or the compound or construct according to claim 85 to a person in
need thereof.
88. A method for reducing and/or inhibiting the efflux of a
compound from cartilaginous tissue, wherein said method comprises
administering pharmaceutically active amount of at least one
polypeptide according to any one of claims 52-75, a construct
according to any one of claims 76-77, or a composition according to
any one of claims 82-86 to a person in need thereof.
89. A method for inhibiting and/or blocking ADAMTS5 activity and/or
MMP13 activity, wherein said method comprises administering a
pharmaceutically active amount of at least one polypeptide
according to any one of claims 52-75, a construct according to any
one of claims 76-77, or a composition according to any one of
claims 82-86 to a person in need thereof.
90. Use of an ISV according to any one of claims 1 to 51, a
polypeptide according to any one of claims 52-75, a construct
according to any one of claims 76-77, or a composition according to
any one of claims 82-86, in the preparation of a pharmaceutical
composition for treating or preventing arthropathies and
chondrodystrophies, arthritic disease, such as osteoarthritis,
rheumatoid arthritis, gouty arthritis, psoriatic arthritis,
traumatic rupture or detachment, achondroplasia, costo-chondritis,
Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar
disk degeneration disease, degenerative joint disease, and
relapsing polychondritis.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to immunoglobulins that bind
Aggrecan and more in particular to polypeptides, that comprise or
essentially consist of one or more such immunoglobulins (also
referred to herein as "immunoglobulin(s) of the invention", and
"polypeptides of the invention", respectively). The invention also
relates to constructs comprising such immunoglobulins or
polypeptides as well as nucleic acids encoding such immunoglobulins
or polypeptides (also referred to herein as "nucleic acid(s) of the
invention"; to methods for preparing such immunoglobulins,
polypeptides and constructs; to host cells expressing or capable of
expressing such immunoglobulins or polypeptides; to compositions,
and in particular to pharmaceutical compositions, that comprise
such immunoglobulins, polypeptides, constructs, nucleic acids
and/or host cells; and to uses of immunoglobulins, polypeptides,
constructs, nucleic acids, host cells and/or compositions, in
particular for prophylactic and/or therapeutic purposes, such as
the prophylactic and/or therapeutic purposes mentioned herein.
Other aspects, embodiments, advantages and applications of the
invention will become clear from the further description
herein.
BACKGROUND
[0002] Osteoarthritis is one of the most common causes of
disability worldwide. It affects 30 million Americans and is the
most common joint disorder. It is projected to affect more than 20
percent of the U.S. population by 2025. The disease can occur in
all joints, most often the knees, hips, hands and spine.
Osteoarthritis (OA) can be defined as a diverse group of conditions
characterised by a combination of joint symptoms, signs stemming
from defects in the articular cartilage and changes in adjacent
tissues including bone, tendons and muscle. OA is characterized by
progressive erosion of articular cartilage (cartilage that covers
the bones). Eventually, the disease leads to the total destruction
of the articular cartilage, sclerosis of underlying bone,
osteophyte formation etc., all leading to loss of movement and
pain. Pain is the most prominent symptom of OA and this is most
often the reason patients seek medical help.
[0003] Aggrecan is the major proteoglycan in the articular
cartilage (Kiani et al. 2002 Cell Research 12:19-32). This molecule
is important in the proper functioning of the articular cartilage
because it provides a hydrated gel structure that endows the
cartilage with load-bearing properties. Aggrecan is a large,
multimodular molecule (2317 amino acids) expressed by chondrocytes.
Its core protein is composed of three globular domains (G1, G2 and
G3) and a large extended region between G2 and G3 for
glycosaminoglycan chain attachment. This extended region comprises
two domains, one substituted with keratan sulfate chains (KS
domain) and one with chondroitin sulfate chains (CS domain). The CS
domain has 100-150 glycosaminoglycan (GAG) chains attached to it.
Aggrecan forms large complexes with Hyaluronan in which 50-100
Aggrecan molecules interact via the G1 domain and Link Protein with
one Hyaluronan molecule. Upon uptake of water (due to the GAG
content) these complexes form a reversibly deformable gel that
resists compression. The structure, fluid retention and function of
joint cartilage is linked to the matrix content of Aggrecan, and
the amount of chondroitin sulfate bound to the intact core
protein.
[0004] OA is characterized by 1) degradation of Aggrecan,
progressively releasing domains G3 and G2 (resulting in `deflation`
of the cartilage) and eventually release of the G1 domain and 2)
degradation of Collagen, irreversibly destroying the cartilage
structure.
[0005] Although aging, obesity and joint injury have been
identified as risk factors leading to osteoarthritis, the cause of
OA is unknown and there are currently no pharmacological treatments
that halt the disease progression or cure the joints. For large
joints, a drug could be injected into the joint to help to limit
potential side effects, like pain. Therapeutic strategies are
primarily aimed at reducing pain and improving joint function.
Fasinumab, a non-opioid anti-NGF pain treatment has been shown to
give improvements on a key pain score during phase II/III trials.
Duloxetine was approved for the treatment of chronic knee pain due
to osteoarthritis and has been conditionally recommended by the
American College of Rheumatology. Strontium ranelate was found to
significantly decrease the rate of decline in joint space width as
well as improve pain scores compared with placebo in a large
multicenter study in patients with symptomatic knee osteoarthritis.
However, at this moment the biologic agents interleukin-1 receptor
antagonists and antitumor necrosis factor antibodies have neither
been shown to be efficacious nor to alter the course of
osteoarthritis (Smelter Hochberg 2013 Current Opin. Rheumatol.
25:310). Hence, many such therapies are ineffective and/or are
associated with side effects. Ultimately patients will undergo
total knee or hip replacement therapy if pain cannot be
controlled.
[0006] Pharmacological therapy begins with oral administration of
paracetamol either combined with NSAIDS or COX-2 inhibitors and a
weak opioid. Major disadvantages of oral administration of drugs
are the limited bio-availability at the site of interest and the
risk of side effects, such as liver damage, Gastro-intestinal
(GI)-ulcers, GI-bleeding and constipation. As OA has a localized
nature, intra-articular administration of drugs provides an
excellent opportunity to improve treatment. However, most of the
newly developed disease modifying osteoarthritis drugs (DMOADs)
have a short residence time in the joint, even when administered
intra-articularly (Edwards 2011 Vet. J. 190:15-21; Larsen et al.
2008 J Pham Sci 97:4622-4654). Intra-articular (IA) delivery of
therapeutic proteins has been limited by their rapid clearance from
the joint space and lack of retention within cartilage. Synovial
residence time of a drug in the joint is often less than 24 h. Due
to the rapid clearance of most IA injected drugs, frequent
injections would be needed to maintain an effective concentration
(Owen et al. 1994 Br. J, Clin Pharmacol. 38349-355). However,
frequent IA-injections are undesired due to the pain and discomfort
they may cause challenging patient compliance, as well as the risk
of introducing joint infections.
[0007] Loffredo et at tested whether targeted delivery to cartilage
by fusion with a heparin-binding domain would be sufficient to
prolong the in viva function of the insulin-like growth factor 1
(IGF-1). Heparin is present in mast cells. However, the natural
role of Heparin is unknown, but it is widely used as a
blood-thinner (Loffredo et al. 2014 Arthritis Rheumatol.
66:1247-1255).
[0008] There remains a need for further cartilage anchoring
proteins (CAP).
SUMMARY OF THE INVENTION
[0009] The present inventors hypothesized that the efficacy of a
therapeutic drug could be increased significantly by coupling the
therapeutic drug to a moiety which would "anchor" the drug in the
joint and consequently increase retention of the drug, but which
should not disrupt the efficacy of said therapeutic drug (also
indicated herein as "cartilage anchoring protein" or "CAP"). This
anchoring concept would not only increase the efficacy of drug, but
also the operational specificity for a diseased joint by decreasing
toxicity and side-effects, thus widening the number of possible
useful drugs. The present inventors further hypothesized that
Aggrecan binders might potentially function as such an anchor,
although Aggrecan is heavily glycosylated and degraded in various
disorders affecting cartilage in joints. Moreover, in view of the
costs and extensive testing in various animal models required
before a drug can enter the clinic, such Aggrecan binders should
preferentially have a broad cross-reactivity, e.g. the Aggrecan
binders should bind to Aggrecan of various species.
[0010] Using various ingenious immunization, screening and
characterization methods, the present inventors were able to
identify a number of Aggrecan binders with superior selectivity,
stability and/or specificity features, which enabled prolonged
retention and activity in the joint.
[0011] Accordingly, the present invention relates to an
immunoglobulin single variable domain (ISV) that specifically binds
to Aggrecan, preferably said ISV specifically binds to human
Aggrecan (SEQ ID NO: 125), and/or wherein said ISV specifically
binds to dog Aggrecan (SEQ ID NO: 126), bovine Aggrecan (SEQ ID NO:
127), rat Aggrecan (SEQ ID NO: 128), pig (core) Aggrecan (SEQ ID
NO: 129), mouse Aggrecan (SEQ ID NO: 130), rabbit Aggrecan (SEQ ID
NO: 131), cynomolgus Aggrecan (SEQ ID NO: 132) and/or rhesus
Aggrecan (SEQ ID NO: 133), even more preferably, wherein said ISV
does not bind substantially to Neurocan (SEQ ID NO: 134) and/or
Brevican (SEQ ID NO: 135).
[0012] In an aspect, the present invention relates to an ISV as
described herein, wherein the ISV has more than 10 fold, more than
100 fold, preferably more than 1000 fold selectivity over Neurocan
and/or Brevican for binding to Aggrecan, and/or said ISV preferably
binds to cartilaginous tissue such as cartilage and/or meniscus,
and/or said ISV has a stability of at least 7 days, such as 14
days, 21 days, 1 month, 2 months or even 3 months in synovial fluid
(SF) at 37.degree. C., and/or said ISV has a cartilage retention of
at least 2, such as at least, 3, 4, 5 or 6 RU in a cartilage
retention assay, and/or said ISV penetrates into the cartilage by
at least 5 pa), such as at least 10 .mu.m, 20 .mu.m, 30 .mu.m, 40
.mu.m, 50 .mu.m or even more, and/or said ISV essentially consists
of a domain antibody, an immunoglobulin that is suitable for use as
a domain antibody, a single domain antibody, an immunoglobulin that
is suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation.
[0013] In an aspect, the present invention relates to an ISV as
described herein, that essentially consists of 4 framework regions
(FR1 to FR4, respectively) and 3 complementarity determining
regions (CDR1 to CDR3, respectively), in which: CDR1 is chosen from
the group consisting of SEQ ID NOs: 24, 20, 21, 22, 23, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37 and 109; CDR2 is chosen from
the group consisting of SEQ ID NOs: 42, 38, 39, 40, 41, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 53, 54, 55 and 110; and CDR3 is chosen
from the group consisting of SEQ ID NOs: 60, 56, 57, 58, 59, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 and 111.
[0014] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV binds to the G1 domain of
Aggrecan, preferably said ISV has a pl of more than 8, and/or said
ISV has a Koff of less than 2*10.sup.-2 s.sup.-1, and/or said ISV
has an EC.sub.50 of less than 1*10.sup.-6M.
[0015] In an aspect, the present invention relates to an ISV as
described herein, that essentially consists of 4 framework regions
(FR1 to FR4, respectively) and 3 complementarity determining
regions (CDR1 to CDR3, respectively), in which: [0016] i) CDR1 is
chosen from the group consisting of: a) SEQ ID NOs: 24, 20, or 21;
or b) amino acid sequences that have 5, 4, 3, 2, or 1 amino acid(s)
difference with the amino acid sequence of SEQ ID NO: 24, wherein
at position 2 the S has been changed into R, F, I, or T; at
position 3 the T has been changed into I; at position 5 the I has
been changed into 5; at position 6 the I has been changed into S,
T, or M; at position 7 the N has been changed into Y, or R; at
position 8 the V has been changed into A, Y, T, or G; at position 9
the V has been changed into M; and/or at position 10 the R has been
changed into G, K, or A; and/or [0017] ii) CDR2 is chosen from the
group consisting of: c) SEQ ID NOs: 42, 38, or 39; or d) amino acid
sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference with
the amino acid sequence of SEQ ID NO: 42, wherein at position 1 the
T has been changed into A, or G; an S or N is inserted between
position 3 and position 4 (position 2a Table 1.3B); at position 3
the S has been changed into R, W, N, or T; at position 4 the S has
been changed into T or G; at position 5 the G has been changed into
S; at position 6 the G has been changed into 5, or R; at position 7
the N has been changed into S, T, or R; at position 8 the A has
been changed into T; and/or at position 9 the N has been changed
into D or Y; and/or [0018] iii) CDR3 is chosen from the group
consisting of: e) SEQ ID NO: 60, 56 or 57; or f) amino acid
sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference with
the amino acid sequence of SEQ ID NO: 60, wherein at position 1 the
P has been changed into G, R, D, or E, or is absent; at position 2
the T has been changed into R, L, P, or V, or is absent; at
position 3 the T has been changed into M, 5, or R, or is absent; at
position 4 the H has been changed into D, Y, G, or T; at position 5
the Y has been changed into F, V, T or G; at position 6 the G has
been changed into L, D, S, Y, or W; an R, T, Y or V is inserted
between position 6 and position 7 (position 6a Table 1.3C); at
position 7 the G has been changed into P, or S; at position 8 the V
has been changed into G, T, H, R, L, or Y; at position 9 the Y has
been changed into R, A, 5, D or G; at position 10 the Y has been
changed into N, E, G, W, or 5; a W is inserted between position 10
and position 11 (position 10a Table 1.3C); at position 11 the G has
been changed into S, K, or V; at position 12 the P has been changed
into E, or D, or is absent; and/or at position 13 the Y has been
changed into L, or is absent.
[0019] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group of
ISVs, wherein: CDR1 is chosen from the group consisting of SEQ ID
NOs: 24, 20, 21, 25, 27, 29, 31, 34, 35, 36, 37 and 109; CDR2 is
chosen from the group consisting of SEQ ID NOs: 42, 38, 39, 43, 45,
47, 49, 50, 53, 54, 55, and 110; and CDR3 is chosen from the group
consisting of SEQ ID NOs: 60, 56, 57, 61, 63, 65, 67, 71, 72, 73,
74, and 111.
[0020] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group of
ISVs, wherein: [0021] CDR1 is SEQ ID NO: 24, CDR2 is SEQ ID NO: 42,
and CDR3 is SEQ ID NO: 60; [0022] CDR1 is SEQ ID NO: 20, CDR2 is
SEQ ID NO: 38, and CDR3 is SEQ ID NO: 56; [0023] CDR1 is SEQ ID NO:
21, CDR2 is SEQ ID NO: 39, and CDR3 is SEQ ID NO: 57; [0024] CDR1
is SEQ ID NO: 25, CDR2 is SEQ ID NO: 43, and CDR3 is SEQ ID NO: 61;
[0025] CDR1 is SEQ ID NO: 27, CDR2 is SEQ ID NO: 45, and CDR3 is
SEQ ID NO: 63; [0026] CDR1 is SEQ ID NO: 29, CDR2 is SEQ ID NO: 47,
and CDR3 is SEQ ID NO: 65; [0027] CDR1 is SEQ ID NO: 31, CDR2 is
SEQ ID NO: 49, and CDR3 is SEQ ID NO: 67; [0028] CDR1 is SEQ ID NO:
34, CDR2 is SEQ ID NO: 50, and CDR3 is SEQ ID NO: 71; [0029] CDR1
is SEQ ID NO: 35, CDR2 is SEQ ID NO: 53, and CDR3 is SEQ ID NO: 72;
[0030] COR1 is SEQ ID NO: 36, CDR2 is SEQ ID NO: 54, and CDR3 is
SEQ ID NO: 73; and [0031] CDR1 is SEQ ID NO: 37, CDR2 is SEQ ID NO:
55, and CDR3 is SEQ ID NO: 74.
[0032] In an aspect, the present invention relates to an ISV as
described herein, that essentially consists of 4 framework regions
(FR1 to FR4, respectively) and 3 complementarity determining
regions (CDR1 to CDR3, respectively), in which: [0033] i) CDR1 is
chosen from the group consisting of: a) SEQ ID NO: 24 and 109; or
b) amino acid sequences that have 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 24, wherein at position
7 the N has been changed into 5; and/or at position 9 the V has
been changed into M; and/or [0034] ii) CDR2 is chosen from the
group consisting of: c) SEQ ID NO: 42 and 110; or d) amino acid
sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference with
the amino acid sequence of SEQ ID NO: 42, wherein at position 1 the
T has been changed into A; at position 3 the S has been changed
into R; at position 4 the S has been changed into T; at position 8
the A has been changed into T; and/or at position 9 the N has been
changed into D; and/or [0035] iii) CDR3 is chosen from the group
consisting of: e) SEQ ID NO: 60 and 111; or f) amino acid sequences
that have 2, or 1 amino acids) difference with the amino acid
sequence of SEQ ID NO: 60, wherein at position 4 the H has been
changed into R; and/or at position 8 the V has been changed into
D.
[0036] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group of
ISVs, wherein CDR1 is chosen from the group consisting of SEQ ID
NOs: 24 and 109; CDR2 is chosen from the group consisting of SEQ ID
NOs: 42 and 110; and CDR3 is chosen from the group consisting of
SEQ ID NOs: 60 and 111.
[0037] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV belongs to epitope bin 1 or
epitope bin 4, preferably said ISV essentially consists of 4
framework regions (ER1 to FR4, respectively) and 3 complementarity
determining regions (CDR1 to CDR3, respectively), in which: [0038]
i) CDR1 is chosen from the group consisting of: a) SEQ ID NO: 36;
and b) amino acid sequences that have 2, or 1 amino acid(s)
difference with the amino acid sequence of SEQ ID NO: 36, wherein
at position 3 the T has been changed into 5; at position 6 the T
has been changed into 5; at position 8 the T has been changed into
A; and/or at position 9 the M has been changed into V; and/or
[0039] ii) CDR2 is chosen from the group consisting of: c) SEQ ID
NO: 54; and d) amino acid sequences that have 5, 4, 3, 2, or 1
amino acid(s) difference with the amino acid sequence of SEQ ID NO:
54, wherein at position 1 the A has been changed into I; at
position 4 the W has been changed into R; at position 7 the G has
been changed into R; and/or at position 8 the T has been changed
into 5; and/or [0040] iii) CDR3 is chosen from the group consisting
of: e) SEQ ID NO: 73; and f) amino acid sequences that have 5, 4,
3, 2, or 1 amino acid(s) difference with the amino acid sequence of
SEQ ID NO: 73, wherein at position 1 the R has been changed into G;
at position 2 the P has been changed into R or L; at position 3 the
R has been changed into L or S; at position 5 the Y has been
changed into R; at position 6 the Y has been changed into S or A;
at position 7 the Y has been changed into T, or is absent; at
position 8 the S has been changed into P; at position 9 the L has
been changed into H or R; at position 10 the Y has been changed
into P or A; at position 11 the S has been changed into A or Y; at
position 12 the Y has been changed into D; at position 13 the D has
been changed into F; at position 14 the Y has been changed into G,
or is absent; and/or after position 14 an S is inserted.
[0041] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group of
ISVs, wherein: CDR1 is chosen from the group consisting of SEQ ID
NOs: 20, 29, and 36; CDR2 is chosen from the group consisting of
SEQ ID NOs: 38, 47, and 54; and CDR3 is chosen from the group
consisting of SEQ ID NOs: 56, 65, and 73.
[0042] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV cross-blocks the binding of
domain antibody, an immunoglobulin that is suitable for use as a
domain antibody, a single domain antibody, an immunoglobulin that
is suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation to the
G1 domain of Aggrecan.
[0043] In an aspect, the present invention relates to an ISV, a
domain antibody, an immunoglobulin that is suitable for use as a
domain antibody, a single domain antibody, an immunoglobulin that
is suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Na nobody, a
VHH sequence, a humanized VHH sequence, a camelized VH sequence, or
a VHH sequence that has been obtained by affinity maturation that
binds to epitope bin 1 of the G1-domain of Aggrecan, and which
competes for binding to the G1 domain of Aggrecan with the ISV as
described herein.
[0044] In an aspect, the present invention relates to an ISV as
described herein, that essentially consists of 4 framework regions
(FR1 to FR4, respectively) and 3 complementarity determining
regions (CDR1 to CDR3, respectively), in which: i) CDR1 is chosen
from the group consisting of: a) SEQ ID NO: 24; and b) amino acid
sequences that have 2, or 1 amino acid(s) difference with the amino
acid sequence of SEQ ID NO: 24, wherein at position 2 the S has
been changed into I or F; at position 5 the I has been changed into
5; at position 6 the I has been changed into S or M; at position 7
the N has been changed into R or Y; at position 8 the V has been
changed into A or Y; at position 9 the V has been changed into M;
and/or at position 10 the R has been changed into K; and/or ii)
CDR2 is chosen from the group consisting of: c) [0045] SEQ ID NO:
42; and d) amino acid sequences that have 5, 4, 3, 2, or 1 amino
acid(s) difference with the amino acid sequence of SEQ ID NO: 42,
wherein at position 1 the T has been changed into A or G; an N is
inserted between position 2 and position 3 (position 2a Table
2.3B); at position 7 the N has been changed into R; at position 8
the A has been changed into T; and/or at position 9 the N has been
changed into D; and/or iii) CDR3 is chosen from the group
consisting of: e) SEQ ID NO: 60; and f) amino acid sequences that
have 5, 4, 3, 2, or 1 amino acid(s) difference with the amino acid
sequence of SEQ ID NO: 60, wherein at position 1 the P is absent;
at position 2 the T has been changed into R or is absent; at
position 3 the T has been changed into M or is absent; at position
4 the H has been changed into D or Y; at position 5 the Y has been
changed into F or V; at position 6 the G has been changed into L or
D; at position 8 the V has been changed into G or T; at position 9
the Y has been changed into R; at position 10 the Y has been
changed into N or E; at position 11 the G has been changed into S
or K; at position 12 the P has been changed into E or is absent;
and/or at position 13 the Y has been changed into L or is absent;
preferably CDR1 is chosen from the group consisting of SEQ ID NOs:
24, 25, and 27; CDR2 is chosen from the group consisting of SEQ ID
NOs: 42, 43, and 45; and CDR3 is chosen from the group consisting
of SEQ ID NOs: 60, 61, and 63; even more preferably, wherein said
ISV cross-blocks the binding of domain antibody, an immunoglobulin
that is suitable for use as a domain antibody, a single domain
antibody, an immunoglobulin that is suitable for use as a single
domain antibody, a dAb, an immunoglobulin that is suitable for use
as a dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation to the G1 domain of Aggrecan.
[0046] In an aspect, the present invention relates to an ISV as
described herein, a domain antibody, an immunoglobulin that is
suitable for use as a domain antibody, a single domain antibody, an
immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation that binds to epitope bin 4 of the G1-domain of
Aggrecan, and which competes for binding to the G1 domain of
Aggrecan with the ISV as described herein.
[0047] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group
consisting of ISVs with SEQ ID NOs: 5, 1, 2, 6, 8, 10, 12, 16, 17,
18, and 19, and ISVs which have more than 80%, such as 90% or 95%
sequence identity with any one of SEQ ID NOs: 5, 1, 2, 6, 8, 10,
12, 16, 17, 18, and 19.
[0048] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV binds to the G1-IGD-G2 domain of
Aggrecan, preferably wherein said ISV has a pi of more than 8
and/or has a Koff of less than 2*10.sup.-2 s.sup.-1 and/or has an
EC50 of less than 1*10.sup.-6M.
[0049] In an aspect, the present invention relates to an ISV as
described herein, in which: i) CDR1 is chosen from the group
consisting of: a) SEQ ID NO: 32, 30 and 23; and b) amino acid
sequences that have 3, 2, or 1 amino acid(s) difference with the
amino acid sequence of SEQ ID NO: 32, wherein at position 2 the R
has been changed into L; at position 6 the S has been changed into
T; and/or at position 8 the T has been changed into A; and/or ii)
CDR2 is chosen from the group consisting of: c) SEQ ID NO: 50, 41,
48 and 51; and d) amino acid sequences that have 2, or 1 amino
acid(s) difference with the amino acid sequence of SEQ ID NO: 50,
wherein at position 7 the G has been changed into S or R; and/or at
position 8 the R has been changed into T; and/or iii) CDR3 is
chosen from the group consisting of: e) SEQ ID NO: 68, 59, 66 and
69; and f) amino acid sequences that have 5, 4, 3, 2, or 1 amino
acid(s) difference with the amino acid sequence of SEQ ID NO: 68,
wherein at position 4 the R has been changed into V, or P; at
position 6 the A has been changed into Y; at position 7 the S has
been changed into T; at position 8 the S is absent; at position 9
the N has been changed into P; at position 10 the R has been
changed into T or L; at position 11 the G has been changed into E;
and/or at position 12 the L has been changed into T or V,
preferably, wherein said ISV is chosen from the group of ISVs,
wherein: CDR1 is chosen from the group consisting of SEQ ID NOs:
32, 30 and 23; CDR2 is chosen from the group consisting of SEQ ID
NOs: 50, 41, 48 and 51; and CDR3 is chosen from the group
consisting of SEQ ID NOs: 68, 59, 66 and 69, even more preferably,
wherein said ISV is chosen from the group of ISVs, wherein: CDR1 is
SEQ ID NO: 32, CDR2 is SEQ ID NO: 50, and CDR3 is SEQ ID NO: 68;
CDR1 is SEQ ID NO: 32, CDR2 is SEQ ID NO: 51, and CDR3 is SEQ ID
NO: 69; CDR1 is SEQ ID NO: 30, CDR2 is SEQ ID NO: 48, and CDR3 is
SEQ ID NO: 66; and CDR1 is SEQ ID NO: 23, CDR2 is SEQ ID NO: 41,
and CDR3 is SEQ ID NO: 59.
[0050] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group
consisting of ISVs with SEQ ID NOs: 13, 4, 11 and 14, and ISVs
which have more than 80%, such as 90% or 95% sequence identity with
any one of SEQ ID NOs: 13, 4, 11 and 14.
[0051] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV cross-blocks the binding of
domain antibody, an immunoglobulin that is suitable for use as a
domain antibody, a single domain antibody, an immunoglobulin that
is suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation to the
G1-IGD-G2 domain of Aggrecan. In an aspect, the present invention
relates to an ISV, a domain antibody, an immunoglobulin that is
suitable for use as a domain antibody, a single domain antibody, an
immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation that binds to the G1-IGD-G2 domain of Aggrecan,
and which competes for binding to the G1-IGD-G2 domain of Aggrecan
with the ISV as described herein.
[0052] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV binds to the G2 domain of
Aggrecan, preferably wherein said ISV has a pl of more than 8,
and/or has a Koff of less than 2*10.sup.-2 s.sup.-1 and/or has an
EC50 of less than 1*10.sup.-6M
[0053] In an aspect, the present invention relates to an ISV as
described herein, in which: i) CDR1 is chosen from the group
consisting of: a) SEQ ID NO: 28; and b) amino acid sequences that
have 5, 4, 3, 2, or 1 amino acid(s) difference with the amino acid
sequence of SEQ ID NO: 28, wherein at position 1 the G has been
changed into R; at position 2 the P has been changed into S or R;
at position 3 the T has been changed into I; at position 5 the S
has been changed into N; at position 6 the R has been changed into
N, M, or 5; at position 7 the Y has been changed into R or is
absent; at position 8 the A has been changed into F or is absent;
and/or at position 10 the G has been changed into Y; and/or ii)
CDR2 is chosen from the group consisting of: c) SEQ ID NO: 46; and
d) amino acid sequences that have 5, 4, 3, 2, or 1 amino acid(s)
difference with the amino acid sequence of SEQ ID NO: 46, wherein
at position 1 the A has been changed into 5, or Y; at position 4
the W has been changed into L; at position 5 the S has been changed
into N; at position 6 the S is absent; at position 7 the G is
absent; at position 8 the G has been changed into A; at position 9
the R has been changed into 5, D, or T; and/or at position 11 the Y
has been changed into N or R; and/or iii) CDR3 is chosen from the
group consisting of: e) SEQ ID NO: 64; and f) amino acid sequences
that have 5, 4, 3, 2, or 1 amino acid(s) difference with the amino
acid sequence of SEQ ID NO: 64, wherein at position 1 the A has
been changed into R, or F; at position 2 the R has been changed
into I, or L; at position 3 the I has been changed into H, or Q; at
position 4 the P has been changed into G, or N; at position 5 the V
has been changed into 5; at position 6 the R has been changed into
G, N, or F; at position 7 the T has been changed into R, W, or Y;
at position 8 the Y has been changed into R, or S, or is absent; at
position 9 the T has been changed into S, or is absent; at position
10 the S has been changed into E, K or is absent; at position 11
the E has been changed into N, A, or is absent; at position 12 the
W has been changed into D, or is absent; at position 13 the N has
been changed into D, or is absent; at position 14 the Y is absent;
and/or D and/or N are added after position 14 of SEQ ID NO: 64;
preferably wherein said ISV is chosen from the group of ISVs,
wherein: CDR1 is chosen from the group consisting of SEQ ID NOs:
28, 22, 26, and 33; CDR2 is chosen from the group consisting of SEQ
ID NOs: 46, 40, 44, and 52; and CDR3 is chosen from the group
consisting of SEQ ID NOs: 64, 58, 62, and 70; even more preferably,
wherein said ISV is chosen from the group of ISVs, wherein: CDR1 is
SEQ ID NO: 28, CDR2 is SEQ ID NO: 46, and CDR3 is SEQ ID NO: 64;
CDR1 is SEQ ID NO: 22, CDR2 is SEQ ID NO: 40, and CDR3 is SEQ ID
NO: 58; CDR1 is SEQ ID NO: 26, CDR2 is SEQ ID NO: 44, and CDR3 is
SEQ ID NO: 62; and CDR1 is SEQ ID NO: 33, CDR2 is SEQ ID NO: 52,
and CDR3 is SEQ ID NO: 70.
[0054] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group
consisting of ISVs with SEQ ID NOs: 9, 3, 7 and 15, and ISVs which
have more than 80%, such as 90% or 95% sequence identity with any
one of SEQ ID NOs: 9, 3, 7 and 15.
[0055] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV cross-blocks the binding of
domain antibody, an immunoglobulin that is suitable for use as a
domain antibody, a single domain antibody, an immunoglobulin that
is suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation to the
G2 domain of Aggrecan. In an aspect, the present invention relates
to an ISV, a domain antibody, an immunoglobulin that is suitable
for use as a domain antibody, a single domain antibody, an
immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation that binds to the G2-domain of Aggrecan, and
which competes for binding to the G2 domain of Aggrecan with the
ISV as described herein.
[0056] In an aspect, the present invention relates to an ISV as
described herein, wherein said ISV is chosen from the group
consisting of SEQ ID NO:s 1-19 and 114-118 and ISVs which have more
than 80%, such as 90% or 95% sequence identity with any one of SEQ
ID NOs: 1-19 and 114-118.
[0057] In an aspect, the present invention relates to a polypeptide
comprising at least one ISV as described herein, preferably said
comprises at least two ISVs as described herein, wherein said at
least two ISVs can be the same or different. Preferably, said at
least two ISVs are independently chosen from the group consisting
of SEQ ID NOs: 1-19 and 114-118, more preferably wherein said at
least two ISVs are chosen from the group consisting of SEQ ID NOs:
5, 6, 8 and 114-117 or wherein said at least two ISVs are chosen
from the group consisting of SEQ ID NOs: 13 and 118.
[0058] Preferably, in an aspect, the polypeptide of the invention
comprises at least one further ISV, e.g. a therapeutic ISV.
Preferably, said at least one further ISV binds to a member of the
serine protease family, cathepsins, matrix metalloproteinases
(MMPs)/Matrixins or A Disintegrin and Metalloproteinase with
Thrombospondin motifs (ADAMTS), preferably MMP8, MMP13, MMP19,
MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4 (Aggrecanase-1) and/or
ADAMTS11; wherein said at least one further ISV, e.g. a therapeutic
ISV, preferably retains activity. Even more preferably, said at
least one further ISV, such as an therapeutic ISV, inhibits an
activity of a member of the serine protease family, cathepsins,
matrix metalloproteinases (MMPs)/Matrixins or A Disintegrin and
Metalloproteinase with Thrombospondin motifs (ADAMTS), preferably
MMP8, MMP13, MMP19, MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4
(Aggrecanase-1) and/or ADAMTS11.
[0059] In an aspect, the present invention relates to a polypeptide
as described herein, wherein said polypeptide has a stability of at
least 7 days, such as at least 14 days, 21 days, 1 month, 2 months
or even 3 months in synovial fluid (SF) at 37.degree. C., and/or
has a cartilage retention of at least 2, such as at least, 3, 4, 5
or 6 RU in a cartilage retention assay, and/or penetrates into the
cartilage by at least 5 .mu.m, such as at least 10 .mu.m, 20 .mu.m,
30 .mu.m, 40 .mu.m, 50 .mu.m or even more.
[0060] In an aspect, the present invention relates to a polypeptide
as described herein, further comprising a serum protein binding
moiety or a serum protein, preferably said serum protein binding
moiety binds serum albumin; even more preferably said serum protein
binding moiety is an ISV binding serum albumin; even more
preferably, said ISV binding serum albumin essentially consists of
4 framework regions (FR1 to FR4, respectively) and 3
complementarity determining regions (CDR1, to CDR3 respectively),
in which CDR1 is SFGMS, CDR2 is SISGSGSDTLYADSVKG and CDR3 is
GGSLSR; even more preferably said ISV binding serum albumin
comprises Alb8, Alb23, Alb129, Alb132, Alb135, Alb11, Alb11
(5112K)-A, Alb82, Alb82-A, Alb82-AA, Alb82-AAA, Alb82-G, Alb82-GG,
Alb82-GGG (cf. Table C). In an aspect, the present invention
relates to a polypeptide as described herein, further comprising a
serum protein binding moiety or a serum protein, wherein said serum
protein binding moiety is a non-antibody based polypeptide. In an
aspect, the present invention relates to a polypeptide as described
herein, further comprising PEG.
[0061] In an aspect, the present invention relates to a polypeptide
as described herein, wherein said ISVs are directly linked to each
other or are linked via a linker. In an aspect, the present
invention relates to a polypeptide as described herein, wherein a
first ISV and/or a second ISV and/or possibly a third ISV and/or
possibly fourth ISV and/or possibly said ISV binding serum albumin
are linked via a linker(s); preferably said linker is chosen from
the group consisting of linkers of 5GS, 7GS, 9G5, 10GS, 15GS, 18GS,
20GS, 25GS, 30GS and 35GS (cf. Table D).
[0062] In an aspect, the present invention relates to a polypeptide
as described herein, wherein said polypeptide is chosen from the
group of polypeptides and/or constructs comprising an ISV binding a
target as indicated and one or two ISVs binding Aggrecan as
indicated in Table E-1 and Table E-2, respectively.
[0063] In an aspect, the present invention relates to a construct
that comprises or essentially consists of an ISV as described
herein, or a polypeptide as described herein, and which optionally
further comprises one or more other groups, residues, moieties or
binding units, optionally linked via one or more peptidic linkers;
preferably said one or more other groups, residues, moieties or
binding units is chosen from the group consisting of a polyethylene
glycol molecule, serum proteins or fragments thereof, binding units
that can bind to serum proteins, an Fc portion, and small proteins
or peptides that can bind to serum proteins.
[0064] In an aspect, the present invention relates to a nucleic
acid encoding an ISV as described herein, a polypeptide as
described herein, or a construct as described herein.
[0065] In an aspect, the present invention relates to an expression
vector comprising a nucleic acid as described herein.
[0066] In an aspect, the present invention relates to a host or
host cell comprising a nucleic acid as described herein, or an
expression vector as described herein.
[0067] In an aspect, the present invention relates to a method for
producing an ISV as described herein or a polypeptide as described
herein, said method at least comprising the steps of: a)
expressing, in a suitable host cell or host organism or in another
suitable expression system, a nucleic acid as described herein;
optionally followed by: b) isolating and/or purifying the ISV as
described herein, or the polypeptide as described herein.
[0068] In an aspect, the present invention relates to a composition
comprising at least one ISV as described herein, a polypeptide as
described herein, a construct as described herein, or a nucleic
acid as described herein; preferably said composition is a
pharmaceutical composition, which preferably further comprises at
least one pharmaceutically acceptable carrier, diluent or excipient
and/or adjuvant, and optionally comprises one or more further
pharmaceutically active polypeptides and/or compounds.
[0069] In an aspect, the present invention relates to a composition
as described herein, an ISV as described herein, a polypeptide as
described herein, or a construct as described herein, for use as a
medicament. Preferably, the composition, the ISV, the polypeptide,
or the construct as described herein, is for use in preventing or
treating arthropathies and chondrodystrophies, arthritic disease,
such as osteoarthritis, rheumatoid arthritis, gouty arthritis,
psoriatic arthritis, traumatic rupture or detachment,
achondroplasia, costo-chondritis, Spondyloepimetaphyseal dysplasia,
spinal disc herniation, lumbar disk degeneration disease,
degenerative joint disease, and relapsing polychondritis.
[0070] In an aspect, the present invention relates to a method for
preventing or treating arthropathies and chondrodystrophies,
arthritic disease, such as osteoarthritis, rheumatoid arthritis,
gouty arthritis, psoriatic arthritis, traumatic rupture or
detachment, achondroplasia, costo-chondritis,
Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar
disk degeneration disease, degenerative joint disease, and
relapsing polychondritis, wherein said method comprises
administering, to a subject in need thereof, a pharmaceutically
active amount of at least a composition, an ISV, a polypeptide, or
a construct as described herein to a person in need thereof.
[0071] In an aspect, the present invention relates to a method for
reducing and/or inhibiting the efflux of a compound, a polypeptide
or construct from cartilaginous tissue, wherein said method
comprises administering pharmaceutically active amount of at least
one polypeptide as described herein, a compound or construct as
described herein, or a composition as described herein to a person
in need thereof.
[0072] In an aspect, the present invention relates to a method for
inhibiting and/or blocking ADAMTS5 activity and/or MMP13 activity,
wherein said method comprises administering a pharmaceutically
active amount of at least one polypeptide as described herein, a
construct as described herein, or a composition as described herein
to a person in need thereof.
[0073] In an aspect, the present invention relates to the use of an
ISV as described herein, a polypeptide as described herein, a
construct as described herein, or a composition as described
herein, in the preparation of a pharmaceutical composition for
treating or preventing arthropathies and chondrodystrophies,
arthritic disease, such as osteoarthritis, rheumatoid arthritis,
gouty arthritis, psoriatic arthritis, traumatic rupture or
detachment, achondroplasia, costo-chondritis,
Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar
disk degeneration disease, degenerative joint disease, and
relapsing polychondritis.
[0074] Other aspects, advantages, applications and uses of the
polypeptides and compositions will become clear from the further
disclosure herein. Several documents are cited throughout the text
of this specification. Each of the documents cited herein
(including all patents, patent applications, scientific
publications, manufacturer's specifications, instructions, etc.),
whether supra or infra, are hereby incorporated by reference in
their entirety. Nothing herein is to be construed as an admission
that the invention is not entitled to antedate such disclosure by
virtue of prior invention.
FIGURE LEGENDS
[0075] FIG. 1: Examples of autoradiography images of sections of
rat joints 2 or 4 weeks post injection with .sup.125I-labeled
ALB26-CAP constructs. For each of the 2 weeks post injection
results and 4 weeks post injection results: Left panel:
histological section; Right panel: autoradiography.
[0076] FIG. 2: Representative MARG images. Specific MARG staining
appears as black grains on the images and is indicated by the
arrows.
[0077] FIG. 3: Inhibition of cartilage degradation by Nanobodies in
a rat MMT model using anti-MMP13-CAP Na nobody (C010100754) or an
anti-ADAMTS5-CAP Nanobody (C010100954). Treatment started 3 days
post-surgery by IA injection. Histopathology was performed at day
42 post surgery. The medial and total substantial cartilage
degeneration width was determined, as well as the percentage
reduction of cartilage degeneration. 20 animals were used per
group.
[0078] FIG. 4: Serum concentrations (mean concentration in ng/ml)
versus time after first dose (h) of polypeptides in osteoarthritis
rats and healthy rats, receiving a single intra-articular injection
of 400 .mu.g Nanobody per joint (right knee). Dots represent
individual concentrations in healthy animals; triangles represent
individual concentrations in OA animals; and lines represent mean
concentrations.
DETAILED DESCRIPTION
[0079] Unless indicated or defined otherwise, all terms used have
their usual meaning in the art, which will be clear to the skilled
person. Reference is for example made to the standard handbooks,
such as Sambrook et al. (Molecular Cloning: A Laboratory Manual
(2.sup.nd Ed.) Vols. 1-3, Cold Spring Harbor Laboratory Press,
1989), F. Ausubel et al. (Current protocols in molecular biology,
Green Publishing and Wiley Interscience, New York, 1987), Lewin
(Genes II, John Wiley & Sons, New York, N.Y., 1985), Old et al.
(Principles of Gene Manipulation: An Introduction to Genetic
Engineering (2.sup.nd edition) University of California Press,
Berkeley, Calif., 1981); Roitt et al. (Immunology (6.sup.th Ed.)
Mosby/Elsevier, Edinburgh, 2001), Roitt et al. (Roitt's Essential
Immunology (10.sup.th Ed.) Blackwell Publishing, U K, 2001), and
Janeway et al. (Immunobiology (6.sup.th Ed.) Garland Science
Publishing/Churchill Livingstone, New York, 2005), as well as to
the general background art cited herein.
[0080] Unless indicated otherwise, ail methods, steps, techniques
and manipulations that are not specifically described in detail can
be performed and have been performed in a manner known per se, as
will be clear to the skilled person. Reference is for example again
made to the standard handbooks and the general background art
mentioned herein and to the further references cited therein; as
well as to for example the following reviews Presta (Adv. Drug Day.
Rev. 58 (5-6): 640-56, 2006), Levin and Weiss (Mal. Biosyst. 2(1):
49-57, 2006), Irving et al. (J. Immunol. Methods 248(1-2): 31-45,
2001), Schmitz et al. (Placenta 21 Suppl. A: S106-12, 2000),
Gonzales et al. (Tumour Biol. 26(1): 31-43, 2005), which describe
techniques for protein engineering, such as affinity maturation and
other techniques for improving the specificity and other desired
properties of proteins such as immunoglobulins.
[0081] The term "sequence" as used herein (for example in terms
like "immunoglobulin sequence", "antibody sequence", "variable
domain sequence", "V.sub.HH sequence" or "protein sequence"),
should generally be understood to include both the relevant amino
acid sequence as well as nucleic acids or nucleotide sequences
encoding the same, unless the context requires a more limited
interpretation.
[0082] Amino acid sequences are interpreted to mean a single amino
acid or an unbranched sequence of two or more amino acids,
depending of the context. Nucleotide sequences are interpreted to
mean an unbranched sequence of 3 or more nucleotides.
[0083] Amino acids are those L-amino acids commonly found in
naturally occurring proteins, Amino acid residues will be indicated
according to the standard three-letter or one-letter amino acid
code. Reference is for instance made to Table A-2 on page 48 of WO
08/020079. Those amino acid sequences containing D-amino acids are
not intended to be embraced by this definition. Any amino acid
sequence that contains post-translationally modified amino acids
may be described as the amino acid sequence that is initially
translated using the symbols shown in this Table A-2 with the
modified positions; e.g., hydroxylations or glycosylations, but
these modifications shall not be shown explicitly in the amino acid
sequence. Any peptide or protein that can be expressed as sequence
modified linkages, cross links and end caps, non-peptidyl bonds,
etc., is embraced by this definition.
[0084] The terms "protein", "peptide", "protein/peptide", and
"polypeptide" are used interchangeably throughout the disclosure
and each has the same meaning for purposes of this disclosure. Each
term refers to an organic compound made of a linear chain of two or
more amino acids. The compound may have ten or more amino acids;
twenty-five or more amino acids; fifty or more amino acids; one
hundred or more amino acids, two hundred or more amino acids, and
even three hundred or more amino acids. The skilled artisan will
appreciate that polypeptides generally comprise fewer amino acids
than proteins, although there is no art-recognized cut-off point of
the number of amino acids that distinguish a polypeptide from a
protein; that polypeptides may be made by chemical synthesis or
recombinant methods; and that proteins are generally made in vitro
or in vivo by recombinant methods, all as known in the art.
[0085] A nucleic acid or amino acid sequence is considered to be
"(in) (essentially) isolated (form)"--for example, compared to the
reaction medium or cultivation medium from which it has been
obtained-when it has been separated from at least one other
component with which it is usually associated in said source or
medium, such as another nucleic acid, another protein/polypeptide,
another biological component or macromolecule or at least one
contaminant, impurity or minor component. In particular, a nucleic
acid or amino acid sequence is considered "(essentially) isolated"
when it has been purified at least 2-fold, in particular at least
10-fold, more in particular at least 100-fold, and up to 1000-fold
or more. A nucleic acid or amino acid that is "in (essentially)
isolated form" is preferably essentially homogeneous, as determined
by using a suitable technique, such as a suitable chromatographical
technique, such as polyacrylamide-gel electrophoresis.
[0086] When a nucleotide sequence or amino acid sequence is said to
"comprise" another nucleotide sequence or amino acid sequence,
respectively, or to "essentially consist of" another nucleotide
sequence or amino acid sequence, this may mean that the latter
nucleotide sequence or amino acid sequence has been incorporated
into the first mentioned nucleotide sequence or amino acid
sequence, respectively, but more usually this generally means that
the first mentioned nucleotide sequence or amino acid sequence
comprises within its sequence a stretch of nucleotides or amino
acid residues, respectively, that has the same nucleotide sequence
or amino acid sequence, respectively, as the latter sequence,
irrespective of how the first mentioned sequence has actually been
generated or obtained (which may for example be by any suitable
method described herein). By means of a non-limiting example, when
a polypeptide of the invention is said to comprise an
immunoglobulin single variable domain ("ISV"), this may mean that
said immunoglobulin single variable domain sequence has been
incorporated into the sequence of the polypeptide of the invention,
but more usually this generally means that the polypeptide of the
invention contains within its sequence the sequence of the ISVs
irrespective of how said polypeptide of the invention has been
generated or obtained. Also, when a nucleic acid or nucleotide
sequence is said to comprise another nucleotide sequence, the first
mentioned nucleic acid or nucleotide sequence is preferably such
that, when it is expressed into an expression product (e.g. a
polypeptide), the amino acid sequence encoded by the latter
nucleotide sequence forms part of said expression product (in other
words, that the latter nucleotide sequence is in the same reading
frame as the first mentioned, larger nucleic acid or nucleotide
sequence). Also, when a construct of the invention is said to
comprise a polypeptide or ISV, this may mean that said construct at
least encompasses said polypeptide or ISV, respectively, but more
usually this means that said construct encompasses groups, residues
(e.g. amino acid residues), moieties and/or binding units in
addition to said polypeptide or ISV, irrespective of how said
polypeptide or ISV is connected to said groups, residues (e.g.
amino acid residues), moieties and/or binding units and
irrespective of how said construct has been generated or
obtained.
[0087] By "essentially consist of" is meant that the ISV used in
the method of the invention either is exactly the same as the ISV
of the invention or corresponds to the ISV of the invention which
has a limited number of amino acid residues, such as 1-20 amino
acid residues, for example 1-10 amino acid residues and preferably
1-6 amino acid residues, such as 1, 2, 3, 4, 5 or 6 amino acid
residues, added at the amino-terminal end, at the carboxy-terminal
end, or at both the amino terminal end and the carboxy-terminal end
of the ISV.
[0088] For the purposes of comparing two or more nucleotide
sequences, the percentage of "sequence identity" between a first
nucleotide sequence and a second nucleotide sequence may be
calculated by dividing [the number of nucleotides in the first
nucleotide sequence that are identical to the nucleotides at the
corresponding positions in the second nucleotide sequence] by [the
total number of nucleotides in the first nucleotide sequence] and
multiplying by [100%], in which each deletion, insertion,
substitution or addition of a nucleotide in the second nucleotide
sequence--compared to the first nucleotide sequence--is considered
as a difference at a single nucleotide (position). Alternatively,
the degree of sequence identity between two or more nucleotide
sequences may be calculated using a known computer algorithm for
sequence alignment such as, e.g. NCBI Blast v2.0, using standard
settings. Some other techniques, computer algorithms and settings
for determining the degree of sequence identity are for example
described in WO 04/037999, EP 0967284, EP 1085089, WO 00/55318, WO
00/78972, WO 98/49185 and GB 2357768. Usually, for the purpose of
determining the percentage of "sequence identity" between two
nucleotide sequences in accordance with the calculation method
outlined hereinabove, the nucleotide sequence with the greatest
number of nucleotides will be taken as the "first" nucleotide
sequence, and the other nucleotide sequence will be taken as the
"second" nucleotide sequence.
[0089] For the purposes of comparing two or more amino acid
sequences, the percentage of "sequence identity" between a first
amino acid sequence and a second amino acid sequence (also referred
to herein as "amino acid identity") may be calculated by dividing
[the number of amino acid residues in the first amino acid sequence
that are identical to the amino acid residues at the corresponding
positions in the second amino acid sequence] by [the total number
of amino acid residues in the first amino acid sequence] and
multiplying by [100%], in which each deletion, insertion,
substitution or addition of an amino acid residue in the second
amino acid sequence--compared to the first amino acid sequence--is
considered as a difference at a single amino acid residue
(position), i.e., as an "amino acid difference" as defined herein.
Alternatively, the degree of sequence identity between two amino
acid sequences may be calculated using a known computer algorithm,
such as those mentioned above for determining the degree of
sequence identity for nucleotide sequences, again using standard
settings. Usually, for the purpose of determining the percentage of
"sequence identity" between two amino acid sequences in accordance
with the calculation method outlined hereinabove, the amino acid
sequence with the greatest number of amino acid residues will be
taken as the "first" amino acid sequence, and the other amino acid
sequence will be taken as the "second" amino acid sequence.
[0090] Also, in determining the degree of sequence identity between
two amino acid sequences, the skilled person may take into account
so-called "conservative" amino acid substitutions, which can
generally be described as amino acid substitutions in which an
amino acid residue is replaced with another amino acid residue of
similar chemical structure and which has little or essentially no
influence on the function, activity or other biological properties
of the polypeptide. Such conservative amino acid substitutions are
well known in the art, for example from WO 04/037999, GB 335768, WO
98/49185, WO 00/46383 and WO 01/09300; and (preferred) types and/or
combinations of such substitutions may be selected on the basis of
the pertinent teachings from, e.g. WO 04/037999 or e.g. WO 98/49185
and from the further references cited therein.
[0091] Such conservative substitutions preferably are substitutions
in which one amino acid within the following groups (a)-(e) is
substituted by another amino acid residue within the same group:
(a) small aliphatic, nonpolar or slightly polar residues: Ala, Ser,
Thr, Pro and Gly; (b) polar, negatively charged residues and their
(uncharged) amides: Asp, Asn, Glu and Gin; (c) polar, positively
charged residues: His, Arg and Lys; (d) large aliphatic, nonpolar
residues: Met, Leu, Ile, Val and Cys; and (e) aromatic residues:
Phe, Tyr and Trp. Particularly preferred conservative substitutions
are as follows: Ala into Gly or into Ser; Arg into Lys; Asn into
Gin or into His; Asp into Glu; Cys into Ser; Gln into Asn; Glu into
Asp; Gly into Ala or into Pro; His into Asn or into Gin; Ile into
Leu or into Val; Leu into Ile or into Val; Lys into Arg, into Gin
or into Glu; Met into Leu, into Tyr or into Ile; Phe into Met, into
Leu or into Tyr; Ser into Thr; Thr into Ser; Trp into Tyr; Tyr into
Trp; and/or Phe into Val, into lie or into Leu.
[0092] Any amino acid substitutions applied to the polypeptides
described herein may also be based on the analysis of the
frequencies of amino acid variations between homologous proteins of
different species such as, for instance, developed by Schulz et al.
("Principles of Protein Structure", Springer-Verlag, 1978), on the
analyses of structure forming potentials developed by, e.g. Chou
and Fasman (Biochemistry 13: 211, 1974; Adv. Enzymol., 47: 45-149,
1978), and on the analysis of hydrophobicity patterns in proteins
developed by e.g. Eisenberg et al. (Proc. Natl. Acad Sci. USA 81:
140-144, 1984), Kyte and Doolittle (J. Molec. Biol. 157: 105-132,
1981) or Goldman et al. (Ann. Rev. Biophys. Chem. 15: 321-353,
1986), all incorporated herein in their entirety by reference.
Information on the primary, secondary and tertiary structure of
Nanobodies is given in the description herein and in the general
background art cited above. Also, for this purpose, the crystal
structure of a V.sub.HH domain from a llama is for example given by
Desmyter et al. (Nature Structural Biology, 3: 803, 1996), Spinelli
et al. (Natural Structural Biology, 3: 752-757, 1996) or Decanniere
et al, (Structure, 7 (4): 361, 1999). Further information about
some of the amino acid residues that in conventional V.sub.H
domains form the V.sub.H/V.sub.L interface and potential camelizing
substitutions on these positions can be found in the prior art
cited above.
[0093] Amino acid sequences and nucleic acid sequences are said to
be "exactly the same" if they have 100% sequence identity (as
defined herein) over their entire length.
[0094] When comparing two amino acid sequences, the term "amino
acid(s) difference" refers to an insertion, deletion or
substitution of a single amino acid residue on a position of the
first sequence, compared to the second sequence; it being
understood that two amino acid sequences can contain one, two or
more such amino acid differences. More particularly, in the amino
acid sequences and/or polypeptides of the present invention, the
term "amino acid(s) difference" refers to an insertion, deletion or
substitution of a single amino acid residue on a position of the
CDR sequence specified in b), d) or f), compared to the CDR
sequence of respectively a), c) or e); it being understood that the
CDR sequence of b), d) and f) can contain one, two, three, four or
maximal five such amino acid differences compared to the CDR
sequence of respectively a), c) or e).
[0095] The "amino acid(s) difference" can be any one, two, three,
four or maximal five substitutions, deletions or insertions, or any
combination thereof, that either improve the properties of the
Aggrecan binder of the invention, such as the polypeptide of the
invention or that at least do not detract too much from the desired
properties or from the balance or combination of desired properties
of the Aggrecan binder of the invention, such as the polypeptide of
the invention. In this respect, the resulting Aggrecan binder of
the invention, such as the polypeptide of the invention should at
least bind Aggrecan with the same, about the same, or a higher
affinity compared to the polypeptide comprising the one or more CDR
sequences without the one, two, three, four or maximal five
substitutions, deletions or insertions, said affinity as measured
by surface plasmon resonance (SPR).
[0096] In this respect, the amino acid sequence of the CDRs
according to b), d) and/or f) may be an amino acid sequence that is
derived from an amino acid sequence according to a), c) and/or e)
respectively by means of affinity maturation using one or more
techniques of affinity maturation known per se.
[0097] For example, and depending on the host organism used to
express the polypeptide of the invention, such deletions and/or
substitutions may be designed in such a way that one or more sites
for post-translational modification (such as one or more
glycosylation sites) are removed, as will be within the ability of
the person skilled in the art.
[0098] A "Na nobody family", "V.sub.HH family" or "family" as used
in the present specification refers to a group of Nanobodies and/or
V.sub.HH sequences that have identical lengths (i.e. they have the
same number of amino acids within their sequence) and of which the
amino acid sequence between position 8 and position 106 (according
to Kabat numbering) has an amino acid sequence identity of 89% or
more.
[0099] The terms "epitope" and "antigenic determinant", which can
be used interchangeably, refer to the part of a macromolecule, such
as a polypeptide or protein that is recognized by antigen-binding
molecules, such as immunoglobulins, conventional antibodies, ISVs
and/or polypeptides of the invention, and more particularly by the
antigen-binding site of said molecules. Epitopes define the minimum
binding site for an immunoglobulin, and thus represent the target
of specificity of an immunoglobulin.
[0100] The part of an antigen-binding molecule (such as an
immunoglobulin, a conventional antibody, an ISV and/or a
polypeptide of the invention) that recognizes the epitope is called
a "paratope".
[0101] An amino acid sequence (such as an ISV, an antibody, a
polypeptide of the invention, or generally an antigen binding
protein or polypeptide or a fragment thereof) that can "bind to" or
"specifically bind to", that "has affinity for" and/or that "has
specificity for" a certain epitope, antigen or protein (or for at
least one part, fragment or epitope thereof) is said to be
"against" or "directed against" said epitope, antigen or protein or
is a "binding" molecule with respect to such epitope, antigen or
protein, or is said to be "anti"-epitope, "anti"-antigen or
"anti"-protein (e.g., "anti"-Aggrecan).
[0102] The affinity denotes the strength or stability of a
molecular interaction. The affinity is commonly given as the
K.sub.D, or dissociation constant, which has units of mol/liter (or
M). The affinity can also be expressed as an association constant,
K.sub.A, which equals 1/K.sub.D and has units of (mol/liter).sup.-1
(or M.sup.-1). In the present specification, the stability of the
interaction between two molecules will mainly be expressed in terms
of the K.sub.D value of their interaction; it being clear to the
skilled person that in view of the relation K.sub.A=1/K.sub.D,
specifying the strength of molecular interaction by its K.sub.D
value can also be used to calculate the corresponding K.sub.A
value. The K-value characterizes the strength of a molecular
interaction also in a thermodynamic sense as it is related to the
change of free energy (DG) of binding by the well-known relation
DG=RTIn(K.sub.D) (equivalently DG=-RTIn(K.sub.A)), where R equals
the gas constant, T equals the absolute temperature and In denotes
the natural logarithm.
[0103] The K.sub.D for biological interactions which are considered
meaningful (e.g. specific) are typically in the range of 10.sup.-12
M (0.001 nM) to 10.sup.-5M (10000 nM). The stronger an interaction
is, the lower is its K.sub.D.
[0104] The K.sub.D can also be expressed as the ratio of the
dissociation rate constant of a complex, denoted as k.sub.off, to
the rate of its association, denoted k.sub.on (so that
K.sub.D=k.sub.off/k.sub.on and K.sub.A=k.sub.on/k.sub.off), The
off-rate k.sub.off has unit s.sup.-1 (where s is the SI unit
notation of second). The on-rate k.sub.on has units M.sup.-1
s.sup.-1. The on-rate may vary between 10.sup.2 M.sup.-1 s.sup.-1
to about 10.sup.7 M.sup.-1 s.sup.-1, approaching the
diffusion-limited association rate constant for bimolecular
interactions. The off-rate is related to the half-life of a given
molecular interaction by the relation t.sub.1/2=In(2)/k.sub.off.
The off-rate may vary between 10.sup.-6 s.sup.-1 (near irreversible
complex with a t.sub.in of multiple days) to 1 s.sup.-1
(t.sub.1/2=0.69 s).
[0105] Specific binding of an antigen-binding protein, such as an
ISVD, to an antigen or antigenic determinant can be determined in
any suitable manner known per se, including, for example,
saturation binding assays and/or competitive binding assays, such
as radio-immunoassays (RIA), enzyme immunoassays (EIA) and sandwich
competition assays, and the different variants thereof known per se
in the art; as well as the other techniques mentioned herein.
[0106] The affinity of a molecular interaction between two
molecules can be measured via different techniques known per se,
such as the well-known surface plasmon resonance (SPR) biosensor
technique (see for example Ober et al, 2001, Intern. Immunology 13:
1551-1559) where one molecule is immobilized on the biosensor chip
and the other molecule is passed over the immobilized molecule
under flow conditions yielding k.sub.on, k.sub.off measurements and
hence K.sub.D (or K.sub.A) values. This can for example be
performed using the well-known BIACORE.RTM. instruments (Pharmacia
Biosensor AB, Uppsala, Sweden). Kinetic Exclusion Assay
(KINEXA.RTM.) (Drake et al. 2004, Analytical Biochemistry 328:
35-43) measures binding events in solution without labeling of the
binding partners and is based upon kinetically excluding the
dissociation of a complex. In-solution affinity analysis can also
be performed using the GYROLAB.RTM. immunoassay system, which
provides a platform for automated bioanalysis and rapid sample
turnaround (Fraley et al. 2013, Bioanalysis 5: 1765-74), or
ELISA.
[0107] It will also be clear to the skilled person that the
measured K.sub.0 may correspond to the apparent K.sub.0 if the
measuring process somehow influences the intrinsic binding affinity
of the implied molecules for example by artifacts related to the
coating on the biosensor of one molecule. Also, an apparent K.sub.D
may be measured if one molecule contains more than one recognition
site for the other molecule. In such situation the measured
affinity may be affected by the avidity of the interaction by the
two molecules. In particular, the accurate measurement of K.sub.D
may be quite labor-intensive and as a consequence, often apparent
K.sub.D values are determined to assess the binding strength of two
molecules. It should be noted that as long as all measurements are
made in a consistent way (e.g. keeping the assay conditions
unchanged) apparent K.sub.D measurements can be used as an
approximation of the true K.sub.D and hence in the present document
K.sub.D and apparent K.sub.D should be treated with equal
importance or relevance.
[0108] The term "specificity" refers to the number of different
types of antigens or antigenic determinants to which a particular
antigen-binding molecule or antigen-binding protein (such as an
ISVD or polypeptide of the invention) molecule can bind. The
specificity of an antigen-binding protein can be determined based
on affinity and/or avidity, for instance as described on pages
53-56 of WO 08/020079 (incorporated herein by reference), which
also describes some preferred techniques for measuring binding
between an antigen-binding molecule (such as a polypeptide or ISVD
of the invention) and the pertinent antigen. Typically,
antigen-binding proteins (such as the ISVDs and/or polypeptides of
the invention) will bind to their antigen with a dissociation
constant (K.sub.D) of 10.sup.-5 to 10.sup.-12 moles/liter or less,
and preferably 10.sup.-7 to 10.sup.-12 moles/liter or less and more
preferably 10.sup.-8 to 10.sup.-12 moles/liter (i.e., with an
association constant (K.sub.A) of 10.sup.5 to 10.sup.12 liter/moles
or more, and preferably 10.sup.7 to 10.sup.12 liter/moles or more
and more preferably 10.sup.8 to 10.sup.12 liter/moles). Any K.sub.D
value greater than 10.sup.-4 mol/liter (or any K.sub.a value lower
than 10.sup.4 liter/mol) is generally considered to indicate
non-specific binding. Preferably, a monovalent ISVD of the
invention will bind to the desired antigen with an affinity less
than 500 nM, preferably less than 200 nM, more preferably less than
10 nM, such as less than 500 pM, such as e.g., between 10 and 5 pM
or less. Reference is also made to paragraph n) on pages 53-56 of
WO 08/020079.
[0109] An ISV and/or polypeptide is said to be "specific for" a
(first) target or antigen compared to another (second) target or
antigen when it binds to the first antigen with an affinity (as
described above, and suitably expressed as a K.sub.D value, K.sub.A
value, K.sub.off rate and/or K.sub.on rate) that is at least 10
times, such as at least 100 times, and preferably at least 1000
times or more better than the affinity with which the ISVD and/or
polypeptide binds to the second target or antigen. For example, the
ISVD and/or polypeptide may bind to the first target or antigen
with a K.sub.D value that is at least 10 times less, such as at
least 100 times less, and preferably at least 1000 times less or
even less than that, than the K.sub.D with which said ISV and/or
polypeptide binds to the second target or antigen. Preferably, when
an ISV and/or polypeptide is "specific for" a first target or
antigen compared to a second target or antigen, it is directed
against (as defined herein) said first target or antigen, but not
directed against said second target or antigen.
[0110] Specific binding of an antigen-binding protein to an antigen
or antigenic determinant can be determined in any suitable manner
known per se, including, for example, saturation binding assays
and/or competitive binding assays, such as radioimmunoassays (RIA),
enzyme immunoassays (EIA) and the different variants thereof known
in the art; as well as the other techniques mentioned herein.
[0111] A preferred approach that may be used to assess affinity is
the 2-step ELISA (Enzyme-Linked Immunosorbent Assay) procedure of
Friguet et al. 1985 (J. Immunol. Methods 77: 305-19). This method
establishes a solution phase binding equilibrium measurement and
avoids possible artifacts relating to adsorption of one of the
molecules on a support such as plastic. As will be clear to the
skilled person, the dissociation constant may be the actual or
apparent dissociation constant. Methods for determining the
dissociation constant will be clear to the skilled person, and for
example include the techniques mentioned on pages 53-56 of WO
08/020079.
[0112] Finally, it should be noted that in many situations the
experienced scientist may judge it to be convenient to determine
the binding affinity relative to some reference molecule. For
example, to assess the binding strength between molecules A and B,
one may e.g, use a reference molecule C that is known to bind to B
and that is suitably labelled with a fluorophore or chromophore
group or other chemical moiety, such as biotin for easy detection
in an ELISA or FACS (Fluorescent activated cell sorting) or other
format (the fluorophore for fluorescence detection, the chromophore
for light absorption detection, the biotin for
streptavidin-mediated ELISA detection). Typically, the reference
molecule C is kept at a fixed concentration and the concentration
of A is varied for a given concentration or amount of B. As a
result an IC.sub.50 value is obtained corresponding to the
concentration of A at which the signal measured for C in absence of
A is halved. Provided K.sub.D ref, the K.sub.D of the reference
molecule, is known, as well as the total concentration c.sub.ref of
the reference molecule, the apparent K.sub.D for the interaction
A-B can be obtained from following formula:
K.sub.D=IC.sub.50/(1+C.sub.ref/K.sub.Dref). Note that if
c.sub.ref<<K.sub.D ref, K.sub.D.apprxeq.IC.sub.50. Provided
the measurement of the IC.sub.50 is performed in a consistent way
(e.g. keeping c.sub.ref fixed) for the binders that are compared,
the difference in strength or stability of a molecular interaction
can be assessed by comparing the IC.sub.50 and this measurement is
judged as equivalent to K.sub.D or to apparent K.sub.D throughout
this text.
[0113] The half maximal inhibitory concentration (IC.sub.50) can
also be a measure of the effectiveness of a compound in inhibiting
a biological or biochemical function, e.g. a pharmacological
effect. This quantitative measure indicates how much of the
polypeptide or ISV (e.g. a Nanobody) is needed to inhibit a given
biological process (or component of a process, i.e. an enzyme,
cell, cell receptor, chemotaxis, anaplasia, metastasis,
invasiveness, etc.) by half. In other words, it is the half maximal
(50%) inhibitory concentration (IC) of a substance (50% IC, or
IC.sub.50). IC.sub.50 values can be calculated for a given
antagonist such as the polypeptide or ISV (e.g. a Nanobody) of the
invention by determining the concentration needed to inhibit half
of the maximum biological response of the agonist. The K.sub.D of a
drug can be determined by constructing a dose-response curve and
examining the effect of different concentrations of antagonist such
as the polypeptide or ISV (e.g. a Nanobody) of the invention on
reversing agonist activity.
[0114] The term half maximal effective concentration (EC.sub.50)
refers to the concentration of a compound which induces a response
halfway between the baseline and maximum after a specified exposure
time. In the present context it is used as a measure of a
polypeptide, ISV (e.g. a Nanobody) its potency. The EC.sub.50 of a
graded dose response curve represents the concentration of a
compound where 50% of its maximal effect is observed. Concentration
is preferably expressed in molar units.
[0115] In biological systems, small changes in ligand concentration
typically result in rapid changes in response, following a
sigmoidal function. The inflection point at which the increase in
response with increasing ligand concentration begins to slow is the
EC.sub.50. This can be determined mathematically by derivation of
the best-fit line. Relying on a graph for estimation is convenient
in most cases. In case the EC.sub.50 is provided in the examples
section, the experiments were designed to reflect the K.sub.D as
accurate as possible. In other words, the EC.sub.50 values may then
be considered as K.sub.D values. The term "average K.sub.D" relates
to the average K.sub.D value obtained in at least 1, but preferably
more than 1, such as at least 2 experiments. The term "average"
refers to the mathematical term "average" (sums of data divided by
the number of items in the data).
[0116] It is also related to IC.sub.50 which is a measure of a
compound its inhibition (50% inhibition). For competition binding
assays and functional antagonist assays IC.sub.50 is the most
common summary measure of the dose-response curve. For
agonist/stimulator assays the most common summary measure is the
EC.sub.50.
[0117] The inhibition constant (Ki) is an indication of how potent
an inhibitor is; it is the concentration required to produce half
maximum inhibition. Unlike IC.sub.50, which can change depending on
the experimental conditions, Ki is an absolute value and is often
referred to as the inhibition constant of a drug. The inhibition
constant K.sub.i can be calculated by using the Cheng-Prusoff
equation:
K i = IC .times. .times. 50 [ L ] K D + 1 ##EQU00001##
in which [L] is the fixed concentration of the ligand.
[0118] An ISV and/or polypeptide is said to be "specific for" a
(first) target or antigen compared to another (second) target or
antigen when it binds to the first antigen with an affinity (as
described above, and suitably expressed as a K.sub.D value, K.sub.A
value, K.sub.off rate and/or K.sub.on rate) that is at least 10
times, such as at least 100 times, and preferably at least 1000
times or more better than the affinity with which the ISV and/or
polypeptide binds to the second target or antigen. For example, the
ISV and/or polypeptide may bind to the first target or antigen with
a K.sub.D value that is at least 10 times less, such as at least
100 times less, and preferably at least 1000 times less or even
less than that, than the K.sub.o with which said ISV and/or
polypeptide binds to the second target or antigen. Preferably, when
an ISV and/or polypeptide is "specific for" a first target or
antigen compared to a second target or antigen, it is directed
against (as defined herein) said first target or antigen, but not
directed against said second target or antigen.
[0119] The terms "(cross)-block", "(cross)-blocked",
"(cross)-blocking", "competitive binding", "(cross)-compete",
"(cross)-competing" and "(cross)-competition" are used
interchangeably herein to mean the ability of an immunoglobulin,
antibody, ISV, polypeptide or other binding agent to interfere with
the binding of other immunoglobulins, antibodies, ISVs,
polypeptides or binding agents to a given target. The extent to
which an immunoglobulin, antibody, ISV, polypeptide or other
binding agent is able to interfere with the binding of another to
the target, and therefore whether it can be said to cross-block
according to the invention, can be determined using competition
binding assays, which are common in the art. Particularly suitable
quantitative cross-blocking assays include an ELISA and a
fluorescence-activated cell sorting (FACS) binding assay with
Aggrecan expressed on cells. In a FACS set up, the extent of
(cross)-blocking can be measured by the (reduced) channel
fluorescence.
[0120] Methods for determining whether an immunoglobulin, antibody,
ISV, polypeptide or other binding agent directed against a target
(cross)-blocks, is capable of (cross)-blocking, competitively binds
or is (cross)-competitive as defined herein are described e.g. in
Xiao-Chi Jia et al. (Journal of Immunological Methods 288: 91-98,
2004), Miller et al. (Journal of Immunological Methods 365:
118-125, 2011) and/or the methods described herein (see e.g,
Example 2.3).
[0121] An amino acid sequence is said to be "cross-reactive" for
two different antigens or antigenic determinants (such as e.g.,
Aggrecan from different species of mammal, such as e.g., human
Aggrecan, dog Aggrecan, bovine Aggrecan, rat Aggrecan, pig
Aggrecan, mouse Aggrecan, rabbit Aggrecan, cynomolgus Aggrecan,
and/or rhesus Aggrecan) if it is specific for (as defined herein)
these different antigens or antigenic determinants.
[0122] In the context of the present invention, "modulating" or "to
modulate" generally means reducing or inhibiting an activity of a
member of the serine protease family, cathepsins, matrix
metallo-proteinases (MMPs)/Matrixins or A Disintegrin and
Metalloproteinase with Thrombospondin motifs (ADAMTS), preferably
MMP8, MMP13, MMP19, MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4
(Aggrecanase-1), ADAMTS11 and/or pro-inflammatory cytokines, such
as e.g. interleukin-1a, and -.beta., interleukin-6 and TNF-.alpha.,
by an ISV, polypeptide or construct of the invention, as measured
using a suitable in vitro, cellular, ex vivo or in vivo assay (such
as those mentioned herein). In particular, "modulating" or "to
modulate" may mean either reducing or inhibiting the activity of
the aforementioned members as measured using a suitable in vitro,
cellular, ex vivo or in vivo assay (such as those mentioned
herein), by at least 1%, preferably at least 5%, such as at least
10% or at least 25%, for example by at least 50%, at least 60%, at
least 70%, at least 80%, or 90% or more, compared to the activity
of the aforementioned members in the same assay under the same
conditions but without the presence of the immunoglobulin or
polypeptide of the invention.
[0123] In the context of the present invention, "enhancing" or "to
enhance" generally means increasing, potentiating or stimulating
the activity of the polypeptides or constructs of the invention, as
measured using a suitable in vitro, cellular, ex vivo or in vivo
assay (such as those mentioned herein). In particular, increasing
or enhancing the activity of a polypeptide or construct of the
invention, as measured using a suitable in vitro, cellular, ex vivo
or in viva assay (such as those mentioned herein), by at least 5%,
preferably at least 10%, at least 15%, at least 20%, at least 25%,
at least 30%, at least 35%, at least 40%, at least 45%, at least
50%, at least 55%, at least 60%, at least 65%, at least 70%, at
least 75%, at least 80%, at least 85%, at least 90%, at least 95%
or more, such as 100%, compared to the activity of the construct or
polypeptide in the same assay under the same conditions but without
the presence of the Aggrecan binder, e.g. ISV binding Aggrecan, of
the invention.
[0124] A "synergistic effect" of two compounds is one in which the
effect of the combination of the two agents is greater than the sum
of their individual effects and is preferably statistically
different from the controls and the single drugs.
[0125] The term "potency" of an ISV or polypeptide of the
invention, as used herein, is a function of the amount of the ISV
or polypeptide of the invention required for its specific effect,
such as, e.g. penetration into the cartilage, specific binding to
Aggrecan and/or cartilage retention, to occur. It can be measured
simply by the methods known to the person skilled in the art, and
for instance as used in the examples section.
[0126] In contrast, the "efficacy" of the ISV or polypeptide of the
invention measures the maximum strength of the effect itself, at
saturating ISV or polypeptide concentrations. Efficacy indicates
the maximum response achievable from the ISV or polypeptide of the
invention. It refers to the ability of an ISV or polypeptide to
produce the desired (therapeutic) effect, such as, e.g. binding to
Aggrecan or retention to Aggrecan, and/or inhibiting an activity of
an ADAMTS family member or MMP family member.
[0127] The "half-life" of a polypeptide or construct of the
invention refers to the time taken for the serum concentration of
the construct or polypeptide to be reduced by 50%, in vivo, for
example due to degradation of the construct or polypeptide and/or
clearance or sequestration of the construct or polypeptide by
natural mechanisms, see e.g. paragraph o) on page 57 of WO
08/020079. The in vivo half-life of a construct or polypeptide of
the invention can be determined in any manner known per se, such as
by pharmacokinetic analysis. Suitable techniques will be clear to
the person skilled in the art, and may for example generally be as
described in paragraph o) on page 57 of WO 08/020079. As also
mentioned in paragraph o) on page 57 of WO 08/020079, the half-life
can be expressed using parameters such as the t1/2-alpha, t1/2-beta
and the area under the curve (AUC). Reference is for example made
to the standard handbooks, such as Kenneth et al. (Chemical
Stability of Pharmaceuticals: A Handbook for Pharmacists, John
Wiley & Sons Inc, 1986) and M Gibaldi and D Perron
("Pharmacokinetics", Marcel Dekker, 2.sup.nd Rev. Edition, 1982).
The terms "increase in half-life" or "increased half-life" refer to
an increase in the t1/2-beta, either with or without an increase in
the t1/2-alpha and/or the AUC or both, for instance as described in
paragraph o) on page 57 of WO 08/020079.
[0128] Unless indicated otherwise, the terms "immunoglobulin" and
"immunoglobulin sequence"--whether used herein to refer to a heavy
chain antibody or to a conventional 4-chain antibody--is used as a
general term to include both the full-size antibody, the individual
chains thereof, as well as all parts, domains or fragments thereof
(including but not limited to antigen-binding domains or fragments
such as V.sub.HH domains or V.sub.H/V.sub.L domains,
respectively).
[0129] The term "domain" (of a polypeptide or protein) as used
herein refers to a folded protein structure which has the ability
to retain its tertiary structure independently of the rest of the
protein. Generally, domains are responsible for discrete functional
properties of proteins, and in many cases may be added, removed or
transferred to other proteins without loss of function of the
remainder of the protein and/or of the domain.
[0130] The term "immunoglobulin domain" as used herein refers to a
globular region of an antibody chain (such as e.g., a chain of a
conventional 4-chain antibody or of a heavy chain antibody), or to
a polypeptide that essentially consists of such a globular region.
Immunoglobulin domains are characterized in that they retain the
immunoglobulin fold characteristic of antibody molecules, which
consists of a two-layer sandwich of about seven antiparallel
beta-strands arranged in two beta-sheets, optionally stabilized by
a conserved disulphide bond.
[0131] The term "immunoglobulin variable domain" as used herein
means an immunoglobulin domain essentially consisting of four
"framework regions" which are referred to in the art and herein
below as "framework region 1" or "FR1"; as "framework region 2" or
"FR2"; as "framework region 3" or "FR3"; and as "framework region
4" or "FR4", respectively; which framework regions are interrupted
by three "complementarity determining regions" or "CDRs", which are
referred to in the art and herein below as "complementarity
determining region 1" or "CDR1"; as "complementarity determining
region 2" or "CDR2"; and as "complementarity determining region 3"
or "CDR3", respectively. Thus, the general structure or sequence of
an immunoglobulin variable domain can be indicated as follows:
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. It is the immunoglobulin variable
domain(s) that confer specificity to an antibody for the antigen by
carrying the antigen-binding site, and in particular CDR1, CDR2
and/or CDR3.
[0132] The term "immunoglobulin single variable domain" ("ISV" or
ISVD''), interchangeably used with "single variable domain",
defines molecules wherein the antigen binding site is present on,
and formed by, a single immunoglobulin domain. This sets ISVs apart
from "conventional" immunoglobulins or their fragments, wherein two
immunoglobulin domains, in particular two variable domains,
interact to form an antigen binding site. Typically, in
conventional immunoglobulins, a heavy chain variable domain (VH)
and a light chain variable domain (VI) interact to form an antigen
binding site. In this case, the complementarity determining regions
(CDRs) of both VH and VL will contribute to the antigen binding
site, i.e. a total of 6 CDRs will be involved in antigen binding
site formation.
[0133] In view of the above definition, the antigen-binding domain
of a conventional 4-chain antibody (such as an IgG, IgM, IgA, IgD
or IgE molecule; known in the art) or of a Fab fragment, a F(ab')2
fragment, an Fv fragment such as a disulphide linked Fv or a scFv
fragment, or a diabody (all known in the art) derived from such
conventional 4-chain antibody, would normally not be regarded as an
ISV, as, in these cases, binding to the respective epitope of an
antigen would normally not occur by one (single) immunoglobulin
domain but by a pair of (associating) immunoglobulin domains such
as light and heavy chain variable domains, i.e., by a VH-VL pair of
immunoglobulin domains, which jointly bind to an epitope of the
respective antigen.
[0134] In contrast, ISVs are capable of specifically binding to an
epitope of the antigen without pairing with an additional
immunoglobulin variable domain. The binding site of an ISV is
formed by a single VH/VHH or VL domain. Hence, the antigen binding
site of an ISV is formed by no more than three CDRs.
[0135] As such, the single variable domain may be a light chain
variable domain sequence (e.g., a VL-sequence) or a suitable
fragment thereof; or a heavy chain variable domain sequence (e.g.,
a VH-sequence or VHH sequence) or a suitable fragment thereof; as
long as it is capable of forming a single antigen binding unit
(i.e., a functional antigen binding unit that essentially consists
of the single variable domain, such that the single antigen binding
domain does not need to interact with another variable domain to
form a functional antigen binding unit).
[0136] In one embodiment of the invention, the ISVs are heavy chain
variable domain sequences (e.g., a VH-sequence); more specifically,
the ISVs can be heavy chain variable domain sequences that are
derived from a conventional four-chain antibody or heavy chain
variable domain sequences that are derived from a heavy chain
antibody.
[0137] For example, the ISV may be a (single) domain antibody, an
amino acid that is suitable for use as a (single) domain antibody,
an immunoglobulin that is suitable for use as a (single) domain
antibody, a "dAb" or sdAb, or an amino acid that is suitable for
use as a dAb, or a Nanobody (as defined herein, and including but
not limited to a VHH); a humanized VHH sequence, a camelized VH
sequence, a VHH sequence that has been obtained by affinity
maturation, other single variable domains, an immunoglobulin single
heavy chain variable domain or any suitable fragment of any one
thereof.
[0138] In particular, the ISV may be a Nanobody.RTM. (as defined
herein) or a suitable fragment thereof. [Note: Nanobody.RTM. and
Nanobodies.RTM. are registered trademarks of Ablynx N.V.] For a
general description of Nanobodies, reference is made to the further
description below, as well as to the prior art cited herein, such
as e.g. described in WO 08/020079 (page 16).
[0139] "VHH domains", also known as VHHs, V.sub.HH domains, VHH
antibody fragments, and VHH antibodies, have originally been
described as the antigen binding immunoglobulin (variable) domain
of "heavy chain antibodies" (i.e., of "antibodies devoid of light
chains"; Hamers-Casterman et al. Nature 363: 446-448, 1993). The
term "VHH domain" has been chosen in order to distinguish these
variable domains from the heavy chain variable domains that are
present in conventional 4-chain antibodies (which are referred to
herein as "V.sub.H domains" or "VH domains") and from the light
chain variable domains that are present in conventional 4-chain
antibodies (which are referred to herein as "V.sub.L domains" or
"VL domains"). For a further description of VHHs and Nanobodies,
reference is for instance made to the review article by Muyldermans
(Reviews in Molecular Biotechnology 74: 277-302, 2001), as well as
to the following patent applications, which are mentioned as
general background art: WO 94/04678, WO 95/04079 and WO 96/34103 of
the Vrije Universiteit Brussel; WO 94/25591, WO 99/37681, WO
00/40968, WO 00/43507, WO 00/65057, WO 01/40310, WO 01/44301, EP
1134231 and WO 02/48193 of Unilever; WO 97/49805, WO 01/21817, WO
03/035694, WO 03/054016 and WO 03/055527 of the Vlaams Instituut
voor Biotechnologie (VIB); WO 03/050531 of Algonomics N.V. and
Ablynx N.V.; WO 01/90190 by the National Research Council of
Canada; WO 03/025020 (=EP 1433793) by the Institute of Antibodies;
as well as WO 04/041867, WO 04/041862, WO 04/041865, WO 04/041863,
WO 04/062551, WO 05/044858, WO 06/40153, WO 06/079372, WO
06/122786, WO 06/122787 and WO 06/122825, by Ablynx N.V. and the
further published patent applications by Ablynx N.V. Reference is
also made to the further prior art mentioned in these applications,
and in particular to the list of references mentioned on pages
41-43 of the international application WO 06/040153, which list and
references are incorporated herein by reference. As described in
these references, ISVs, Nanobodies (in particular VHH sequences and
partially humanized Nanobodies) can in particular be characterized
by the presence of one or more "Hallmark residues" in one or more
of the framework sequences. A further description of the ISVs,
Nanobodies, including humanization and/or camelization of
Nanobodies, as well as other modifications, parts or fragments,
derivatives or "Nanobody fusions", multivalent constructs
(including some non-limiting examples of linker sequences) and
different modifications to increase the half-life of the ISVs,
Nanobodies and their preparations can be found e.g. in WO 08/101985
and WO 08/142164. For a further general description of Nanobodies,
reference is made to the prior art cited herein, such as e.g.,
described in WO 08/020079 (page 16).
[0140] "Domain antibodies", also known as "Dab" (s), "Domain
Antibodies", and "dAbs" (the terms "Domain Antibodies" and "dAbs"
being used as trademarks by the GlaxoSmithKline group of companies)
have been described in e.g., EP 0368684, Ward et al. (Nature 341:
544-546, 1989), Holt et al. (Tends in Biotechnology 21: 484-490,
2003) and WO 03/002609 as well as for example WO 04/068820, WO
06/030220, WO 06/003388 and other published patent applications of
Domantis Ltd. Domain antibodies essentially correspond to the VH or
VL domains of non-camelid mammalians, in particular human 4-chain
antibodies. In order to bind an epitope as a single antigen binding
domain, i.e., without being paired with a VL or VH domain,
respectively, specific selection for such antigen binding
properties is required, e.g. by using libraries of human single VH
or VL domain sequences. Domain antibodies have, like VHHs, a
molecular weight of approximately 13 to approximately 16 kDa and,
if derived from fully human sequences, do not require humanization
for e.g. therapeutic use in humans.
[0141] It should also be noted that, although less preferred in the
context of the present invention because they are not of mammalian
origin, single variable domains can be derived from certain species
of shark (for example, the so-called "IgNAR domains", see for
example WO 05/18629).
[0142] Thus, in the meaning of the present invention, the term
"immunoglobulin single variable domain" or "single variable domain"
comprises polypeptides which are derived from a non-human source,
preferably a camelid, preferably a camelid heavy chain antibody.
They may be humanized, as previously described. Moreover, the term
comprises polypeptides derived from non-camelid sources, e.g. mouse
or human, which have been "camelized", as e.g., described in Davies
and Riechmann (FEBS 339: 285-290, 1994; Biotechnol. 13: 475-479,
1995; Prot. Eng. 9: 531-537, 1996) and Riechmann and Muyldermans
(J. Immunol. Methods 231: 25-38, 1999).
[0143] The amino acid residues of a VHH domain are numbered
according to the general numbering for V.sub.H domains given by
Kabat et al. ("Sequence of proteins of immunological interest", US
Public Health Services, NIH Bethesda, Md., Publication No. 91), as
applied to VHH domains from Camelids, as shown e.g., in FIG. 2 of
Riechmann and Muyldermans Immunol. Methods 231: 25-38, 1999).
Alternative methods for numbering the amino acid residues of
V.sub.H domains, which methods can also be applied in an analogous
manner to VHH domains, are known in the art. However, in the
present description, claims and figures, the numbering according to
Kabat applied to VHH domains as described above will be followed,
unless indicated otherwise.
[0144] It should be noted that--as is well known in the art for
V.sub.H domains and for VHH domains--the total number of amino acid
residues in each of the CDRs may vary and may not correspond to the
total number of amino acid residues indicated by the Kabat
numbering (that is, one or more positions according to the Kabat
numbering may not be occupied in the actual sequence, or the actual
sequence may contain more amino acid residues than the number
allowed for by the Kabat numbering). This means that, generally,
the numbering according to Kabat may or may not correspond to the
actual numbering of the amino acid residues in the actual sequence.
The total number of amino acid residues in a VH domain and a VHH
domain will usually be in the range of from 110 to 120, often
between 112 and 115. It should however be noted that smaller and
longer sequences may also be suitable for the purposes described
herein.
[0145] Determination of CDR regions may also be done according to
different methods. In the CDR determination according to Kabat, FR1
of a VHH comprises the amino acid residues at positions 1-30, CDR1
of a VHH comprises the amino acid residues at positions 31-35, FR2
of a VHH comprises the amino acids at positions 36-49, CDR2 of a
VHH comprises the amino acid residues at positions 50-65, FR3 of a
VHH comprises the amino acid residues at positions 66-94, CDR3 of a
VHH comprises the amino acid residues at positions 95-102, and FR4
of a VHH comprises the amino acid residues at positions
103-113.
[0146] In the present application, however, CDR sequences were
determined according to Kontermann and Dubel (Eds., Antibody
Engineering, vol 2, Springer Verlag Heidelberg Berlin, Martin,
Chapter 3, pp. 33-51, 2010). According to this method, FR1
comprises the amino acid residues at positions 1-25, CDR1 comprises
the amino acid residues at positions 26-35, FR2 comprises the amino
acids at positions 36-49, CDR2 comprises the amino acid residues at
positions 50-58, FR3 comprises the amino acid residues at positions
59-94, CDR3 comprises the amino acid residues at positions 95-102,
and FR4 comprises the amino acid residues at positions 103-113
(according to Kabat numbering).
[0147] ISVs such as Domain antibodies and Nanobodies (including VHH
domains) can be subjected to humanization. In particular, humanized
immunoglobulin single variable domains, such as Nanobodies
(including VHH domains) may be immunoglobulin single variable
domains that are as generally defined for in the previous
paragraphs, but in which at least one amino acid residue is present
(and in particular, at least one framework residue) that is and/or
that corresponds to a humanizing substitution (as defined herein).
Potentially useful humanizing substitutions can be ascertained by
comparing the sequence of the framework regions of a naturally
occurring V.sub.HH sequence with the corresponding framework
sequence of one or more closely related human V.sub.H sequences,
after which one or more of the potentially useful humanizing
substitutions (or combinations thereof) thus determined can be
introduced into said V.sub.HH sequence (in any manner known per se,
as further described herein) and the resulting humanized V.sub.HH
sequences can be tested for affinity for the target, for stability,
for ease and level of expression, and/or for other desired
properties. In this way, by means of a limited degree of trial and
error, other suitable humanizing substitutions (or suitable
combinations thereof) can be determined by the skilled person based
on the disclosure herein. Also, based on the foregoing, (the
framework regions of) an immunoglobulin single variable domain,
such as a Nanobody (including VHH domains) may be partially
humanized or fully humanized.
[0148] ISVs such as Domain antibodies and Nanobodies (including VHH
domains and humanized VHH domains), can also be subjected to
affinity maturation by introducing one or more alterations in the
amino acid sequence of one or more CDRs, which alterations result
in an improved affinity of the resulting immunoglobulin single
variable domain for its respective antigen, as compared to the
respective parent molecule. Affinity-matured immunoglobulin single
variable domain molecules of the invention may be prepared by
methods known in the art, for example, as described by Marks et al.
(Biotechnology 10:779-783, 1992), Barbas, et al. (Proc. Nat. Acad.
Sci, USA 91: 3809-3813, 1994), Shier et al. (Gene 169: 147455,
1995), Yelton et al. (Immunol. 155: 1994-2004, 1995), Jackson et
al. (J. Immunol. 154: 3310-9, 1995), Hawkins et al. (J. Mol. Biol.
226: 889 896, 1992), Johnson and Hawkins (Affinity maturation of
antibodies using phage display, Oxford University Press, 1996).
[0149] The process of designing/selecting and/or preparing a
polypeptide, starting from an ISV such as a Domain antibody or a Na
nobody, is also referred to herein as "formatting" said ISV; and an
ISV that is made part of a polypeptide is said to be "formatted" or
to be "in the format of" said polypeptide. Examples of ways in
which an ISV can be formatted and examples of such formats will be
clear to the skilled person based on the disclosure herein; and
such formatted ISV form a further aspect of the invention.
[0150] For example, and without limitation, one or more ISVs may be
used as a "binding unit", "binding domain" or "building block"
(these terms are used interchangeable) for the preparation of a
polypeptide, which may optionally contain one or more further ISVs
that can serve as a binding unit (i.e., against the same or another
epitope on Aggrecan and/or against one or more other antigens,
proteins or targets than Aggrecan).
[0151] The present invention provides Aggrecan binders, such as
ISVs (also referred to herein as "ISVs of the invention") and/or
polypeptides (also referred to herein as "polypeptides of the
invention") that have specificity for and/or that bind
Aggrecan.
[0152] Aggrecan is also known as aggrecan 1, ACAN, AGC1, AGCAN,
CSPGCP, MSK16, SEDK, cartilage-specific proteoglycan core protein
(CSPCP) or chondroitin sulfate proteoglycan 1 (CSPG1). Aggrecan is
in humans encoded by the ACAN gene, which is located at chromosome
Chr 15: q26.1.
[0153] Aggrecan is a large, multimodular molecule (2317 amino
acids). Its core protein is composed of three globular domains (G1,
G2 and G3) and a large extended region (CS) between 62 and G3 onto
which a multitude of N-linked oligosaccharides and chondroitin
sulfate chains and keratan sulfate chains are attached. Aggrecan is
the major proteoglycan in the articular cartilage. It plays an
important role in the proper functioning of articular cartilage by
providing a hydrated gel structure through its interaction with
hyaluronan and link proteins, which endows the cartilage with
load-bearing properties. The G1 domain interacts with hyaluronan
acid and link proteins, forming stable ternary complexes in the
extracellular matrix (ECM). The G2 domain is homologous to the
tandem repeats of G1 and link proteins, and is involved in product
processing. G3 makes up the carboxyl terminus of the core protein,
and enhances glycosaminoglycan modification and product secretion.
Also, the G3 domain links the proteoglycan aggregates to the ECM
proteins (fibulins and tenascins). Degradation of Aggrecan appears
to initiate at the C-terminus. The population of Aggrecan molecules
without the 63 domain increases with aging. Aggrecan interacts with
laminin, fibronectin, tenascin, and collagen, but it is also an
enzymatic substrate of various A Disintegrin And Metalloprotease
with Thrombo-spondin Motifs (ADAMTSs) such as ADAMTS4, ADAMTS5 and
ADAMTS11 and matrix metallo-proteinases (MMPs) such as MMP8, MMP13,
MMP19 and MMP20.
[0154] In one aspect, the invention relates to Aggrecan binders
such as ISVs and polypeptides that specifically bind Aggrecan.
[0155] The Aggrecan binders of the invention are eventually
intended for use as medicaments in humans. Accordingly, in one
aspect the invention relates to Aggrecan binders, such as ISVs and
polypeptides that specifically bind human Aggrecan (SEQ ID NO:
125).
[0156] The inventors identified Aggrecan binders with highly
improved interspecies cross-reactivity and exquisite selectivity
properties.
[0157] Accordingly, in an aspect the invention relates to an
Aggrecan binder, such as an ISV or polypeptide, wherein said
Aggecan binder specifically binds to human Aggrecan (P16112; SEQ ID
NO: 125), dog Aggrecan (028343; SEQ ID NO: 126), bovine Aggrecan
(P13608; SEQ ID NO: 127), rat Aggrecan (P07897; SEQ ID NO: 128);
pig Aggrecan (core; Q29011, SEQ ID NO: 129); mouse Aggrecan
(061282; SEQ ID NO: 130), rabbit Aggrecan (G1U677-1; SEQ ID NO:
131); cynomolgus Aggrecan (XP_005560513.1; SEQ ID NO: 132) and/or
rhesus Aggrecan (XP_002804990.1; SEQ ID NO: 133) (cf. Table B).
[0158] The present inventors surprisingly observed that the
Aggrecan binders of the invention, such as the ISVs and/or
polypeptides of the invention have favorable characteristics over
the prior art molecules; they are stable in joints, they retain in
the cartilage for prolonged times and they are specific for
cartilaginous tissue, e.g. do not bind substantially to Neurocan
(014594, SEQ ID NO: 134) and/or Brevican (Q96GW7, SEQ ID NO: 135)
(cf. Table B).
[0159] Accordingly, in one aspect the invention relates to an
Aggrecan binder, such as an ISV or polypeptide, wherein said
Aggrecan binder does not bind substantially to Neurocan (014594,
SEQ ID NO: 134) and/or Brevican (Q96GW7, SEQ ID NO: 135),
preferably wherein said Aggrecan binds to Neurocan and/or Brevican
with a K.sub.D value greater than 10.sup.-5 mol/liter, such as
10.sup.-4 mol/liter.
[0160] In one aspect the invention relates to an Aggrecan binder,
such as an ISV, wherein said Aggrecan binder has more than 10 fold,
more than 100 fold, preferably more than 1000 fold selectivity over
Neurocan and/or Brevican for binding to Aggrecan.
[0161] Preferred Aggrecan binders of the invention include
immunoglobulins (such as heavy chain antibodies, conventional
4-chain antibodies (such as IgG, IgM, IgA, IgD or IgE molecules),
Fab fragments, F(ab')2 fragments, Fv fragments such as disulfide
linked Fv or scFv fragments, or diabodies derived from such
conventional 4-chain antibody, the individual chains thereof, as
well as all parts, domains or fragments thereof (including but not
limited to antigen-binding domains or fragments such as
immunoglobulin single variable domains), monovalent polypeptides of
the invention, or other binding agents).
[0162] It was observed that the Aggrecan binders of the invention
had a pl over 8, with only one exception (cf. Table 2.2). Without
being bound by theory, the present inventors hypothesized that the
high positive charge of the Aggrecan may influence retention and
cartilage penetration of the whole moiety, i.e. even when coupled
to another building block such as in a multispecific polypeptide.
Accordingly, the present invention relates to an Aggrecan binder,
such as an ISV, polypeptide or construct of the invention,
preferably an ISV of the invention, having a pl of more than 8,
such as 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0 or even
more, such as 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8 or even
9.8.
[0163] Binding of the Aggrecan binders of the invention, such as
the ISVs and/or polypeptides of the invention, to Aggrecan can be
measured in various binding assays, commonly known in the art.
Typical assays include (without being limiting) Fluorescent ligand
binding assays, Fluorescence-activated cell sorting (FACS),
Radioligand binding assays, Surface plasmon resonance (SPR),
Plasmon-waveguide resonance (PWR), SPR imaging for affinity-based
biosensors, Whispering gallery microresonator (WGM), Resonant
waveguide grating (RWG), Biolayer Interferometry Biosensor (BIB)
assays, Nuclear magnetic resonance (NMR), X-ray crystallography,
Thermal denaturation assays (TDA), Isothermal titration calorimetry
(ITC), ELISA and Whole cell ligand-binding assays such as Surface
acoustic wave (SAW) biosensor and RWG biosensor assays. A preferred
assay for measuring binding of the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
to Aggrecan is SPR, such as e.g. the SPR as described in the
examples, wherein binding of the Aggrecan binders of the invention,
such as the ISVs and/or polypeptides of the invention, to Aggrecan
was determined. Some preferred KD values for binding of the
Aggrecan binders of the invention, such as the ISVs and/or
polypeptides of the invention, to Aggrecan will become clear from
the further description and examples herein. Another particularly
preferred assay is ELISA as detailed in the Examples (cf. Examples
1.2 and 2.4).
[0164] Binding of the Aggrecan binders of the invention to Aggrecan
can also be measured in binding assays that preferably preserve the
conformation of the Aggrecan target. Typical assays include
(without being limiting) assays in which Aggrecan is exposed on a
cell surface (such as e.g. CHO cells).
[0165] In an embodiment of the invention, the Aggrecan binders of
the invention, such as the ISVs and/or polypeptides of the
invention, have an on rate constant (Kon) for binding to said
Aggrecan selected from the group consisting of at least about
10.sup.2 M.sup.-1 s.sup.-1, at least about 10.sup.3 M.sup.1
s.sup.-1, at least about 10.sup.4 M.sup.-1 s.sup.-1, at least about
10.sup.5 M.sup.-1 s.sup.-1, at least about 10.sup.6 M.sup.-1
s.sup.-1, 10.sup.7 M.sup.-1 s.sup.-1, at least about 10.sup.8
M.sup.-1 s.sup.-1, at least about 10.sup.9 M.sup.-1 s.sup.-1, and
at least about 10.sup.10 M.sup.-1 s.sup.-1, preferably as measured
by surface plasmon resonance.
[0166] In an embodiment of the invention, the Aggrecan binders of
the invention, such as the ISVs and/or polypeptides of the
invention, have an off rate constant {Koff} for binding to said
Aggrecan selected from the group consisting of at most about
10.sup.-3 s.sup.-1, at most about 10.sup.-4 s.sup.-1, at most about
10.sup.-5 s.sup.-1, at most about 10.sup.-6 s.sup.-1, at most about
10.sup.-7 s.sup.-1, at most about 10.sup.-8 s.sup.-1, at most about
10.sup.-9 s.sup.-1, and at most about 10.sup.-10 s.sup.-1,
preferably as measured by surface plasmon resonance.
[0167] In an embodiment of the invention, the Aggrecan binders of
the invention, such as the ISVs and/or polypeptides of the
invention, bind to said Aggrecan with an average KD value of
between 100 nM and 10 pM, such as at an average KD value of 90 nM
or less, even more preferably at an average KD value of 80 nM or
less, such as less than 70, 60, 50, 40, 30, 20, 10, 5 nM or even
less, such as less than 4, 3, 2, or 1 nM, such as less than 500,
400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20 pM, or even less
such as less than 10 pM. Preferably, the KD is determined by SPR,
for instance as determined by Proteon.
[0168] Some preferred EC50 values for binding of the
immunoglobulins and/or polypeptides of the invention to Aggrecan
will become clear from the further description and examples
herein.
[0169] In an ELISA binding assay, the Aggrecan binders of the
invention, such as ISVs and/or polypeptides of the present
invention, preferably binding the G1 domain and/or G1-IGD-G2
domain, may have EC50 values in binding human Aggrecan of 10.sup.-8
M or lower, more preferably of 10.sup.-9 M or lower, or even of
10.sup.-10 M or lower. For example, in such ELISA binding assay,
the immunoglobulins and/or polypeptides of the present invention
may have EC50 values in binding human Aggrecan between 10.sup.-10 M
and 10.sup.-8 M, such as between 10.sup.-9 M and 10.sup.-8 M or
between 10.sup.-10 M and 10.sup.-9 M.
[0170] In such ELISA binding assay, the Aggrecan binders of the
invention, such as ISVs and/or polypeptides of the present
invention, preferably binding the G1 domain and/or G1-IGD-G2
domain, may have EC50 values in binding cynomolgus (cyno) Aggrecan
of 10.sup.-7 M or lower, preferably of 10.sup.-8 M or lower, more
preferably of 10.sup.-9 M or lower, or even of 10.sup.-10 M or
lower. For example, in such ELISA binding assay, the polypeptides
of the present invention may have EC50 values in binding cyno
Aggrecan between 10.sup.-10 M and 10.sup.-7 M, such as between
10.sup.-10 M and 10.sup.-8 M, between 10.sup.-10 M and 10.sup.-9
M.
[0171] In such ELISA binding assay, the Aggrecan binders of the
invention, such as ISVs and/or polypeptides of the present
invention, preferably binding the G1 domain and/or G1-IGD-G2
domain, may have EC50 values in binding rat Aggrecan of 10.sup.-6 M
or lower, preferably of 10.sup.-7 M or lower, preferably of
10.sup.-8 M or lower, more preferably of 10.sup.-9 M or lower, or
even of 10.sup.-10 M or lower. For example, in such ELISA binding
assay, the polypeptides of the present invention may have EC50
values in binding rat Aggrecan between 10.sup.-10 M and 10.sup.-6
M, such as between 10.sup.-10 M and 10.sup.-7 M, between 10.sup.-10
M and 10.sup.-8 M, between 10.sup.-10 M and 10.sup.-9 M.
[0172] In such ELISA binding assay, the Aggrecan binders of the
invention, such as ISVs and/or polypeptides of the present
invention, preferably binding the G1 domain and/or G1-IGD-G2
domain, may have EC50 values in binding dog Aggrecan of 10.sup.-5 M
or lower, preferably of 10.sup.-7 M or lower, preferably of
10.sup.-8 M or lower, more preferably of 10.sup.-9 M or lower, or
even of 10.sup.-10 M or lower. For example, in such ELISA binding
assay, the polypeptides of the present invention may have EC50
values in binding dog Aggrecan between 10.sup.-10 M and 10.sup.-6
M, such as between 10.sup.-10 M and 10.sup.-7 M, between 10.sup.-10
M and 10.sup.-8 M, between 10.sup.-10 M and 10.sup.-9 M.
[0173] In such ELISA binding assay, the Aggrecan binders of the
invention, such as ISVs and/or polypeptides of the present
invention may, preferably binding the G1 domain and/or G1-IGD-G2
domain, have EC50 values in binding bovine Aggrecan of 10.sup.-6 M
or lower, preferably of 10.sup.-7 M or lower, preferably of
10.sup.-8 M or lower, more preferably of 10.sup.-9 M or lower, or
even of 10.sup.-10 M or lower. For example, in such ELISA binding
assay, the polypeptides of the present invention may have EC50
values in binding bovine Aggrecan between 10.sup.-10 M and
10.sup.-6M, such as between 10.sup.-10 M and 10.sup.-7M, between
10.sup.-10 M and 10.sup.-8 M, between 10.sup.-10 M and
10.sup.-9M.
[0174] The term "cartilaginous tissue" as used herein, refers to
cartilage, including elastic cartilage, hyaline cartilage and
fibrocartilage, which are defined by the ratio of cells
(chondrocytes) to intercellular space and relative amounts of
collagen and proteoglycan. "Articular cartilage" is the cartilage
found on the articular surface of bones and is mostly hyaline
cartilage. Menisci are made entirely of fibrocartilage. Aggrecan is
the main proteoglycan in the extracellular matrix (ECM) and
accounts for ca. 50% of total protein content (the other ca. 50%
are collagen II and some minor proteins, such as, e.g. collagen
IX).
[0175] The Aggrecan binders of the invention demonstrated a
preference to bind to cartilaginous tissues in a joint such as
cartilage and meniscus over non-cartilaginous tissue such as
synovial membrane, tendon, and/or epimysium. Accordingly, the
present invention relates to an Aggrecan binder, such as an ISV or
polypeptide, wherein said Aggrecan binder preferably binds to
cartilaginous tissue such as cartilage and/or meniscus, preferably
by at least a factor 1.5, a factor 2, a factor 3, a factor 4, a
factor 5 or even more compared to non-cartilaginous tissue.
[0176] It is appreciated that joints are the areas where two or
more bones meet. Most joints are mobile, allowing the bones to
move. Joints consist of the following: cartilage, synovial
membrane, ligaments, tendons, bursas and synovial fluid. Some
joints also have a meniscus.
[0177] As demonstrated in the examples, the Aggrecan binders of the
invention have various cartilage retention characteristics, which
enables customizing retention in joints according to the specific
needs (cf. Example 2.2). Preferably, the Aggrecan binders have the
ability to retain in cartilage for prolonged periods of time
following a relatively short exposure of the Aggrecan binders to
the cartilage, which can be expected upon intra-articular
injection. The cartilage retention can be measured via an ex vivo
cartilage retention assay as set out in the examples section. The
degree of retention can be measured by visual inspection of Western
blots or via densitometric quantification. The scale used for
determining the degree of retention can be defined by the person
skilled in the art, for instance a scale from 0 to 6 RU (Retention
Units), wherein 0 is no retention and 6 is full retention in this
assay. If necessary, the scale can be quantified by using the
Aggrecan binders of the invention in which each Aggrecan binder is
assigned a score, e.g. full retention and no retention are fixed.
In the alternative, the scale can be set by various intermediate
scores, which are assigned via the Aggrecan binders of the
invention, e.g. an Aggrecan binder comprising two 114F08=6 RU and a
dummy Aggrecan binder, e.g. ALB26-ALB26=0 RU; or an Aggrecan binder
comprising two 114F08=6; Aggrecan binders comprising 608A05=5;
Aggrecan binder 604G01=4; Aggrecan binder comprising two 601D02=3;
Aggrecan binder comprising two 606A07=2; Aggrecan binder 112A01=1;
and a dummy Aggrecan binder, e.g. ALB26-ALB26=0 (cf. Table 2.2).
Accordingly, the present invention relates to an Aggrecan binder,
such as an ISV and/or polypeptide according to the invention
wherein said Aggrecan binder has a cartilage retention of at least
2, such as at least, 3, 4, 5 or 6 RU in a cartilage retention
assay.
[0178] The Aggrecan binders of the invention should preferably be
stable. As a first prerequisite, the biophysical properties of the
Aggrecan binders were tested as detailed in Example 3, in which it
was demonstrated that these Aggrecan binders demonstrated
favourable stability characteristics as shown by the high melting
temperatures and the absence of signs of aggregation and
multimerisation. Next, the Aggrecan binders were tested for their
activity in the joints for prolonged periods by incubation in
synovial fluids at 37.degree. C. (cf. Example 6). No degradation of
any of the constructs could be detected, indicating that the
constructs were stable under circumstances mimicking the in vivo
situation.
[0179] In an aspect the invention relates to Aggrecan binders, such
as ISVs wherein said Aggrecan binder has a stability of at least 3
days, 4 days, 5 days, 6 days, 7 days, such as 14 days, 21 days, 1
month, 2 months or even 3 months in synovial fluid (SF) at
37.degree. C.
[0180] The present invention provides stretches of amino acid
residues (SEQ ID NOs: 20-37 and 109, SEQ ID NOs: 38-55 and 110, and
SEQ ID NOs: 56-74 and 111; Table A-2) that are particularly suited
for binding to Aggrecan. In particular, the invention provides
stretches of amino acid residues which bind to human Aggrecan and
wherein the binding of said stretches to said Aggrecan retains the
presence in cartilaginous tissue (as described above). These
stretches of amino acid residues may be present in, and/or may be
incorporated into, a construct or polypeptide of the invention, in
particular in such a way that they form (part of) the antigen
binding site of the polypeptide of the invention. These stretches
of amino acid residues have been generated as CDR sequences of
heavy chain antibodies or V.sub.HH sequences that were raised
against Aggrecan. These stretches of amino acid residues are also
referred to herein as "CDR sequence(s) of the invention" ("CDR1
sequence(s) of the invention", "CDR2 sequence(s) of the invention"
and "CDR3 sequence(s) of the invention", respectively).
[0181] It should however be noted that the invention in its
broadest sense is not limited to a specific structural role or
function that these stretches of amino acid residues may have in a
polypeptide of the invention, as long as these stretches of amino
acid residues allow the polypeptide of the invention to bind to
Aggrecan with a desired affinity and potency. Thus, generally, the
invention in its broadest sense provides polypeptides (also
referred to herein as "polypeptide(s) of the invention") that are
capable of binding to Aggrecan with a certain specified affinity,
avidity, efficacy and/or potency and that comprises one or more CDR
sequences as described herein and, in particular a suitable
combination of two or more such CDR sequences, that are suitably
linked to each other via one or more further amino acid sequences,
such that the entire polypeptide forms a binding domain and/or
binding unit that is capable of binding to Aggrecan. It should
however also be noted that the presence of only one such CDR
sequence in a polypeptide of the invention may by itself already be
sufficient to provide the polypeptide of the invention the capacity
of binding to Aggrecan; reference is for example again made to the
so-called "Expedite fragments" described in WO 03/050531.
[0182] In a specific, but non-limiting aspect, the Aggrecan binder
of the invention such as the ISV and/or polypeptide of the
invention, may essentially consist of or comprise at least one
stretch of amino acid residues that is chosen from the group
consisting of: [0183] i) CDR1 sequences: [0184] a) SEQ ID NOs: 24,
32, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37
and 109; and [0185] b) amino acid sequences that have 4, 3, 2, or 1
amino acid(s) difference with the amino acid sequence of SEQ ID NO:
24; [0186] and/or [0187] ii) CDR2 sequences: [0188] c) SEQ ID NOs:
42, 50, 38, 39, 40, 41, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54,
55 and 110; and [0189] d) amino acid sequences that have 4, 3, 2,
or 1 amino acid(s) difference with the amino acid sequence of SEQ
ID NO: 42; [0190] and/or [0191] iii) CDR3 sequences: [0192] e) SEQ
ID NOs: 60, 68, 56, 57, 58, 59, 61, 62, 63, 64, 65, 66, 67, 69, 70,
71, 72, 73, 74 and 111; and [0193] f) amino acid sequences that
have 4, 3, 2, or 1 amino acid(s) difference with the amino acid
sequence of SEQ ID NO: 60, [0194] preferably, the Aggrecan binder,
such as the ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0195] In a further aspect, the Aggrecan binder of the invention,
such as the polypeptide and/or ISV of the invention, may comprise
at least one stretch of amino acid residues that is chosen from the
group consisting of SEQ ID NOs: 20-74 and 109-111.
[0196] In particular, the Aggrecan binder of the invention, such as
the polypeptide and/or ISV of the invention, may be an Aggrecan
binder that comprises one antigen binding site, wherein said
antigen binding site comprises at least one stretch of amino acid
residues that is chosen from the group consisting of the CDR1
sequences, CDR2 sequences and CDR3 sequences as described above (or
any suitable combination thereof). In a preferred aspect, however,
the Aggrecan binder of the invention, such as the polypeptide
and/or ISV of the invention, comprises more than one, such as two
or more stretches of amino acid residues chosen from the group
consisting of the CDR1 sequences of the invention, the CDR2
sequences of the invention and/or the CDR3 sequences of the
invention. Preferably, the Aggrecan binder of the invention, such
as the polypeptide and/or ISV of the invention, comprises three
stretches of amino acid residues chosen from the group consisting
of the CDR1 sequences of the invention, the CDR2 sequences of the
invention and the CDR3 sequences of the invention, respectively.
The combinations of CDR's that are mentioned herein as being
preferred for the Aggrecan binder of the invention, such as the
polypeptide and/or ISV of the invention, are listed in Table A-2,
i.e. preferably the CDR combination shown on a single row in said
table.
[0197] Representative polypeptides of the present invention having
the CDRs described above are shown in Table A-1 (SEQ ID NO:s 1-19
and 114-118).
[0198] In a preferred embodiment, the present invention relates to
an Aggrecan binder of the invention, such as an ISV and/or
polypeptide of the invention, that comprises 3 complementarity
determining regions (CDR1 to CDR3, respectively), wherein: [0199]
CDR1 is chosen from the group consisting of SEQ ID NOs: 24, 32, 20,
21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37 and 109;
[0200] CDR2 is chosen from the group consisting of SEQ ID NOs: 42,
50, 38, 39, 40, 41, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55
and 110; and [0201] CDR3 is chosen from the group consisting of SEQ
ID NOs: 60, 68, 56, 57, 58, 59, 61, 62, 63, 64, 65, 66, 67, 69, 70,
71, 72, 73, 74 and 111 preferably the Aggrecan binder, such as the
ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0202] In a preferred embodiment, the present invention relates to
an Aggrecan binder of the invention, such as an ISV and/or
polypeptide of the invention, that comprises 3 complementarity
determining regions (CDR1 to CDR3, respectively), wherein: [0203]
CDR1 is SEQ ID NO: 24, CDR2 is SEQ ID NO: 42, and CDR3 is SEQ ID
NO: 60; [0204] CDR1 is SEQ ID NO: 32, CDR2 is SEQ ID NO: 50, and
CDR3 is SEQ ID NO: 68; [0205] CDR1 is SEQ ID NO: 20, CDR2 is SEQ ID
NO: 38, and CDR3 is SEQ ID NO: 56; [0206] CDR1 is SEQ ID NO: 21,
CDR2 is HQ ID NO: 39, and CDR3 is SEQ ID NO: 57; [0207] CDR1 is SEQ
ID NO: 22, CDR2 is SEQ ID NO: 40, and CDR3 is SEQ ID NO: 58; [0208]
CDR1 is SEQ ID NO: 23, CDR2 is SEQ ID NO: 41, and CDR3 is SEQ ID
NO: 59; [0209] CDR1 is SEQ ID NO: 25, CDR2 is SEQ ID NO: 43, and
CDR3 is SEQ ID NO: 61; [0210] CDR1 is SEQ ID NO: 26, CDR2 is SEQ ID
NO: 44, and CDR3 is SEQ ID NO: 62; [0211] CDR1 is SEQ ID NO: 27,
CDR2 is SEQ ID NO: 45, and CDR3 is SEQ ID NO: 63; [0212] CDR1 is
SEQ ID NO: 28, CDR2 is SEQ ID NO: 46, and CDR3 is SEQ ID NO: 64;
[0213] COR1 is SEQ ID NO: 29, CDR2 is SEQ ID NO: 47, and CDR3 is
SEQ ID NO: 65; [0214] CDR1 is SEQ ID NO: 30, CDR2 is SEQ ID NO: 48,
and CDR3 is SEQ ID NO: 66; [0215] CDR1 is SEQ ID NO: 31, CDR2 is
SEQ ID NO: 49, and CDR3 is SEQ ID NO: 67; [0216] CDR1 is SEQ ID NO:
32, CDR2 is SEQ ID NO: 51, and CDR3 is SEQ ID NO: 69; [0217] CDR1
is SEQ ID NO: 33, CDR2 is SEQ ID NO: 52, and CDR3 is SEQ ID NO: 70;
[0218] CDR1 is SEQ ID NO: 34, CDR2 is SEQ ID NO: 50, and CDR3 is
SEQ ID NO: 71; [0219] CDR1 is SEQ ID NO: 35, CDR2 is SEQ ID NO: 53,
and CDR3 is SEQ ID NO: 72; [0220] CDR1 is SEQ ID NO: 36, CDR2 is
SEQ ID NO: 54, and CDR3 is SEQ ID NO: 73; [0221] CDR1 is SEQ ID NO:
37, CDR2 is SEQ ID NO: 55, and CDR3 is SEQ ID NO: 74; or [0222]
CDR1 is SEQ ID NO: 109, CDR2 is SEQ ID NO: 110, and CDR3 is SEQ ID
NO: 111; [0223] preferably the Aggrecan binder, such as the ISV
and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0224] In a preferred embodiment, the present invention relates to
an Aggrecan binder, such as an ISV, wherein said ISV has been
chosen from the group consisting of SEQ ID NOs: 117, 5, 118, 13,
114-116, 1-4, 6-12 and 14-19.
[0225] It should be further noted that the invention is not limited
as to the origin of the Aggrecan binder of the invention, such as
the ISV and/or polypeptide of the invention, (or of the nucleic
acid of the invention used to express it), nor as to the way that
the Aggrecan binder of the invention, such as the ISV and/or
polypeptide of the invention, or nucleic acid of the invention is
(or has been) generated or obtained, Thus, the Aggrecan binder of
the invention, such as the ISV and/or polypeptide of the invention,
may be naturally occurring ISVs (from any suitable species) or
synthetic or semi-synthetic ISVs and/or polypeptides.
[0226] Furthermore, it will also be clear to the skilled person
that it is possible to "graft" one or more of the CDRs mentioned
above onto other "scaffolds", including but not limited to human
scaffolds or non-immunoglobulin scaffolds. Suitable scaffolds and
techniques for such CDR grafting will be clear to the skilled
person and are well known in the art, see for example U.S. Pat. No.
7,180,370, WO 01/27160, EP 0605522, EP 0460167, U.S. Pat. No.
7,054,297, Nicaise et al. (Protein Science 13: 1882-1891, 2004),
Ewert et al. (Methods 34: 184-199, 2004), Kettleborough et al.
(Protein Eng. 4: 773-783, 1991), O'Brien and Jones (Methods Mob.
Biol. 207: 81-100, 2003), Skerra (J. Mol. Recognit. 13: 167-187,
2000) and Saerens et al. (J. Mol. Biol. 352: 597-607, 2005) and the
further references cited therein. For example, techniques known per
se for grafting mouse or rat CDR's onto human frameworks and
scaffolds can be used in an analogous manner to provide chimeric
proteins comprising one or more of the CDR sequences defined herein
for the monovalent polypeptides of the invention and one or more
human framework regions or sequences. Suitable scaffolds for
presenting amino acid sequences will be clear to the skilled
person, and for example comprise binding scaffolds based on or
derived from immunoglobulins (i.e. other than the immunoglobulin
sequences already described herein), protein scaffolds derived from
protein A domains (such as Affibodies.TM.), tendamistat,
fibronectin, lipocalin, CTLA-4, T-cell receptors, designed ankyrin
repeats, avimers and PDZ domains (Binz et al. Nat Biotech 23:1257,
2005), and binding moieties based on DNA or RNA including but not
limited to DNA or RNA aptamers (Ulrich et al. Corn Chem High
Throughput Screen 9:619-32, 2006).
[0227] In the Aggrecan binder of the invention, such as the ISV
and/or polypeptide of the invention, the CDRs may be linked to
further amino acid sequences and/or may be linked to each other via
amino acid sequences, in which said amino acid sequences are
preferably framework sequences or are amino acid sequences that act
as framework sequences, or together form a scaffold for presenting
the CDRs.
[0228] According to a preferred embodiment, the Aggrecan binders of
the invention, such as the ISVs and/or polypeptides of the
invention, comprise at least three CDR sequences linked to at least
two framework sequences, in which preferably at least one of the
three CDR sequences is a CDR3 sequence, with the other two CDR
sequences being CDR1 or CDR2 sequences, and preferably being one
CDR1 sequence and one CDR2 sequence. According to one specifically
preferred, but non-limiting embodiment, the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
have the structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which CDR1,
CDR2 and CDR3 are as defined herein for the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
and FR1, FR2, FR3 and FR4 are framework sequences. In such an
Aggrecan binder of the invention, such as an ISV and/or polypeptide
of the invention, the framework sequences may be any suitable
framework sequence, and examples of suitable framework sequences
will be clear to the skilled person, for example on the basis of
the standard handbooks and the further disclosure and prior art
mentioned herein.
[0229] Accordingly, an Aggrecan binder of the invention, such as an
ISV and/or polypeptide of the invention, comprises 3
complementarity determining regions (CDR1 to CDR3, respectively),
in which: [0230] (i) CDR1 is chosen from the group consisting of:
[0231] (a) SEQ ID NOs: 24, 32, 20, 21, 22, 23, 25, 26, 27, 28, 29,
30, 31, 33, 34, 35, 36, 37 and 109; and [0232] (b) amino acid
sequences that have 4, 3, 2, or 1 amino acid(s) difference with the
amino acid sequence of SEQ ID NO: 24 or with any of SEQ ID NOs:
20-23, 25-37 and 109; and/or [0233] (ii) CDR2 is chosen from the
group consisting of: [0234] (c) SEQ ID NOs: 42, 50, 38, 39, 40, 41,
43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55 and 110; and [0235]
(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s)
difference with the amino acid sequence of SEQ ID NO: 42 or with
any of SEQ ID NOs: 38-41, 43-55 and 110; and/or [0236] (iii) CDR3
is chosen from the group consisting of: [0237] (e) SEQ ID NOs: 60,
68, 56, 57, 58, 59, 61, 62, 63, 64, 65, 66, 67, 69, 70, 71, 72, 73,
74 and 111; and [0238] (f) amino acid sequences that have 4, 3, 2,
or 1 amino acid(s) difference with the amino acid sequence of SEQ
ID NO: 60 or with any of SEQ ID NOs: 56-59, 61-74 and 111 [0239]
preferably the Aggrecan binder, such as the ISV and/or polypeptide,
comprises the structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which
FR1, FR2, FR3 and FR4 are framework sequences.
[0240] The Aggrecan binders of the invention could be mapped to the
G1-region, the G1-IGD-G2 region or the G2 region of Aggrecan.
[0241] Accordingly, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides that
bind to the G2 domain of Aggrecan. As set out in the examples,
these Aggrecan binders of the invention, such as ISVs and/or
polypeptides have various preferred characteristics. Preferably,
the Aggrecan binders of the invention, such as ISVs and/or
polypeptides, have a pl of more than 8, and/or have a Koff of less
than 2*10.sup.-2 s.sup.-1, and/or have an EC50 of less than
1*10.sup.-6M.
[0242] A comparison of the CDRs of the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
revealed a number of permissible amino changes in the CDRs, while
retaining binding to the G2 domain of Aggrecan. The sequence
variability in the CDRs of all clones against the CDRs of 601D02,
which was used as reference, is depicted in the Tables 1.5A, 1.58
and 1.5C.
[0243] In an embodiment, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides, in
which: [0244] I) CDR1 is chosen from the group consisting of:
[0245] a) SEQ ID NO:s 28, 22, 26, and 33; and [0246] b) amino acid
sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference with
the amino acid sequence of SEQ ID NO: 28, wherein the amino acid
difference(s) are defined as follows: [0247] at position 1 the G
has been changed into R; [0248] at position 2 the P has been
changed into S or R; [0249] at position 3 the T has been changed
into I; [0250] at position 5 the S has been changed into N; [0251]
at position 6 the R has been changed into N, M, or S; [0252] at
position 7 the Y has been changed into R or is absent; [0253] at
position 8 the A has been changed into F or is absent; and/or
[0254] at position 10 the G has been changed into Y; [0255] and/or
[0256] ii) CDR2 is chosen from the group consisting of: [0257] c)
SEQ ID NO: 46, 40, 44, and 52; and [0258] d) amino acid sequences
that have 5, 4, 3, 2, or 1 amino acid(s) difference with the amino
acid sequence of SEQ ID NO: 46, wherein the amino acid
difference(s) are defined as follows: [0259] at position 1 the A
has been changed into S, or Y; [0260] at position 4 the W has been
changed into L; [0261] at position 5 the S has been changed into N;
[0262] at position 6 the S is absent; [0263] at position 7 the G is
absent; [0264] at position 8 the G has been changed into A; [0265]
at position 9 the R has been changed into S, D, or T; and/or [0266]
at position 11 the Y has been changed into N or R; [0267] and/or
[0268] iii) CDR3 is chosen from the group consisting of: [0269] e)
SEQ ID NO: 64, 58, 62, and 70; and [0270] f) amino acid sequences
that have 5, 4, 3, 2, or 1 amino acid(s) difference with the amino
acid sequence of SEQ ID NO: 64, wherein the amino acid
difference(s) are defined as follows: [0271] at position 1 the A
has been changed into R, or F; [0272] at position 2 the R has been
changed into 1, or L; [0273] at position 3 the I has been changed
into H, or Q; [0274] at position 4 the P has been changed into G,
or N; [0275] at position 5 the V has been changed into S; [0276] at
position 6 the R has been changed into G, N, or F; [0277] at
position 7 the T has been changed into R, W, or Y; [0278] at
position 8 the Y has been changed into R, or S, or is absent;
[0279] at position 9 the T has been changed into 5, or is absent;
[0280] at position 10 the S has been changed into E, K or is
absent; [0281] at position 11 the E has been changed into N, A, or
is absent; [0282] at position 12 the W has been changed into D, or
is absent; [0283] at position 13 the N has been changed into D, or
is absent; [0284] at position 14 the Y is absent; and/or [0285] D
and N are added after position 14 of SEQ ID NO: 64; [0286]
preferably the Aggrecan binder, such as the ISV and/or polypeptide,
comprises the structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which
FR1, FR2, FR3 and FR4 are framework sequences.
[0287] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group of Aggrecan binders, wherein: [0288] CDR1 is chosen
from the group consisting of SEQ ID NOs: 28, 22, 26, and 33; [0289]
CDR2 is chosen from the group consisting of SEQ ID NOs: 46, 40, 44,
and 52; and [0290] CDR3 is chosen from the group consisting of SEQ
ID NOs: 64, 58, 62, and 70; preferably the Aggrecan binder, such as
the ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0291] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group of Aggrecan binders, wherein: [0292] CDR1 is SEQ ID
NO: 28, CDR2 is SEQ ID NO: 46, and CDR3 is SEQ ID NO: 64; [0293]
CDR1 is SEQ ID NO: 22, CDR2 is SEQ ID NO: 40, and CDR3 is SEQ ID
NO: 58; [0294] COR1 is SEQ ID NO: 26, CDR2 is SEQ ID NO: 44, and
CDR3 is SEQ ID NO: 62; and CDR1 is SEQ ID NO: 33, CDR2 is SEQ ID
NO: 52, and CDR3 is SEQ ID NO: 70; preferably the Aggrecan binder,
such as the ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0295] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group of Aggrecan binders chosen from the group consisting
of SEQ ID NOs: 9, 3, 7 and 15, and Aggrecan binders which have more
than 80%, such as 90% or 95% sequence identity with any one of SEQ
ID NOs: 9, 3, 7 and 15.
[0296] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides that
cross-block the binding of domain antibody, an immunoglobulin that
is suitable for use as a domain antibody, a single domain antibody,
an immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation to the G2 domain of Aggrecan.
[0297] In an aspect, the present invention relates to a domain
antibody, an immunoglobulin that is suitable for use as a domain
antibody, a single domain antibody, an immunoglobulin that is
suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation that
binds to G2-domain of Aggrecan, and which competes for binding to
the G2 domain of Aggrecan with Aggrecan binders of the invention,
such as ISVs and/or polypeptides of the invention, preferably
represented by any one of SEQ ID NOs: 9, 3, 7 and 15.
[0298] The present invention also relates to Aggrecan binders of
the invention, such as ISVs and/or polypeptides that bind to the
G1-IGD-G2 domain of Aggrecan. As set out in the examples, these
Aggrecan binders of the invention, such as ISVs and/or polypeptides
have various preferred characteristics. Preferably, the Aggrecan
binders of the invention, such as ISVs and/or polypeptides have a
pl of more than 8, and/or have a Koff of less than 2*10.sup.-2
s.sup.-1, and/or have an EC50 of less than 1*10.sup.-6M.
[0299] A comparison of the CDRs of the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
revealed a number of permissible amino changes in the CDRs, while
retaining binding to the G1-IGD-G2 domain of Aggrecan. The sequence
variability in the CDRs of all clones against the CDRs of 604F02,
which was used as reference, is depicted in the Tables 1.4A, 1.4B
and 1.4C.
[0300] In an aspect the present invention also relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides, in
which: [0301] i) COR1 is chosen from the group consisting of:
[0302] a) SEQ ID NOs: 32, 30 and 23; and [0303] b) amino acid
sequences that have 3, 2, or 1 amino acid(s) difference with the
amino acid sequence of SEQ ID NO: 32, wherein the amino acid
difference(s) are defined as follows: [0304] at position 2 the R
has been changed into L; [0305] at position 6 the S has been
changed into T; and/or [0306] at position 8 the T has been changed
into A; [0307] and/or [0308] ii) CDR2 is chosen from the group
consisting of: [0309] c) SEQ ID NOs: 50, 41, 48 and 51; and [0310]
d) amino acid sequences that have 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 50, wherein the amino
acid difference(s) are defined as follows: [0311] at position 7 the
G has been changed into S or R; and/or [0312] at position 8 the R
has been changed into T; [0313] and/or [0314] iii) CDR3 is chosen
from the group consisting of: [0315] e) SEQ ID NOs: 68, 59, 66 and
69; and [0316] f) amino acid sequences that have 5, 4, 3, 2, or 1
amino acid(s) difference with the amino acid sequence of SEQ ID NO:
68, wherein the amino acid difference(s) are defined as follows:
[0317] at position 4 the R has been changed into V, or P; [0318] at
position 6 the A has been changed into Y; [0319] at position 7 the
S has been changed into T; [0320] at position 8 the S is absent;
[0321] at position 9 the N has been changed into P; [0322] at
position 10 the R has been changed into T or L; [0323] at position
11 the G has been changed into E; and/or [0324] at position 12 the
L has been changed into T or V; [0325] preferably the Aggrecan
binder, such as the ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0326] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides,
wherein: [0327] CDR1 is chosen from the group consisting of SEQ ID
NOs: 32, 30 and 23; [0328] CDR2 is chosen from the group consisting
of SEQ ID NOs: 50, 41, 48 and 51; and [0329] CDR3 is chosen from
the group consisting of SEQ ID NOs: 68, 59, 66 and 69; [0330]
preferably the Aggrecan binder, such as the ISV and/or polypeptide,
comprises the structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which
FR1, FR2, FR3 and FR4 are framework sequences.
[0331] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group of Aggrecan binders, wherein: [0332] CDR1 is SEQ ID
NO: 32, CDR2 is SEQ ID NO: 50, and CDR3 is SEQ ID NO: 68; [0333]
CDR1 is SEQ ID NO: 32, CDR2 is SEQ ID NO: 51, and CDR3 is SEQ ID
NO: 69; [0334] CDR1 is SEQ ID NO: 30, CDR2 is SEQ ID NO: 48, and
CDR3 is SEQ ID NO: 66; and [0335] CDR1 is SEQ ID NO: 23, CDR2 is
SEQ ID NO: 41, and CDR3 is SEQ ID NO: 59; [0336] preferably the
Aggrecan binder, such as the ISV and/or polypeptide, comprises the
structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3
and FR4 are framework sequences.
[0337] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group consisting of Aggrecan binders with SEQ ID NOs: 118,
13, 4, 11 and 14, and Aggrecan binders which have more than 80%,
such as 90% or 95% sequence identity with any one of SEQ ID NOs:
118, 13, 4, 11 and 14.
[0338] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides that
cross-block the binding of domain antibody, an immunoglobulin that
is suitable for use as a domain antibody, a single domain antibody,
an immunoglobulin that is suitable for use as a single domain
antibody, a dAb, an immunoglobulin that is suitable for use as a
dAb, a Nanobody, a VHH sequence, a humanized VHH sequence, a
camelized VH sequence, or a VHH sequence that has been obtained by
affinity maturation to the G1-IGD-G2 domain of Aggrecan.
[0339] In an aspect, the present invention relates to a domain
antibody, an immunoglobulin that is suitable for use as a domain
antibody, a single domain antibody, an immunoglobulin that is
suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation that
binds to the G1-IGD-G2 domain of Aggrecan, and which competes for
binding to the G1-IGD-G2 domain of Aggrecan with the Aggrecan
binder of the invention, such as the ISV and/or polypeptide of the
invention, preferably represented by any one of SEQ ID NOs: 118,
13, 4, 11 and 14.
[0340] In a particularly preferred embodiment the present invention
relates to Aggrecan binders of the invention, such as ISVs and/or
polypeptides of the invention, which bind to the G1 domain of
Aggrecan. As set out in the examples, these Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
have various preferred characteristics. Preferably, the Aggrecan
binders of the invention, such as ISVs and/or polypeptides have a
pl of more than 8, and/or have a Koff of less than 2*10.sup.-2
s.sup.-1, and/or have an EC50 of less than 1*10.sup.-6M.
[0341] A comparison of the CDRs of the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
revealed a number of permissible amino changes in the CDRs, while
retaining binding to the G1 domain of Aggrecan. The sequence
variability in the CDRs of all clones against the CDRs of 114F08,
which was used as reference, is depicted in the Tables 1.3A, 1.3B
and 1.3C.
[0342] In a preferred aspect, the present invention relates to
Aggrecan binders of the invention, such as ISVs and/or polypeptides
of the invention that comprises 3 complementarity determining
regions (CDR1 to CDR3, respectively), in which: [0343] i) CDR1 is
chosen from the group consisting of: [0344] a) SEQ ID NOs: 24, 20,
21, 25, 27, 29, 31, 34, 35, 36, and 37; and [0345] b) amino acid
sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference with
the amino acid sequence of SEQ ID NO: 24, wherein the amino acid
difference(s) are defined as follows: [0346] at position 2 the S
has been changed into R, F, I, or T; [0347] at position 3 the T has
been changed into I; [0348] at position 5 the I has been changed
into S; [0349] at position 6 the I has been changed into S. T, or
M; [0350] at position 7 the N has been changed into Y, or R; [0351]
at position 8 the V has been changed into A, Y, T, or G; [0352] at
position 9 the V has been changed into M; and/or at position 10 the
R has been changed into G, K, or A; [0353] and/or [0354] ii) CDR2
is chosen from the group consisting of: [0355] c) SEQ ID NOs: 42,
38, 39, 43, 45, 47, 49, 50, 53, 54, and 55; and [0356] d) amino
acid sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 42, wherein the amino
acid difference(s) are defined as follows: [0357] at position 1 the
T has been changed into A, or G; [0358] an S or N is inserted
between position 3 and position 4 (position 2a, Table 1.38); [0359]
at position 3 the S has been changed into R, W, N, or T; [0360] at
position 4 the S has been changed into T or G; [0361] at position 5
the G has been changed into S; [0362] at position 6 the G has been
changed into S, or R; [0363] at position 7 the N has been changed
into S, T, or R; [0364] at position 8 the A has been changed into
T; and/or [0365] at position 9 the N has been changed into D or Y;
[0366] and/or [0367] iii) CDR3 is chosen from the group consisting
of: [0368] e) SEQ ID NOs: 60, 56, 57, 61, 63, 65, 67, 71, 72, 73
and 74; and [0369] f) amino acid sequences that have 5, 4, 3, 2, or
1 amino acid(s) difference with the amino acid sequence of SEQ ID
NO: 60, wherein the amino acid difference(s) are defined as
follows: [0370] at position 1 the P has been changed into G, R, D,
or E, or is absent; [0371] at position 2 the T has been changed
into R, L, P, or V, or is absent; [0372] at position 3 the T has
been changed into M, S, or R, or is absent; [0373] at position 4
the H has been changed into D, Y, G, or T; [0374] at position 5 the
Y has been changed into F, V, T or G; [0375] at position 6 the G
has been changed into L, D, S, Y, or W; [0376] an R, T, Y or V is
inserted between position 6 and position 7 (position 6a, Table
1.3C); [0377] at position 7 the G has been changed into P, or S,
[0378] at position 8 the V has been changed into G, T, H, R, L, or
Y; [0379] at position 9 the Y has been changed into R, A, S, D or
G; [0380] at position 10 the Y has been changed into N, E, G, W, or
S; [0381] a W is inserted between position 10 and position 11
(position 10a, Table 1.3C); [0382] at position 11 the G has been
changed into 5, K, or Y; [0383] at position 12 the P has been
changed into E, or D, or is absent; and/or [0384] at position 13
the Y has been changed into L, or is absent; [0385] preferably the
Aggrecan binder, such as the ISV and/or polypeptide, comprises the
structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3
and FR4 are framework sequences.
[0386] In a preferred aspect, the present invention relates to
Aggrecan binders of the invention, such as ISVs and/or polypeptides
chosen from the group of Aggrecan binders, wherein: CDR1 is chosen
from the group consisting of SEQ ID NOs: 24, 20, 21, 25, 27, 29,
31, 34, 35, 36, 37 and 109; CDR2 is chosen from the group
consisting of SEQ ID NOs: 42, 38, 39, 43, 45, 47, 49, 50, 53, 54,
55, and 110; and CDR3 is chosen from the group consisting of SEQ ID
NOs: 60, 56, 57, 61, 63, 65, 67, 71, 72, 73, 74, and 111;
preferably the Aggrecan binder, such as the ISV and/or polypeptide,
comprises the structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which
FR1, FR2, FR3 and FR4 are framework sequences.
[0387] In a preferred aspect, the present invention relates to
Aggrecan binders of the invention, such as ISVs and/or polypeptides
chosen from the group of Aggrecan binders, wherein: [0388] CDR1 is
SEQ ID NO: 24, CDR2 is SEQ ID NO: 42, and CDR3 is SEQ ID NO: 60;
[0389] CDR1 is SEQ ID NO: 20, CDR2 is SEQ ID NO: 38, and CDR3 is
SEQ ID NO: 56; [0390] CDR1 is SEQ ID NO: 21, CDR2 is SEQ ID NO: 39,
and CDR3 is SEQ ID NO: 57; [0391] CDR1 is SEQ ID NO: 25, CDR2 is
SEQ ID NO: 43, and CDR3 is SEQ ID NO: 61; [0392] CDR1 is SEQ ID NO:
27, CDR2 is SEQ ID NO: 45, and CDR3 is SEQ ID NO: 63; [0393] CDR1
is SEQ ID NO: 29, CDR2 is SEQ ID NO: 47, and CDR3 is SEQ ID NO: 65;
[0394] CDR1 is SEQ ID NO: 31, CDR2 is SEQ ID NO: 49, and CDR3 is
SEQ ID NO: 67; [0395] CDR1 is SEQ ID NO: 34, CDR2 is SEQ ID NO: 50,
and CDR3 is SEQ ID NO: 71; [0396] CDR1 is SEQ ID NO: 35, CDR2 is
SEQ ID NO: 53, and CDR3 is SEQ ID NO: 72; [0397] CDR1 is SEQ ID NO:
36, CDR2 is SEQ ID NO: 54, and CDR3 is SEQ ID NO: 73; [0398] CDR1
is SEQ ID NO: 37, CDR2 is SEQ ID NO: 55, and CDR3 is SEQ ID NO: 74;
and [0399] CDR1 is SEQ ID NO: 109, CDR2 is SEQ ID NO: 110, and CDR3
is SEQ ID NO: 111; [0400] preferably the Aggrecan binder, such as
the ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0401] It has been demonstrated in the examples section that the
exemplary clone 114108 has particularly preferred characteristics.
Clone 114F08 represents a family or set of clones, further
comprising clone 114A09 (SEQ ID NO: 114) and 114B04 (SEQ ID NO:
115), which have been grouped based on similarities in the CDRs
(cf. Table A-2 and Tables 3.3A, 3,3B, and 3.3C), which translates
into similarities in functional characteristics. Hence, in another
particularly preferred aspect, the present invention relates to
Aggrecan binders of the invention, such as ISVs and/or polypeptides
that comprises 3 complementarity determining regions (CDR1 to CDR3,
respectively), in which: [0402] i) CDR' is chosen from the group
consisting of: [0403] a) SEQ ID NO:s 24 and 109; and [0404] b)
amino acid sequences that have 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 24, wherein the amino
acid difference(s) are defined as follows: [0405] at position 7 the
N has been changed into S; and/or [0406] at position 9 the V has
been changed into M; [0407] and/or [0408] ii) CDR2 is chosen from
the group consisting of: [0409] c) SEQ ID NO:s 42 and 110; and
[0410] d) amino acid sequences that have 5, 4, 3, 2, or 1 amino
acid(s) difference with the amino acid sequence of SEQ ID NO: 42,
wherein the amino acid difference(s) are defined as follows: [0411]
at position 1 the T has been changed into A; [0412] at position 3
the S has been changed into R; [0413] at position 4 the S has been
changed into T; [0414] at position 8 the A has been changed into T;
and/or [0415] at position 9 the N has been changed into D; [0416]
and/or [0417] iii) CDR3 is chosen from the group consisting of:
[0418] e) SEQ ID NO:s 60 and 111; and [0419] f) amino acid
sequences that have 2, or 1 amino acid(s) difference with the amino
acid sequence of SEQ ID NO: 60, wherein the amino acid
difference(s) are defined as follows: [0420] at position 4 the H
has been changed into R; and/or [0421] at position 8 the V has been
changed into D; [0422] preferably the Aggrecan binder, such as the
ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0423] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides, chosen
from the group of Aggrecan binders, wherein: [0424] CDR1 is chosen
from the group consisting of SEQ ID NOs: 24 and 109; [0425] CDR2 is
chosen from the group consisting of SEQ ID NOs: 42 and 110; and
[0426] CDR3 is chosen from the group consisting of SEQ ID NOs: 60
and 111 [0427] preferably the Aggrecan binder, such as the ISV
and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0428] It further has been demonstrated in the examples section
that Aggrecan binders binding to the G1 region of Aggrecan and
belonging to epitope bin 1 or epitope bin 4 are particularly
effective in cartilage retention assays. In an aspect, the present
invention relates to Aggrecan binders of the invention, such as
ISVs and/or polypeptides that belong to epitope bin 1 or epitope
bin 4.
[0429] A comparison of the CDRs of the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
belonging to epitope bin 1 revealed a number of permissible amino
changes in the CDRs, while retaining binding to the G1 domain of
Aggrecan. The sequence variability in the CDRs of all clones
against the CDRs of 608A05, which was used as reference, is
depicted in the Tables 2.3D, 2.3E and 2.3F.
[0430] In a preferred aspect, the present invention relates to
Aggrecan binders of the invention, such as ISVs and/or polypeptides
that comprises 3 complementarity determining regions (CDR1 to CDR3,
respectively), in which: [0431] i) CDR1 is chosen from the group
consisting of: [0432] a) SEQ ID NO:s 36, 20 and 29; and [0433] b)
amino acid sequences that have 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 36, wherein the amino
acid difference(s) are defined as follows: [0434] at position 3 the
T has been changed into S; [0435] at position 6 the T has been
changed into S; [0436] at position 8 the T has been changed into A;
and/or [0437] at position 9 the M has been changed into V; [0438]
and/or [0439] ii) CDR2 is chosen from the group consisting of:
[0440] c) SEQ ID NO:s 54, 38 and 37; and [0441] d) amino acid
sequences that have 2, or 1 amino acid(s) difference with the amino
acid sequence of SEQ ID NO: 54, wherein the amino acid
difference(s) are defined as follows: [0442] at position 1 the A
has been changed into I; [0443] at position 4 the W has been
changed into R; [0444] at position 7 the G has been changed into R;
and/or [0445] at position 8 the T has been changed into S; [0446]
and/or [0447] iii) CDR3 is chosen from the group consisting of:
[0448] e) SEQ ID NO: 73, 56 and 65; and [0449] f) amino acid
sequences that have 5, 4, 3, 2, or 1 amino acid(s) difference with
the amino acid sequence of SEQ ID NO: 73, wherein the amino acid
difference(s) are defined as follows: [0450] at position 1 the R
has been changed into G; [0451] at position 2 the P has been
changed into R or L; [0452] at position 3 the R has been changed
into L or S; [0453] at position 5 the Y has been changed into R;
[0454] at position 6 the Y has been changed into S or A; [0455] at
position 7 the Y has been changed into T, or is absent; [0456] at
position 8 the S has been changed into P; [0457] at position 9 the
L has been changed into H or R; [0458] at position 10 the Y has
been changed into P or A; [0459] at position 11 the S has been
changed into A or V; [0460] at position 12 the Y has been changed
into O; [0461] at position 13 the D has been changed into F; [0462]
at position 14 the Y has been changed into G, or is absent; and/or
[0463] after position 14 an S is inserted; [0464] preferably the
Aggrecan binder, such as the ISV and/or polypeptide, comprises the
structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3
and FR4 are framework sequences.
[0465] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group of Aggrecan binders, wherein: [0466] CDR1 is chosen
from the group consisting of SEQ ID NOs: 20, 29, and 36; [0467]
CDR2 is chosen from the group consisting of SEQ ID NOs: 38, 47, and
54; and [0468] CDR3 is chosen from the group consisting of SEQ ID
NOs: 56, 65, and 73; preferably the Aggrecan binder, such as the
ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0469] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides
belonging to epitope bin 1 that cross-block the binding of domain
antibody, an immunoglobulin that is suitable for use as a domain
antibody, a single domain antibody, an immunoglobulin that is
suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation to the
G1 domain of Aggrecan.
[0470] In an aspect, the present invention relates to a domain
antibody, an immunoglobulin that is suitable for use as a domain
antibody, a single domain antibody, an immunoglobulin that is
suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation that
binds to epitope bin 1 of the G1-domain of Aggrecan, and which
competes for binding to the G1 domain of Aggrecan with the Aggrecan
binders of the invention, such as ISVs and/or polypeptides that
belong to epitope bin 1, preferably such as e.g. represented by any
one of SEQ ID NO:s 1, 10 and 18.
[0471] A comparison of the CDRs of the Aggrecan binders of the
invention, such as the ISVs and/or polypeptides of the invention,
belonging to epitope bin 4 revealed a number of permissible amino
changes in the CDRs, while retaining binding to the G1 domain of
Aggrecan. The sequence variability in the CDRs of all clones
against the CDRs of 114F08, which was used as reference, is
depicted in the Tables 2.3A, 2.3B and 2.3C.
[0472] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides that
comprises 3 complementarity determining regions (CDR1 to CDR3,
respectively), in which: [0473] i) CDR1 is chosen from the group
consisting of: [0474] a) SEQ ID NO: 24, 25 and 27; and [0475] b)
amino acid sequences that have 2, or 1 amino acid(s) difference
with the amino acid sequence of SEQ ID NO: 24, wherein the amino
acid difference(s) are defined as follows: [0476] at position 2 the
S has been changed into I or F; [0477] at position 5 the I has been
changed into S; [0478] at position 6 the I has been changed into S
or M; [0479] at position 7 the N has been changed into R or Y;
[0480] at position 8 the V has been changed into A or Y; [0481] at
position 9 the V has been changed into M; and/or [0482] at position
10 the R has been changed into K; [0483] and/or [0484] ii) CDR2 is
chosen from the group consisting of: [0485] c) SEQ ID NO: 42, 43
and 45; and [0486] d) amino acid sequences that have 5, 4, 3, 2, or
1 amino acids) difference with the amino acid sequence of SEQ ID
NO: 42, wherein the amino acid difference(s) are defined as
follows: [0487] at position 1 the T has been changed into A or G;
[0488] an N is inserted between position 2 and position 3 (position
2a Table 2.3B); [0489] at position 7 the N has been changed into R;
[0490] at position 8 the A has been changed into T; and/or [0491]
at position 9 the N has been changed into D; [0492] and/or [0493]
iii) CDR3 is chosen from the group consisting of: [0494] e) SEQ ID
NO: 60, 61 and 63; and [0495] f) amino acid sequences that have 5,
4, 3, 2, or 1 amino acids) difference with the amino acid sequence
of SEQ ID NO: 60, wherein the amino acid difference(s) are defined
as follows: [0496] at position 1 the P is absent; [0497] at
position 2 the T has been changed into R or is absent; [0498] at
position 3 the T has been changed into M or is absent; [0499] at
position 4 the H has been changed into D or Y; [0500] at position 5
the Y has been changed into F or V; [0501] at position 6 the G has
been changed into L. or D; [0502] at position 8 the V has been
changed into G or T; [0503] at position 9 the Y has been changed
into R; [0504] at position 10 the Y has been changed into N or E;
[0505] at position 11 the G has been changed into S or K; [0506] at
position 12 the P has been changed into E or is absent; and/or
[0507] at position 13 the Y has been changed into L or is absent;
[0508] preferably the Aggrecan binder, such as the ISV and/or
polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0509] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group of Aggrecan binders, wherein: [0510] CDR1 is chosen
from the group consisting of SEQ ID NOs: 24, 25, and 27; [0511]
CDR2 is chosen from the group consisting of SEQ ID NOs: 42, 43, and
45; and [0512] CDR3 is chosen from the group consisting of SEQ ID
NOs: 60, 61, and 63; [0513] preferably the Aggrecan binder, such as
the ISV and/or polypeptide, comprises the structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, in which FR1, FR2, FR3 and FR4 are
framework sequences.
[0514] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides
belonging to epitope bin 4 that cross-block the binding of domain
antibody, an immunoglobulin that is suitable for use as a domain
antibody, a single domain antibody, an immunoglobulin that is
suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation to the
G1 domain of Aggrecan.
[0515] In an aspect, the present invention relates to a domain
antibody, an immunoglobulin that is suitable for use as a domain
antibody, a single domain antibody, an immunoglobulin that is
suitable for use as a single domain antibody, a dAb, an
immunoglobulin that is suitable for use as a dAb, a Nanobody, a VHH
sequence, a humanized VHH sequence, a camelized VH sequence, or a
VHH sequence that has been obtained by affinity maturation that
binds to epitope bin 4 of the G1-domain of Aggrecan, and which
competes for binding to the G1 domain of Aggrecan with the Aggrecan
binders of the invention, such as ISVs and/or polypeptides that
belong to epitope bin 4, such as e.g. represented by any one of SEQ
ID NO:s 117, 114, 115, 116, 5, 6 and 8.
[0516] In an aspect, the present invention relates to Aggrecan
binders of the invention, such as ISVs and/or polypeptides chosen
from the group consisting of Aggrecan binders represented by SEQ ID
NOs: 117, 118, 116, 114, 115, 5, 13, 1, 2, 6, 8, 10, 12, 16, 17,
18, and 19, and ISVs which have more than 80%, such as 90% or 95%,
or even more sequence identity with any one of SEQ ID NOs: 117,
118, 116, 114, 115, 5, 13, 1, 2, 6, 8, 10, 12, 16, 17, 18, and
19.
[0517] In a specific, but non-limiting aspect, the Aggrecan binder
of the invention may be a stretch of amino acid residues that
comprises an immunoglobulin fold or an Aggrecan binder that, under
suitable conditions (such as physiological conditions) is capable
of forming an immunoglobulin fold (i.e., by folding). Reference is
inter alia made to the review by Halaby et al. (i. Protein Eng. 12:
563-71, 1999). Preferably, when properly folded so as to form an
immunoglobulin fold, the stretches of amino acid residues may be
capable of properly forming the antigen binding site for binding to
Aggrecan. Accordingly, in a preferred aspect the Aggrecan binder of
the invention is an immunoglobulin, such as e.g. an immunoglobulin
single variable domain.
[0518] Accordingly, the framework sequences are preferably (a
suitable combination of) immunoglobulin framework sequences or
framework sequences that have been derived from immunoglobulin
framework sequences (for example, by sequence optimization such as
humanization or camelization). For example, the framework sequences
may be framework sequences derived from an immunoglobulin single
variable domain such as a light chain variable domain (e.g., a
V.sub.L-sequence) and/or from a heavy chain variable domain (e.g.,
a V.sub.H-sequence). In one particularly preferred aspect, the
framework sequences are either framework sequences that have been
derived from a V.sub.HH-sequence (in which said framework sequences
may optionally have been partially or fully humanized) or are
conventional V.sub.H sequences that have been camelized (as defined
herein).
[0519] The framework sequences may preferably be such that the
Aggrecan binder of the invention is an ISV such as a Domain
antibody (or an amino acid sequence that is suitable for use as a
domain antibody); a single domain antibody (or an amino acid that
is suitable for use as a single domain antibody); a "dAb" (or an
amino acid that is suitable for use as a dAb); a Nanobody.RTM.; a
V.sub.HH sequence; a humanized V.sub.HH sequence; a camelized
V.sub.H sequence; or a V.sub.HH sequence that has been obtained by
affinity maturation. Again, suitable framework sequences will be
clear to the skilled person, for example on the basis of the
standard handbooks and the further disclosure and prior art
mentioned herein.
[0520] Another particularly preferred class of ISVs of the
invention comprises ISVs with an amino acid sequence that
corresponds to the amino acid sequence of a naturally occurring
V.sub.H domain, but that has been "camelized", i.e. by replacing
one or more amino acid residues in the amino acid sequence of a
naturally occurring V.sub.H domain from a conventional 4-chain
antibody by one or more of the amino acid residues that occur at
the corresponding position(s) in a V.sub.HH domain of a heavy chain
antibody. This can be performed in a manner known per se, which
will be clear to the skilled person, for example on the basis of
the description herein. Such "camelizing" substitutions are
preferably inserted at amino acid positions that form and/or are
present at the V.sub.H--V.sub.L interface, and/or at the so-called
Camelidae hallmark residues, well known to the person skilled in
the art and which have been defined for example in WO 94/04678 and
Davies and Riechmann (1994 and 1996). Preferably, the V.sub.H
sequence that is used as a starting material or starting point for
generating or designing the camelized ISVs is preferably a V.sub.H
sequence from a mammal, more preferably the V.sub.H sequence of a
human being, such as a V.sub.H3 sequence. However, it should be
noted that such camelized ISVs of the invention can be obtained in
any suitable manner known per se and thus are not strictly limited
to polypeptides that have been obtained using a polypeptide that
comprises a naturally occurring V.sub.H domain as a starting
material.
[0521] For example, again as further described herein, both
"humanization" and "camelization" can be performed by providing a
nucleotide sequence that encodes a naturally occurring V.sub.HH
domain or V.sub.H domain, respectively, and then changing, in a
manner known per se, one or more codons in said nucleotide sequence
in such a way that the new nucleotide sequence encodes a
"humanized" or "camelized" ISV of the invention, respectively. This
nucleic acid can then be expressed in a manner known per se, so as
to provide the desired ISVs of the invention. Alternatively, based
on the amino acid sequence of a naturally occurring V.sub.HH domain
or V.sub.H domain, respectively, the amino acid sequence of the
desired humanized or camelized ISVs of the invention, respectively,
can be designed and then synthesized de nova using techniques for
peptide synthesis known per se. Also, based on the amino acid
sequence or nucleotide sequence of a naturally occurring V.sub.HH
domain or V.sub.H domain, respectively, a nucleotide sequence
encoding the desired humanized or camelized ISVs of the invention,
respectively, can be designed and then synthesized de novo using
techniques for nucleic acid synthesis known per se, after which the
nucleic acid thus obtained can be expressed in a manner known per
se, so as to provide the desired ISVs of the invention.
[0522] In particular, the framework sequences present in the
Aggrecan binders of the invention, such as the ISVs and/or
polypeptides of the invention, may contain one or more of Hallmark
residues for instance as defined in WO 08/020079 (Tables A-3 to
A-8), such that the Aggrecan binder of the invention is a Nanobody.
Some preferred, but non-limiting examples of (suitable combinations
of) such framework sequences will become clear from the further
disclosure herein (see e.g., Table A-2). Generally, Nanobodies (in
particular V.sub.HH sequences and partially humanized Nanobodies)
can in particular be characterized by the presence of one or more
"Hallmark residues" in one or mare of the framework sequences (as
e.g., further described in WO 08/020079, page 61, line 24 to page
98, line 3). As used herein "represented by" in the context of any
SEQ ID NO is equivalent to "comprises or consists of" said SEQ ID
NO and preferably equivalent to "consists of" said SEQ ID NO.
[0523] More in particular, the invention provides Aggrecan binders
comprising at least one ISV that is an amino acid sequence with the
(general) structure
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
in which FR1 to FR4 refer to framework regions 1 to 4,
respectively, and in which COR1 to CDR3 refer to the
complementarity determining regions 1 to 3, respectively, and
which: [0524] i) have at least 80%, more preferably 90%, even more
preferably 95% amino acid identity with at least one of the amino
acid sequences of SEQ ID NOs: 117, 116, 118, 116, 115, 114 and 1-19
(see Table A-2), in which for the purposes of determining the
degree of amino acid identity, the amino acid residues that form
the CDR sequences are disregarded. In this respect, reference is
also made to Table A-2, which lists the framework 1 sequences (SEQ
ID NOs: 119, 120 and 75-84), framework 2 sequences (SEQ ID NOs: 121
and 85-93), framework 3 sequences (SEQ ID NOs: 123, 124, 122,
94-104 and 112-113) and framework 4 sequences (SEQ ID NOs: 105-108)
of the immunoglobulin single variable domains of SEQ ID NOs: 117,
118, 116, 115, 114 and 1-19; or [0525] ii) combinations of
framework sequences as depicted in Table A-2; [0526] and in which:
[0527] iii) preferably one or more of the amino acid residues at
positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according to
the Kabat numbering are chosen from the Hallmark residues such as,
e.g. mentioned in Table A-3 to Table A-8 of WO 08/020079.
[0528] Accordingly, the present invention relates to an ISV and/or
polypeptide, wherein said ISV essentially consists of 4 framework
regions (FR1 to FR4, respectively) and said 3 complementarity
determining regions CDR1 to CDR3, e.g. the ISV that specifically
binds Aggrecan consists of 4 framework regions (FR1 to FR4,
respectively) and said 3 complementarity determining regions CDR1
to CDR3, the therapeutic ISV, e.g. the ISV that binds to a member
of the serine protease family, cathepsins, matrix
metalloproteinases (MMPs)/Matrixins or A Disintegrin and
Metalloproteinase with Thrombospondin motifs (ADAMTS), preferably
MMP8, MMP13, MMP19, MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4
(Aggrecanase-1) and/or ADAMTS11 consists of 4 framework regions
(FR1 to FR4, respectively) and said 3 complementarity determining
regions CDR1 to CDR3; the ISV binding serum albumin essentially
consists of 4 framework regions (FR1 to FR4, respectively) and 3
complementarity determining regions (CDR1 to CDR3
respectively).
[0529] The Aggrecan binders of the invention, such as the ISVs
and/or polypeptides of the invention, may also contain the specific
mutations/amino acid residues described in the following co-pending
US provisional applications, all entitled "Improved immunoglobulin
variable domains": U.S. 61/994,552 filed May 16, 2014; U.S.
61/014,015 filed Jun. 18, 2014; U.S. 62/040,167 filed Aug. 21,
2014; and U.S. 62/047,560, filed Sep. 8, 2014 (all assigned to
Ablynx N.V.).
[0530] In particular, the Aggrecan binders of the invention, such
as the ISVs and/or polypeptides of the invention, may suitably
contain (i) a K or Q at position 112; or (ii) a K or Q at position
110 in combination with a V at position 11; or (iii) a T at
position 89; or (iv) an L on position 89 with a K or Q at position
110; or (v) a V at position 11 and an L at position 89; or any
suitable combination of (i) to (v).
[0531] As also described in said co-pending US provisional
applications, when the Aggrecan binder of the invention, such as
the ISV and/or polypeptide of the invention, contain the mutations
according to one of (i) to (v) above (or a suitable combination
thereof): [0532] the amino acid residue at position 11 is
preferably chosen from L, V or K (and is most preferably V); and
[0533] the amino acid residue at position 14 is preferably suitably
chosen from A or P; and [0534] the amino acid residue at position
41 is preferably suitably chosen from A or P; and [0535] the amino
acid residue at position 89 is preferably suitably chosen from T, V
or L; and [0536] the amino acid residue at position 108 is
preferably suitably chosen from Q or L; and [0537] the amino acid
residue at position 110 is preferably suitably chosen from T, K or
Q; and [0538] the amino acid residue at position 112 is preferably
suitably chosen from S, K or Q.
[0539] As mentioned in said co-pending US provisional applications,
said mutations are effective in preventing or reducing binding of
so-called "pre-existing antibodies" to the ISVs, polypeptides and
constructs of the invention. For this purpose, the Aggrecan binders
of the invention, such as the ISVs and/or polypeptides of the
invention, may also contain (optionally in combination with said
mutations) a C-terminal extension (X)n (in which n is 1 to 10,
preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2,
such as 1); and each X is an (preferably naturally occurring) amino
acid residue that is independently chosen, and preferably
independently chosen from the group consisting of alanine (A),
glycine (G), valine (V), leucine (L) or isoleucine (I)), for which
reference is again made to said US provisional applications as well
as to WO 12/175741. In particular, an Aggrecan binder of the
invention, such as an ISV and/or polypeptide of the invention, may
contain such a C-terminal extension when it forms the C-terminal
end of a protein, polypeptide or other compound or construct
comprising the same (again, as further described in e.g. said US
provisional applications as well as WO 12/175741).
[0540] An Aggrecan binder of the invention may be an
immunoglobulin, such as an ISV, derived in any suitable manner and
from any suitable source, and may for example be naturally
occurring V.sub.HH sequences (i.e., from a suitable species of
Camelid) or synthetic or semi-synthetic amino acid sequences,
including but not limited to "humanized" (as defined herein)
Nanobodies or VHH sequences, "camelized" (as defined herein)
immunoglobulin sequences (and in particular camelized heavy chain
variable domain sequences), as well as Nanobodies that have been
obtained by techniques such as affinity maturation (for example,
starting from synthetic, random or naturally occurring
immunoglobulin sequences), CDR grafting, veneering, combining
fragments derived from different immunoglobulin sequences, PCR
assembly using overlapping primers, and similar techniques for
engineering immunoglobulin sequences well known to the skilled
person; or any suitable combination of any of the foregoing as
further described herein. Also, when an immunoglobulin comprises a
V.sub.HH sequence, said immunoglobulin may be suitably humanized,
as further described herein, so as to provide one or more further
(partially or fully) humanized immunoglobulins of the invention.
Similarly, when an immunoglobulin comprises a synthetic or
semi-synthetic sequence (such as a partially humanized sequence),
said immunoglobulin may optionally be further suitably humanized,
again as described herein, again so as to provide one or more
further (partially or fully) humanized immunoglobulins of the
invention.
[0541] In an aspect, the present invention provides an Aggrecan
binder of the invention, such as an ISV, wherein said Aggrecan
binder is chosen from the group consisting of SEQ ID NO:s 117, 118,
116, 115, 114 and 1-19.
[0542] The ISVs may be used as a "building block" for the
preparation of a polypeptide, which may optionally contain one or
more further "building blocks", such as ISVs, against the same or
another epitope on To Aggrecan and/or against one or more other
antigens, proteins or targets than Aggrecan, e.g. building blocks
having a therapeutic mode of action, e.g. therapeutic ISVs.
[0543] Generally, proteins or polypeptides or constructs that
comprise or essentially consist of a single building block, single
ISV or single Nanobody will be referred to herein as "monovalent"
proteins or polypeptides or as "monovalent constructs",
respectively. Polypeptides or constructs that comprise two or more
building blocks or binding units (such as e.g., ISVs) will also be
referred to herein as "multivalent" polypeptides or constructs, and
the building blocks/ISVs present in such polypeptides or constructs
will also be referred to herein as being in a "multivalent format".
For example, a "bivalent" polypeptide may comprise two ISVs,
optionally linked via a linker sequence, whereas a "trivalent"
polypeptide may comprise three ISVs, optionally linked via two
linker sequences; whereas a "tetravalent" polypeptide may comprise
four ISVs, optionally linked via three linker sequences, etc.
[0544] In a multivalent polypeptide or construct, the two or more
ISVs, such as Nanobodies may be the same or different, and may be
directed against the same antigen or antigenic determinant (for
example against the same part(s) or epitope(s) or against different
parts or epitopes) or may alternatively be directed against
different antigens or antigenic determinants; or any suitable
combination thereof. Polypeptides or constructs that contain at
least two building blocks (such as e.g., ISVs) in which at least
one building block is directed against a first antigen (i.e.,
Aggrecan) and at least one building block is directed against a
second antigen (i.e., different from Aggrecan, such as e.g. a
therapeutic target) will also be referred to as "multispecific"
polypeptides or multispecific constructs, respectively, and the
building blocks (such as e.g., ISVs) present in such polypeptides
or constructs will also be referred to herein as being in a
"multispecific format". Thus, for example, a "bispecific"
polypeptide of the invention is a polypeptide that comprises at
least one ISV directed against a first antigen (i.e., Aggrecan) and
at least one further ISV directed against a second antigen (i.e.,
different from Aggrecan, such as e.g. a therapeutic target),
whereas a "trispecific" polypeptide of the invention is a
polypeptide that comprises at least one ISV directed against a
first antigen (i.e., Aggrecan), at least one further ISV directed
against a second antigen (i.e., different from Aggrecan, such as
e.g. a therapeutic target) and at least one further ISV directed
against a third antigen (i.e., different from both Aggrecan and the
second antigen); etc.
[0545] "Multiparatopic" polypeptides and "multiparatopic"
constructs, such as e.g., "biparatopic" polypeptides or constructs
and "triparatopic" polypeptides or constructs, comprise or
essentially consist of two or more building blocks that each have a
different paratope.
[0546] Accordingly, the ISVs of the invention that bind Aggrecan
can be in essentially isolated form (as defined herein), or they
may form part of a construct or polypeptide, which may comprise or
essentially consist of one or more ISVs that bind Aggrecan and
which may optionally further comprise one or more further amino
acid sequences (all optionally linked via one or more suitable
linkers). The present invention relates to a polypeptide or
construct that comprises or essentially consists of at least one
ISV according to the invention, such as one or more ISVs of the
invention (or suitable fragments thereof), binding Aggrecan.
[0547] The one or more ISVs of the invention can be used as a
binding unit or building block in such a polypeptide or construct,
so as to provide a monovalent, multivalent or multiparatopic
polypeptide or construct of the invention, respectively, all as
described herein. The present invention thus also relates to a
polypeptide which is a monovalent construct comprising or
essentially consisting of one monovalent polypeptide or ISV of the
invention. The present invention thus also relates to a polypeptide
or construct which is a multivalent polypeptide or multivalent
construct, respectively, such as e.g., a bivalent or trivalent
polypeptide or construct comprising or essentially consisting of
two or more ISVs of the invention (for multivalent and
multispecific polypeptides containing one or more VHH domains and
their preparation, reference is e.g. also made to Conrath et al.
(J. Biol. Chem. 276: 7346-7350, 2001), as well as to for example WO
96/34103, WO 99/23221 and WO 2010/115998.
[0548] The invention further relates to a multivalent polypeptide
(also referred to herein as a "multivalent polypeptide(s) of the
invention") that comprises or (essentially) consists of at least
one ISV, such as one or two ISVs (or suitable fragments thereof)
directed against Aggrecan, preferably human Aggrecan, and one
additional ISV.
[0549] In an aspect, in its simplest form, the multivalent
polypeptide or construct of the invention is a bivalent polypeptide
or construct of the invention comprising a first ISV, such as a
Nanobody, directed against Aggrecan, and an identical second ISV,
such as a Nanobody, directed against Aggrecan, wherein said first
and said second ISVs, such as Nanobodies, may optionally be linked
via a linker sequence (as defined herein). In another form, a
multivalent polypeptide or construct of the invention may be a
trivalent polypeptide or construct of the invention, comprising a
first ISV, such as Nanobody, directed against Aggrecan, an
identical second ISV, such as Nanobody, directed against Aggrecan
and a third ISV, such as a Nanobody, directed against an antigen
different from Aggrecan, such as e.g. a therapeutic target, in
which said first, second and third ISVs, such as Nanobodies, may
optionally be linked via one or more, and in particular two, linker
sequences.
[0550] In another aspect, the multivalent polypeptide or construct
of the invention may be a bispecific polypeptide or construct of
the invention, comprising a first ISV, such as a Nanobody, directed
against Aggrecan, and a second ISV, such as a Nanobody, directed
against a second antigen, such as e.g. a therapeutic target, in
which said first and second ISVs, such as Nanobodies, may
optionally be linked via a linker sequence (as defined herein);
whereas a multivalent polypeptide or construct of the invention may
also be a trispecific polypeptide or construct of the invention,
comprising a first ISV, such as a Nanobody, directed against
Aggrecan, a second ISV, such as a Nanobody, directed against a
second antigen, such as e.g. a therapeutic target, and a third ISV,
such as a Na nobody, directed against a third antigen, such as e.g.
also therapeutic target but different from said second antigen, in
which said first, second and third ISVs, such as Nanobodies, may
optionally be linked via one or more, and in particular two, linker
sequences.
[0551] In a preferred aspect, the polypeptide or construct of the
invention is a trivalent, bispecific polypeptide or construct,
respectively. A trivalent, bispecific polypeptide or construct of
the invention in its simplest form may be a trivalent polypeptide
or construct of the invention (as defined herein), comprising two
identical ISVs, such as Nanobodies, against Aggrecan and a third
ISV, such as a Nanobody, directed against another antigen, such as
e.g. a therapeutic target, in which said first, second and third
ISVs, such as Nanobodies, may optionally be linked via one or more,
and in particular two, linker sequences.
[0552] In a preferred aspect, the polypeptide or construct of the
invention is a trivalent, bispecific polypeptide or construct,
respectively. A trivalent, bispecific polypeptide or construct of
the invention may be a trivalent polypeptide or construct of the
invention (as defined herein), comprising two ISVs, such as
Nanobodies, against Aggrecan, wherein said ISVs against Aggrecan
may be the same or different and a third ISV, such as a Nanobody,
directed against another antigen, such as e.g. a therapeutic
target, in which said first, second and third ISVs, such as
Nanobodies, may optionally be linked via one or more, and in
particular two, linker sequences.
[0553] Particularly preferred trivalent, bispecific polypeptides or
constructs in accordance with the invention are those shown in the
Examples described herein and in Tables E-1 and E-2.
[0554] In another aspect, the polypeptide of the invention is a
bispecific polypeptide or construct. A bispecific polypeptide or
construct of the invention in its simplest form may be a bivalent
polypeptide or construct of the invention (as defined herein),
comprising an ISV, such as a Nanobody, against Aggrecan and a
second ISV, such as a Nanobody, directed against another antigen,
such as e.g. a therapeutic target, in which said first and second
ISVs, such as Nanobodies, may optionally be linked via a linker
sequence.
[0555] In a preferred aspect, the multivalent polypeptide or
construct of the invention comprises or essentially consists of two
or more ISVs directed against Aggrecan. In an aspect, the invention
relates to a polypeptide or construct that comprises or essentially
consists of at least two ISVs according to the invention, such as
2, 3 or 4 ISVs (or suitable fragments thereof), binding Aggrecan.
The two or more ISVs may optionally be linked via one or more
peptidic linkers.
[0556] The two or more ISVs present in the multivalent polypeptide
or construct of the invention may consist of a light chain variable
domain sequence (e.g., a V.sub.L sequence) or of a heavy chain
variable domain sequence (e.g., a V.sub.H-sequence); they may
consist of a heavy chain variable domain sequence that is derived
from a conventional four-chain antibody or of a heavy chain
variable domain sequence that is derived from heavy chain antibody.
In a preferred aspect, they consist of a Domain antibody (or an
amino acid that is suitable for use as a domain antibody), of a
single domain antibody (or an amino acid that is suitable for use
as a single domain antibody), of a "dAb" (or an amino acid that is
suitable for use as a dAb), of a Nanobody.RTM. (including but not
limited to V.sub.HH), of a humanized V.sub.HH sequence, of a
camelized V.sub.H sequence; or of a V.sub.HH sequence that has been
obtained by affinity maturation. The two or more ISVs may consist
of a partially or fully humanized Nanobody or a partially or fully
humanized VHH.
[0557] In an aspect of the invention, the first ISV and the second
ISV present in the multiparatopic (preferably biparatopic or
triparatopic) polypeptide or construct of the invention do not
(cross)-compete with each other for binding to Aggrecan and, as
such, belong to different families. Accordingly, the present
invention relates to a multiparatopic (preferably biparatopic)
polypeptide or construct comprising two or more ISVs wherein each
ISV belongs to a different family. In an aspect, the first ISV of
this multiparatopic (preferably biparatopic) polypeptide or
construct of the invention does not cross-block the binding to
Aggrecan of the second ISV of this multiparatopic (preferably
biparatopic) polypeptide or construct of the invention and/or the
first ISV is not cross-blocked from binding to Aggrecan by the
second ISV. In another aspect, the first ISV of a multiparatopic
(preferably biparatopic) polypeptide or construct of the invention
cross-blocks the binding to Aggrecan of the second ISV of this
multiparatopic (preferably biparatopic) polypeptide or construct of
the invention and/or the first ISV is cross-blocked from binding to
Aggrecan by the second ISV.
[0558] In a preferred aspect, the polypeptide or construct of the
invention comprises or essentially consists of two or more ISVs, of
which at least one ISV is directed against Aggrecan. In a
particularly preferred aspect, the polypeptide or construct of the
invention comprises or essentially consists of three or more ISVs,
of which at least two ISVs are directed against Aggrecan. It will
be appreciated that said at least two ISVs directed against
Aggrecan can be the same or different, can be directed against the
same epitope or different epitopes of Aggrecan, can belong to the
same epitope bin or to different epitope bins, and/or can bind to
the same or different domains of Aggrecan.
[0559] In a preferred aspect, the polypeptide or construct of the
invention comprises or essentially consists of at least two ISVs,
wherein said at least two ISVs can be the same or different, which
are independently chosen from the group consisting of SEQ ID NOs:
117, 118, 116, 115 and 1-19, more preferably said at least two ISVs
are chosen from the group consisting of SEQ ID NOs: 117, 5, 6, 8,
114-116 and/or said at least two ISVs are chosen from the group
consisting of SEQ ID NOs: 118 and 13.
[0560] In a further aspect, the invention relates to a
multiparatopic (preferably biparatopic) polypeptide or construct
comprising two or more immunoglobulin single variable domains
directed against Aggrecan that bind the same epitope(s) as is bound
by any one of SEQ ID NOs: 117, 118, 114, 115, 116 and 1-19.
[0561] It is anticipated that the final format of a molecule for
clinical use comprises one or two building blocks, such as ISVs,
binding Aggrecan and one or more building blocks, such as ISVs,
with a therapeutic mode of action, and possibly further moieties.
In the examples section it is demonstrated that such formats retain
both Aggrecan binding and retention properties as well as the
therapeutic effect, e.g. enzymatic and/or inhibitory functions. The
one or more building blocks, such as ISVs, with a therapeutic mode
of action can be any building block having a therapeutic effect
("therapeutic building block" or "therapeutic ISV") in diseases in
which Aggrecan is involved, such as arthritic disease,
osteoarthritis, spondyloepimetaphyseal dysplasia, lumbar disk
degeneration disease, Degenerative joint disease, rheumatoid
arthritis, osteochondritis dissecans, aggrecanopathies and/or in
which Aggrecan is used for directing, anchoring and/or retaining
other, e.g. therapeutic, building blocks at the desired site, such
as e.g. in a joint. The present invention thus pertains to a
polypeptide or construct according to the invention, wherein the
one or more further building block(s), e.g. further ISV(s), retain
activity.
[0562] The present invention relates to a polypeptide or construct
that comprises or essentially consists of at least one ISV
according to the invention, such as one or more ISVs of the
invention (or suitable fragments thereof), binding Aggrecan, and at
least one further ISV, in particular a therapeutic ISV, wherein
said at least one further ISV preferably binds to a therapeutic
target, such as binds to a member of the serine protease family,
cathepsins, matrix metalloproteinases (MMPs)/Matrixins or A
Disintegrin and Metalloproteinase with Thrombospondin motifs
(ADAMTS), preferably MMP8, MMP13, MMP19, MMP20, ADAMTS5
(Aggrecanase-2), ADAMTS4 (Aggrecanase-1) and/or ADAMTS11.
[0563] In an aspect the present invention relates to a polypeptide
or construct of the invention essentially consisting of or
comprising at least one ISV binding Aggrecan and at least one
further ISV which has a therapeutic effect, e.g. a therapeutic
building block. The therapeutic effect can be any desired effect
which ameliorates, treats or prevents a disease as will be further
detailed below. Preferably the further ISV, e.g. a therapeutic ISV,
inhibits or decreases a protease activity, e.g. inhibits or
decreases an activity of a therapeutic target, i.e. of a member of
the serine protease family, cathepsins, matrix metalloproteinases
(MMPs)/Matrixins or A Disintegrin and Metalloproteinase with
Thrombospondin motifs (ADAMTS), preferably MMP8, MMP13, MMP19,
MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4 (Aggrecanase-1) and/or
ADAMTS11. Inhibiting or decreasing an activity may be achieved by
binding to the active site or by modifying the structure of a
protease or proteinase, thereby preventing and/or decreasing the
hydrolysis of the target protein of the protease or proteinase.
[0564] In an aspect the present invention relates to a polypeptide
or construct of the invention chosen from the polypeptides and
constructs of Table E-1 and Table E-2.
[0565] In an aspect the present invention relates to an ISV,
polypeptide or construct of the invention having a stability of at
least 7 days, such as at least 14 days, 21 days, 1 month, 2 months
or even 3 months in synovial fluid (SF) at 37.degree. C.
[0566] In an aspect the present invention relates to an ISV,
polypeptide or construct of the invention having cartilage
retention of at least 2, such as at least, 3, 4, 5 or 6 RU in a
cartilage retention assay.
[0567] In an aspect the present invention relates to an ISV,
polypeptide or construct of the invention penetrating into the
cartilage by at least 5 .mu.m, such as at least 10 .mu.M, 20 .mu.m,
30 .mu.m, 40 .mu.m, 50 .mu.m or even more.
[0568] The stability of a polypeptide, construct or ISV of the
invention can be measured by routine assays known to the person
skilled in the art. Typical assays include (without being limiting)
assays in which the activity of said polypeptide, construct or ISV
is determined, followed by incubating in Synovial Fluid for a
desired period of time, after which the activity is determined
again, for instance as detailed in the examples section (cf.
Example 6).
[0569] The desired activity of the therapeutic building block in
the multivalent polypeptide or construct of the invention can be
measured by routine assays known to the person skilled in the art.
Typical assays include assays in which GAG release is assayed as
detailed in the examples section (cf. Example 8).
[0570] The relative affinities may depend on the location of the
ISVDs in the polypeptide. It will be appreciated that the order of
the ISVDs in a polypeptide of the invention (orientation) may be
chosen according to the needs of the person skilled in the art. The
order of the individual ISVDs as well as whether the polypeptide
comprises a linker is a matter of design choice. Some orientations,
with or without linkers, may provide preferred binding
characteristics in comparison to other orientations. For instance,
the order of a first ISV (e.g. ISV 1) and a second ISV (e.g. ISV 2)
in the polypeptide of the invention may be (from N-terminus to
C-terminus): (i) ISV 1 (e.g. Nanobody 1)--[linker]ISV 2 (e.g.
Nanobody 2)--[C-terminal extension]; or (ii) ISV 2 (e.g. Nanobody
2)-[linker]-ISV 1 (e.g. Nanobody 1)-[C-terminal extension];
(wherein the moieties between the square brackets, i.e. linker and
C-terminal extension, are optional). All orientations are
encompassed by the invention. Polypeptides that contain an
orientation of ISVs that provides desired binding characteristics
may be easily identified by routine screening, for instance as
exemplified in the examples section. A preferred order is from
N-terminus to C-terminus: therapeutic ISV-[linker]-ISV binding
Aggrecan-[C-terminal extension], wherein the moieties between the
square brackets are optional. Another preferred order is from
N-terminus to C-terminus: therapeutic ISV-[linker]-ISV binding
Aggrecan-[linker]-ISV binding Aggrecan-[C-terminal extension],
wherein the moieties between the square brackets are optional.
[0571] The Aggrecan binders of the invention, such as the
polypeptides and/or ISVs of the invention, may or may not further
comprise one or more other groups, residues (e.g. amino acid
residues), moieties or binding units (these Aggrecan binders, such
as polypeptides and/or ISVs (with or without additional groups,
residues, moieties or binding units) are all referred to as
"compound(s) of the invention", "construct(s) of the invention"
and/or "polypeptide(s) of the invention"). If present, such further
groups, residues, moieties or binding units may or may not provide
further functionality to the Aggrecan binder such as the
polypeptide and/or ISV and may or may not modify the properties of
the Aggrecan binder such as the polypeptide and/or ISV.
[0572] For example, such further groups, residues, moieties or
binding units may be one or more additional amino acid sequences,
such that the resulting polypeptide is a (fusion) polypeptide. In a
preferred but non-limiting aspect, said one or more other groups,
residues, moieties or binding units are immunoglobulins. Even more
preferably, said one or more other groups, residues, moieties or
binding units are ISVs chosen from the group consisting of Domain
antibodies, amino acids that are suitable for use as a domain
antibody, single domain antibodies, amino acids that are suitable
for use as a single domain antibody, dAbs, amino acids that are
suitable for use as a dAb, Nanobodies (such as e.g. VHH, humanized
VHH or camelized VH sequences).
[0573] As described above, additional binding units, such as ISVs
having different antigen specificity can be linked to form
multispecific polypeptides. By combining ISVs of two or more
specificities, bispecific, trispecific etc. polypeptides or
constructs can be formed. For example, a polypeptide according to
the invention may comprise one, two or more ISVs directed against
Aggrecan and at least one ISV domain against another target. Such
constructs and modifications thereof, which the skilled person can
readily envisage, are all encompassed by the term "compound of the
invention, construct of the invention and/or polypeptide of the
invention" as used herein.
[0574] In the compounds, constructs and/or polypeptides described
above, the one, two, three or more ISVs and the one or more groups,
residues, moieties or binding units may be linked directly to each
other and/or via one or more suitable linkers or spacers. For
example, when the one or more groups, residues, moieties or binding
units are amino acid sequences, the linkers may also be amino acid
sequences, so that the resulting polypeptide is a fusion (protein)
or fusion (polypeptide).
[0575] The one or more further groups, residues, moieties or
binding units may be any suitable and/or desired amino acid
sequences. The further amino acid sequences may or may not change,
alter or otherwise influence the (biological) properties of the
polypeptide of the invention, and may or may not add further
functionality to the polypeptide of the invention. Preferably, the
further amino acid sequence is such that it confers one or more
desired properties or functionalities to the polypeptide of the
invention.
[0576] Examples of such amino acid sequences will be clear to the
skilled person, and may generally comprise all amino acid sequences
that are used in peptide fusions based on conventional antibodies
and fragments thereof (including but not limited to ScFv's and
single domain antibodies). Reference is for example made to the
review by Holliger and Hudson (Nature Biotechnology 23: 1126-1136,
2005).
[0577] For example, such an amino acid sequence may be an amino
acid sequence that increases the half-life, the solubility, or the
absorption, reduces the immunogenicity or the toxicity, eliminates
or attenuates undesirable side effects, and/or confers other
advantageous properties to and/or reduces the undesired properties
of the compound, construct and/or polypeptide of the invention,
compared to polypeptide of the invention per se. Some non-limiting
examples of such amino acid sequences are serum proteins, such as
human serum albumin (see for example WO 00/27435) or haptenic
molecules (for example haptens that are recognized by circulating
antibodies, see for example WO 98/22141).
[0578] In a specific aspect of the invention, a construct or
polypeptide of the invention may have a moiety conferring an
increased half-life, compared to the corresponding construct or
polypeptide of the invention without said moiety. Some preferred,
but non-limiting examples of such constructs and polypeptides of
the invention will become clear to the skilled person based on the
further disclosure herein, and for example comprise ISVs or
polypeptides of the invention that have been chemically modified to
increase the half-life thereof (for example, by means of
pegylation); Aggrecan binders of the invention, such as ISVs and/or
polypeptides of the invention that comprise at least one additional
binding site for binding to a serum protein (such as serum
albumin); or polypeptides of the invention which comprise at least
one amino acid sequence of the invention that is linked to at least
one moiety (and in particular at least one amino acid sequence)
which increases the half-life of the amino acid sequence of the
invention. Examples of constructs of the invention, such as
polypeptides of the invention, which comprise such half-life
extending moieties or ISVs will become clear to the skilled person
based on the further disclosure herein; and for example include,
without limitation, polypeptides in which the one or more ISVs of
the invention are suitably linked to one or more serum proteins or
fragments thereof (such as (human) serum albumin or suitable
fragments thereof) or to one or more binding units that can bind to
serum proteins (such as, for example, domain antibodies, ISVs that
are suitable for use as a domain antibody, single domain
antibodies, ISVs that are suitable for use as a single domain
antibody, dAbs, ISVs that are suitable for use as a dAb, or
Nanobodies that can bind to serum proteins such as serum albumin
(such as human serum albumin), serum immunoglobulins such as IgG,
or transferrin; reference is made to the further description and
references mentioned herein); polypeptides in which an amino acid
sequence of the invention is linked to an Fc portion (such as a
human Fc) or a suitable part or fragment thereof; or polypeptides
in which the one or more ISVs of the invention are suitable linked
to one or more small proteins or peptides that can bind to serum
proteins, such as, for instance, the proteins and peptides
described in WO 91/01743, WO 01/45746, WO 02/076489, WO2008/068280,
WO2009/127691 and PCT/EP2011/051559.
[0579] In an aspect the present invention provides a construct of
the invention, such as a polypeptide, wherein said polypeptide
further comprises a serum protein binding moiety or a serum
protein.
[0580] Preferably, said serum protein binding moiety binds serum
albumin, such as human serum albumin.
[0581] Generally, the constructs or polypeptides of the invention
with increased half-life preferably have a half-life that is at
least 1.5 times, preferably at least 2 times, such as at least 5
times, for example at least 10 times or more than 20 times, greater
than the half-life of the corresponding constructs or polypeptides
of the invention per se, i.e. without the moiety conferring the
increased half-life. For example, the constructs or polypeptides of
the invention with increased half-life may have a half-life e.g.,
in humans that is increased with more than 1 hours, preferably more
than 2 hours, more preferably more than 6 hours, such as more than
12 hours, or even more than 24, 48 or 72 hours, compared to the
corresponding constructs or polypeptides of the invention per se,
i.e. without the moiety conferring the increased half-life.
[0582] In a preferred, but non-limiting aspect of the invention,
the constructs of the invention, such as polypeptides of the
invention, have a serum half-life e.g. in humans that is increased
with more than 1 hours, preferably more than 2 hours, more
preferably more than 6 hours, such as more than 12 hours, or even
more than 24, 48 or 72 hours, compared to the corresponding
constructs or polypeptides of the invention per se, i.e. without
the moiety conferring the increased half-life.
[0583] In another preferred, but non-limiting aspect of the
invention, such constructs of the invention, such as polypeptides
of the invention, exhibit a serum half-life in human of at least
about 12 hours, preferably at least 24 hours, more preferably at
least 48 hours, even more preferably at least 72 hours or more. For
example, compounds or polypeptides of the invention may have a
half-life of at least 5 days (such as about 5 to 10 days),
preferably at least 9 days (such as about 9 to 14 days), more
preferably at least about 10 days (such as about 10 to 15 days), or
at least about 11 days (such as about 11 to 16 days), more
preferably at least about 12 days (such as about 12 to 18 days or
more), or more than 14 days (such as about 14 to 19 days).
[0584] In a particularly preferred but non-limiting aspect of the
invention, the invention provides a construct of the invention,
such as a polypeptide of the invention, comprising besides the one
or more building blocks binding Aggrecan and possibly the one or
more therapeutic building blocks, at least one building block
binding serum albumin, such as an ISV binding serum albumin, such
as human serum albumin as described herein, wherein said ISV
binding serum albumin comprises or essentially consists of 4
framework regions (FR1 to FR4, respectively) and 3 complementarity
determining regions (CDR1 to CDR3 respectively), in which CDR1 is
SFGMS, CDR2 is SISGSGSDTLYADSVKG and CDR3 is GGSLSR. Preferably,
said ISV binding human serum albumin is chosen from the group
consisting of Alb8, Alb23, Alb129, Alb132, Alb135, Alb11, Alb11
(S11210-A, Alb82, Alb82-A, Alb82-AA, Alb82-AAA, Alb82-G, Alb82-GG,
Alb82-GGG, Alb92 or Alb223 (cf. Table C).
[0585] In an embodiment, the present invention relates to construct
of the invention, such as a polypeptide comprising a serum protein
binding moiety, wherein said serum protein binding moiety is a
non-antibody based polypeptide.
[0586] In an aspect, the present invention relates to a compound or
construct as described herein comprising one or more other groups,
residues, moieties or binding units, preferably chosen from the
group consisting of a polyethylene glycol molecule, serum proteins
or fragments thereof, binding units that can bind to serum
proteins, an Fc portion, and small proteins or peptides that can
bind to serum proteins.
[0587] In an embodiment, the present invention relates to construct
of the invention, such as a polypeptide comprising a moiety
conferring half-life extension, wherein said moiety is a PEG.
Hence, the present invention relates to a construct or polypeptide
of the invention comprising PEG.
[0588] The further amino acid residues may or may not change, alter
or otherwise influence other (biological) properties of the
polypeptide of the invention and may or may not add further
functionality to the polypeptide of the invention. For example,
such amino acid residues: [0589] a) can comprise an N-terminal Met
residue, for example as result of expression in a heterologous host
cell or host organism. [0590] b) may form a signal sequence or
leader sequence that directs secretion of the polypeptide from a
host cell upon synthesis (for example to provide a pre-, pro- or
prepro-form of the polypeptide of the invention, depending on the
host cell used to express the polypeptide of the invention).
Suitable secretory leader peptides will be clear to the skilled
person, and may be as further described herein. Usually, such a
leader sequence will be linked to the N-terminus of the
polypeptide, although the invention in its broadest sense is not
limited thereto; [0591] c) may form a "tag", for example an amino
acid sequence or residue that allows or facilitates the
purification of the polypeptide, for example using affinity
techniques directed against said sequence or residue. Thereafter,
said sequence or residue may be removed (e.g. by chemical or
enzymatical cleavage) to provide the polypeptide (for this purpose,
the tag may optionally be linked to the amino acid sequence or
polypeptide sequence via a cleavable linker sequence or contain a
cleavable motif). Some preferred, but non-limiting examples of such
residues are multiple histidine residues, glutathione residues and
a myc-tag such as AAAEQKLISEEDLNGAA; [0592] d) may be one or more
amino acid residues that have been functionalized and/or that can
serve as a site for attachment of functional groups. Suitable amino
acid residues and functional groups will be clear to the skilled
person and include, but are not limited to, the amino acid residues
and functional groups mentioned herein for the derivatives of the
polypeptides of the invention.
[0593] In the constructs of the invention, such as the polypeptides
of the invention, the two or more building blocks, such as e.g.
ISVs, and the optionally one or more other groups, drugs, agents,
residues, moieties or binding units may be directly linked to each
other (as for example described in WO 99/23221) and/or may be
linked to each other via one or more suitable spacers or linkers,
or any combination thereof. Suitable spacers or linkers for use in
multivalent and multispecific polypeptides will be clear to the
skilled person, and may generally be any linker or spacer used in
the art to link amino acid sequences. Preferably, said linker or
spacer is suitable for use in constructing constructs, proteins or
polypeptides that are intended for pharmaceutical use.
[0594] For instance, the polypeptide of the invention may, for
example, be a trivalent, trispecific polypeptide, comprising one
building block, such as an ISV, binding Aggrecan, one therapeutic
building block, such as an ISV, and one building block, such as an
ISV, binding (human) serum albumin, in which said first, second and
third building blocks, such as ISVs, may optionally be linked via
one or more, and in particular two, linker sequences. Also, the
present invention provides a construct or polypeptide of the
invention comprising a first ISV binding Aggrecan and/or a second
ISV and/or possibly a third ISV and/or possibly an ISV binding
serum albumin, wherein said first ISV and/or said second ISV and/or
possibly said third ISV and/or possibly said ISV binding serum
albumin are linked via a linker.
[0595] Some particularly preferred spacers include the spacers and
linkers that are used in the art to link antibody fragments or
antibody domains. These include the linkers mentioned in the
general background art cited above, as well as for example linkers
that are used in the art to construct diabodies or ScFv fragments
(in this respect, however, it should be noted that, whereas in
diabodies and in ScFv fragments, the linker sequence used should
have a length, a degree of flexibility and other properties that
allow the pertinent V.sub.H and V.sub.L domains to come together to
form the complete antigen-binding site, there is no particular
limitation on the length or the flexibility of the linker used in
the polypeptide of the invention, since each ISV, such as a
Nanobody, by itself forms a complete antigen-binding site).
[0596] For example, a linker may be a suitable amino acid sequence,
and in particular amino acid sequences of between 1 and 50,
preferably between 1 and 30, such as between 1 and 10 amino acid
residues. Some preferred examples of such amino acid sequences
include gly-ser linkers, for example of the type (gly.sub.x
ser.sub.y).sub.z, such as (for example (gly.sub.4 ser).sub.3 or
(gly.sub.3 ser.sub.2).sub.3, as described in WO 99/42077 and the
GS30, GS15, G59 and GS7 linkers described in the applications by
Ablynx mentioned herein (see for example WO 06/040153 and WO
06/122825), as well as hinge-like regions, such as the hinge
regions of naturally occurring heavy chain antibodies or similar
sequences (such as for instance described in WO 94/04678).
Preferred linkers are depicted in Table D (SEQ ID NO:s
154-170).
[0597] Other suitable linkers generally comprise organic compounds
or polymers, in particular those suitable for use in proteins for
pharmaceutical use. For instance, polyethyleneglycol) moieties have
been used to link antibody domains, see for example WO
04/081026.
[0598] It is encompassed within the scope of the invention that the
length, the degree of flexibility and/or other properties of the
linker(s) used (although not critical, as it usually is for linkers
used in ScFv fragments) may have some influence on the properties
of the final the construct of the invention, such as the
polypeptide of the invention, including but not limited to the
affinity, specificity or avidity for a chemokine, or for one or
more of the other antigens. Based on the disclosure herein, the
skilled person will be able to determine the optimal linker(s) for
use in a specific construct of the invention, such as the
polypeptide of the invention, optionally after some limited routine
experiments.
[0599] For example, in multivalent polypeptides of the invention
that comprise building blocks, ISVs or Nanobodies directed against
Aggrecan and another target, the length and flexibility of the
linker are preferably such that it allows each building block, such
as an ISV, of the invention present in the polypeptide to bind to
its cognate target, e.g. the antigenic determinant on each of the
targets. Again, based on the disclosure herein, the skilled person
will be able to determine the optimal linker(s) for use in a
specific construct of the invention, such as a polypeptide of the
invention, optionally after some limited routine experiments.
[0600] It is also within the scope of the invention that the
linker(s) used, confer one or more other favourable properties or
functionality to the constructs of the invention, such as the
polypeptides of the invention, and/or provide one or more sites for
the formation of derivatives and/or for the attachment of
functional groups (e.g., as described herein for the derivatives of
the ISVs of the invention). For example, linkers containing one or
more charged amino acid residues can provide improved hydrophilic
properties, whereas linkers that form or contain small epitopes or
tags can be used for the purposes of detection, identification
and/or purification. Again, based on the disclosure herein, the
skilled person will be able to determine the optimal linkers for
use in a specific polypeptide of the invention, optionally after
some limited routine experiments.
[0601] Finally, when two or more linkers are used in the constructs
such as polypeptides of the invention, these linkers may be the
same or different. Again, based on the disclosure herein, the
skilled person will be able to determine the optimal linkers for
use in a specific construct or polypeptide of the invention,
optionally after some limited routine experiments.
[0602] Usually, for the ease of expression and production, a
construct of the invention, such as a polypeptide of the invention,
will be a linear polypeptide. However, the invention in its
broadest sense is not limited thereto. For example, when a
construct of the invention, such as a polypeptide of the invention,
comprises three of more building blocks, ISVs or Nanobodies, it is
possible to link them by use of a linker with three or more "arms",
which each "arm" being linked to a building block, ISV or Nanobody,
so as to provide a "star-shaped" construct. It is also possible,
although usually less preferred, to use circular constructs.
[0603] Accordingly, the present invention relates to a construct of
the invention, such as a polypeptide of the invention, wherein said
ISVs are directly linked to each other or are linked via a
linker.
[0604] Accordingly, the present invention relates to a construct of
the invention, such as a polypeptide of the invention, wherein a
first ISV and/or a second ISV and/or possibly an ISV binding serum
albumin are linked via a linker.
[0605] Accordingly, the present invention relates to a construct of
the invention, such as a polypeptide of the invention, wherein said
linker is chosen from the group consisting of linkers of 5GS, 765,
9GS, 10GS, 1565, 1865, 20GS, 25GS, 3065, 3565, poly-A, 8G5, 40GS,
G1 hinge, 9GS-G1 hinge, llama upper long hinge region, and 63
hinge.
[0606] Accordingly, the present invention relates to a construct of
the invention, such as a polypeptide of the invention, wherein said
polypeptide is chosen from the group consisting of polypeptides of
Table E-1 and Table E-2.
[0607] Also encompassed in the present invention are compounds,
constructs and/or polypeptides that comprise an ISV or polypeptide
of the invention and further comprise tags or other functional
moieties, e.g., toxins, labels, radiochemicals, etc.
[0608] The other groups, residues, moieties or binding units may
for example be chemical groups, residues, moieties, which may or
may not by themselves be biologically and/or pharmacologically
active. For example, and without limitation, such groups may be
linked to the one or more ISVs or polypeptides of the invention so
as to provide a "derivative" of the polypeptide of the
invention.
[0609] Accordingly, the invention in its broadest sense also
comprises compounds, constructs and/or polypeptides that are
derivatives of the polypeptides of the invention. Such derivatives
can generally be obtained by modification, and in particular by
chemical and/or biological (e.g., enzymatic) modification, of the
polypeptides of the invention and/or of one or more of the amino
acid residues that form a polypeptide of the invention.
[0610] Examples of such modifications, as well as examples of amino
acid residues within the polypeptide sequences that can be modified
in such a manner (i.e. either on the protein backbone but
preferably on a side chain), methods and techniques that can be
used to introduce such modifications and the potential uses and
advantages of such modifications will be clear to the skilled
person (see also Zangi et al., Nat Biotechnol 31(10):898-907,
2013).
[0611] For example, such a modification may involve the
introduction (e.g., by covalent linking or in any other suitable
manner) of one or more (functional) groups, residues or moieties
into or onto the polypeptide of the invention, and in particular of
one or more functional groups, residues or moieties that confer one
or more desired properties or functionalities to the polypeptide of
the invention. Examples of such functional groups will be clear to
the skilled person.
[0612] For example, such modification may comprise the introduction
(e.g., by covalent binding or in any other suitable manner) of one
or more functional groups that increase the half-life, the
solubility and/or the absorption of the polypeptide of the
invention, that reduce the immunogenicity and/or the toxicity of
the polypeptide of the invention, that eliminate or attenuate any
undesirable side effects of the polypeptide of the invention,
and/or that confer other advantageous properties to and/or reduce
the undesired properties of the polypeptide of the invention; or
any combination of two or more of the foregoing. Examples of such
functional groups and of techniques for introducing them will be
clear to the skilled person, and can generally comprise all
functional groups and techniques mentioned in the general
background art cited hereinabove as well as the functional groups
and techniques known per se for the modification of pharmaceutical
proteins, and in particular for the modification of antibodies or
antibody fragments (including ScFv's and single domain antibodies),
for which reference is for example made to Remington
(Pharmaceutical Sciences, 16.sup.th ed., Mack Publishing Co.,
Easton, Pa., 1980). Such functional groups may for example be
linked directly (for example covalently) to a polypeptide of the
invention, or optionally via a suitable linker or spacer, as will
again be clear to the skilled person.
[0613] One specific example is a derivative polypeptide of the
invention wherein the polypeptide of the invention has been
chemically modified to increase the half-life thereof (for example,
by means of pegylation). This is one of the most widely used
techniques for increasing the half-life and/or reducing the
immunogenicity of pharmaceutical proteins and comprises attachment
of a suitable pharmacologically acceptable polymer, such as
polyethyleneglycol) (PEG) or derivatives thereof (such as
methoxypoly(ethyleneglycol) or mPEG). Generally, any suitable form
of pegylation can be used, such as the pegylation used in the art
for antibodies and antibody fragments, such as e.g. (single) domain
antibodies and ScFv's; reference is made to for example Chapman
(Nat. Biotechnol. 54: 531-545, 2002), Veronese and Harris (Adv.
Drug Deliv. Rev. 54: 453-456, 2003), Harris and Chess (Nat. Rev.
Drug. Discov. 2: 214-221, 2003) and WO 04/060965. Various reagents
for pegylation of proteins are also commercially available, for
example from Nektar Therapeutics, USA.
[0614] Preferably, site-directed pegylation is used, in particular
via a cysteine-residue (see for example Yang et al. (Protein
Engineering 16: 761-770, 2003). For example, for this purpose, PEG
may be attached to a cysteine residue that naturally occurs in a
polypeptide of the invention, a polypeptide of the invention may be
modified so as to suitably introduce one or more cysteine residues
for attachment of PEG, or an amino acid sequence comprising one or
more cysteine residues for attachment of PEG may be fused to the N-
and/or C-terminus of a polypeptide of the invention, all using
techniques of protein engineering known per se to the skilled
person.
[0615] Preferably, for the polypeptides of the invention, a PEG is
used with a molecular weight of more than 5000, such as more than
10,000 and less than 200,000, such as less than 100,000; for
example in the range of 20,000-80,000.
[0616] Another, usually less preferred modification comprises
N-linked or O-linked glycosylation, usually as part of
co-translational and/or post-translational modification, depending
on the host cell used for expressing the polypeptide of the
invention.
[0617] Yet another modification may comprise the introduction of
one or more detectable labels or other signal-generating groups or
moieties, depending on the intended use of the labelled polypeptide
of the invention. Suitable labels and techniques for attaching,
using and detecting them will be clear to the skilled person, and
for example include, but are not limited to, fluorescent labels
(such as fluorescein, isothiocyanate, rhodamine, phycoerythrin,
phycocyanin, allophycocyanin, o-phthaldehyde, and fluorescamine and
fluorescent metals, such as, .sup.152Eu or others metals from the
lanthanide series), phosphorescent labels, chemiluminescent labels
or bioluminescent labels (such as luminal, isoluminol, theromatic
acridinium ester, imidazole, acridinium salts, oxalate ester,
dioxetane or GFP and its analogs), radio-isotopes (such as .sup.3H,
.sup.125I, .sup.32P, .sup.35S, .sup.14C, .sup.51Cr, .sup.36Cl,
.sup.57Co, .sup.58Co, .sup.59Fe, and .sup.75Se), metals, metal
chelates or metallic cations (for example metallic cations such as
.sup.99mTC, .sup.123I, .sup.111In, .sup.131I, .sup.97Ru, .sup.67Cu,
.sup.67Ga, and .sup.68Ga or other metals or metallic cations that
are particularly suited for use in in vivo, in vitro or in situ
diagnosis and imaging, such as (.sup.157Gd, .sup.55Mn, .sup.162Dy,
.sup.52Cr, and .sup.56Fe)), as well as chromophores and enzymes
(such as malate dehydrogenase, staphylococcal nuclease,
delta-V-steroid isomerase, yeast alcohol dehydrogenase,
alpha-glycerophosphate dehydrogenase, triose phosphate isomerase,
biotinavidin peroxidase, horseradish peroxidase, alkaline
phosphatase, asparaginase, glucose oxidase, galactosidase,
ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase,
glucoamylase and acetylcholine esterase). Other suitable labels
will be clear to the skilled person, and for example include
moieties that can be detected using NMR or ESR spectroscopy.
[0618] Such labelled polypeptides of the invention may for example
be used for in vitro, in vivo or in situ assays (including
immunoassays known per se such as ELISA, RIA, EIA and other
"sandwich assays", etc.) as well as in vivo diagnostic and imaging
purposes, depending on the choice of the specific label.
[0619] As will be clear to the skilled person, another modification
may involve the introduction of a chelating group, for example to
chelate one of the metals or metallic cations referred to above.
Suitable chelating groups for example include, without limitation,
diethyl-enetriaminepentaacetic acid (DTPA) or
ethylenediaminetetraacetic acid (EDTA).
[0620] Yet another modification may comprise the introduction of a
functional group that is one part of a specific binding pair, such
as the biotin-(strept)avidin binding pair. Such a functional group
may be used to link the polypeptide of the invention to another
protein, polypeptide or chemical compound that is bound to the
other half of the binding pair, i.e. through formation of the
binding pair. For example, a polypeptide of the invention may be
conjugated to biotin, and linked to another protein, polypeptide,
compound or carrier conjugated to avidin or streptavidin. For
example, such a conjugated polypeptide of the invention may be used
as a reporter, for example in a diagnostic system where a
detectable signal-producing agent is conjugated to avidin or
streptavidin. Such binding pairs may for example also be used to
bind the polypeptide of the invention to a carrier, including
carriers suitable for pharmaceutical purposes. See, for instance,
the liposomal formulations described by Cao and Suresh (Journal of
Drug Targeting 8: 257, 2000). Such binding pairs may also be used
to link a therapeutically active agent to the polypeptide of the
invention.
[0621] Other potential chemical and enzymatical modifications will
be clear to the skilled person. Such modifications may also be
introduced for research purposes (e.g, to study function-activity
relationships). Reference is for example made to Lundblad and
Bradshaw (Biotechnol. Appl. Biochem. 26: 143-151, 1997).
[0622] Preferably, the compounds, constructs, polypeptides and/or
derivatives are such that they bind to Aggrecan, with an affinity
(suitably measured and/or expressed as a K.sub.0-value (actual or
apparent), a K.sub.A-value (actual or apparent), a k.sub.on-rate
and/or a k.sub.off-rate, or alternatively as an IC.sub.50 value, as
further described herein) that is as defined herein (i.e. as
defined for the polypeptides of the invention).
[0623] Such compounds, constructs and/or polypeptides of the
invention and derivatives thereof may also be in essentially
isolated form.
[0624] In an aspect, the present invention relates to a construct
of the invention, that comprises or essentially consists of an ISV
according to the invention or a polypeptide according to the
invention, and which further comprises one or more other groups,
residues, moieties or binding units, optionally linked via one or
more peptidic linkers.
[0625] In an aspect, the present invention relates to a construct
of the invention, in which one or more other groups, residues,
moieties or binding units are chosen from the group consisting of a
polyethylene glycol molecule, serum proteins or fragments thereof,
binding units that can bind to serum proteins, an Fc portion, and
small proteins or peptides that can bind to serum proteins.
[0626] The invention further relates to methods for preparing the
compounds, constructs, polypeptides, nucleic acids, host cells, and
compositions described herein.
[0627] The multivalent polypeptides of the invention can generally
be prepared by a method which comprises at least the step of
suitably linking the ISV and/or monovalent polypeptide of the
invention to one or more further ISVs, optionally via the one or
more suitable linkers, so as to provide the multivalent polypeptide
of the invention. Polypeptides of the invention can also be
prepared by a method which generally comprises at least the steps
of providing a nucleic acid that encodes a polypeptide of the
invention, expressing said nucleic acid in a suitable manner, and
recovering the expressed polypeptide of the invention. Such methods
can be performed in a manner known per se, which will be clear to
the skilled person, for example on the basis of the methods and
techniques further described herein.
[0628] A method for preparing multivalent polypeptides of the
invention may comprise at least the steps of linking two or more
ISVs of the invention and for example one or more linkers together
in a suitable manner. The ISVs of the invention (and linkers) can
be coupled by any method known in the art and as further described
herein. Preferred techniques include the linking of the nucleic
acid sequences that encode the ISVs of the invention (and linkers)
to prepare a genetic construct that expresses the multivalent
polypeptide. Techniques for linking amino acids or nucleic acids
will be clear to the skilled person, and reference is again made to
the standard handbooks, such as Sambrook et al. and Ausubel et al.,
mentioned above, as well as the examples below.
[0629] Accordingly, the present invention also relates to the use
of an ISV of the invention in preparing a multivalent polypeptide
of the invention. The method for preparing a multivalent
polypeptide will comprise the linking of an ISV of the invention to
at least one further ISV of the invention, optionally via one or
more linkers. The ISV of the invention is then used as a binding
domain or building block in providing and/or preparing the
multivalent polypeptide comprising 2 (e.g., in a bivalent
polypeptide), 3 (e.g., in a trivalent polypeptide), 4 (e.g., in a
tetravalent) or more (e.g., in a multivalent polypeptide) building
blocks. In this respect, the ISV of the invention may be used as a
binding domain or binding unit in providing and/or preparing a
multivalent, such as bivalent, trivalent or tetravalent polypeptide
of the invention comprising 2, 3, 4 or more building blocks.
[0630] Accordingly, the present invention also relates to the use
of an ISV polypeptide of the invention (as described herein) in
preparing a multivalent polypeptide. The method for the preparation
of the multivalent polypeptide will comprise the linking of the ISV
of the invention to at least one further ISV of the invention,
optionally via one or more linkers.
[0631] The polypeptides and nucleic acids of the invention can be
prepared in a manner known per se, as will be clear to the skilled
person from the further description herein. For example, the
polypeptides of the invention can be prepared in any manner known
per se for the preparation of antibodies and in particular for the
preparation of antibody fragments (including but not limited to
(single) domain antibodies and ScFv fragments). Some preferred, but
non-limiting methods for preparing the polypeptides and nucleic
acids include the methods and techniques described herein.
[0632] The method for producing a polypeptide of the invention may
comprise the following steps: [0633] the expression, in a suitable
host cell or host organism (also referred to herein as a "host of
the invention") or in another suitable expression system of a
nucleic acid that encodes said polypeptide of the invention (also
referred to herein as a "nucleic acid of the invention"),
optionally followed by: [0634] isolating and/or purifying the
polypeptide of the invention thus obtained. In particular, such a
method may comprise the steps of: [0635] cultivating and/or
maintaining a host of the invention under conditions that are such
that said host of the invention expresses and/or produces at least
one polypeptide of the invention; optionally followed by: [0636]
isolating and/or purifying the polypeptide of the invention thus
obtained.
[0637] Accordingly, the present invention also relates to a nucleic
acid or nucleotide sequence that encodes a polypeptide, ISV or
construct of the invention (also referred to as "nucleic acid of
the invention").
[0638] A nucleic acid of the invention can be in the form of single
or double stranded DNA or RNA. According to one embodiment of the
invention, the nucleic acid of the invention is in essentially
isolated from, as defined herein. The nucleic acid of the invention
may also be in the form of, be present in and/or be part of a
vector, e.g. expression vector, such as for example a plasmid,
cosmid or YAC, which again may be in essentially isolated form.
Accordingly, the present invention also relates to an expression
vector comprising a nucleic acid or nucleotide sequence of the
invention.
[0639] The nucleic acids of the invention can be prepared or
obtained in a manner known per se, based on the information on the
polypeptides of the invention given herein, and/or can be isolated
from a suitable natural source. Also, as will be clear to the
skilled person, to prepare a nucleic acid of the invention, also
several nucleotide sequences, such as at least two nucleic acids
encoding ISVs of the invention and for example nucleic acids
encoding one or more linkers can be linked together in a suitable
manner. Techniques for generating the nucleic acids of the
invention will be clear to the skilled person and may for instance
include, but are not limited to, automated DNA synthesis;
site-directed mutagenesis; combining two or more naturally
occurring and/or synthetic sequences (or two or more parts
thereof), introduction of mutations that lead to the expression of
a truncated expression product; introduction of one or more
restriction sites (e.g, to create cassettes and/or regions that may
easily be digested and/or ligated using suitable restriction
enzymes), and/or the introduction of mutations by means of a PCR
reaction using one or more "mismatched" primers. These and other
techniques will be clear to the skilled person, and reference is
again made to the standard handbooks, such as Sambrook et al. and
Ausubel et al., mentioned above, as well as to the Examples
below.
[0640] In a preferred but non-limiting embodiment, a genetic
construct of the invention comprises [0641] a) at least one nucleic
acid of the invention; [0642] b) operably connected to one or more
regulatory elements, such as a promoter and optionally a suitable
terminator; and optionally also [0643] c) one or more further
elements of genetic constructs known per se; in which the terms
"regulatory element", "promoter", "terminator" and "operably
connected" have their usual meaning in the art.
[0644] The genetic constructs of the invention may generally be
provided by suitably linking the nucleotide sequence(s) of the
invention to the one or more further elements described above, for
example using the techniques described in the general handbooks
such as Sambrook et al. and Ausubel et al., mentioned above.
[0645] The nucleic acids of the invention and/or the genetic
constructs of the invention may be used to transform a host cell or
host organism, i.e., for expression and/or production of the
polypeptide of the invention. Suitable hosts or host cells will be
clear to the skilled person, and may for example be any suitable
fungal, prokaryotic or eukaryotic cell or cell line or any suitable
fungal, prokaryotic or (non-human) eukaryotic organism as well as
all other host cells or (non-human) hosts known per se for the
expression and production of antibodies and antibody fragments
(including but not limited to (single) domain antibodies and ScFv
fragments), which will be clear to the skilled person. Reference is
also made to the general background art cited hereinabove, as well
as to, for example, WO 94/29457; WO 96/34103; WO 99/42077; Frenken
et al. (Res Immunol. 149: 589-99, 1998); Riechmann and Muyldermans
(1999), supra; van der Linden (J. Biotechnol. 80: 261-70, 2000);
Joosten et al. (Microb. Cell Fact. 2: 1, 2003); Joosten et al.
(Appl. Microbiol. Biotechnol. 66: 384-92, 2005); and the further
references cited herein. Furthermore, the polypeptides of the
invention can also be expressed and/or produced in cell-free
expression systems, and suitable examples of such systems will be
clear to the skilled person. Suitable techniques for transforming a
host or host cell of the invention will be clear to the skilled
person and may depend on the intended host cell/host organism and
the genetic construct to be used. Reference is again made to the
handbooks and patent applications mentioned above. The transformed
host cell (which may be in the form or a stable cell line) or host
organisms (which may be in the form of a stable mutant line or
strain) form further aspects of the present invention. Accordingly,
the present invention relates to a host or host cell comprising a
nucleic acid according to the invention, or an expression vector
according to the invention. Preferably, these host cells or host
organisms are such that they express, or are (at least) capable of
expressing (e.g., under suitable conditions), a polypeptide of the
invention (and in case of a host organism; in at least one cell,
part, tissue or organ thereof). The invention also includes further
generations, progeny and/or offspring of the host cell or host
organism of the invention, which may for instance be obtained by
cell division or by sexual or asexual reproduction.
[0646] To produce/obtain expression of the polypeptides of the
invention, the transformed host cell or transformed host organism
may generally be kept, maintained and/or cultured under conditions
such that the (desired) polypeptide of the invention is
expressed/produced. Suitable conditions will be clear to the
skilled person and will usually depend upon the host cell/host
organism used, as well as on the regulatory elements that control
the expression of the (relevant) nucleotide sequence of the
invention. Again, reference is made to the handbooks and patent
applications mentioned above in the paragraphs on the genetic
constructs of the invention.
[0647] The polypeptide of the invention may then be isolated from
the host cell/host organism and/or from the medium in which said
host cell or host organism was cultivated, using protein isolation
and/or purification techniques known per se, such as (preparative)
chromatography and/or electrophoresis techniques, differential
precipitation techniques, affinity techniques (e.g., using a
specific, cleavable amino acid sequence fused with the polypeptide
of the invention) and/or preparative immunological techniques (i.e.
using antibodies against the polypeptide to be isolated).
[0648] In an aspect the invention relates to method for producing a
construct, polypeptide or ISV according to the invention comprising
at least the steps of: (a) expressing, in a suitable host cell or
host organism or in another suitable expression system, a nucleic
acid sequence according to the invention; optionally followed by
(b) isolating and/or purifying the construct, polypeptide or ISV
according to the invention.
[0649] In an aspect the invention relates to a composition
comprising a construct, polypeptide, ISV or nucleic acid according
to the invention.
[0650] Generally, for pharmaceutical use, the constructs,
polypeptides and/or ISVDs of the invention may be formulated as a
pharmaceutical preparation or composition comprising at least one
construct, polypeptide and/or ISVD of the invention and at least
one pharmaceutically acceptable carrier, diluent or excipient
and/or adjuvant, and optionally one or more pharmaceutically active
polypeptides and/or compounds. By means of non-limiting examples,
such a formulation may be in a form suitable for oral
administration, for parenteral administration (such as by
intravenous, intramuscular or subcutaneous injection or intravenous
infusion), for topical administration (such as intra-articular
administration), for administration by inhalation, by a skin patch,
by an implant, by a suppository, etc., wherein the intra-articular
administration is preferred. Such suitable administration
forms--which may be solid, semi-solid or liquid, depending on the
manner of administration--as well as methods and carriers for use
in the preparation thereof, will be clear to the skilled person,
and are further described herein. Such a pharmaceutical preparation
or composition will generally be referred to herein as a
"pharmaceutical composition".
[0651] Thus, in a further aspect, the invention relates to a
pharmaceutical composition that contains at least at least one
construct of the invention, at least one polypeptide of the
invention, at least one ISV of the invention, or at least one
nucleic acid of the invention and at least one suitable carrier,
diluent or excipient (i.e., suitable for pharmaceutical use), and
optionally one or more further active substances. In a particular
aspect, the invention relates to a pharmaceutical composition that
comprises a construct, polypeptide, ISV or nucleic acid according
to the invention, preferably at least one of Table E-1 or Table E-2
and at least one suitable carrier, diluent or excipient (i.e.,
suitable for pharmaceutical use), and optionally one or more
further active substances.
[0652] Generally, the constructs, polypeptides, and/or ISVs of the
invention can be formulated and administered in any suitable manner
known per se. Reference is for example made to the general
background art cited above (and in particular to WO 04/041862, WO
04/041863, WO 04/041865, WO 04/041867 and WO 08/020079) as well as
to the standard handbooks, such as Remington's Pharmaceutical
Sciences, 18.sup.th Ed., Mack Publishing Company, USA (1990),
Remington, the Science and Practice of Pharmacy, 21.sup.st Edition,
Lippincott Williams and Wilkins (2005); or the Handbook of
Therapeutic Antibodies (S. Dubel, Ed.), Wiley, Weinheim, 2007 (see
for example pages 252-255).
[0653] In a particular aspect, the invention relates to a
pharmaceutical composition that comprises a construct, polypeptide,
ISV or nucleic acid according to the invention, and which further
comprises at least one pharmaceutically acceptable carrier, diluent
or excipient and/or adjuvant, and optionally comprises one or more
further pharmaceutically active polypeptides and/or compounds.
[0654] The constructs, polypeptides, and/or ISVs of the invention
may be formulated and administered in any manner known per se for
conventional antibodies and antibody fragments (including SaFv's
and diabodies) and other pharmaceutically active proteins. Such
formulations and methods for preparing the same will be clear to
the skilled person, and for example include preparations suitable
for parenteral administration (e.g. intravenous, intraperitoneal,
subcutaneous, intramuscular, intraluminal, intra-arterial or
intrathecal administration) or for topical (e.g., intra-articular,
transdermal or intradermal) administration.
[0655] Preparations for parenteral administration may for example
be sterile solutions, suspensions, dispersions or emulsions that
are suitable for infusion or injection. Suitable carriers or
diluents for such preparations for example include those mentioned
on page 143 of WO 08/020079. Usually, aqueous solutions or
suspensions will be preferred.
[0656] The constructs, polypeptides, and/or ISVs of the invention
can also be administered using methods of delivery known from gene
therapy, see, e.g., U.S. Pat. No. 5,399,346, which is incorporated
by reference for its gene therapy delivery methods. Using a gene
therapy method of delivery, primary cells transfected with the gene
encoding a construct, polypeptide, and/or ISV of the invention can
additionally be transfected with tissue specific promoters to
target specific organs, tissue, grafts, tumors, joints or cells and
can additionally be transfected with signal and stabilization
sequences for subcellularly localized expression.
[0657] The constructs, polypeptides, and/or ISVs of the invention
may also be administered intravenously, intra-articularly or
intraperitoneally by infusion or injection. Particular examples are
as further described on pages 144 and 145 of WO 08/020079 or in
PCT/EP2010/062975 (entire document).
[0658] Useful dosages of the constructs, polypeptides, and/or ISVs
of the invention can be determined by comparing their in vitro
activity, and in vivo activity in animal models. Methods for the
extrapolation of effective dosages in mice, and other animals, to
humans are known to the art; see for example U.S. Pat. No.
4,938,949.
[0659] The amount of the constructs, polypeptides, and/or ISVs of
the invention required for use in treatment will vary not only with
the particular ISV, polypeptide, compound and/or construct selected
but also with the route of administration, the nature of the
condition being treated and the age and condition of the patient
and will be ultimately at the discretion of the attendant physician
or clinician. Also the dosage of the constructs, polypeptides,
and/or ISVs of the invention varies depending on the target cell,
tumor, joint, tissue, graft, or organ.
[0660] The desired dose may conveniently be presented in a single
dose or as divided doses administered at appropriate intervals, for
example, as two, three, four or more sub-doses per day. The
sub-dose itself may be further divided, e.g., into a number of
discrete loosely spaced administrations. Preferably, the dose is
administered once per week or even less frequent, such as once per
two weeks, once per three weeks, once per month or even once per
two months.
[0661] An administration regimen could include long-term treatment.
By "long-term" is meant at least two weeks and preferably, several
weeks, months, or years of duration. Necessary modifications in
this dosage range may be determined by one of ordinary skill in the
art using only routine experimentation given the teachings herein.
See for instance Remington's Pharmaceutical Sciences (Martin, E.
W., ed. 4.sup.th), Mack Publishing Co., Easton, Pa. The dosage can
also be adjusted by the individual physician in the event of any
complication.
[0662] The art is in need of more effective therapies for disorders
affecting cartilage in joints, such as osteoarthritis. Even when
administered intra-articularly, the residence time of most drugs
for treating affected cartilage is insufficient. The present
inventors hypothesized that the efficacy of a therapeutic drug
could be increased significantly by coupling the therapeutic drug
to a moiety which would "anchor" the drug in the joint and
consequently increase retention of the drug, but which should not
disrupt the efficacy of said therapeutic drug (also indicated as
"cartilage anchoring protein" or "CAP"). This anchoring concept not
only increases the efficacy of drug, but also the operational
specificity for a diseased joint by decreasing toxicity and
side-effects, thus widening the number of possible useful drugs.
The present inventors further hypothesized that Aggrecan binders
might potentially function as such an anchor, although Aggrecan is
heavily glycosylated and degraded in various disorders affecting
cartilage in joints. Moreover, in view of the costs and extensive
testing in various animal models required before a drug can enter
the clinic, such Aggrecan binders should preferentially have a
broad cross-reactivity, e.g. the Aggrecan binders should bind to
Aggrecan of various species. Using various ingenious immunization,
screening and characterization methods, the present inventors were
able to identify various Aggrecan binders with superior
selectivity, stability and specificity features, which enabled
prolonged retention and activity in the joint.
[0663] In an aspect the present invention relates to a composition
according to the invention, an ISV according to the invention, a
polypeptide according to the invention, and/or a construct
according to the invention for use as a medicament.
[0664] In an aspect the present invention relates to a method for
reducing and/or inhibiting the efflux of a composition, a
polypeptide or a construct from a joint, wherein said method
comprises administering a pharmaceutically active amount of at
least one polypeptide according to the invention, a construct
according to the invention, or a composition according to the
invention to a person in need thereof.
[0665] In the present invention the term "reducing and/or
inhibiting the efflux" means reducing and/or inhibiting the outward
flow of the composition, polypeptide or construct from within a
joint to the outside. Preferably, the efflux is reduced and/or
inhibited by at least 10% such as at least 20%, 30%, 40% or 50% or
even more such as at least 60%, 70%, 80%, 90% or even 100%,
compared to the efflux of the aforementioned composition,
polypeptide or construct in a joint under the same conditions but
without the presence of the Aggrecan binder of the invention, e.g.
ISV(s) binding Aggrecan.
[0666] It is anticipated that the Aggrecan binders of the invention
can be used in various diseases affecting cartilage, such as
arthropathies and chondrodystrophies, arthritic disease, such as
osteoarthritis, rheumatoid arthritis, gouty arthritis, psoriatic
arthritis, traumatic rupture or detachment, achondroplasia,
costochondritis, Spondyloepimetaphyseal dysplasia, spinal disc
herniation, lumbar disk degeneration disease, degenerative joint
disease, and relapsing polychondritis (commonly indicated herein as
"Aggrecan associated diseases").
[0667] In an aspect the present invention relates to a composition,
an ISV, a polypeptide, and/or a construct according to the
invention for use in preventing or treating an Aggrecan associated
disease, such as e.g. arthropathies and chondrodystrophies,
arthritic disease, such as osteoarthritis, rheumatoid arthritis,
gouty arthritis, psoriatic arthritis, traumatic rupture or
detachment, achondroplasia, costo-chondritis,
Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar
disk degeneration disease, degenerative joint disease, and
relapsing polychondritis.
[0668] In an aspect the present invention relates to a method for
preventing or treating arthropathies and chondrodystrophies,
arthritic disease, such as osteoarthritis, rheumatoid arthritis,
gouty arthritis, psoriatic arthritis, traumatic rupture or
detachment, achondroplasia, costo-chondritis,
Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar
disk degeneration disease, degenerative joint disease, and
relapsing polychondritis wherein said method comprises
administering, to a subject in need thereof, a pharmaceutically
active amount of at least a composition, ISV, polypeptide, or
construct according to the invention to a person in need
thereof.
[0669] In an aspect the present invention relates to the use of an
ISV, polypeptide, composition or construct according to the
invention, in the preparation of a pharmaceutical composition for
treating or preventing arthropathies and chondrodystrophies,
arthritic disease, such as osteoarthritis, rheumatoid arthritis,
gouty arthritis, psoriatic arthritis, traumatic rupture or
detachment, achondroplasia, costo-chondritis,
Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar
disk degeneration disease, degenerative joint disease, and
relapsing polychondritis.
[0670] It is expected that by binding to Aggrecan, the Aggrecan
binders of the invention may reduce or inhibit an activity of a
member of the serine protease family, cathepsins, matrix
metallo-proteinases (MMPs)/Matrixins or A Disintegrin and
Metalloproteinase with Thrombospondin motifs (ADAMTS), preferably
MMP8, MMP13, MMP19, MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4
(Aggrecanase-1) and/or ADAMTS11 in degrading Aggrecan.
[0671] Accordingly, in an aspect the invention relates to a method
for reducing or inhibiting an activity of a member of the serine
protease family, cathepsins, matrix metallo-proteinases
(MMPs)/Matrixins or A Disintegrin and Metalloproteinase with
Thrombospondin motifs (ADAMTS), preferably MMP8, MMP13, MMP19,
MMP20, ADAMTS5 (Aggrecanase-2), ADAMTS4 (Aggrecanase-1) and/or
ADAMTS11 in degrading Aggrecan, wherein said method comprises
administering a pharmaceutically active amount of at least an ISV,
polypeptide, construct or composition according to the invention to
a person in need thereof.
[0672] In the context of the present invention, the term
"prevention and/or treatment" not only comprises preventing and/or
treating the disease, but also generally comprises preventing the
onset of the disease, slowing or reversing the progress of disease,
preventing or slowing the onset of one or more symptoms associated
with the disease, reducing and/or alleviating one or more symptoms
associated with the disease, reducing the severity and/or the
duration of the disease and/or of any symptoms associated therewith
and/or preventing a further increase in the severity of the disease
and/or of any symptoms associated therewith, preventing, reducing
or reversing any physiological damage caused by the disease, and
generally any pharmacological action that is beneficial to the
patient being treated.
[0673] The subject to be treated may be any warm-blooded animal,
but is in particular a mammal, and more in particular a human
being. As will be clear to the skilled person, the subject to be
treated will in particular be a person suffering from, or at risk
of, the diseases, disorders and conditions mentioned herein.
[0674] Generally, the treatment regimen will comprise the
administration of one or more ISVs, polypeptides, compounds and/or
constructs of the invention, or of one or more compositions
comprising the same, in one or more pharmaceutically effective
amounts or doses. The specific amount(s) or doses to be
administered can be determined by the clinician, again based on the
factors cited above.
[0675] Generally, depending on the specific disease, disorder or
condition to be treated, the potency of the specific ISV,
polypeptide, compound and/or construct of the invention to be used,
the specific route of administration and the specific
pharmaceutical formulation or composition used, the clinician will
be able to determine a suitable daily dose.
[0676] Usually, in the above method, an ISV, polypeptide, compound
and/or construct of the invention will be used. It is however
within the scope of the invention to use two or more ISVs,
polypeptides and/or constructs of the invention in combination.
[0677] The ISVs, polypeptides and/or constructs of the invention
may be used in combination with one or more further
pharmaceutically active compounds or principles, i.e., as a
combined treatment regimen, which may or may not lead to a
synergistic effect.
[0678] Again, the clinician will be able to select such further
compounds or principles, as well as a suitable combined treatment
regimen, based on the factors cited above and his expert
judgment.
[0679] In particular, the ISVs, polypeptides and/or constructs of
the invention may be used in combination with other
pharmaceutically active compounds or principles that are or can be
used for the prevention and/or treatment of the diseases, disorders
and conditions cited herein, as a result of which a synergistic
effect may or may not be obtained. Examples of such compounds and
principles, as well as routes, methods and pharmaceutical
formulations or compositions for administering them will be clear
to the clinician.
[0680] When two or more substances or principles are to be used as
part of a combined treatment regimen, they can be administered via
the same route of administration or via different routes of
administration, at essentially the same time or at different times
(e.g. essentially simultaneously, consecutively, or according to an
alternating regime). When the substances or principles are to be
administered simultaneously via the same route of administration,
they may be administered as different pharmaceutical formulations
or compositions or part of a combined pharmaceutical formulation or
composition, as will be clear to the skilled person.
[0681] Also, when two or more active substances or principles are
to be used as part of a combined treatment regimen, each of the
substances or principles may be administered in the same amount and
according to the same regimen as used when the compound or
principle is used on its own, and such combined use may or may not
lead to a synergistic effect. However, when the combined use of the
two or more active substances or principles leads to a synergistic
effect, it may also be possible to reduce the amount of one, more
or all of the substances or principles to be administered, while
still achieving the desired therapeutic action. This may for
example be useful for avoiding, limiting or reducing any unwanted
side-effects that are associated with the use of one or more of the
substances or principles when they are used in their usual amounts,
while still obtaining the desired pharmaceutical or therapeutic
effect.
[0682] The effectiveness of the treatment regimen used according to
the invention may be determined and/or followed in any manner known
per se for the disease, disorder or condition involved, as will be
clear to the clinician. The clinician will also be able, where
appropriate and on a case-by-case basis, to change or modify a
particular treatment regimen, so as to achieve the desired
therapeutic effect, to avoid, limit or reduce unwanted
side-effects, and/or to achieve an appropriate balance between
achieving the desired therapeutic effect on the one hand and
avoiding, limiting or reducing undesired side effects on the other
hand.
[0683] Generally, the treatment regimen will be followed until the
desired therapeutic effect is achieved and/or for as long as the
desired therapeutic effect is to be maintained. Again, this can be
determined by the clinician.
[0684] In another aspect, the invention relates to the use of an
ISV, polypeptide, compound and/or construct of the invention in the
preparation of a pharmaceutical composition for prevention and/or
treatment of at least an Aggrecan associated disease; and/or for
use in one or more of the methods of treatment mentioned
herein.
[0685] The invention also relates to the use of an ISV,
polypeptide, compound and/or construct of the invention in the
preparation of a pharmaceutical composition for the prevention
and/or treatment of at least one disease or disorder that can be
prevented and/or treated by modulating Aggrecan, e.g. inhibiting
Aggrecan degradation.
[0686] The invention also relates to the use of an ISV,
polypeptide, compound and/or construct of the invention in the
preparation of a pharmaceutical composition for the prevention
and/or treatment of at least one disease, disorder or condition
that can be prevented and/or treated by administering an ISV,
polypeptide, compound and/or construct of the invention to a
patient.
[0687] The invention further relates to an ISV, polypeptide,
compound and/or construct of the invention or a pharmaceutical
composition comprising the same for use in the prevention and/or
treatment of at least one Aggrecan associated disease.
[0688] The subject to be treated may be any warm-blooded animal,
but is in particular a mammal, and more in particular a human
being. In veterinary applications, the subject to be treated
includes any animal raised for commercial purposes or kept as a
pet. As will be clear to the skilled person, the subject to be
treated will in particular be a person suffering from, or at risk
of, the diseases, disorders and conditions mentioned herein.
[0689] Again, in such a pharmaceutical composition, the one or more
ISVs, polypeptides, compounds and/or constructs of the invention,
or nucleotide encoding the same, and/or a pharmaceutical
composition comprising the same, may also be suitably combined with
one or more other active principles, such as those mentioned
herein.
[0690] The invention also relates to a composition (such as,
without limitation, a pharmaceutical composition or preparation as
further described herein) for use, either in vitro (e.g. in an in
vitro or cellular assay) or in vivo (e.g. in an a single cell or
multi-cellular organism, and in particular in a mammal, and more in
particular in a human being, such as in a human being that is at
risk of or suffers from a disease, disorder or condition of the
invention).
[0691] It is to be understood that reference to treatment includes
both treatment of established symptoms and prophylactic treatment,
unless explicitly stated otherwise.
[0692] Sequences are disclosed in the main body of the description
and in a separate sequence listing according to WIPO standard
ST.25. A SEQ ID specified with a specific number should be the same
in the main body of the description and in the separate sequence
listing. By way of example SEQ ID NO.: 1 should define the same
sequence in both, the main body of the description and in the
separate sequence listing. Should there be a discrepancy between a
sequence definition in the main body of the description and the
separate sequence listing (if e.g. SEQ ID NO.: 1 in the main body
of the description erroneously corresponds to SEQ ID NO.: 2 in the
separate sequence listing) then a reference to a specific sequence
in the application, in particular of specific embodiments, is to be
understood as a reference to the sequence in the main body of the
application and not to the separate sequence listing. In other
words a discrepancy between a sequence definition/designation in
the main body of the description and the separate sequence listing
is to be resolved by correcting the separate sequence listing to
the sequences and their designation disclosed in the main body of
the application which includes the description, examples, figures
and claims.
[0693] The invention will now be further described by means of the
following non-limiting preferred aspects, examples and figures.
[0694] The entire contents of all of the references (including
literature references, issued patents, published patent
applications, and co-pending patent applications) cited throughout
this application are hereby expressly incorporated by reference, in
particular for the teaching that is referenced hereinabove.
EXAMPLES
Example 1 Immunization of Llamas with Aggrecan, Cloning of the
Heavy Chain-Only Antibody Fragment Repertoires and Preparation of
Phage
[0695] The present inventors realized that the purpose of animal
models of OA is to controllably reproduce the scale and progression
of joint damage, so that opportunities to detect and modulate
symptoms and disease progression can be identified and new
therapies developed. An ideal animal model is of relatively low
cost and displays reproducible disease progression with a magnitude
of effect large enough to detect differences within a short period
of time. If the model progresses too rapidly to end-stage
degeneration, intermediate time points, which are representative of
OA pathophysiology, may not be obtainable and in IT the absence of
this information, subtle effects of potential interventions may be
missed. Recognizing that OA is an end-stage phenotype, the result
of an interaction of mechanical and biochemical processes, animal
models allow these factors to be studied in a controlled
environment (cf. Teeple et al. 2013 AAPS J. 15: 438-446).
[0696] The final goal of animal models is to reproduce human
diseases (cf. Cohen-Solal et al. 2013 Bonekey Rep. 2: 422). Given
the heterogeneity of profiles in human OA, many models are needed.
They are either spontaneous or induced. Most of them focus on one
factor that favors the development of OA such as aging, mechanical
stress (surgery), chemical defect (enzyme) or in genetic factors.
All of them differ in terms of severity, localization of lesions
and pathogenesis. However, no animal model addresses all aspects of
developing OA.
[0697] Thus, in order to be useful in different animal models as
well as ultimately in the human patient, the CAP-binder preferably
has a broad cross-reactivity, e.g. binds to Aggrecan of more than
one species, Preferably, the Aggrecan binder binds to human
Aggrecan, as well as one or more of dog Aggrecan, bovine Aggrecan,
rat Aggrecan, pig Aggrecan, mouse Aggrecan, rabbit Aggrecan,
cynomolgus Aggrecan and/or rhesus Aggrecan.
[0698] Moreover, the present inventors realized that degradation of
Aggrecan appears to initiate within the C-terminal region. The
population of Aggrecan molecules without the G3 domain increases
also with aging. A major feature of cartilage degeneration
associated with arthritis is the loss of Aggrecan due to
proteolytic cleavage within the interglobular region between the G1
and G2 domains. Hence, preferably, the Aggrecan binder binds to the
N-terminal region of Aggrecan, i.e., a region other than the CS or
G3 domain, such as the G1-IGD-G2 region, or the G1-domain, the IGD,
or the G2 domain. Most preferably, the Aggrecan binder would bind
to the G1 domain, which remains present in chondrocytes and the
ECM.
1.1 Immunizations
[0699] Five llamas were immunized with recombinant (rec) human
Aggrecan (G1-IGD-G2 domains, R&D Systems it 1220-PG) (see
Example 1.2). Serum samples were taken after antigen
administrations and titers were determined by ELISA against human
recombinant Aggrecan G1-IGD-G2. All llamas gave specific serum
titers.
1.2 Primary Screening
[0700] RNA was extracted from PBLs (primary blood lymphocytes) and
used as template for RT-PCR to amplify ISV encoding gene fragments.
These fragments were cloned into phagemid vector pAX212 enabling
production of phage particles displaying ISVs fused with His6- and
FLAG3-tags. Phages were prepared and stored according to standard
protocols (cf. Phage Display of Peptides and Proteins: A Laboratory
Manual 1.sup.st Edition, Brian K. Kay, Jill Winter, John
McCafferty, Academic Press, 1996).
[0701] Phage Display selections were performed with five immune
libraries and two synthetic ISV libraries. The libraries were
subjected to two to three rounds of enrichment against different
combinations of recombinant human and (biotin-)rat Aggrecan
G1-IGD-G2 domain, full length extracted bovine Aggrecan or intact
bovine cartilage. Individual clones from the selection outputs were
screened for binding in ELISA (using periplasmic extracts from E.
coli cells expressing the ISVs) against the human G1-IGD-G2 domain.
Sequencing of 542 ELISA-positive clones identified 144 unique ISV
sequences. ISVs were assessed for species cross-reactivity and
mapped by ELISA for binding to the individual human G1, IGD and G2
domains. Only a few ISVs showed similar binding levels to
recombinant human, rat, dog and bovine Aggrecan G1-IGD-G2. The
limited species cross-reactivity was particularly evident for G1
domain binders, for which binding to especially bovine and dog
Aggrecan was poor. To identify more species cross-reactive G1
domain-binding ISVs, Phage Display selections against bovine
G1-IGD-G2, dog G1-IGD-G2 and human G1 domains were performed. Of
1245 clones screened in ELISA for binding to human, cynomolgus,
rat, dog and bovine G1-IGD-G2, only 15 novel species cross-reactive
ISVs were identified of which nine could be mapped to the
G1-domain.
[0702] A total of 19 unique clones were selected as `Lead panel`
for further characterization. An overview of the domain-mapping and
species cross-reactivity data for this lead panel is provided in
Table 1.2.
TABLE-US-00001 TABLE 1.2 Overview of periplasmic extract-based
screening data for the lead panel. Periplasmic extract ELISA. OD
450 nm Hu G1- Cy G1- Rat G1- Dog G1- Boy G1- Mapping Clone IGD-G2
IGD-G2 IGD-G2 IGD-G2 IGD-G2 G1 C0101PMP601E08 2.28 1.32 2.49 0.57
1.68 G1 C0101PMP102G11 1.69 0.60 0.16 1.02 0.32 G1 C0101PMP114F08
2.38 2.32 2.05 1.90 1.18 G1 C0101PMP112A01 2.50 2.50 2.03 1.57 2.41
G1 C0101PMP115B08 1.65 1.18 1.85 1.80 0.84 G1 C0101PMP117G09 2.21
2.21 2.29 1.68 0.76 G1 C0101PMP604B05 2.48 2.04 1.98 1.27 1.63 G1
C0101PMP606A05 0.25 1.24 0.93 0.51 0.19 G1 C0101PMP606A07 0.71 2.41
2.31 1.47 0.10 G1 C0101PMP608A05 2.33 2.48 2.39 0.86 2.27 G1
C0101PMP609C09 2.10 1.83 0.97 1.52 1.08 G2 C0101PMP112A03 2.51 2.36
1.69 1.47 0.73 G2 C0101PMP117D05 2.25 2.12 2.35 1.53 1.92 G2
C0101PMP604G09 2.41 1.57 1.40 1.16 1.21 G1-IGD-G2 C0101PMP113A01
2.56 2.57 2.53 2.51 2.54 G1-IGD-G2 C0101PMP601D02 2.58 nd 2.59 2.58
nd G1-IGD-G2 C0101PMP601E09 2.59 nd 2.61 2.57 nd G1-IGD-G2
C0101PMP604F02 2.41 1.37 0.78 1.04 0.82 G1-IGD-G2 C0101PMP604G01
2.27 1.25 0.60 1.55 0.68 control cAbLys3 0.05 0.06 0.06 0.06 0.06
control cAbLys3 0.05 0.05 0.06 0.06 0.05 Nd: not determined.
1.3 G1 Binders
[0703] The sequence variability in the CDRs of the G1-binders has
been determined against clone 114F08. The amino acid sequences of
the CDRs of clone 114F08 were used as reference, against which the
CDRs of all other clones (G1-binders) were compared, and are
depicted in the Tables 1.3A, 1.3B and 1.3C below (CDR1 starts at
Kabat position 26, CDR2 starts at Kabat position 50, and CDR3
starts at Kabat position 95).
TABLE-US-00002 TABLE 1.3A G1 CDR1* absolute 1 2 3 4 5 6 7 8 9 10
numbering wildtype G S T F I I N V V R sequence mutation R I S S Y
A M G mutation F M R G K mutation I T Y A mutation T T *up to 2
CDR1 mutations in one clone
TABLE-US-00003 TABLE 1.3B G1 CDR2* absolute 1 2 2a 3 4 5 6 7 8 9
numbering wildtype T I -- S S G G N A N sequence mutations A S R T
S S S T D G N W G R T Y T R N *up to 5 CDR2 mutations in one
clone
TABLE-US-00004 TABLE 1.3C G1 CDR3* absolute 1 2 3 4 5 6 6a 7 8 9 10
10a 11 12 13 numbering wildtype P T T H Y G -- G V Y Y -- G P Y
sequence mutations -- -- -- D F L R P G R N W S -- -- G R M Y V D T
S T A E K E L D L S G T S Y H S G Y D R P R T G Y V R D W E V W L G
S Y *up to 5 CDR3 mutations in one clone
1.4 G1-IGD-G2 Binders
[0704] The sequence variability in the CDRs of the G1-IGD-G2 (GIG)
binders has been determined against clone 604F02. The amino acid
sequences of the CDRs of clone 604F02 were used as reference,
against which the CDRs of all other clones (GIG binders) were
compared, and are depicted in the Tables 1.4A, 1.4B and 1.4C below
(CDR1 starts at Kabat position 26, CDR2 starts at Kabat position
50, and CDR3 starts at Kabat position 95).
TABLE-US-00005 TABLE 1.4A GIG CDR1* absolute 1 2 3 4 5 6 7 8 9 10
numbering wildtype G R T F S S Y T M G sequence mutation L T A *up
to 2 CDR1 mutations in one clone
TABLE-US-00006 TABLE 1.4B GIG CDR2* absolute 1 2 3 4 5 6 7 8 9 10
numbering wildtype A I S W S G G R T Y sequence mutations S T R *up
to 2 CDR2 mutations in one clone
TABLE-US-00007 TABLE 1.4C GIG CDR3* absolute 1 2 3 4 5 6 7 8 9 10
11 12 13 14 15 numbering wildtype Y R R R R A S S N R G L W D Y
sequence mutations V Y T -- P T E T P L V *up to 5 CDR3 mutations
in one clone
1.5 G2 Binders
[0705] The sequence variability in the CDRs of the G2-binders has
been determined against clone 601D02. The amino acid sequences of
the CDRs of clone 601002 were used as reference, against which the
CDRs of all other clones (G2 binders) were compared, and are
depicted in the Tables 1.5A, 1.5B and 1.5C below (CDR1 starts at
Kabat position 26, CDR2 starts at Kabat position 50, and CDR3
starts at Kabat position 95).
TABLE-US-00008 TABLE 1.5A G2 CDR1* absolute 1 2 3 4 5 6 7 8 9 10
numbering wildtype G P T F S R Y A M G sequence mutation R S I N N
R F Y mutation R M -- -- S *up to 5 CDR1 mutations in one clone
TABLE-US-00009 TABLE 1.5B G2 CDR2* absolute 1 2 3 4 5 6 7 8 9 10 11
numbering wildtype A I T W S S G G R T Y sequence mutations S L N A
S N Y D R T *up to 5 CDR2 mutations in one clone
TABLE-US-00010 TABLE 1.5C G2 CDR3* absolute 1 2 3 4 5 6 7 8 9 10 11
12 13 14 15 16 numbering wildtype A R I P V R T Y T S E W N Y -- --
sequence mutations R I H G S G R R S E N D D -- D N F L Q N N W S
-- K A -- -- F Y -- -- -- *up to 5 CDR3 mutations in one clone
1.6 Sequence Optimization of ISVs
[0706] Various ISVs were subjected to a sequence optimisation
process. Sequence optimisation is a process in which a parental ISV
sequence is mutated. This process covers the humanisation (i) of
the ISV and knocks-out post-translational modifications (ii) as
well as epitopes for potential pre-existing antibodies (iii).
[0707] (i) for humanisation purposes the parental ISV sequence is
mutated to yield a ISV sequence which is more identical to the
human IGHV3-IGHJ germline consensus sequence. Specific amino acids
in the framework regions (with the exception of the so-called
hallmark residues) that differ between the ISV and the human
IGHV3-IGHJ germline consensus are altered to the human counterpart
in such a way that the protein structure, activity and stability
are kept intact. A handful of hallmark residues are known to be
critical for the stability, activity and affinity of the ISV and
are therefore not mutated. [0708] (ii) the amino acids present in
the CDRs and for which there is experimental evidence that they are
sensitive to post-translational modifications (PTM) are altered in
such a way that the PTM site is inactivated while the protein
structure, activity and stability are kept intact. [0709] (iii) the
sequence of the ISV is optimised, without affecting protein
structure, activity and stability, to minimise binding of any
naturally occurring pre-existing antibodies and reduce the
potential to evoke a treatment-emergent immunogenicity
response.
[0710] For the generation of sequence optimised formatted ISVs, the
ISV building were produced in Pichia pastoris as tagless proteins
and purified via Protein A affinity chromatography, followed by
desalting, all according to standard protocols.
[0711] Various sequence optimised formatted ISVs are shown in
Tables A-1 and A-2.
Example 2 Characterization of the Lead Panel (Purified ISVs)
Aggrecan
[0712] After the primary screening, initial assessment of binding
via ELISA, determination of off-rate and species cross-reactivity,
the ISVs of the Lead panel were subjected to further
characterization.
2.1 Formatting Aggrecan Lead Panels with ALB26 (n=19)
[0713] It is anticipated that the final format of a molecule for
clinical use comprises one or two Aggrecan binding ISVs ("anchors")
and also one, two or more ISVs or other moieties with a therapeutic
mode of action. Hence, the 19 selected clones were fused in
monovalent or bivalent format to ALB26 (CAP-ALB26 or ALB26-CAP-CAP)
and expressed in P. pastoris. ALB26 is a variant of ALB11 (Albumin
binding ISV) with w two mutations in CDR1, which completely abolish
binding to Albumin from different species. The fusion to ALB26 was
performed in order to mimic the size of a final polypeptide format
comprising an Aggrecan binder. Without being bound by any theory,
the inventors hypothesized that the pl may influence cartilage
penetration and retention. As negative control, or `dummy`,
bivalent ALB26 (C01010030) was used.
2.2 Ex Vivo Bovine Cartilage Retention
[0714] Since there is no established assay for assessing cartilage
retention, the inventors developed reliable and reproducible ex
vivo cartilage retention assay using bovine cartilage.
[0715] Bovine bones were typically collected from the local
slaughter house. Cartilage was cut off the bones in .about.1 mm
thick strips and further cut into circular discs with a diameter of
3 mm with biopsy cutters. The cartilage discs were preferentially
taken from fresh cartilage.
[0716] The ability of the ISVs to be retained in the cartilage for
a prolonged period of time, following a relatively short exposure
of the Nanobody to the cartilage (which can be expected upon
intra-articular injection), was determined. The assay consisted of
incubating ex vivo cartilage, typically 3 mm bovine discs
(.about.10 mg wet weight) with 10 .mu.g/ml. Nanobody (100 .mu.l)
ON, followed by washing for up to 5 days (PBS/0.1% BSA/0.1%
NaN.sub.3/100 mM NaCl). Hereafter, bound (retained) Nanobody was
released from the cartilage in SDS-containing SDS-PAGE sample
buffer (LDS sample buffer Invitrogen) and analysed by Western Blot
(WB). The assay was typically performed with 4 cartilage discs per
Nanobody sample; 2 discs were analysed right after the Nanobody
incubation (t.sub.0) to determine the initial amount of bound
Nanobody; 2 discs were analysed after washing (t.sub.1-5 days). The
degree of retention was defined as the ratio of the amount of
Nanobody detected at t.sub.3-5 days and t.sub.0. To increase the
throughput of the assay, the determination of this ratio was
performed by visual inspection of the Western Blots giving a score
from 0-6, where 0 is no retention and 6 is furl retention.
[0717] A summary of the results is shown in Table 2.2.
TABLE-US-00011 TABLE 2.2 Epitope binning and cartilage retention of
the ALB26-formatted Aggrecan Lead Panel. Epitope Cartilage Target
bin C01010# Construct pl retention * G1 4 118 ALB26-114F08- 9.09
6.00 114F08 G1 1 131 ALB26-601E08- 9.00 6.00 601E08 G1-IGD-G2 8 106
ALB26-604F02- 9.61 6.00 604F02 G1-IGD-G2 8 94 604F02-ALB26 9.47
5.33 G1 4 54 114F08-ALB26 9.02 5.00 G1 4 93 117G09-ALB26 9.13 5.00
G1 1 97 608A05-ALB26 9.09 5.00 G1 1 109 ALB26-608A05- 8.95 5.00
608A05 G2 7 115 ALB26-117D05- 8.73 5.00 117D05 G1-IGD-G2 8 47
601E09-ALB26 9.13 4.83 G2 6 108 ALB26-604G09- 9.13 4.00 604G09
G1-IGD-G2 8 95 604G01-ALB26 6.96 4.00 G1-IGD-G2 8 116 ALB26-113A01-
8.73 4.00 113A01 G1-IGD-G2 8 88 113A01-ALB26 8.53 3.50 G2 6 45
601D02-ALB26 9.15 3.40 G2 7 99 117D05-ALB26 9.10 3.33 G2 6 96
604G09-ALB26 8.99 3.00 G2 6 130 ALB26-601D02- 9.24 3.00 601D02 G1 1
46 601E08-ALB26 8.96 2.60 G1 5 60 606A07-ALB26 9.09 2.25 G1 5 113
ALB26-606A07- 8.62 2.00 606A07 G1 4 119 ALB26-115B08- 9.49 2.00
115B08 G2 6 117 ALB26-112A03- 9.12 2.00 112A03 G2 6 62 112A03-ALB26
9.21 1.66 G1 4 104 115B08-ALB26 8.66 1.50 G1 1 40 102G11-ALB26 9.20
1.33 G1 2 53 112A01-ALB26 9.17 1.00 G1 2 111 ALB26-112A01- 8.64
1.00 112A01 G1 3 56 604B05-ALB26 9.89 0.66 G1 3 59 606A05-ALB26
9.19 0.33 G1 2 98 609C09-ALB26 9.72 0.33 G1 2 110 ALB26-609C09-
8.13 0.00 609C09 G1 3 112 ALB26-604B05- 9.06 0.00 604B05 G1 3 114
ALB26-606A05- 9.03 0.00 606A05 Dummy 30 ALB26-ALB26 8.75 0.00 * The
table lists average scores from a number (n) of independent ex vivo
bovine cartilage retention assays on a scale from 0-6, in which 0
is no retention and 6 is full retention.
[0718] It was found that 9 constructs were retained very well
(scores 5-6) in the cartilage. This `top-9` included both
monovalent and bivalent constructs for the Aggrecan binding moiety
binding to all of the recombinant G1, G2 or G1-IGD-G2 domains. 14
constructs showed moderate retention (scores between <5 and 2)
and 5 constructs showed low albeit detectable retention (scores
between <2 and 1) in this assay. It is notable that all Aggrecan
constructs, except one, had pl values ranging from 8 to above
9.
2.3 Epitope Binning
[0719] For epitope-binning the purified ALB26-fused Nanobodies
constructs were screened against the same set of Nanobodies fused
with a FLAG-tag in a competition ELISA.
[0720] In short, the assay set up was as follows. Monoclonal phage
ELISA were incubated at half-saturating dilution of phage with or
without 1 .mu.M purified Nanobody (or 5 .mu.g/mL mAb). The ratio
between the absorbance at 450 nm in the presence and absence of
purified Nanobody (or mAb) was used to determine if the Nanobodies
recognised overlapping or non-overlapping epitopes.
[0721] The resulting epitope bins are shown in Table 2.2 (above).
Constructs in epitope bins 2 and 3 (on the G1-domain) had low
cartilage retention scores (0-1) in the ex vivo bovine cartilage
retention assay. There appears to be, however, no direct
correlation between binding to bovine Aggrecan G1-IGD-G2 as
measured by ELISA and bovine cartilage retention. Without being
bound to any theory, the inventors hypothesized that these epitopes
may not be easily accessible in the native cartilage tissue.
[0722] The sequence variability of the CDRs of clones belonging to
a bin is depicted below and above (i.e. bin 8 with 604F02 as
reference compound; Tables 1.4A-C).
[0723] The sequence variability of the G1-binders of epitope bin 4
against 114F08 is depicted in the Tables 2.3A, 2.3B and 2.3C below.
The amino acid sequences of the CDRs of clone 114F08 were used as
reference, against which the CDRs of all other clones (epitope bin
4 binders) were compared (CDR1 starts at Kabat position 26, CDR2
starts at Kabat position 50, and CDR3 starts at Kabat position
95).
TABLE-US-00012 TABLE 2.3A (114F08) G1 bin 4 CDR1* absolute 1 2 3 4
5 6 7 8 9 10 numbering wildtype G S T F I I N V V R sequence
mutations I S S R Y M K F M Y A *Up to 2 CDR1 mutations in one
clone
TABLE-US-00013 TABLE 2.3B (114F08) G1 bin 4 CDR2* absolute 1 2 2a 3
4 5 6 7 8 9 numbering wildtype T I -- S S G G N A N sequence
mutations A N R T D G *Up to 2 CDR2 mutations in one clone
TABLE-US-00014 TABLE 2.3C (114F08) G1 bin 4 CDR3* absolute 1 2 3 4
5 6 7 8 9 10 11 12 13 numbering wildtype P T T H Y G G V Y Y G P V
sequence mutations -- -- -- D F L G R N S -- -- R M Y V D T E K E L
*Up to 5 CDR3 mutations in one clone
[0724] The sequence variability of the G1-binders of epitope bin 1
against 608A05 is depicted in the Tables 2.30, 2.3E and 2.3F below.
The amino acid sequences of the CDRs of clone 608A05 were used as
reference, against which the CDRs of all other clones (epitope bin
1 binders) were compared (CDR1 starts at Kabat position 26, CDR2
starts at Kabat position 50, and CDR3 starts at Kabat position
95).
TABLE-US-00015 TABLE 2.3D (608A05) G1 bin 1 CDR1* absolute 1 2 3 4
5 6 7 8 9 10 numbering wildtype G R T F S T Y T M G sequence
mutation S S A V *up to 2 CDR1 mutations in one clone
TABLE-US-00016 TABLE 2.3E (608A05) G1 bin 1 CDR2* absolute 1 2 3 4
5 6 7 8 9 10 numbering wildtype A I S W S G G T T Y sequence I R R
S mutations *up to 2 CDR2 mutations in one clone
TABLE-US-00017 TABLE 2.3F (608A05) G1 bin1 CDR3* absolute 1 2 3 4 5
6 7 8 9 10 11 12 13 14 15 numbering wilcitype R P R Y Y Y Y S L Y S
Y D Y -- sequence mutations G L L R S T P H P Y D F G S R S A -- R
A A *up to 5 CDR3 mutations in one clone
2.4 Binding Characteristics--ELISA and SPR
[0725] Based on the ex viva bovine cartilage retention and the
epitope binning data, some exemplary constructs from different
epitope bins were selected for further characterization. Binders to
the G2-domain were excluded from further characterization at this
stage for the reasons set out before.
[0726] The selected constructs were characterized in ELISA on the
recombinant G1-IGD-G2 region from human, cynomolgus, rat, dog and
bovine Aggrecan to determine their species cross-reactivity and on
recombinant human Neurocan and Brevican to determine selectivity.
The determined EC.sub.50 values are listed in Table 2.4A.
[0727] SPR (ProteOn) experiments were carried out for the
"monovalent" Aggrecan-ALB26 formats in order to determine
off-rates. The interaction of the Nanobodies with the Aggrecan
surface was found to be heterogeneous. The heterogeneity could be
due to re-binding events, a heterogeneous population of immobilized
Aggrecan and/or heterogeneous glycosylation patterns. As a
consequence, the calculated off-rates are only indicative. Overall
it appears that the dissociation kinetics were fast for the
Aggrecan comprising Nanobodies (Table 2.4B).
TABLE-US-00018 TABLE 2.4A Characterization of the ALB26-formatted
Aggrecan Lead panel by ELISA. EC50 (M) Epitope C01010 Neuro- Brevi-
Target bin # Construct Hu Cy Rat Dog Bov can can G1 4 54
114F08-ALB26 6.0E-09 4.4E-09 7.6E-09 3.0E-09 5.6E-09 No bind No
bind G1 4 118 ALB26-114F08-114F08 1.1E-10 7.6E-11 1.9E-10 2.4E-10
3.7E-10 No bind No bind G1 1 97 608A05-ALB26 2.4E-10 2.1E-10
3.3E-10 2.5E-08 2.8E-10 No bind No bind G1 1 109
ALB26-608A05-608A05 1.0E-10 9.1E-11 9.5E-11 3.3E-10 7.7E-11 No bind
No bind G1 1 46 601E08-ALB26 5.1E-09 6.8E-09 3.2E-10 6.1E-10
1.2E-09 No bind No bind G1 5 60 606A07-ALB26 1.2E-08 5.4E-09
8.4E-09 6.9E-09 No fit No fit No bind G1 5 113 AL326-606A07-606A07
6.7E-10 3.0E-10 1.2E-10 3.0E-09 No fit 8.7E-10 No bind G1-IGD-G2 8
94 604F02-ALB26 1.2E-09 2.2E-09 5.9E-09 2.6E-09 1.6E-09 No bind No
bind G1-IGD-G2 8 106 ALB26-604F02-604F02 6.6E-11 6.8E-11 1.0E-10
9.7E-11 No fit No bind No bind Dummy 30 ALB26-ALB26 No bind No bind
No bind No bind No bind No bind No bind
TABLE-US-00019 TABLE 2.4B Characterization of the `monovalent`
ALB26-formatted Aggrecan Lead Panel (n = 5) by SPR (off-rate).
Off-rates are only indicative due to heterogeneous binding
patterns. C01010 G1-IGD-G2 (kd 1/s) Target # Construct human Cyno
Rat Dog Bovine G1 54 114F08-ALB26 1.3E-02 6.9E-03 6.5E-01 1.1E-02
4.7E-01 G1 97 608A05-ALB26 2.5E-03 1.8E-03 1.5E-03 8.3E-02 2.7E-03
G1 46 601E08-ALB26 3.4E-03 3.1E-03 2.5E-04 7.1E-03 1.3E-03 G1 60
606A07-ALB26 2.1E-02 2.0E-02 2.1E-02 3.8E-02 2.7E-02 G1-IGD-G2 94
604F02-ALB26 1.7E-01 1.5E-01 2.6E-01 1.2E-01 2.6E-01
Example 3 Biophysical Characterization of Monovalent Lead
Constructs--Aggrecan
[0728] Since all selected constructs demonstrated various
favourable characteristics, whether or not in combination, the ISVs
114F08 and 604F02 and their corresponding ALB26-formats
(C010100054, -118 and -094) were used as exemplary constructs
representing the Lead panel for further characterization,
3.1 Expression of Monovalent 114F08 and 604F02 in E. coli and P.
pastoris
[0729] For biophysical characterization, the monovalent Nanobodies
114F08 and 604F02 were expressed with FLAG.sub.3-His.sub.6-tags in
E. coli and/or P. pastoris and purified according to standard
protocols (e.g. Maussang et al. 2013 J Biol Chem 288(41):
29562-72).
3.2 pl, Tm and analytical SEC of 114F08 and 604F02
[0730] For the Thermal shift assay (TSA), 5 .mu.L purified
monovalent Nanobody (800 .mu.g/ml) was incubated with 5 .mu.L of
the fluorescent probe Sypro Orange (Invitrogen, 56551) (final
concentration 10.times.) in 10 .mu.L buffer (100 mM phosphate, 100
mM borate, 100 mM citrate, 115 mM NaCl, buffered at different pH
ranging from 3.5 to 9). The samples were heated in a LightCycler
48011 machine (Roche), from 37 to 99.degree. C. at the rate of
4.4.degree. C./s, after which they were cooled down to 37.degree.
C. at a rate of 0.03.degree. C./s. Upon heat-induced unfolding,
hydrophobic patches of the proteins are exposed to which the Sypro
Orange binds resulting in an increase in fluorescence intensity
(Ex/Em=465/580 nm). The inflection point of the first derivative of
the fluorescence intensity curve serves as a measure of the melting
temperature (Tm), essentially according to Ericsson et al. 2006
(Anals of Biochemistry, 357: 289-298).
[0731] The Analytical size exclusion chromatography (Analytical
SEC) experiments were performed on an Ultimate 3000 machine
(Dionex) in combination with a Biosep-SEC-3 (Agilent) column using
10 mM phosphate, 300 mM Arg-HCl, pH 6.0 as mobile phase. 8 .mu.g of
Nanobody sample (0.5 mg/mL in d-PBS) were injected.
[0732] The isoelectric points of the two Aggrecan ISVs are
relatively basic. The sequences are shown in Table A-1). The
melting temperature was determined to be 61.0.degree. C. for 114F08
and 70.0.degree. C. for 604F02. None of the clones showed signs of
aggregation or multimerisation as determined by analytical SEC.
[0733] Accordingly, next to the positive functional properties, the
ISVs demonstrate favourable biophysical properties.
3.3 114F08 Family Members
[0734] The sequence variability in the CDRs of the family members
of 114F08 is depicted in the Tables 3.3A, 3.3B and 3.3C below. The
amino acid sequences of the CDRs of clone 114F08 were used as
reference, against which the CDRs of all other clones (114F08
family members) were compared (CDR1 starts at Kabat position 26,
CDR2 starts at Kabat position 50, and CDR3 starts at Kabat position
95).
TABLE-US-00020 TABLE 3.3A 114F08 CDR1* Kabat 26 27 28 29 30 31 32
33 34 35 numbering absolute 1 2 3 4 5 6 7 8 9 10 numbering wildtype
G S T F I I N V V R sequence mutations S M *Up to 2 CDR1 mutations
in one clone
TABLE-US-00021 TABLE 3.3B 114F08 CDR2* Kabat 50 51 52 53 54 55 56
57 58 numbering absolute 1 2 3 4 5 6 7 8 9 numbering wildtype T I S
S G G N A N sequence mutations A R T T D *Up to 5 CDR2 mutations in
one done
TABLE-US-00022 TABLE 3.3C 114F08 CDR3* Kabat 95 96 97 98 99 100
100a 100b 100c 100d 100e 100f 100g numbering absolute 1 2 3 4 5 6 7
8 9 10 11 12 13 numbering wildtype P T T H Y G G V Y Y G P Y
sequence mutations . . . R . . . D . . . . . *Up to 2 CDR3
mutations in one clone
Example 4 Ex Vivo Binding to Cartilage from Various Species
[0735] The exemplary CAP comprising polypeptides (also designated
herein as "CAP comprising constructs" or "constructs") were shown
to bind recombinant/extracted human proteins and bovine cartilage
in the bovine ex vivo cartilage retention assay. In order to
demonstrate that these exemplary CAP comprising constructs also
bind to cartilage from other species, experiments as set out above
with bovine cartilage were repeated in essence with human cartilage
and rat cartilage.
4.1 Binding to Ex Vivo Human Cartilage
[0736] In order to confirm that the exemplary CAP comprising
constructs also bind to human cartilage, selected constructs were
tested in the ex vivo cartilage binding assay using frozen human
cartilage chips. Binding was determined after a 30 min wash by
means of Western Blot.
[0737] The results are summarized in Table 4.1.
[0738] It was found that all constructs bound better to the human
cartilage than the Dummy construct.
4.2 Binding to Ex Vivo Rat Cartilage
[0739] To facilitate testing of constructs in a rat in vivo model,
binding to rat cartilage was assessed. Therefore, an assay was set
up using femurs from rat with intact cartilage. Exemplary
constructs C010100054, -118, and -094 were incubated with the rat
cartilage overnight, followed by a 30 min wash, release of bound
constructs followed by Western Blot analysis.
[0740] The results are shown in Table 4.2.
[0741] It was found that all the tested constructs bound well to
Rat cartilage.
Example 5 Tissue Specificity
[0742] It was demonstrated above that the constructs of the
invention bind specifically to Aggrecan both in vitro and ex vivo.
In addition, these constructs should also bind preferably to the
cartilage of a joint, while not or less to other tissues in a
joint.
[0743] Binding of exemplary CAP comprising constructs to synovial
membrane, tendon, epimysium and meniscus was assessed using the
same set up as for the ex vivo cartilage binding assay. Construct
release and Western Blot analysis were performed following a brief
wash of the tissues (30 min) after ON incubation with the
constructs.
[0744] The results are summarized in Table 5.
[0745] The results show that CAP binders show preferential binding
to the cartilaginous tissues, including meniscus, over the other
tissues found in the joint.
TABLE-US-00023 TABLE 5 Tissue specificity. Binding of the
ALB26-formatted Lead Panel (n = 10) to articular cartilage,
synovial membrane, tendon, epimysium and meniscus. C010100 Synovial
Target # Construct Cartilage Membrane Tendon Epimysium Meniscus G1
054 114F08-AB26 +++++ +/- + +/- nd G1 118 ALB26-114F08-114F08 +++++
+ + + nd G1-IGD-G2 094 604F02-ALB26 +++++ + + +/- nd G1 046
601E08-ALB26 ++++ +/- + nd +++ Dummy 030 ALB26-ALB26 +/- +/- +/- -
-
Example 6 Nanobody Stability in Bovine Synovial Fluid
[0746] For various reasons, including patient convenience and
safety, it is preferred that the constructs remain stable for
longer periods in the synovium.
[0747] Accordingly, the stability of the exemplary ALB26-fused CAP
constructs in Synovial Fluid (SF) was assessed by incubation of the
constructs in non-arthritic bovine SF for up to 7 days at
37.degree. C.
[0748] The results are summarized in Table 6.
TABLE-US-00024 TABLE 6 Stability of ALB26-formatted Lead Panel in
bovine SF. Stability in Bovine Target C010100# Construct SF,
37.degree. C. G1 054 114F08-ALB26 >7 days G1 118
ALB26-114F08-114F08 >7 days G1-IGD-G2 094 604F02-ALB26 >7
days Dummy 030 ALB26-ALB26 >7 days
[0749] No degradation of any of the constructs could be
detected.
Example 7 Retention in IL-1.alpha.-Stimulated Explant Cartilage
[0750] Up to this point, all experiments addressing cartilage
binding and retention of the CAP comprising Nanobodies were
performed in healthy (non-arthritic) ex vivo cartilage. Arthritic
cartilage is characterized by degraded Collagen and Aggrecan. It is
therefore of relevance to also assess binding and retention of the
Aggrecan-binders in cartilage where degradation of these proteins
has taken place. To this end, the exemplary ALB26-fused CAP
constructs were tested in a cartilage explant assay in which
cartilage was stimulated to induce degradation.
[0751] In short, the exemplary CAP comprising constructs were
incubated overnight (ON) with bovine cartilage explants that were
cultured with, or without, IL-1.alpha. and Oncostatin M, followed
by 5 days of culture with daily change of medium (wash).
IL-1.alpha. and Oncostatin M primarily induce the degradation of
Aggrecan within the 6 days of the experiment. The cartilage
explants were analysed for construct binding and retention by WB.
Two independent experiments were performed (Exp A and Exp B).
[0752] The results of the Western Blots are depicted in Table
7.1.
[0753] The results of the CAP comprising construct retention in
stimulated cartilage explants are summarized in Table 7.2.
TABLE-US-00025 TABLE 7.2 Summary of CAP binding and retention in
stimulated bovine cartilage explant assay. Binding stimulated vs
non- Retention Target C010100# Construct stimulated day 5 G1 054
114F08-ALB26 Reduced Partial G1 118 ALB26-114F08- Equal Full 114F08
G1-IGD-G2 094 604F02-ALB26 Reduced Partial G1 045 601D02-ALB26
Reduced Partial Dummy 030 ALB26-ALB26 No binding No binding
[0754] The results show that the constructs C01010054 ("054" or
"54") and C01010045 ("045" or "45") have reduced retention in
stimulated cartilage after 5 days of wash as compared to
non-stimulated cartilage, while constructs C01010118 ("118") and
C01010094 ("094" or "94") showed little sensitivity to
stimulation.
[0755] It further appears that binding to the G2 Aggrecan domain
(as exemplified by C01010045) is reduced more than binding to the
other domains, which would be consistent with the hypothesis that
Aggrecan degradation proceeds from the C-terminus.
Example 8 ADAMTS5-CAP GAG-Release Assay
[0756] In order to address the possible impact of CAP, the
cartilage anchoring moiety, on the potency of a protease inhibiting
Nanobody in cartilage tissue, the exemplary CAP constructs were
fused to an ADAMTS5 (ATS5) blocking ISV and tested in a GAG
(GlycosAminoGlycan)-release cartilage explant assay.
[0757] Before testing the constructs in the GAG-release cartilage
explant assay, the in vitro cartilage binding and ADAMTS5
inhibiting properties were confirmed. For the latter, an enzymatic
peptide assay was performed that showed that the enzyme-blocking
function of the ADAMTS5 ISV was not impaired in any of the
CAP-fusion constructs in vitro.
[0758] In the GAG-release assay, bovine cartilage explants were
cultured for 5 days in the presence of IL-1.alpha. and Oncostatin M
(for induction of ADAMTS5) and a dose range of constructs followed
by quantification of the released GAG content in the culture
supernatant.
[0759] The tested constructs and the results of the GAG-release
assay are summarized in Table 8.
TABLE-US-00026 TABLE 8 Summary of ADAMTS5-CAP GAG-release assay.
IC50 (nM) Peptide GAG- Target ID Construct assay release
ADAMTS-5-G1 C010100270 ATS5-114F08 0.11 4.17 ADAMTS-5-G1 C010100276
ATS5-114F08- 0.06 19.15 114F08 ADAMTS-5-G1- C010100271 ATS5-604F02
0.19 2.15 IGD-G2 ADAMTS-5-G1 C011400510 ATS5 (Tag-less) 0.12
0.87
[0760] The results show that adding the anchoring arm (CAP-ISV
construct) to the ADAMTS5 inhibitor still allowed for efficient
inhibition of GAG-release.
Example 9 In Vivo Bio-Imaging of CAP-Constructs
[0761] In parallel to the in vitro and ex vivo characterization of
the exemplary Aggrecan CAP constructs, in vivo bio-distribution was
determined for several of the ALB26-fusion constructs, in order to
confirm the retention properties.
9.1 Biodistribution Studies of ALB26-CAP Constructs
[0762] The Na nobodies were labeled with .sup.125I (via Lysine
coupling of .sup.125I-SIB). The constructs were injected into the
knee joints of healthy rats. Autoradiography images of the joints
were produced for different time points up to 4 weeks post
injection. These images allowed assessing the retention and the
tissue (cartilage) specificity of the constructs in an in
vivo-setting.
[0763] Representative images are shown in FIG. 1.
[0764] From the results it can be concluded that all constructs
showed specific binding to the cartilage. A clear staining--even 4
weeks post injection--was observed for both `monovalent` and
`bivalent` Aggrecan binders.
9.2 MARG of ALB26-CAP Constructs
[0765] The biodistribution study described above (Example 9.1)
demonstrated specific retention in the cartilage of the ALB26-CAP
constructs. However, the resolution of the images did not allow
investigation of the depth of penetration into the cartilage. In
order to increase the resolution of the imaging and thus to be able
to evaluate penetration into the cartilage, MARG
(Micro-Auto-Radio-Graphy) was used.
[0766] The exemplary constructs that went into the study are listed
in Table 9.2A. For this study, the Nanobodies were labelled with
.sup.3H (via lysine coupling of .sup.3H-NSP (N-Succinimidyl
propionate)) and injected into the healthy and osteoarthritic
(surgically induced via transection of the anterior cruciate
ligament) rat joints; 8 rats per group. 7 to 14 days after
injection the rats were sacrificed and the injected healthy and
OA-induced joints were processed for MARG.
[0767] Representative MARG images are shown in FIG. 2.
TABLE-US-00027 TABLE 9.2A Exemplary Nanobody constructs tested
Target C010100# Construct Aggrecan #54 114F08-ALB26 Aggrecan #626
ALB26-114F08-114F08 SO Aggrecan #94 604F02-ALB26 Dummy #30
ALB26-ALB26
[0768] All of the Aggrecan binders generally showed penetration
into the healthy cartilage. Construct 626 occasionally also showed
some more intense staining on the surface. Various degrees of
cartilage staining and penetration were seen in the operated knee:
no staining was observed with monovalent construct 054; staining
was absent or mild with monovalent construct 094 while the bivalent
construct 626 resulted in a somewhat more consistent staining
albeit with varying depths of penetration (see Table 9.2B)
TABLE-US-00028 TABLE 9.2B Summary MARG staining results. Healthy
Knee joint Operated Knee joint Silver grain Penetration Silver
grain Penetration Construct* evaluation Depth evaluation Depth 030
0% of samples na 0% of samples na stained stained 054 100% samples
C 0% of samples na with minimal stained staining 094 83% samples C
60% samples C with mostly with mostly mild staining mild staining
626 100% samples B-C 100% samples A-B-C with mostly with minimal
mild staining to mild staining *Overall results of 8 animals are
presented, based on a silver grain evaluation. Scoring of
distribution: A = surface of cartilage with virtually no deeper
staining, B = Surface of cartilage with some deeper staining, C =
Staining in deeper layers of cartilage with no accumulation at
surface
Example 10 In Vivo Rat MMT DMOAD Demonstrated a Statistical
Significant Effect
[0769] In order to further demonstrate the in vivo efficacy of the
CAP binders of the invention, a surgically induced Medial Meniscal
Tear (MMT) model in rats was used. In short, CAP binders of the
invention were coupled to an anti-MMP13 ISV (designated as "0754"
or "C010100754") or an anti-ADAMTS5 ISV (designated as "0954" or
"C010100954"). Rats were operated in one knee to induce OA-like
symptoms. Treatment started 3 days post-surgery by IA injection.
Histopathology was performed at day 42 post surgery. Interim and
terminal serum samples were taken for exploratory biomarker
analysis. The medial and total substantial cartilage degeneration
width was determined, as well as the percentage reduction of
cartilage degeneration. 20 animals were used per group.
[0770] The inhibition of cartilage degradation by Nanobodies in the
medial tibia is shown in FIG. 3.
[0771] The results demonstrate that the cartilage width was
substantially reduced by the ADAMTS5-CAP construct and the
MMP13-CAP construct after 42 days compared to the vehicle. These
results suggest that the CAP-moiety (a) has no negative impact on
the activity of either the anti-MMP13 ISV (0754) or the
anti-ADAMTS5 ISV (0954); and (b) enables the retention of these
constructs for prolonged extension of time in the joints.
Example 11 Retention of CAP Binders in Healthy and Osteoarthritic
Rats is Similar In Vivo
[0772] It was demonstrated in a cartilage retention study in
healthy rats that the polypeptides of the invention were measurable
in cartilage up to 112 days after intra-articular (I.A.) injection
(data not shown). Since the cartilage composition can have an
influence on cartilage binding and absorption in systemic
circulation, the pharmacokinetics of the polypeptides of the
invention were compared in diseased osteoarthritis and healthy rats
in vivo by following the serum level of the polypeptides in
time.
[0773] In particular, the surgically induced Medial Meniscal Tear
(MMT) model in rats was used as described in Example 10, but with
some modifications. In short, the polypeptides of the invention
were coupled to an anti-MMP13 ISV and an anti-ADAMTS5 ISV,
resulting in an MMP13-ADAMTS5-CAP-CAP construct (designated as
"0949" or "C010100949" Nanobodies). Rats were operated in one knee
to induce OA-like symptoms (OA-group). Each treatment group
(healthy and OA) comprised of 15 animals, and received a single
I.A. injection of 400 .mu.g/30 .mu.l Nanobody at day 7 (healthy) or
7 days post-surgery (MMT). Serum samples were collected from
anesthetized rats at day 0, at day 7 (at 0 h=pre-dose sample) at
day 8 (at different times post treatment up to 24 h), day 9 (48 h
post-treatment), d10 (3 days post-treatment), d14 (7 days
post-treatment), d21 (14 days post-treatment) and d42 (35 days
post-treatment). Collected serum samples were used for the
determination of the polypeptide concentrations in an
electrochemoluminescence (ECL) based total PK assay format,
followed by a non-compartmental analysis.
[0774] The retention of the polypeptides in the serum of healthy
and OA rats is shown in FIG. 4.
[0775] The results demonstrate that no obvious differences can be
seen in the serum concentrations of the polypeptides in healthy
rats and OA rats. These results suggest that cartilage degradation
has no influence on the pharmacokinetics of the polypeptides of the
invention.
TABLE-US-00029 TABLE A-1 Amino acid sequences of monovalent
Aggrecan binders (''ID'' refers to the SEQ ID NO as used herein)
Name In Amino acid sequence 102G11 1
EVQLVESGGGLVQAGGSLRLSCAASGRSESSYAMGWERQAPGKEREFVSIISWSGGSTVYADS-
VKGRFTI SRDNAKNTVYLQMNSLKPEDTAIYYCAAGRLYRATPRPADFGSWGQGTQVTVSS
112A01 2
EVQLVESGGGLVQTGGSLRLSCVASGRAFSNYIMGWERQAPGKERDEVAAINWNGVTTHYTDS-
VKGRFTI SRDNAKSTSYLQMDSLKPDDTAVYFCAARGTVYSRTYGVSEEGYMYWGQGTQVTVSS
112A03 3
EVQLVESGGGLVQPGGSLRLSCAASGSIFSNREMYWYRQAPGKQRELVASITLSGSTNYADSV-
KGRFTIS RDNAKNTVYLQMNSLKPEDTAVYYCNTFLQNSFYWGQGTQVTVSS 113A01 4
EVOLVESGGGLVQPGGSLRLSCSASOFTFSGSWMFWVRQAPGKDYEWVASINSSGGRTYYDDS-
VKGRFTI SRDSAKNTLYLEMNNLKPEDTALYFCARSPRVGSWGQGTQVTVSS 114F08 5
EVQLVESGGGLVQAGGSLRLSCAASGSTFIINVVRWYRRTPGKQRELVATISSGGNANYVDSV-
RGRFSIS RDGAKNAVDLQMNGLKBEDTAVYYCNVPTTHYGGVYYGPYWGQGTQVTVSS 115B08
6 KVQLVESGGGINQPGGSLRLSCAASGFTESMYAMKWVRQAPGKGLEWVSGINSSGGRTNYAGS-
VKGRFTI SRDNAKNTLYLQMNSLKPEDTAVYYCATDFLGGRNSRGQGTQVTVSS 117D05 7
KVQLVESGGGLVQAGGSLRLSCAASRRTFNMMGWFRQAPGKEREFVAYITWNGGDTRYAESVK-
GRFTVSR DDVKNTMALQMNRLDPLDTAVYYCGVRINGSNWSTKADDYDNWGQGTQVTVSS
117G09 8
EVQLVESGGGSALPGGSLRLSCAASGITESSRYMRWYRQAPGRQRELVAAISSGGRTDYVDSV-
RGRFTLS INNAKNTVYLQMNDLKPEDTAVYYCYRPRMYVDGTYEKELWGQGTLVTVES 601D02
9 DVQLVESGGGLVQPGGSLRLSCAASGPTESRYAMGWFRQAPGKEREFVAAITWSSGGRTYYAD-
SVKGRFT ISRDNSKNTVYLQMNSLRFEDTAVYYCAAARIPVRTYTSEWNYWGQGTLVTVES
601E08 10
DVOLVESGGGLVQPGGSLRLSCTASGRTESSYAVGWERQAPGKEREFVAAISRSGRSTYYADS-
VKGRFTI SRDNSKNTVYLQMNSLRPEDTAVYYCAAGLSYYSPHAYYDYWGQGTLVTVSS 601E09
11 DVQLVESGGGLVQPGGSLRLSCAASGLTESTYAMGWERQAPGKEREFVAAISWSGSRTYYADS-
VKGRFTI SRDNSKNTVYLQMNSLRPEDTAVYYCAAYRRPRYSPTGTWDYWGQGTLVTVSS
604B05 12
DVQLVESGGGLVQPGGSLRLSCVASGRTFSIYTMAWFRQARGKEREFVAAISWSSGRTYYADS-
VKGRFTI SRDNSKNTVYLQMNSLRPEDTAVYYCTAYTGPRSGYDYWGQGTLVTVSS 604E02 13
DVQLVESGGGLVQPGGSLRLSCAASGRTESSYTMGWERQAPGKEREFVAAISWSGGRTYYADS-
VKGRFTI SRDNSKNTVYLQMNSLRPEDTAVYYCAAYRRRRASSNRGLWDYWGQGTLVTVSS
604G01 14
DVQLVESGGGLVQPGGSLRLSCAASGRTESSYTMGWERQAPGKEREFVAAISWSGRTTYYADS-
VKGRFTI SRDNSKNTVYLQMNSLRFEDTAVYYCAAYRRVRYTNLEVWDYWGQGTLVTVSS
604G09 15
DVQLVESGGGLVQPGGSLRLSCVASGRTESSYAMGWFRQAPGKEREFVAATTWSSATTYYADS-
VKGRETT SRDNSKNTVYLQMNSLRPEDTAVYYCAAARIPVGRRSENWDYWGQGTLVTVSS
606A05 16
DVQLVESGGGLVQPGGSLRLSCVASGRTFSIYTMGWERQAPGKEREFVAAISWSGGRTYYADS-
VYGRFTI SRDNSKNTVYLQMNSLRPEDTAVYYCTAYTGRSYGSYDYWGQGTLVTVSS 606A07
17 DVQLVESGGGLVQPGGSLRLSCVASGRTFSIYGMGWERQAPGKEREFVAAINGGSRTYYADSV-
KGRFTIS RDNSKNTVYLQMNSLRFEDTAVYYCAADRSGYGTSLDWWYDYWGQGTLVTVSS
608A05 18
DVQLVESGGGLVQPGGSLRLSCAASGRTFSTYTMGWFRQAPGKEREFVAAISWSGGTTYYADS-
VKGRFTI SRDNSKNIVYLQMNSLRPEDTAVYYCAARPRYYYYSLYSYDYWGQGTLVTVSS
609C09 19
DVQLVESGGGLVQPGGSLRLSCAASGTIFSINVMGWYRQAPGKEREFVAAITTGGRTNYADSV-
KGRFTIS RDNSKNTVYLQMNSLRPBDTAVYYCNAEVTTGWVGYSWYDYWGQGTMVTVSS 114A09
114
EVQLVESGGGINQAGGSLRLSCAASGSTFIISVMRWYRQAPGKQRELVAAIRTGGNTDYAGPV-
RGRESIS RDGAKNAVDLQMNGLKPEDTAVYYCNVPTTRYGGDYYGPYWGQGTQVTVSS 114B04
115
EVQLVESGGGLVQAGGSLRLSCAASGSTFIISVMRWYRQAPGKQRELVAAIRTGGNTDYAGPV-
RGRESIS RDGAKDAVDLQMNGLKPEDTAVYYCNVPTTRYGGDYYGPYWGQGTQVTVSS 00269
116
EVQLVESGGGLVQPGGSLRLSCAASGSTFIINVVRWYRRAPGKQRELVATISSGGNANYVDSVR-
GRFTIS SO114F08 RDNSKNTVYLQMNSLRPEDTAVYYCNVPTTHYGGVYYGPYWGQGTLVTVSS
00745 117
EVQLVESGGGVVQPGGSLRLSCAASGSTFTINVVRWYRRAPGKQRELVATISSGGNANYVDSVR-
GRFTIS PEA114F08
RDNSKNTVYLOMNSLRPEDTALYYCNVPTTHYGGVYYGPYWGQGTLVTVSSA 00747 118
EVQLVESGGGVVQPGGSLRLSCAASGRTFSSYTMGWERQAPGKEREFVAAISWSGGRTYYADSV-
KGRFTI PEA604F02
SRDNSKNTVYLQMNSTAPEDTALYYCAAYRRRRASSNRGLWDYWGQGTLVTVSSA
TABLE-US-00030 TABLE A-2 Sequences for CDRs and frameworks, plus
preferred combinations as provided in formula I, namely
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (the following terms: ''ID'' refers
to the given SEQ ID NO) Nano- ID body ID FR1 ID CDR1 ID FR2 ID CDR2
ID FR3 ID CDR3 ID FR4 1 102G11 75 EVQLVESGGGLVQ 20 GRSFSSYAMG 85
WFRQAPGKEREFVS 38 IISWSGGSTV 94 YADSVKGRFTISRDNAKNTV 56
GRLYRATPRPADFGS 105 WGQGTQVTV AGGSLRLSCAAS YLQMNSLKPEDTAIYYCAA SS 2
112A01 76 EVQLVESGGGLVQ 21 GRAFSNYIMG 86 WFRQAPGKERDFVA 39
AINWNGVTTH 95 YTDSVKGRFTISRDNAKSTS 57 RGTVYSRTYGVSEEG 105 WGQGTQVTV
TGGSLRLSCVAS YLQMDSLKPDDTAVYFCAA YMY SS 3 112A03 77 EVQLVESGGGLVQ
22 GSIFSNRFMY 87 WYRQAPGKQRELVA 40 SITLSGSTN 96
YADSVKGRFTISRDNAKNTV 58 FLQNSFY 105 WGQGTQVTV PGGSLRLSCAAS
YLQMNSLKPEDTAVYYCNT SS 4 113A01 78 EVQLVESGGGLVQ 23 GFTFSGSWMF 88
WVRQAPGKDYEWVA 41 SINSSGGRTY 97 YDDSVKGRFTISRDSAKNTL 59 SPRVGS 105
WGQGTQVTV PGGSLRLSCSAS YLEMNNLKPEDTALYFCAR SS 5 114F08 75
EVQLVESGGGLVG 24 GSTFIINVVR 89 WYRRTPGKQRELVA 42 TISSGGNAN 98
YVDSVRGRFSISRDGAKNAV 60 PTTHYGGVYYGPY 105 WGQGTQVTV AGGSLRLSCAAS
DLQMNGLKPEDTAVYYCNV SS 6 115B08 79 KVQLVESGGGLVQ 25 GFTFSMYAMK 90
WVRQAPOKGLEWVS 43 GINSSGGRTN 99 YAGSVKGRFTISRDNAKNTL 61 DFLGGRNS
106 RGQGTQVTV PGGSLRLSCAAS YLQMNSLKPEDTAVYYCAT SS 7 117D05 80
KVQLVESGGGLVQ 26 RRTFNMMG 91 WFRGAPGKEREFVA 44 YITWNGGDTR 100
YAESVKGRFTVSRDDVKNTM 62 RIHGSNWSTKADDYD 105 WGQGTQVTV AGGSLRLSCAAS
ALQMNRLDPLDTAVYYCGV N SS 8 117G09 81 EVQLVESGGGSAL 27 GITFSSRYMR 92
WYRQAPGRQRELVA 45 AISSGGRTD 101 YVDSVRGRFTLSINNAKNTV 63
PRMYVDGTYEKEL 107 WGQGTLVTV PGGSLRLSCAAS YLQMNDLKPEDTAVYYCYR SS 9
601D02 82 DVQLVESGGGLVQ 28 GPTFSRYAMG 91 WFRQAPGKEREFVA 46
AITWSSGGRTY 102 YADSVKGRFTISRDNSKNTV 64 ARIPVRTYTSEWNY 107
WGQGTLVTV PGGSLRLSCAAS YLQMNSLRPEDTAVYYCAA SS 10 601E08 83
DVQLVESGGGLVQ 29 GRTFSSYAVG 91 WFRQAPGKEREFVA 47 AISRSGRSTY 102
YADSVKGRFTISRDNSKNTV 65 GLSYYSPHAYYDY 107 WGQGTLVTV PGGSLRLSCTAS
YLQMNSLRPEDTAVYYCAA SS 11 601E09 82 DVQLVESGGGLVQ 30 GLTSTYANIG 91
WFRQAPGKEREFVA 48 AISWSGSRTY 102 YADSVKGRFTISRDNSKNTV 66
YRRPRYSPTGTWDY 107 WGQGTLVTV PGGSLRLSCAAS YLQMNSLRPEDTAVYYCAA SS 12
604B05 84 DVQLVESGGGLVQ 31 GRTFSIYTMA 91 WFRQAPGKEREFVA 49
AISWSSGRTY 183 YADSVKGRFTISRDNSKNTV 67 YTGPRSGYDY 107 WGQGTLVTV
PGGSLRLSCVAS YLQMNSLRPEDTAVYYCTA SS 13 604F02 82 DVQLVESGGGLVQ 32
GRTFSSYTMG 91 WFRQAPGKERFFVA 50 AISWSGGRTY 102 YADSVKGRFTISRDNSKNTV
68 YRRRRASSNRGLWDY 107 WGQGTLVTV PGGSLRLSCAAS YLQMNSLRPEDTAVYYCAA
SS 14 604G01 82 DVQLVDSGGGLVQ 32 GRTFSSYTMG 91 WFRQAFGKEREEVA 51
AISWSGRTTY 102 YADSVKGRFTISRDNSKNTV 69 YRRVRYTNLEVWDY 107 WGQGTLVTV
PGGSLRLSCAAS YLQMNSLRPEDTAVYYCAA SS 15 604G09 84 DVQLVESGGGLVQ 33
GRTFSSYAMG 91 WFRQAPGKEREEVA 52 AITWSSATTY 102 YADSVKGRFTISRDNSKNTV
70 ARIPVGRRSENWDY 107 WGQGTLVTV PCCSDRLSCVAS YLQMNSLRFEDTAvYYCAA SS
16 606A05 84 DVQLVESGGGLVQ 34 GRTFSIYTMG 91 WFRQAPGKEREFVA 50
AISWSGGRTY 103 YADSVKGRFTISRDNSKNTV 71 YTGRSYGSYDY 147 WGQGTLVTV
PGGSLRLSCVAS YLQMNSLRPEDTAVYYCTA SS 17 606A07 84 DVQLVESGGGLVQ 35
GRTFSIYGMG 91 WFRQAPGKEREFVA 53 AINGGSRTY 102 YADSVKGRFTISRDNSKNTV
72 DRSGYGTSLDWWYDY 107 WGQGTLVTV PGGSLRLSCVAS YLQMNSLRFEDTAVYYCAA
SS 18 608A05 82 DVQLVESGGGLVQ 36 GRTFSTYTMG 91 WFRQAPGKEREFVA 54
AISWSGGTTY 102 YADSVKGRFTISRDNSKNTV 73 RPRYYYYSLYSYDY 107 WGQGTLVTV
PGGSLRLSCAAS YLQMNSLRPEDTAVYYCAA SS 19 609C09 82 DVQLVESGGGLVQ 37
GTIFSINVMG 93 WYRQAPGKEREEVA 55 AITTGGRTN 104 YADSVKGRFTISRDNSKNTV
74 EVTTGWVGYSWYDY 108 WGQGTMVTV PGGSLRLSCAAS YLQMNSLRPEDTAVYYCNA SS
114 114A09 75 EVQLVESGGGLVQ 109 GSTFIISVMR 87 WYRQAPGKQRELVA 110
AIRTGGNTD 112 YAGPVRGRFSISRDGAKNAV 111 PTTRYGGDYYGPY 105 WGQGTQVTV
AGGSLRLSCAAS DLQMNGLKPEDTAVYYCNV SS 115 114B04 75 EVQLVESGGGLVQ 109
GSTFIISVMR 87 WYRQAPGKQRELVA 110 AIRTGGNTD 113 YAGFVRGRFSISRDGAKDAV
111 PTTRYGGDYYGPY 105 WGQGTQVTV AGGSLRLSCAAS DLOMNGLKPEDTAVYYCNV SS
116 0269 77 EVQLVESGGGLVQ 24 GSTFIINVVR 121 WYRRAPGKQRELVA 42
TISSGGNAN 122 YVDSVRGRFTISRDNSKNTV 60 PTTHYGGVYYGPY 107 WGQGTLVTV
PGGSLRLSCAAS YLQMNSLRPEDTAVYYCNV SS 117 0745 119 EVQLVESOGGVVQ 24
GSTFIINVVR 121 WYRRAPGKQRELVA 42 TISSGGNAN 123 YVDSVRGRFTISMNSKNTV
60 PTTHYGGVYYGPY 107 WGQGTLVTV PGGSLRLSCAAS YLQMNSLRFEDTALYYCNV SS
118 0747 120 DVQLVESGGGVVQ 32 GRTFSSYTMG 91 WFRQAPGKEREFVA 50
AISWSGGRTY 124 YADSVKGRFTISRDNSKNTV 68 YRRRRASSNRGLWDY 107
WGQGTLVTV PGGSLRLSCAAS YLQMNSLRPEDTALYyCAA SS
TABLE-US-00031 TABLE B Aggrecan sequences and others from various
species (''ID'' refers to the SEQ ID NO as used herein) Name ID
Amino acid sequence human 125
MTTLLWVFVTLRVITAAVTVETSDHIDNSLSVSIPUSPLRVLLGTSLTIPCYFIDPMHPVTTAP-
STAPLA Aggrecan
PRIKWSRVSKEKEVVLLVATEGRVRVNSAYQDKVSLPNYPAIPSDATLEVQSLASNDSGVYRCE-
VMHGIE
DSEATLEVVVKGIVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVR
YPIHTPREGCYGDKDEFPGVRTYGIRDTNETYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRRLGARL
ATTGHVYLAWQAGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYVHANQTGYPDPSSRYDAICYT
GEDFVDIPENFFGVGGEEDITVQTVTWPDMELPLPRNITEGEARGSVILTVKPIFEVSPSPLEPEEPFTF
APEIGATAFAEVENETGEATRPWGFPTPGLGPATAFTSEDLVVQVTAVPGQPHLPGGVVFHYRPGPTRYS
LTFEEAQQACPGTGAVIASPEQLQAAYEAGYEQCDAGWLRDQTVRYPIVSPRTPCVGDKDSSPGVRTYGV
RPSTETYDVYCFVDRLEGEVFFATRLEQFTFQEALEFCESHNATATTGQLYAAWSRGLDKCYAGWLADGS
LRYPIVTPRPACGGDKPGVRTVYLYPNQTGLPDPLSRHHAFCFRGISAVPSPGEEEGGITTSPSGVEEWI
VTQVVPGVAAVPVEEETTAVPSGETTATLEFTTEPENQTEWEPAYTENGTSPLPGILPTWPPTCAETEES
TEGPSATEVPSASEEPSPSEVPFPSEEPSPSEEPFPSVRPFPSVELFPSEEPFPSKEPSPSEEPSASEEP
YTPSPPEPSWTELPSSGEESGAPDVSGDFTGSGDVSMILDFSGQLSGDRASGLPSGDLDSSGLTSTVGSG
LTVESGLPSGDEERIEWPSTPTVGELPSGAEILEGSASGVGDLSGLPSGEVLETSASGVGDLSGLPSGEV
LETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISGLPSGEVLETTAPGVEDISG
LPSGEVLETTAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPG
VEDISCLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVL
ETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGLPSGEVLETAAPGVEDISGL
PSGEVLETAAPGVEDISGLPSGEVLETTAPGVERISGLPSGEVLETTAPGVDEISGLPSGEVLETTAPGV
EEISGLPSGEVLETSTSAVGDLSGLPSGGEVLEISVSGVEDISGLPSGEVVETSASGIEDVSELPSGEGL
ETSASGVEDLSRLFSGEEVLEISASGFGDLSGVPSGGEGLETSASEVGTDLSGLPSGREGIETSASGAED
LSGLPSGKEDLVGSASGDLDLGKLIDSGTLGSWAPETSGLPSGFSGEYSGVDLGSGPPSGLPDFSGLPSG
FPTVSLVDSTINEVVTASTASELEGRGTIGISGAGEISGLPSSELDISGRASGLPSGTELSGQASGSPDV
SGEIPGLFGVSGQPSGFPDTSGETSGVTELSGLSSGQPGVSGEASGVLYGTSQPFGITDLSGETSGVPDL
SGQRSGLPGFSGATSGVPDLVSGTTSGSGESSGITFVDTSLVEVAPTTFKEEEGLGSVELSGLPSGEADL
SGKSGMVDVSGQFSGTVDSSGFTSQTPEFSGLPSGIAEVSGESSRAEIGSSLPSGAYYGSGTPSSFPTVS
LVDRTLVESVTQAPTAQEAGEGPSGILELSGAHSGAPDMSGEHSGPLDLSGLQSGLIEPSGEPPGTPYFS
GDFASTTNVSGESSVAMGTSGEASGLPEVTLITSEFVEGVTEPTISQELGQRPPVTHTPQLFESSGKVST
AGDISGATPVLPGSGVEVSSVPESSSETSAYPEAGFGASAAPEASREDSGSPDLSETTSAPHEANLERSS
GLGVSGSTLTFQEGEASAAPEVSGESTTTSDVGTEAPGLPSATPTASGDRTEISGDLSGHTSQLGVVIST
SIPESEWTQQTQRPAETHLEIESSSLLYSGEETHTVETATSPTDASIPASPEWKRESESTAAAPARSCAE
EPCGAGTCKETEGHVICLCPPGYTGEHCNIDQEVCEEGWNKYQGHCYRHFPDRETWVDAERRCREQQSHL
SSIVTPEEQEFVNNNAQDYQWIGLNDRTIEGDFRWSDGHPMQFENWRPNQPDMFFAAGEDCVVMIWHEKG
EWNDVPCNYHLPFTCKKGTVACGEPPVVEHARTFGQKKDRYEINSLVRYQCTEGFVQRHMPTIRCQRSGH
WEEPRITCTDATTYKRRLQKRSSRHPRRSRPSTAH dog 126
MTTLLWVFVTLRVITAASSEETSDHDNSLSVSIPEPSPMRVLLGSSLTIPCYFIDPMHPVTTAPST-
APLA Aggrecan
PRINNSRITKEKEVVLLVATEGQVRINSAYQDKVSLPNYPAIPSDATLEIQNLRSNDSGIYECE-
VMHGIE
DSEATLEVVVKGIVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVR
YPIHTPREGCYGDKDEFPGVRTYGIRDTNETYDVYCFAEEMEGEVLYATSPEKETEQEAANECRRLGARL
ATTGQLYLAWQGGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYLHANQTGYPDESSRYDATCYT
GEDFVDIPENFFGVGGEEDITIQTVTWPDVELPLPRNITEGEARGNVILTVKPIFDLSPTAPEPEEPFTF
VPEPEKPFTFATDVGVTAFPEAENRTGEATRPWGVPEESTPGPAFTAFTSEDIWVQVTAVPGAAEVPGQP
RLPGGVVEHYRPGSARYSLTFEEAQQACLETGAVIASPEQLQAAYEAGYEQCDAGWLQDQTVRYPIVSPR
TPCVGDKDSSPGVRTYGVRPPSETYDVYCYVDKLEGEVFFITRLEQFTFQEALAFCESHNATIASTGQLY
AAWRQGLDKCYAGWLSDGSLRYPIVTPRPSCGGDKPGVRTVYLYPNQTGLPDPLSRHHVECFRGVSGVPS
PGEEEGGTPTPSVVEDWIPTQVGPVVPSVPMGEETTAILDFTIEPENQTEWEPAYSPAGTSPLPGIPPTW
PPTSTATEESTEGPSGTEVPSVSEEPSPSEEPFPWEELSTLSPPGPSGTELPGSGEASGVPEVSGDFTGS
GEVSGHPDSSGQLSGESASGLESEDLDSSGLTSAVGSGLASGDEDRITLSSIPKVEGEGLETSASGVEDL
SGLPSGREGLETSTSGVGDLSGLPSGEGLEVSASGVEDLSGLPSGEGPETSTSGVGDLSRLPSGEGPEVS
ASGVGDLSGLPSGREGLETSTSGVEDLSGLPSGEGPEASTSGVGDLSRLPSGEGPEVSASGVEDLSGLPS
GEGLEASASGVGDLSGLPSGEGPEASASGVGDLSRLPSGEGPEVSASGVEDLSGLSSGESPEASASGVGD
LSGLPSGREGLETSASGVGDLSGLPSGEGQEASASGVEDLSRLESGEGPEASASGVGELSGLPSGREGLE
TSASGVGDLSGLPSGEGPEAEASGVEDLSILPSGEGPEASASGVGDLSGLPSGREGLETSTSGVGDLSGL
PSGREGLETSTSGVGDLSGLPSGEGPEASASGIGDISGLESGREGLETSSSGVEDHPETSASGVEDLSGL
PSGVEGHPETSASGVEDLSDLSEGGEGLETSASGAEDLSGEPSGKEDLIGSASGALDEGRIPSGTLGSGQ
APEASSLPSGESGEYSGVDEGSGPISGLPDFSGLPSGEPTISLVDTTLVEVITTTSASELEGRGTIGISG
AGETSGLPVSELDISGAVSGLPSGAELSGQASGSPDMSGETSGFFGVSGQPSGFPDISGGTSGLFEVSGQ
PSGFSGETSGVTELSGLYSGQPDVSGEASGVPSGSGQPFGMTDLSGETSGVEDISGQPSGLPEFSGTTSG
IPDLVSSTMSGSGESSGITFVDTSLVEVTPTTFKEKKRLGSVELSGLPSGEVDLSGASGTMDISGQSSGA
TDSSGLTSHLPKESGLPSGAAEVSGESSGAEVGSSLPSGTYEGSGNEHEAFPTVELVDETLVESVTQAPT
AQEAGEGPSGILELSGAHSGAPDVSGDESGSLDLSGMQSGLVEPSGEPSSTPYFSGDFSGTMDVTGEPST
AMSASGEASGLLEVTLITSEFVEGVTEPTVSQELAQRPPVTHTPQLFESSGERSASGEISGATPAPPGSG
LEASSVPESSSETSDEPERAVGVSAAPEASGGASGAPDVSEATSTFPEADVEGASGLGVSGGTSAFPEAP
REGSATPEVINEPTTSYDVGREALGWPSATPTASGDRIEVSGDLSGHTSGLDVVISTSVPESEWIQQTQR
PAEAHLEIEASSPLESGEETQTAETATSPTDDASIPTSPSGTDESAPAIPDIDECLSSPCLNGATCVDAI
DSFTCLCLPSYRGDLCEIDQELCEEGWTKEQGHCYRYFPDRESWVDAESECEAQQSELSSIVTPEEQEEV
NNNAQDYQWIGLNDRTIEGDFRWSDGHSLQFENWRPNQPDNEEVSGEDCVVMIWHEKGEWNDVPCNYYLP
FTCKKGTVACGDPPVVEHARTEGQKKDRYEINSLVRYQCTEGEVQRHVPTIRCQPSGHWEKPRITCTDES
TYKRRLQKRSSRAPRRSRPSTAH bovine 127
MTTLLLVFVTLRVITAAISVEVSEPDNSLSVSIPEPSPLRVLLGSSLTIPCYFIDPMHPVTTA-
PSTAPLA Aggrecan
PRIKWSRISKEKEVVLLVATEGRVRVNSAYQDKVTLPNYPAIPSDATLEIQNMRSNDSGILRCE-
VMHGIE
DSQATLEVVVKGIVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVR
YPIHTPREGCYGDKDEFPGVRTYGIRDTNETYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRRLGARL
ATTGQLYLAWQGGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYLHANQTGYPDPSSRYDAICYT
GEDFVDTPESPFGVGGEEDITIQTVTWPDVELPLPRNITEGEARGSVILTAKPDFEVSPTAPEPEEPFTF
VPEVRATAFPEVENRTEEATRPWAFPRESTPGLGAPTAFTSEDLVVQVTLAPGAAEVPGQPRLPGGVVFH
YRPGSSRYSLTFEEAKQACLRTGAIIASPEQLQAAYEAGYEQCDAGWLQDQTVRYPTVSPRTPCVGDKDS
SPGVRTYGVRPPSETYDVYCYVDRLEGEVFFATRLEQFTFWEAQEFCESQNATLATTGQLYAAWSRGLDK
CYAGWLADGSLRYPTVTPRPACGGDKPGVRTVYLYPNQTGLLDPLSRHHAFCFRGVSAAPSPEEEEGSAP
TAGPDVEEWMVTQVGPGVAAVPIGEETTAIPGFTVEPENKTEWELAYTPAGTLPLPGIPPTWPPTGEATE
EHTEGPSATEVPSASEKPFPSEEPFPPEEPFPSEKPFPPEELFPSEKPFPSEKPFPSEEPFPSEKPFPPE
ELFPSEKPIPSEEPFPSEEPFPSEKPFPPEEPFPSEKPIPSEEPFPSEKPFPSEEPPPSEEPSTLSAPVP
SRTELFSSGEVSGVPEISGDFTGSGEISGHLDFSGQPSGESASGLPSEDLDSSGLTSTVGSGLPVESGLP
SGEEERITWTSAPKVDRLPSGGEGPEVSGVEDISCLPSGGEVHLETSASGVEDISGLPSGGEVHLEISAS
GVEDLSRIPSGEGETISASGVEDISGLPSGEEGHLEISASGVEDLSGIPSGEGPEVSASGVEDLIGLPSG
EGPEVSASGVEDLSRLPSGEGPEVSASGVEDLSGLPSGEGPEVSVSGVEDLSRLPSGEGFEVSASGVEDL
SRLPSGEGPEISVSGVEDISILPSGEGPEVSASGVEDLSVLPSGEGHLEISTSGVEDLSVLPSGEGHLET
SSGVEDISRLPSGEGPEVSASGVEDLSVLPSGEDHLEISASGVEDLGVLPSGEDHLEISASGVEDISRLP
SGEGPEVSASGVEDLSVLPSGEGHLEISASGVEDLSRLPSGGEDHLETSASGVGDLSGLPSGREGLEISA
SGAGDLSGLTSGKEDLTGSASGALDLGRIPSVTLGSGQAPEASGLPSGFSGEYSGVDLESGPSSGLPDFS
GLPSGFPTVSLVDTTLVEVVTATTAGELEGRGTIDISGAGETSGLPFSELDISGGASGLSSGAELSGQAS
GSPDISGETSGLFGVSGQPSGFPDISGETSGLLEVSGQPSGFYGEISGVTELSGLASGQPEISGEASGIL
SGLGPPFGITDLSGEAPGIPDLSGQPSGLPEFSGTASGTPDLVSSAVSGSGESSGITFVDTSLVEVTPTT
FKEEEGLGSVELSGLPSGELGVSGTSGLADVSGLSSGAIDSSGFTSQPPEFSGLPSGVTEVSGEASGAES
GSSLPSGAYDSSGLPSGFPTVSFVDRTINESVTQAPTAQEAGEGPSGILELSGAPSGAPDMSGDHLGSLD
QSGLQSGLVEPSGEPASTPYFSGDFSGTTDVSGESSAATSTSGEASGLPEVTLITSELVEGVTEPTVSQE
LGQRPPVTYTPQLFESSGEASASGDVPRFPGSGVEVSSVPESSGETSAYPEAEVGASAAPEASGGASGSP
NLSETTSTFHEADLEGTSGLGVSGSPSAFFEGPTEGLATPEVSGESTTAFDVSVEASGSPSATPLASGDR
TDTSGDLSGHTSGLDIVISTTIPESEWTQQTQRPAEARLEIESSSPVHSGEESQTADTATSPTDASIPAS
AGGTDDSEATTTDIDECLSSPCLNGATCVDAIDSFTCLCLPSYQGDVCEIQKLCEEGWTKFQGHCYRHFP
DRATWVDAESQCRKQQSHLSSIVTPEEQEFVNNNAQDYQWIGLNDKTIEGDFRWSDGHSLQFENWRPNQP
DNFFATGEDCVVMIWHEKGEWNDVPCNYQLPFTCKKGTVACGEPPVVEHARIFGQKKDRYEINALVRYQC
TEGFIQGHVPTIRCQPSGHWEEPRITCTDPATYKRRLQKRSSRPLRRSHPSTAH rat 128
MTTLLLVFVTLRVIAAVISEEVETHDNSLSVSIPQPSPLKALLGTSLTIPCYFIDPMHPVTTAPST-
APLT Aggrecan
PRIKWSRVSKEKEVVLLVATEGQVRVNSIYQDKVSLPNYPAIPSDATLEIQNLRSNDSGIYRCE-
VMHGIE
DSEATLEVIVKGIVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVR
YPIHTPREGCYGDKDEFPGVRTYGIRDTNETYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRTVGARL
ATTGQLYLAWQGGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYLHANQTGYPDPSSRYDATCYT
GEDFVDIPENFFGVGGEEDITIQTVTWPDLELPLPRNITEGEARGNVILTAKPIFDMSPTVSEPGEALTL
APEVGTTVFPEAGERTEKTTRPWGFPEEATRGPDSATAFASEDLVVRVTISPGAVEVPGQPRLPGGVVFH
YRPGSTRYSLTFEEAQQACIRTGAAIASPEQLQAAYEAGYEQCDAGWLQDQTVRYPIVSPRTPCVGDKDS
SPGVRTYGVRPSSETYDVYCYVDKLEGEVFFATQMEQFTFQEAQAFCAAQNATLASTGQLYAAWSQGLDK
CYAGWLADGTLRYPIVNPRPACGGDKPGVRTVYLYPNQTGLPDPLSKBHAFCFRGVSVVPSPGGTPTSPS
DIEDWIVTRVEPGVDAVPLEPETTEVPYFTTEPEKQTEWEPAYTPVGTSPLPGIPPTWLPTVPAAEEHTE
SPSASQEPSASQVPSTSEEPYTPSLAVPSGTELPSSGDTSGAPDLSGDFTGSTDTSGRLDSSGEPSGGSE
SGLPSGDLDSSGLGPTVSSGLPVESGSASGDGEIPWSSTPTVDRLPSGGESLEGSASASGTGDLSGLPSG
GEITETSASGTEEISGLPSGGDDLETSTSGIDGASVLPTGRGGLETSASGVEDLSGLPSGEEGSETSTSG
IEDISVLPTGESPETSASGVGDLSGLPSGGESLETSASGVEDVTQLPTERGGLETSASGIEDITVLPTGR
ENLETSASGVEDVSGLPSGKEGLETSASGIEDISVFPTEAEGLETSASGGYVSGIPSGEDGTETSTSGVE
GVSGLPSGGEGLETSASGVEDLGLPTRDSLETSASGVDVTGYPSGREDTETSVPGVGDDLSGLPSGQEGL
ETSASGAEDLGGLPSGKEDLVGSASGALDFGKLPSGTLGSGQTPEASGLPSGFSGEYSGVDIGSGPSSGL
PDFSGLPSGFPTVSLVDSTLVEVITATTASELEGRGTISVSGSGEESGPPLSELDSSADTSGLPSGTELS
GQTSGSLDVSGETSGFFDVSGQPFGSSGTGEGTSGTPEVSGQAVRSPDTTEISELSGLSSGQPDVSGEGS
GILFGSGQSSGITSVSGETSGISDLSGQPSGFPVLSGTTPGTPDLASGANSGSGDSSGITFVDTSLIEVT
PTTFREEEGLGSVELSGLPSGETDLSGTSGMVDVSGQSSGAIDSSGLISPTPEFSGLPSGVAEVSGEVSG
VETGSSLSSGAFDGSGLVSGFPTVSLVDRTLVESITLAPTAQEAGEGPSSILEFSGAHSGTPDISGDLSG
SLDQSTWQPGWTEASTEPPSSPYFSGDFSSTTDASGESITAPTGSGETSGLPEVTLITSELVEGVTEPTV
SQELGEGPSMTYTPRLFEASGEASASGDLGGPVTIFPGSGVEASVPEGSSDPSAYPEAGVGVSAAPEASS
QLSEFPDLHGITSASRETDLEMTTPGTEVSSNPWTFQEGTREGSAAPEVSGESSTTSDIDAGTSGVPFAT
PMTSGDRTEISGEWSDHTSEVNVTVSTTVPESRWAQSTQHPTETLQEIGSPNPSYSGEETQTAETAKSLT
DTPTLASPEGSGETESTAADQEQCEEGWTKFQGHCYRHFPDRETWVDAERRCREQQSHLSSIVTPEEQEF
VNKNAQDYQWIGLNDRTIEGDFRWSDGHSLQFEKWRPNQPDNFFATGEDCVVMIWHERGEWNDVPCNYQL
PFTCKKGTVACGEPPAVEHARTLGQKKDRYEISSLVRYQCTEGFVQRHVPTIRCQPSADWEEPRITCTDP
NTYKERLQKRTMRPTRRSRPSMAH Pig 129
AISVEVSEPDNSLSVSIPQPSPLRVLLGGSLTIPCYFIDPMHPVXTAPXTAPLAPRIKWSRVSKEK-
EVVL Aggrecan
LVATEGQVRVNSAYQDRVTLPNYPAIPSDATLETQNLRSNDSGIYRCEVMHGIEDSEATLEVVV-
KGIVPH (core)
YRAISXRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVRYPIHTPREGCYG-
DKDE
FPGVITYGIRDTNETYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRRLGARLATTGQLYLAWRGGMDM
CSAGWLADRSVRYPISKARPNCGGNLLGVRTVYLHANQTGYPDPSSRYDAICYTGEDFVDIPENFFGVGG
EEDITIQTVTWPDVELPLPRNITEGEARGTVILTVKPVFEFSPTAPEPEEPFTFAPGTGATAFPEAENRT
GEATRPWAFPEESTPGLGAPTAFTSEDINVQVTSAATEEGTEGPSATEAPSTSEEPFPSEKPFPSEEPFP
SEEPFPSEKPSASEEPFPSEQPSTLSAPVPSRTELPGSGEVSGAPEV mouse 130
MTTLLLVEVTLRVIAAVISEEVPDHDNSLSVSIPQPSPLKVLLGSSLTIPCYPIDPMHPVTTAP-
STAPLT Aggrecan
PRIKWSRVSKEKEVVLLVATEGQVRVNSIYQDKVSLPNYPAIPSDATLEIQNLRSNDSGIYRCE-
VMHGIE
DSEATLEVIVKGIVFHYRAISTRYTLDFDRAQRACLQNSAITATPEQLQAAYEDGFHQCDAGWLADQTVR
YPIHTPREGCYGDKEEFPGVRTYGIRDTNETYDVYCFAEEMEGEVEYATSPEKFTFQEAANECRRLGARL
ATTGQLYLAWQGGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYLHANQTGYPDPSSRYDAICYT
GEDFVDIPENFFGVGGEDDITIQTVTWPDLELPLPRNVTEGEALGSVILTAKPIFDLSPTISEPGEALTL
APEVGSTAFPEAEERTGEATRPWGEPAEVTRGPDSATAFASEDLVVRVTISPGAAEVPGQPRLPGGVVFH
YRPGSTRYSLTFEEAQQACMHTGAVIASPEQLQAAYEAGYEQCDAGWLQDQTVRYPIVSPRTPCVGDKDS
SPGVRTYGVRPSSETYDVYCYVDKLEGEVEFATRLEQFTEQEARAFCAAQNATLASTGQLYAAWSQGLDK
CYAGWLADGTLRYPIITPRPACGGDKPGVRTVYLYPNQTGLPDPLSKHHAFCFRGVSVAPSPGEEGGSTP
TSPSDIEDWIVTQVGPGVDAVPLEPKTTEVPYFTTEPRKQTEWEPAYTPVGTSPQRGIPPTWLPTLPAAE
EHTESPSASEEPSASAVPSTSEEPYTSSFAVPSMTELPGSGEASGAPDLSGDFTGSGDASGRLDSSGQPS
GGIESGLPSGDLDSSGLSPTVSSGLPVESGSASGDGEVPWSHTPTVGRLPSGGESPEGSASASGTGDLSG
LPSGGEITETSISGAEETSGLPSGGDGLETSTSGVDDVSGIPTGREGLETSASGVEDLSGLPSGEEGSET
STSGIEDISVLPTGGESLETSASGVGDLSGLPSGGESLETSASGAEDVTQLPTERGGLETSASGVEDITV
LPTGRESLETSASGVEDVSGLPSGREGLETSASGIEDISVEPTEAEGLDTSASGGYVSGIPSGGDGTETS
ASGVEDVSGLPSGGEGLETSASGVEDLGPSTRDSLETSASGVDVTGFPSGRGDPETSVSGVGDDFSGLPS
GKEGLETSASGAEDLSGLPSGKEDLVGSASGALDEGKLPPGTLGSGQTPEVNGEPSGFSGEYSGADIGSG
PSSGLPDFSGLPSGFPTVSLVDSTLVEVITATTSSELEGRGTIGTSGSGEVSGLPLGELDSSADISGLPS
GTELSGQASGSPDSSGETSGFEDVSGQPEGSSGVSEETSGIPEISGQPSGTPDTTATSGVTELNELSSGQ
PDVSGDGSGILFGSGQSSGITSVSGETSGISDLSGQPSGFPVFSGTATRTPDLASGTISGSGESSGITFV
DTSFVEVTPTTFREEEGLGSVELSGFPSGETELSGTSGTVDVSEQSSGAIDSSGLTSPTPEFSGLPSGVA
EVSGEFSGVETGSSLPSGAEDGSGINSGFPTVSLVDRTLVESITQAPTAQEAGEGPSGILEFSGAHSGTP
DISGELSGSLDLSTLQSGQMETSTETPSSPYFSGDFSSTTDVSGESIAATTGSGESSGLPEVTLNTSELV
EGVTEPTVSQELGHGPSMTYTPRLFEASGDASASGDLGGAVINFPGSGIEASVPEASSDLSAYPEAGVGV
SAAPEASSKLSEFPDLHGITSAFHETDLEMTTPSTEVNSNPWTFQEGTREGSAAPEVSGESSTTSDIDTG
TSGVPSATPMASGDRTEISGEWSDHTSEVNVAISSTITESEWAQPTRYPTETLQEIESPNPSYSGEETQT
AETTMSLTDAPTLSSSEGSGETESTVADQEQCEEGWTKEQGHCYRHEHDRETWVDAERRCREQQSHLSSI
VTPEEQEFVNKNAQDYQWIGLNDRTIEGDFRWSDGESLQFEKWRPNQPDNEFATGEDCVVMIWHERGEWN
DVPCNYQLPFTCKKGTVACGDPPVVEHARTLGQKKERYEISSLVRYQCTEGFVQRHVPTIRCQPSGHWEE
PRITCTDPNTYKERLQKRSMRPTRRSRPSMAH rabbit 131
MTTLLLVLVALRVIAAAISGDVSDLDNALSVSIPQPSPVRALLGTSLTIPCYFIDPVHPVTTA-
PSTAPLT Aggrecan
PRIKWSRISKDKEVVLLVANEGAVRINSAYQDKVSLPNYPAIPSDATLEIQSLRSNDSGIYRCE-
VMHGLE
DEEATLEVVVKGVVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVR
YPIHTPREGCYGDKDEFPGVRTYGIRDTNETYDVYCFAEEMEGEVFYATSPEKFTFQEAASECRRLGARL
ATTGQLYLAWQAGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYVHANQTGYPDPSSRYDAICYT
GEDFMDIPENFFGVGGEEDITVQTVTWPDVELPVPRNITEGEARGSVVLTAKPVLDVSPTAPQPEETFAP
GVGATAFPGVENGTEEATRPRGFADEATLGPSSATAFTSADLVVQVTAAPGVAEVPGQPRLPGGVVFHYR
PGPTRYSLTFEEAQQACLIRTGAAMASAEQLQAAYEAGYEQCDAGWLQWTVRYPIVSPRTPCVGDKDSSP
GVRTYGVRPPSETYDVYCYVDRLEGEVFFATRLEQFTFQEALESCESHNATIASTGQLYAAWSRGLDRCY
AGWLADGSLRYPTVTPRPACGGDKPGVRTVYLYPNQTGLPDPLSRHHAFCFROTSEAPSPGPEEGGTATP
ASGLEDWIVTQVGPGVAATPRAEERTAVPSFATEPGNQTGWEAASSPVGTSLLPGIPPTWPPTGTAAEGT
TEGLSTAAMPSASEGPYTPSSLVARETELPGLGVTSVPPDISGDLTSSGEASGLFGPTGQPLGGSASGLP
SGELDSGSLTPTVGSGLPIGSGLASGDEDRTQWSSSTEVGGVTSGAEIPETSASGVGTDLSGLPSGAEIP
ETFASGVGTDLSGLPSGAEIPETFASGVGTDLSGLPSGAEILETSASGVGTDLSGLPSGAEILETSASGV
GTDLSGLPSGAETLETSASGVGTDLSGLPSGAETRETFASGVGTDLSGLPSGAETLETSASGVGTDLSGL
PSGAEIPETSASGVGTDLSGLPSGAEILETSASGVGTDLSGLPSGAEILETSASGVGTDLSGLPSGAEIL
ETSASGVGTDLSGLFSGAEILETSASGVGTDLSGLPSGAEILETSASGVGTDLSGLPSGGEIPETFASGV
GDLSGLPPGREDLETLTSGVGDLSGLSSGKDGLVGSASGALDFGGTLGSGQIPETSGLPSGYSGEYSEVD
LGSGPSSGLPDFSGLPSGEPTVSLVDTPLVEVVTATTARELEGRGTIGISGAGETSGLPSSELDVSGGTS
GADISGEADVGGEASGLIVRGQPSGFPDTSGEAFGVTEVSGLSSGQPDLSGEASGVLFGSGPPPGITDLS
GEPSGQPSGLPEFSGTTHRIPDLVSGATSGSGESSGIAFVDTSVVEVTPTTLREEEGLGSVEFSGFPSGE
TGLSGTPETIDVSGQSSGTIDSSGFTSLAPEVSGSPSGVAEVSGEASCTEITSGLPSGVFDSSGLPSGFP
TVSLVDRTLVESVTQAPTAINAEGPSDILELSGVHSGLPDVSGAHSGFLDPSGLQSGLVEPSGEPPRTPY
FSGDFPSTPDVSGEASAATSSSGDISGLPEVTLVTSEFMEGVTRPTVSQELGQGPPMTHVPKLFESSGEA
LASGDTSGAAPAPPGSGLEASSVPESHGETSAYAEPGTKAAAAPDASGEASGSPDSGEITSVFREAAGEG
ASGLEVSSSSLASQQGPREGSASPEVSGESTTSYEIGTETSGLPLATPAASEDRAEVSGDLSGRTPVPVD
VVTNVPEAEWIQHSQRPAEMWPETKSSSPSYSGEDTAGTAASPASADTPGEPGPTTAAPRSCAEEPCGPG
TCQETEGRVTCLCPPGHTGEYCDTDIDECLSSPCVNGATCVDASDSFTCLCLPSYGGEILCETWEVCEEG
WTKFQGHCYRHFPDRETWVDAEGRCREQQSHLSSIVTPEEQEFVNNNAQDYQWIGLNDRTIEGDFRWSDG
HPLQFENWRPNQPDNFFATGEDCVVMIWHEKGEWNDVPCNYHLPFTCKKGTVACGDPEWVEHARTFGQKK
DRYEINSLVRYQCAEGFTQRHVPTIRCQPSGHWEEPRITCTHPTTYKRRVQKRSSRTLQRSQASSAP
cynomolgus 132
MTTLLWVFVTLRVIAAAVTVETSDHDNSLSVSIPQPSPLRVLLGTSLTIPCYFIDPMHPVTTAPSTAPLA
Aggrecan
PRIKWSRVSKEKEVVLLVATEGRVRVNSAYQDKVSLPNYPAIPSDATLEIQSLRSNDSGVYRCE-
VMHGIE
DSEATLEVVVKGIVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTVR
YPIHTPREGCYGDKDEFPGVRTYGIRDINETYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRRLGARL
ATTGQLYLAWQAGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYLHANQTGYPDPSSRYDAICYT
GEDFVDIPENFFGVGGEEDTTVQTVTWPDMELPLPRNITEGEARGSVILTVKPIFDVSPSPLEPEEPFTF
APEIGATAFPEVENETGEATRPWGFPTPGLGPATAFTSEDLVVQVTAVPGQPHLPGGVVPHYRPGSTRYS
LTFEEAQQACLRTGAVIASPEQLQAAYEAGYEQCDAGWLRDQTVRYPIVSPRTPCVGDKDSSPGVRTYGV
RPSTETYDVYCYVDRLEGEVFFATRLEQFTFQEALEFCESHNATLATTGQLYAAWSRGLDKCYAGWLADG
SLRYPIVTPRPACGGDKPGVRTVYLYPNQTGLPDPLSRHHAFCFRGVSAVPSPGEEEGGTPTSPSGVEDW
TATQVVPGVAAVPVEEETTAVPLGETTAILEFTTEPENQTEWEPAYTPMGTSPLPGILPTWPPTGTATEE
STEGPSATEVITASKEPSPPEVPFPSEEPSPSEEPFPSVRPFPSVEPSPSEEPFPSVEPSPSEEPSASEE
PYTPSPPVPSWTELPGSGEESGAPDVSGDFIGSGDVSGHLDFSGQLSGDRISGLPSGDLDSSGLTSTVGS
GLPVDSGLASGDEERTEWSSTPTVGELPSGAEILEGSASEVGDLSGLPSGENLETSASGVGDLSGLPSGE
VLETSASGVGDLSGLPSGEVLETSTSGVGDLSGLPSGEVLETSTSGVGDLSGLPSAGEVLETTASGVEDT
SGLPSGEVLETTASGVEDISGFPSGEVLETTASGVEDISGLPSGEVLETTASGVEDISGLPSGEVLETTA
SGVGDLGGLPSGEVLETSTSGVGDLSGLPSGEVVETSTSGVEDLSGLPSGGEVLETSTSGVEDISGLPSG
EVLETTASGIEDVSELPSGEGLETSASGVEDLSRLPSGEVLETSASGVGDISGLPSGGEVLETSASGVGD
LSGLPSGGEGLETSASGVGTDLSGLPSGREGLETSASGAEDLSGLPSGKEDLVGPASGDLDLGKLPSGTL
RSGQAPETSGLPSGFSGEYSGVDLGSGPPSGLPDFSGLPSGFPTVSLVDSTLVEVVTASTASELEGRGTI
GISGAGEISGLPSSELDISGEASGLPSGTELSGQASGSPDVSRETPGLFDVSGQPSGFPDISGGTSGISE
VSGQPSGFPDTSGETSGVTELSGLPSGQPGVSGEASGVPYGSSQPFGITDISGETSGVPDLSGQPSGLPG
FSGATSGVPDLVSGATSGSGESSGITFVDTSLVEVTPTTFKEREGLGSVELSGLPSGEADLSGRSGMVDV
SGQFSGTVDSSGFTSQTPEFSGLPTGIAEVSGESSGAETGSSLPSGAYYGSGLPSGFPTVSLVDRTINES
VTQAPTAQEAGEGPPGILELSGTHSGAPDMSGDHSGFLDVSGLQFGLVEPSGEPPSTPYFSGDFASTTDV
SGESSAAMGTSGEASGLPGVTLITSEFMEGVTEPTVSQELGQRPPVTHTPQLFESSGEASAAGDISGATP
VLPGSGVEVSSVPESSSETSAYPEAGVGASAAPETSGEDSGSPDLSETTSAFHEADLERSSGLGVSGSTL
TFQEGEPSASPEVSGESTTTGDVGTEAPGLPSATPTASGDRTEISGDLSGHTSGLGVVISTSIPESEWTQ
QTQRPAEAHLETESSSLLYSGEETHTAETATSPTDASIPASPEWTGESESTVADIDECLSSPCLNGATCV
DAIDSFTCLCLPSYGGDLCEIDQEVCEEGWTKYQGHCYRHFPDRETWVDAERRCREQQSHLSSIVTPEEQ
EFVNNNAQDYQWIGLNDRTIEGDFRWSDGHPMQFENWRPNQPDNFFAAGEDCVVMIWHEKGEWNDVPCNY
HLPFTCKKGTVACGEPPMVQHARTFGQKKDRYEINSLVRYQCTEGFVQRHVPTIRCQPSGHWEEPRITCT
DATAYKRRLQKRSSRHPRRSRPSTAH rhesus 133
MTTLLWVFVTLRVIAAAVTVETSDHDNSLSVSIPQPSPLRVLLGTSLTIPCYFIDPMHPVTTA-
PSTAPLA Aggrecan
PRIKWSRVSKEKEVVLLVATEGRVRVNSAYQDKVSLPNYPAIPSDATLEIQSLRSNDSGVYRCE-
VMHGIE XM_
DSEATLEVVVKGIVFHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYEDGFHQCDAGWLADQTV-
R 002804944.1
YPIHTPREGCYGDKDEFPGVRTYGIRDTNETYDVYCFAEEMEGEVFYATSPEKFTFQEAANECRRLGARL
ATTGQLYLAWQAGMDMCSAGWLADRSVRYPISKARPNCGGNLLGVRTVYLHANQTGYPDPSSRYDAICYT
GEDFVDIPENFFGVGGEEDITVQTVTWPDMELPLPRNITEGEARGSVILTVKPIFDVSPSPLEPEEPFTF
APEIGATAFPEVENETGEATRPWGFPTPGLGPATAFTSEDLVVQVTAVPGQPHLPGGVVFHYRPGSTRYS
LTFEEAQQACLRTGAVIASPEQLQAAYEAGYEQCDAGWLRDQTVRYPIVSPRTPCVGDKDSSPGVRTYGG
RPSTETYDVYCYVDRLEGEVFFATRLEQFTFQEALEFCESHNATLATTGQLYAAWSRGLDKCYAGWLADG
SLRYPIVTPRPACCGDKPGVRTVYLYPNQTGLPDPLSRHHAFCFRGVSAVPSPGEEEGGTPTSPSGVEDW
IATQVVPGVAAVPVEEETTAVPLGETTAILEFTTEPENQTEWEPAYTPMGTSPLPGILPTWPPTGTATEE
STEGPSATEVLTASKEPSPPEVPFPSEEPSPSEEPFPSVRPFPSVEPSPSEEPFPSVEPSPSEEPSASEE
PYTPSPPVPSWTELPGSGEESGAPDVSGDFIGSGDVSGHLDFSGQLSGDRISGLPSGDLDSSGLTSTVGS
GLPVDSGLASGDEERIEWSSTPTVGELPSGAEILEGSASEVGDLSGLPSGDVLETSASGVGDLSGLPSGE
VLETSVSGVGDLSGLPSGEVLETSTSGVGDLSGLPSGEVLETSTSGVGDLSGLPSAGEVLETTASGVEDI
SGLPSGEVLETTASGVEDISGFPSGEVLETTASGVEDISGLPSGEVLETTASGVEDISCIPSGEVLETTA
SGVGDLGGLPSGEVLETSTSGVGDLSGLPSGEVVETSTSGVEDLSGLPSGGEVLETSTSGVEDISGLPSG
EVLETTASGTEDVSELPSGEGLETSASGVEDLSRLPSGEVLETSASGVGDISGLPSGGEVLEISASGVGD
LSGLPSGGEGLETSASGVGTDLSGLPSGREGLETSASGAEDLSGLPSGKEDINGPASGDLDLGKLPSGTL
GSGQAPETSGLPSGFSGEYSGVDLGSGPPSGLPDFSGLPSGFPTVSLVDSTLVEVVTASTASELEGRGTI
GISGAGEISGLPSSELDISGEASGLPSGTELSGQASGSPDVSRETSGLFDVSGQPSGFPDTSGETSGVTE
LSGLPSGQPGVSGEASGVPYGSSQPFGITDLSGETSGVPDLSGQRSGLPGFSGATSGVPDINSGATSGSG
ESSDITFVDTSLVEVTPTTFKEEEGLGSVELSGLPSGEADLSGRSGMVDVSGQFSGTVDSSGFTSQTPEF
SGLPIGIAEVSGESSGAETGSSLPSGAYYGSELPSGFPTVSLVDRTLVESVTQAPTAQEAGEGPPGILEL
SGTHSGAPDMSGDHSGFLDVSGLQFGLVEPSGEPPSTPYFSGDFASTTDVSGESSAAMGTNGEASGLPEV
TLITSEFMEGVTEPTVSQELGQRPPVTHTPQLFESSGEASAAGDISGATPVLPGSGVEVSSVPESSSETS
AYPEAGVGASAAPETSGEDSGSPDLSETTSAFHEADLERSSGLGVSGSTLTFQEGEPSASPEVSGESTTT
GDVGTEAPGLPSATPTASGXXXXXXPTRSCAEEPCGAGTCKETEGHVICLCPPGYTGEHCNIDQEVCEEG
WTKYQGHCYRHFPDRETWVDAERRCREQQSHLSSIVTPEEQEFVNNNAQDYQWIGLNDRTIEGDFRWSDG
HPMQFENWRPNQPDNFFAAGEDCVVMIWHEKGEWNDVPCNYHLPFTCKKGTVACGEPPMVQHARTFGQKK
DRYEINSLVRYQCTEGFVQRHVPTIRCQPSGHWEEPRITCTDATAYKRRLQKRSSRHPRRSRPSTAH
human 134
MGAPFVWALGLLMLQMLLFVAGEQGTQDITDASERGLHMQKLGSGSVQAALAELVALPCLFTLQ-
PRPSAA neurocan
RDAPRIKWTKVRTASGQRQDLPILVAKDNVVRVAKSWQGRVSLPSYPRRRANATLLLGPLRASD-
SGLYRC
QVVRGIEDEQDLVPLEVTGVVFHYRSARDRYALTFAEAQEACRLSSAIIAAPRHLQAAFEDGFDNCDAGW
LSDRTVRYPITQSRPGCYGDRSSLPGVRSYGRRNPQELYDVYCFARELGGEVFYVGPARRLTLAGARAQC
RRQGAALASVGQLHLAWHEGLOQCDPGWLADGSVRYPIQTPRRRCGGPAPGVRTVYRFANRTGFPSPAER
FDAYCFRAHHPTSQHGDLETPSSGDEGEILSAEGPPVRELEPTLEEEEVVTPDFQEPLVSSGEEETLILE
EKQESQQTLSPIPGDPMLASWPTGEVWLSTVAPSPEDMGAGTAASSHTEVAPTDPMPRRRGRFKGLNGRY
FQQQEPEPGLQGGMEASAQPPTSEAAVNQMEPPLAMAVTEMLGSGQSRSPWADLTNEVDMPGAGSAGGKS
SPEPWLWPPTMVPPSTSGHSRAPVLELEKAEGPSARPATPDLFWSPLEATVSAPSPAPWEAFPVATSPDL
PMMAMLRGPKEWMLPHPTPISTEANRVEAHGEATATAPPSPAAETKVYSLPLSLTPTGQGGEAMPTTPES
PRADFRETGETSPAQVNKAEHSSSSPWPSVNRNVAVGFVPTETATEPTGLRGIPGSESGVEDTAESPTSG
LQATVDEVQDPWPSVYSKGLDASSPSAPLGSPGVFLVPKVTPNLEPWVATDEGPTVNPMDSTVTPAPSDA
SGIWEPGSQVFEEAESTTLSPQVALDTSIVTPLTTLEQGDKVGVPAMSTLGSSSSQPHPEPEDQVETQGT
SGASVPPHQSSPLGKPAVPPGTPTAASVGESASVSSGEPTVPWDPSSTLLPVTLGIEDFELEVLAGSPGV
ESFWEEVASGEEPALPGTPMNAGABEVHSDPCENNPCLHGGTCNANGTMYGCSCDQGFAGENCEIDIDDC
LCSPCENGGTCIDEVNGFVCLCLPSYGGSFCEKDTEGCDRGWHKFQGHCYRYFAHRRAWEDAEKDCRRRS
GHLTSVHSPEEHSFINSFGHENTWIGLNDRIVERDFQWTDNTGLQFENWRENQPDNFFAGGEDCVVMVAH
ESGRWNDVPCNYNLPYVCKKGTVLCGPPPAVENASLIGARKAKYNVHATVRYQCNEGFAQHHVATIRCRS
NGKWDRPQIVCTKPRRSHRMRRHHHHHQHHHQHHHHKSRKERRKHKKHPTEDWEKDEGNFC human
135
MAQLFLPLLAALVLAQAPAALADVLEGDSSEDRAFRVRIAGDAPLOGVLGGALTIPCHVHYLRP-
PPSRRA brevican
VIGSPRVKWTPLSRGREAEVLVARGVRVKVNEAYRFRVALPAYPASLTDVSLALSELRPNDSGI-
YRCEVQ
HGIDDSSDAVEVKVKGVVPLYREGSARYAFSFSGAQEACARIGAHIATPEQLYAAYLGGYEQCDAGWLSD
QTVRYPIQTPREACYGDMDGFPGVRNYGVVDPDDLYDVYCYAEDLNGELFLGDPPEKLTLEEARAYCQER
GAEIATTGQLYAAWDGGLDHCSPGWLADGSVRYPIVTPSQRCGGGLPGVKTLFLFPNQTGFPNKHSRFNV
YCFRDSAQPSAIPEASNPASNPASDGLEAIVTVTETLEELQLPQEATESESRGAIYSIPIMEDGGGGSST
PEDPAEAPRTLLEFETQSMVPPTGFSEEEGKALEEEEKYEDEEEKEEEEEETEVEDEALWAWPSELSSPG
PEASLPTEPAAQESSLSQAPARAVLQPGASPLPDGESEASRPPRVAGPPTETLPTPRERNLASPSPSTLV
EAREVGEATGGPELSGVPRGESEETGSSEGAPSLLPATRAPEGTRELEAPSEDNSGRTAPAGTSVQAQPV
LPTDSASRGGVAVVPASGDCVPSPCHNGGTCLEEEEGVRCLCLPGYGGDLCDVGLRFCNPGWDAFQGACY
KHFSTRRSWEEAETQCRMYGAHLASISTPEEQDFINNRYREYQWIGLNDRTIEGDFLWSDGVPLLYENWN
PGQPDSYFLSGENCVVMVWHDQGQWSDVPCNYHLSYTCKMGLVSCGPPPELPLAQVFGRPRLRYEVDTVL
RYRCREGLAQRNLPLIRCQENGRWEAPQISCVPRRPARALHPEEDPEGRQGRLLGRWKALLIPPSSPMPG
P
TABLE-US-00032 TABLE C Serum albumin binding ISV sequences (''ID''
refers to the SEQ ID NO as used herein) Name ID Amino acid sequence
Alb8 136
EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS Alb23 137
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTL
YADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS Alb129 138
EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDIATYYCTIGGSLSRSSQGTLVTVSSA Alb132
139 EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTL
YADSVKGRFTISRDNSKNTLYLQMNSLRPEDTATYYCTIOGSLSRSSQGTLVTVSSA Alb11 140
EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCIIGGSLSRSSQGTLVTVSS Alb11 141
EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
(S112K)-A YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVKVSSA
Alb82 142
EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS Alb82-A
143 EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEMVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSA Alb82-AA
144 EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSAA
Alb82-AAA 145
EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSAAA Alb82-G
146 EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLOMNSLRPEDIALYYCTIGGSLSRSSQGTLVTVSSG Alb82-GG
147 EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTTSRDNAKTTLYIQMNSLRPEDTALTYCITGGSLSRSSQGTLVTVSSGG
Alb82-GGG 148
EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALTYCTIGGSLSRSSQGTLVTVSSGGG Alb92
149 EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTL
YADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS Alb223 150
EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTL
YADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSSA ALB-COR1
151 SFGMS ALB-CDR2 152 STSGSGSDTLYADSVKG ALB-CDR3 153 GGSLSR Alb135
171 EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL
YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVKSA
TABLE-US-00033 TABLE D Linker sequences (''ID'' refers to the SEQ
ID NO as used herein) Name ID Amino acid sequence 3A linker
(Poly-A) 154 AAA 5GS linker 155 GGGGS 7GS linker 156 SGGSGGS 8GS
linker 157 GGGGGGGS 9GS linker 158 GGGGSGGGS 10GS linker 159
GGGGSGGGGS 15GS linker 160 GGGGSGGGGSGGGGS 18GS linker 161
GGGGSGGGGSGGGGGGGS 20GS linker 162 GGGGSGGGGSGGGGSGGGGS 25GS linker
163 GGGGSGGGGSGGGGSGGGGSGGGGS 30GS linker 164
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 35GS linker 165
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 40GS linker 166
GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGG GS G1 hinge 167
EPKSCDKTHTCPPCP 9GS-G1 hinge 168 GGGGSGGGSEPKSCDKTHTCPPCP Llama
upper long hinge 169 EPKTPKPQPAAA region G3 hinge 170
ELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCP RCPEPKSCDTPPPCPRCP
TABLE-US-00034 TABLE E-1 Polypeptides/constructs comprising a
therapeutic ISV as indicated and an ISV binding Aggrecan as
indicated Target (ISV binding) CAP (ISV) Cathepsin A 604F02
Cathepsin B 604F02 Cathepsin C 604F02 Cathepsin D 604F02 Cathepsin
E 604F02 Cathepsin F 604F02 Cathepsin G 604F02 Cathepsin H 604F02
Cathepsin K 604F02 Cathepsin L1 604F02 Cathepsin L2 (or V) 604F02
Cathepsin 0 604F02 Cathepsin S 604F02 Cathepsin W 604F02 Cathepsin
Z (or X) 604F02 ADAMTS1 604F02 ADAMTS2 604F02 ADAMTS3 604F02
ADAMTS4 604F02 ADAMTS5 604F02 ADAMTS6 604F02 ADAMTS7 604F02 ADAMTS8
604F02 ADAMTS9 604F02 ADAMTS10 604F02 ADAMTS11 604F02 ADAMTS12
604F02 ADAMTS13 604F02 ADAMTS14 604F02 ADAMTS15 604F02 ADAMTS16
604F02 ADAMTS17 604F02 ADAMTS18 604F02 ADAMTS19 604F02 ADAMTS20
604F02 MMP1 604F02 MMP2 604F02 MMP3 604F02 MMP7 604F02 MMP8 604F02
MMP9 604F02 MMP10 604F02 MMP11 604F02 MMP12 604F02 MMP13 604F02
MMP14 604F02 MMP15 604F02 MMP16 604F02 MMP17 604F02 MMP18 604F02
MMP19 604F02 MMP20 604F02 MMP21 604F02 MMP23A 604F02 MMP23B 604F02
MMP24 604F02 MMP25 604F02 MMP26 604F02 MMP27 604F02 MMP28
604F02
TABLE-US-00035 TABLE E-2 Polypeptides/constructs comprising a
therapeutic ISV as indicated and two ISVs binding Aggrecan as
indicated Target (ISV binding) CAP (ISV) Cathepsin A 114F08-114F08
Cathepsin B 114F08-114F08 Cathepsin C 114F08-114F08 Cathepsin D
114F08-114F08 Cathepsin E 114F08-114F08 Cathepsin F 114F08-114F08
Cathepsin G 114F08-114F08 Cathepsin H 114F08-114F08 Cathepsin K
114F08-114F08 Cathepsin L1 114F08-114F08 Cathepsin L2 (or V)
114F08-114F08 Cathepsin 0 114F08-114F08 Cathepsin S 114F08-114F08
Cathepsin W 114F08-114F08 Cathepsin Z (or X) 114F08-114F08 ADAMTS1
114F08-114F08 ADAMTS2 114F08-114F08 ADAMTS3 114F08-114F08 ADAMTS4
114F08-114F08 ADAMTS5 114F08-114F08 ADAMTS6 114F08-114F08 ADAMTS7
114F08-114F08 ADAMTS8 114F08-114F08 ADAMTS9 114F08-114F08 ADAMTS10
114F08-114F08 ADAMTS11 114F08-114F08 ADAMTS12 114F08-114F08
ADAMTS13 114F08-114F08 ADAMTS14 114F08-114F08 ADAMTS15
114F08-114F08 ADAMTS16 114F08-114F08 ADAMTS17 114F08-114F08
ADAMTS18 114F08-114F08 ADAMTS19 114F08-114F08 ADAMTS20
114F08-114F08 MMP1 114F08-114F08 MMP2 114F08-114F08 MMP3
114F08-114F08 MMP7 114F08-114F08 MMP8 114F08-114F08 MMP9
114F08-114F08 MMP10 114F08-114F08 MMP11 114F08-114F08 MMP12
114F08-114F08 MMP13 114F08-114F08 MMP14 114F08-114F08 MMP15
114F08-114F08 MMP16 114F08-114F08 MMP17 114F08-114F08 MMP18
114F08-114F08 MMP19 114F08-114F08 MMP20 114F08-114F08 MMP21
114F08-114F08 MMP23A 114F08-114F08 MMP23B 114F08-114F08 MMP24
114F08-114F08 MMP25 114F08-114F08 MMP26 114F08-114F08 MMP27
114F08-114F08 MMP28 114F08-114F08
Sequence CWU 1
1
1721124PRTArtificial SequenceNanobody Sequence 1Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser Ser Tyr 20 25 30Ala Met Gly
Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ser Ile
Ile Ser Trp Ser Gly Gly Ser Thr Val Tyr Ala Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75
80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95Ala Ala Gly Arg Leu Tyr Arg Ala Thr Pro Arg Pro Ala Asp Phe
Gly 100 105 110Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115
1202127PRTArtificial SequenceNanobody Sequence 2Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Val Ala Ser Gly Arg Ala Phe Ser Asn Tyr 20 25 30Ile Met Gly
Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Asp Phe Val 35 40 45Ala Ala
Ile Asn Trp Asn Gly Val Thr Thr His Tyr Thr Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Ser Tyr65 70 75
80Leu Gln Met Asp Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Phe Cys
85 90 95Ala Ala Arg Gly Thr Val Tyr Ser Arg Thr Tyr Gly Val Ser Glu
Glu 100 105 110Gly Tyr Met Tyr Trp Gly Gln Gly Thr Gln Val Thr Val
Ser Ser 115 120 1253115PRTArtificial SequenceNanobody Sequence 3Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Asn Arg
20 25 30Phe Met Tyr Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu
Val 35 40 45Ala Ser Ile Thr Leu Ser Gly Ser Thr Asn Tyr Ala Asp Ser
Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr
Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala
Val Tyr Tyr Cys Asn 85 90 95Thr Phe Leu Gln Asn Ser Phe Tyr Trp Gly
Gln Gly Thr Gln Val Thr 100 105 110Val Ser Ser 1154115PRTArtificial
SequenceNanobody Sequence 4Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ser Ala Ser
Gly Phe Thr Phe Ser Gly Ser 20 25 30Trp Met Phe Trp Val Arg Gln Ala
Pro Gly Lys Asp Tyr Glu Trp Val 35 40 45Ala Ser Ile Asn Ser Ser Gly
Gly Arg Thr Tyr Tyr Asp Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile
Ser Arg Asp Ser Ala Lys Asn Thr Leu Tyr65 70 75 80Leu Glu Met Asn
Asn Leu Lys Pro Glu Asp Thr Ala Leu Tyr Phe Cys 85 90 95Ala Arg Ser
Pro Arg Val Gly Ser Trp Gly Gln Gly Thr Gln Val Thr 100 105 110Val
Ser Ser 1155121PRTArtificial SequenceNanobody Sequence 5Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ile Ile Asn 20 25 30Val
Val Arg Trp Tyr Arg Arg Thr Pro Gly Lys Gln Arg Glu Leu Val 35 40
45Ala Thr Ile Ser Ser Gly Gly Asn Ala Asn Tyr Val Asp Ser Val Arg
50 55 60Gly Arg Phe Ser Ile Ser Arg Asp Gly Ala Lys Asn Ala Val Asp
Leu65 70 75 80Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr
Tyr Cys Asn 85 90 95Val Pro Thr Thr His Tyr Gly Gly Val Tyr Tyr Gly
Pro Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser 115
1206117PRTArtificial SequenceNanobody Sequence 6Lys Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Met Tyr 20 25 30Ala Met Lys
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly
Ile Asn Ser Ser Gly Gly Arg Thr Asn Tyr Ala Gly Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Thr Asp Phe Leu Gly Gly Arg Asn Ser Arg Gly Gln Gly Thr
Gln 100 105 110Val Thr Val Ser Ser 1157123PRTArtificial
SequenceNanobody Sequence 7Lys Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Arg Arg Thr Phe Asn Met Met 20 25 30Gly Trp Phe Arg Gln Ala Pro Gly
Lys Glu Arg Glu Phe Val Ala Tyr 35 40 45Ile Thr Trp Asn Gly Gly Asp
Thr Arg Tyr Ala Glu Ser Val Lys Gly 50 55 60Arg Phe Thr Val Ser Arg
Asp Asp Val Lys Asn Thr Met Ala Leu Gln65 70 75 80Met Asn Arg Leu
Asp Pro Leu Asp Thr Ala Val Tyr Tyr Cys Gly Val 85 90 95Arg Ile His
Gly Ser Asn Trp Ser Thr Lys Ala Asp Asp Tyr Asp Asn 100 105 110Trp
Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 1208121PRTArtificial
SequenceNanobody Sequence 8Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Ser Ala Leu Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Ile Thr Phe Ser Ser Arg 20 25 30Tyr Met Arg Trp Tyr Arg Gln Ala
Pro Gly Arg Gln Arg Glu Leu Val 35 40 45Ala Ala Ile Ser Ser Gly Gly
Arg Thr Asp Tyr Val Asp Ser Val Arg 50 55 60Gly Arg Phe Thr Leu Ser
Ile Asn Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Asp
Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr 85 90 95Arg Pro Arg
Met Tyr Val Asp Gly Thr Tyr Glu Lys Glu Leu Trp Gly 100 105 110Gln
Gly Thr Leu Val Thr Val Ser Ser 115 1209124PRTArtificial
SequenceNanobody Sequence 9Asp Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Pro Thr Phe Ser Arg Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala
Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Trp Ser Ser
Gly Gly Arg Thr Tyr Tyr Ala Asp Ser 50 55 60Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ser Lys Asn Thr Val65 70 75 80Tyr Leu Gln Met
Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Ala
Ala Arg Ile Pro Val Arg Thr Tyr Thr Ser Glu Trp Asn 100 105 110Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
12010122PRTArtificial SequenceNanobody Sequence 10Asp Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ala Val
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala
Ala Ile Ser Arg Ser Gly Arg Ser Thr Tyr Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Ala Gly Leu Ser Tyr Tyr Ser Pro His Ala Tyr Tyr Asp
Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
12011123PRTArtificial SequenceNanobody Sequence 11Asp Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Thr Tyr 20 25 30Ala Met
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala
Ala Ile Ser Trp Ser Gly Ser Arg Thr Tyr Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Ala Tyr Arg Arg Pro Arg Tyr Ser Pro Thr Gly Thr Trp
Asp Tyr 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
12012119PRTArtificial SequenceNanobody Sequence 12Asp Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ile Tyr 20 25 30Thr Met
Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala
Ala Ile Ser Trp Ser Ser Gly Arg Thr Tyr Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Thr Ala Tyr Thr Gly Pro Arg Ser Gly Tyr Asp Tyr Trp Gly
Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11513124PRTArtificial SequenceNanobody Sequence 13Asp Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Thr Met
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala
Ala Ile Ser Trp Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Ala Tyr Arg Arg Arg Arg Ala Ser Ser Asn Arg Gly Leu
Trp Asp 100 105 110Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 12014123PRTArtificial SequenceNanobody Sequence 14Asp Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Thr
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40
45Ala Ala Ile Ser Trp Ser Gly Arg Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Ala Tyr Arg Arg Val Arg Tyr Thr Asn Leu Glu
Val Trp Asp Tyr 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser
Ser 115 12015123PRTArtificial SequenceNanobody Sequence 15Asp Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25
30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45Ala Ala Ile Thr Trp Ser Ser Ala Thr Thr Tyr Tyr Ala Asp Ser
Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95Ala Ala Ala Arg Ile Pro Val Gly Arg Arg Ser
Glu Asn Trp Asp Tyr 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val
Ser Ser 115 12016120PRTArtificial SequenceNanobody Sequence 16Asp
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ile Tyr
20 25 30Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe
Val 35 40 45Ala Ala Ile Ser Trp Ser Gly Gly Arg Thr Tyr Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Thr Ala Tyr Thr Gly Arg Ser Tyr Gly Ser
Tyr Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser
115 12017123PRTArtificial SequenceNanobody Sequence 17Asp Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ile Tyr 20 25 30Gly
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40
45Ala Ala Ile Asn Gly Gly Ser Arg Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr
Leu65 70 75 80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95Ala Asp Arg Ser Gly Tyr Gly Thr Ser Leu Asp Trp
Trp Tyr Asp Tyr 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser
Ser 115 12018123PRTArtificial SequenceNanobody Sequence 18Asp Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Tyr 20 25
30Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45Ala Ala Ile Ser Trp Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser
Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95Ala Ala Arg Pro Arg Tyr Tyr Tyr Tyr Ser Leu
Tyr Ser Tyr Asp Tyr 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val
Ser Ser 115 12019122PRTArtificial SequenceNanobody Sequence 19Asp
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Thr Ile Phe Ser Ile Asn
20 25 30Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe
Val 35 40 45Ala Ala Ile Thr Thr Gly Gly Arg Thr Asn Tyr Ala Asp Ser
Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr Cys Asn 85 90 95Ala Glu Val Thr Thr Gly Trp Val Gly Tyr
Ser Trp Tyr Asp Tyr Trp 100 105 110Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 1202010PRTArtificial SequenceCDR1 20Gly Arg Ser Phe Ser
Ser Tyr Ala Met Gly1 5 102110PRTArtificial SequenceCDR1 21Gly Arg
Ala Phe Ser Asn Tyr Ile Met Gly1 5 102210PRTArtificial SequenceCDR1
22Gly Ser Ile Phe Ser Asn Arg Phe Met Tyr1 5 102310PRTArtificial
SequenceCDR1 23Gly Phe Thr Phe Ser Gly Ser Trp Met Phe1 5
102410PRTArtificial SequenceCDR1
24Gly Ser Thr Phe Ile Ile Asn Val Val Arg1 5 102510PRTArtificial
SequenceCDR1 25Gly Phe Thr Phe Ser Met Tyr Ala Met Lys1 5
10268PRTArtificial SequenceCDR1 26Arg Arg Thr Phe Asn Met Met Gly1
52710PRTArtificial SequenceCDR1 27Gly Ile Thr Phe Ser Ser Arg Tyr
Met Arg1 5 102810PRTArtificial SequenceCDR1 28Gly Pro Thr Phe Ser
Arg Tyr Ala Met Gly1 5 102910PRTArtificial SequenceCDR1 29Gly Arg
Thr Phe Ser Ser Tyr Ala Val Gly1 5 103010PRTArtificial SequenceCDR1
30Gly Leu Thr Phe Ser Thr Tyr Ala Met Gly1 5 103110PRTArtificial
SequenceCDR1 31Gly Arg Thr Phe Ser Ile Tyr Thr Met Ala1 5
103210PRTArtificial SequenceCDR1 32Gly Arg Thr Phe Ser Ser Tyr Thr
Met Gly1 5 103310PRTArtificial SequenceCDR1 33Gly Arg Thr Phe Ser
Ser Tyr Ala Met Gly1 5 103410PRTArtificial SequenceCDR1 34Gly Arg
Thr Phe Ser Ile Tyr Thr Met Gly1 5 103510PRTArtificial SequenceCDR1
35Gly Arg Thr Phe Ser Ile Tyr Gly Met Gly1 5 103610PRTArtificial
SequenceCDR1 36Gly Arg Thr Phe Ser Thr Tyr Thr Met Gly1 5
103710PRTArtificial SequenceCDR1 37Gly Thr Ile Phe Ser Ile Asn Val
Met Gly1 5 103810PRTArtificial SequenceCDR2 38Ile Ile Ser Trp Ser
Gly Gly Ser Thr Val1 5 103910PRTArtificial SequenceCDR2 39Ala Ile
Asn Trp Asn Gly Val Thr Thr His1 5 10409PRTArtificial SequenceCDR2
40Ser Ile Thr Leu Ser Gly Ser Thr Asn1 54110PRTArtificial
SequenceCDR2 41Ser Ile Asn Ser Ser Gly Gly Arg Thr Tyr1 5
10429PRTArtificial SequenceCDR2 42Thr Ile Ser Ser Gly Gly Asn Ala
Asn1 54310PRTArtificial SequenceCDR2 43Gly Ile Asn Ser Ser Gly Gly
Arg Thr Asn1 5 104410PRTArtificial SequenceCDR2 44Tyr Ile Thr Trp
Asn Gly Gly Asp Thr Arg1 5 10459PRTArtificial SequenceCDR2 45Ala
Ile Ser Ser Gly Gly Arg Thr Asp1 54611PRTArtificial SequenceCDR2
46Ala Ile Thr Trp Ser Ser Gly Gly Arg Thr Tyr1 5
104710PRTArtificial SequenceCDR2 47Ala Ile Ser Arg Ser Gly Arg Ser
Thr Tyr1 5 104810PRTArtificial SequenceCDR2 48Ala Ile Ser Trp Ser
Gly Ser Arg Thr Tyr1 5 104910PRTArtificial SequenceCDR2 49Ala Ile
Ser Trp Ser Ser Gly Arg Thr Tyr1 5 105010PRTArtificial SequenceCDR2
50Ala Ile Ser Trp Ser Gly Gly Arg Thr Tyr1 5 105110PRTArtificial
SequenceCDR2 51Ala Ile Ser Trp Ser Gly Arg Thr Thr Tyr1 5
105210PRTArtificial SequenceCDR2 52Ala Ile Thr Trp Ser Ser Ala Thr
Thr Tyr1 5 10539PRTArtificial SequenceCDR2 53Ala Ile Asn Gly Gly
Ser Arg Thr Tyr1 55410PRTArtificial SequenceCDR2 54Ala Ile Ser Trp
Ser Gly Gly Thr Thr Tyr1 5 10559PRTArtificial SequenceCDR2 55Ala
Ile Thr Thr Gly Gly Arg Thr Asn1 55615PRTArtificial SequenceCDR3
56Gly Arg Leu Tyr Arg Ala Thr Pro Arg Pro Ala Asp Phe Gly Ser1 5 10
155718PRTArtificial SequenceCDR3 57Arg Gly Thr Val Tyr Ser Arg Thr
Tyr Gly Val Ser Glu Glu Gly Tyr1 5 10 15Met Tyr587PRTArtificial
SequenceCDR3 58Phe Leu Gln Asn Ser Phe Tyr1 5596PRTArtificial
SequenceCDR3 59Ser Pro Arg Val Gly Ser1 56013PRTArtificial
SequenceCDR3 60Pro Thr Thr His Tyr Gly Gly Val Tyr Tyr Gly Pro Tyr1
5 10618PRTArtificial SequenceCDR3 61Asp Phe Leu Gly Gly Arg Asn
Ser1 56216PRTArtificial SequenceCDR3 62Arg Ile His Gly Ser Asn Trp
Ser Thr Lys Ala Asp Asp Tyr Asp Asn1 5 10 156313PRTArtificial
SequenceCDR3 63Pro Arg Met Tyr Val Asp Gly Thr Tyr Glu Lys Glu Leu1
5 106414PRTArtificial SequenceCDR3 64Ala Arg Ile Pro Val Arg Thr
Tyr Thr Ser Glu Trp Asn Tyr1 5 106513PRTArtificial SequenceCDR3
65Gly Leu Ser Tyr Tyr Ser Pro His Ala Tyr Tyr Asp Tyr1 5
106614PRTArtificial SequenceCDR3 66Tyr Arg Arg Pro Arg Tyr Ser Pro
Thr Gly Thr Trp Asp Tyr1 5 106710PRTArtificial SequenceCDR3 67Tyr
Thr Gly Pro Arg Ser Gly Tyr Asp Tyr1 5 106815PRTArtificial
SequenceCDR3 68Tyr Arg Arg Arg Arg Ala Ser Ser Asn Arg Gly Leu Trp
Asp Tyr1 5 10 156914PRTArtificial SequenceCDR3 69Tyr Arg Arg Val
Arg Tyr Thr Asn Leu Glu Val Trp Asp Tyr1 5 107014PRTArtificial
SequenceCDR3 70Ala Arg Ile Pro Val Gly Arg Arg Ser Glu Asn Trp Asp
Tyr1 5 107111PRTArtificial SequenceCDR3 71Tyr Thr Gly Arg Ser Tyr
Gly Ser Tyr Asp Tyr1 5 107215PRTArtificial SequenceCDR3 72Asp Arg
Ser Gly Tyr Gly Thr Ser Leu Asp Trp Trp Tyr Asp Tyr1 5 10
157314PRTArtificial SequenceCDR3 73Arg Pro Arg Tyr Tyr Tyr Tyr Ser
Leu Tyr Ser Tyr Asp Tyr1 5 107414PRTArtificial SequenceCDR3 74Glu
Val Thr Thr Gly Trp Val Gly Tyr Ser Trp Tyr Asp Tyr1 5
107525PRTArtificial SequenceFR1 75Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser 20 257625PRTArtificial SequenceFR1 76Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Val Ala Ser 20 257725PRTArtificial SequenceFR1 77Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser 20 257825PRTArtificial SequenceFR1
78Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ser Ala Ser 20 257925PRTArtificial
SequenceFR1 79Lys Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser 20
258025PRTArtificial SequenceFR1 80Lys Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser 20 258125PRTArtificial SequenceFR1 81Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Ser Ala Leu Pro Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser 20 258225PRTArtificial SequenceFR1 82Asp Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser 20 258325PRTArtificial SequenceFR1
83Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser 20 258425PRTArtificial
SequenceFR1 84Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser 20
258514PRTArtificial SequenceFR2 85Trp Phe Arg Gln Ala Pro Gly Lys
Glu Arg Glu Phe Val Ser1 5 108614PRTArtificial SequenceFR2 86Trp
Phe Arg Gln Ala Pro Gly Lys Glu Arg Asp Phe Val Ala1 5
108714PRTArtificial SequenceFR2 87Trp Tyr Arg Gln Ala Pro Gly Lys
Gln Arg Glu Leu Val Ala1 5 108814PRTArtificial SequenceFR2 88Trp
Val Arg Gln Ala Pro Gly Lys Asp Tyr Glu Trp Val Ala1 5
108914PRTArtificial SequenceFR2 89Trp Tyr Arg Arg Thr Pro Gly Lys
Gln Arg Glu Leu Val Ala1 5 109014PRTArtificial SequenceFR2 90Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser1 5
109114PRTArtificial SequenceFR2 91Trp Phe Arg Gln Ala Pro Gly Lys
Glu Arg Glu Phe Val Ala1 5 109214PRTArtificial SequenceFR2 92Trp
Tyr Arg Gln Ala Pro Gly Arg Gln Arg Glu Leu Val Ala1 5
109314PRTArtificial SequenceFR2 93Trp Tyr Arg Gln Ala Pro Gly Lys
Glu Arg Glu Phe Val Ala1 5 109439PRTArtificial SequenceFR3 94Tyr
Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala1 5 10
15Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr
20 25 30Ala Ile Tyr Tyr Cys Ala Ala 359539PRTArtificial SequenceFR3
95Tyr Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala1
5 10 15Lys Ser Thr Ser Tyr Leu Gln Met Asp Ser Leu Lys Pro Asp Asp
Thr 20 25 30Ala Val Tyr Phe Cys Ala Ala 359639PRTArtificial
SequenceFR3 96Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ala1 5 10 15Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys
Pro Glu Asp Thr 20 25 30Ala Val Tyr Tyr Cys Asn Thr
359739PRTArtificial SequenceFR3 97Tyr Asp Asp Ser Val Lys Gly Arg
Phe Thr Ile Ser Arg Asp Ser Ala1 5 10 15Lys Asn Thr Leu Tyr Leu Glu
Met Asn Asn Leu Lys Pro Glu Asp Thr 20 25 30Ala Leu Tyr Phe Cys Ala
Arg 359839PRTArtificial SequenceFR3 98Tyr Val Asp Ser Val Arg Gly
Arg Phe Ser Ile Ser Arg Asp Gly Ala1 5 10 15Lys Asn Ala Val Asp Leu
Gln Met Asn Gly Leu Lys Pro Glu Asp Thr 20 25 30Ala Val Tyr Tyr Cys
Asn Val 359939PRTArtificial SequenceFR3 99Tyr Ala Gly Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala1 5 10 15Lys Asn Thr Leu Tyr
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 20 25 30Ala Val Tyr Tyr
Cys Ala Thr 3510039PRTArtificial SequenceFR3 100Tyr Ala Glu Ser Val
Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Val1 5 10 15Lys Asn Thr Met
Ala Leu Gln Met Asn Arg Leu Asp Pro Leu Asp Thr 20 25 30Ala Val Tyr
Tyr Cys Gly Val 3510139PRTArtificial SequenceFR3 101Tyr Val Asp Ser
Val Arg Gly Arg Phe Thr Leu Ser Ile Asn Asn Ala1 5 10 15Lys Asn Thr
Val Tyr Leu Gln Met Asn Asp Leu Lys Pro Glu Asp Thr 20 25 30Ala Val
Tyr Tyr Cys Tyr Arg 3510239PRTArtificial SequenceFR3 102Tyr Ala Asp
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser1 5 10 15Lys Asn
Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr 20 25 30Ala
Val Tyr Tyr Cys Ala Ala 3510339PRTArtificial SequenceFR3 103Tyr Ala
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser1 5 10 15Lys
Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr 20 25
30Ala Val Tyr Tyr Cys Thr Ala 3510439PRTArtificial SequenceFR3
104Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser1
5 10 15Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp
Thr 20 25 30Ala Val Tyr Tyr Cys Asn Ala 3510511PRTArtificial
SequenceFR4 105Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser1 5
1010611PRTArtificial SequenceFR4 106Arg Gly Gln Gly Thr Gln Val Thr
Val Ser Ser1 5 1010711PRTArtificial SequenceFR4 107Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser1 5 1010811PRTArtificial SequenceFR4
108Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser1 5
1010910PRTArtificial SequenceCDR1 109Gly Ser Thr Phe Ile Ile Ser
Val Met Arg1 5 101109PRTArtificial SequenceCDR2 110Ala Ile Arg Thr
Gly Gly Asn Thr Asp1 511113PRTArtificial SequenceCDR3 111Pro Thr
Thr Arg Tyr Gly Gly Asp Tyr Tyr Gly Pro Tyr1 5 1011239PRTArtificial
SequenceFR3 112Tyr Ala Gly Pro Val Arg Gly Arg Phe Ser Ile Ser Arg
Asp Gly Ala1 5 10 15Lys Asn Ala Val Asp Leu Gln Met Asn Gly Leu Lys
Pro Glu Asp Thr 20 25 30Ala Val Tyr Tyr Cys Asn Val
3511339PRTArtificial SequenceFR3 113Tyr Ala Gly Pro Val Arg Gly Arg
Phe Ser Ile Ser Arg Asp Gly Ala1 5 10 15Lys Asp Ala Val Asp Leu Gln
Met Asn Gly Leu Lys Pro Glu Asp Thr 20 25 30Ala Val Tyr Tyr Cys Asn
Val 35114121PRTArtificial SequenceNanobody Sequence 114Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ile Ile Ser 20 25 30Val
Met Arg Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40
45Ala Ala Ile Arg Thr Gly Gly Asn Thr Asp Tyr Ala Gly Pro Val Arg
50 55 60Gly Arg Phe Ser Ile Ser Arg Asp Gly Ala Lys Asn Ala Val Asp
Leu65 70 75 80Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr
Tyr Cys Asn 85 90 95Val Pro Thr Thr Arg Tyr Gly Gly Asp Tyr Tyr Gly
Pro Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser 115
120115121PRTArtificial SequenceNanobody Sequence 115Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ile Ile Ser 20 25 30Val Met
Arg Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala
Ala Ile Arg Thr Gly Gly Asn Thr Asp Tyr Ala Gly Pro Val Arg 50 55
60Gly Arg Phe Ser Ile Ser Arg Asp Gly Ala Lys Asp Ala Val Asp Leu65
70 75 80Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
Asn 85 90 95Val Pro Thr Thr Arg Tyr Gly Gly Asp Tyr Tyr Gly Pro Tyr
Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser 115
120116121PRTArtificial SequenceNanobody Sequence 116Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ile Ile Asn 20 25 30Val Val
Arg Trp Tyr Arg Arg Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala
Thr Ile Ser Ser Gly Gly Asn Ala Asn Tyr Val Asp Ser Val Arg 50 55
60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65
70 75 80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
Asn 85 90 95Val Pro Thr Thr His Tyr Gly Gly Val Tyr Tyr Gly Pro Tyr
Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115
120117122PRTArtificial SequenceNanobody Sequence 117Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ile Ile Asn 20 25 30Val Val
Arg Trp Tyr Arg Arg Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala
Thr Ile Ser Ser Gly Gly Asn Ala Asn Tyr Val Asp Ser Val Arg 50 55
60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu65
70 75 80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
Asn 85 90 95Val Pro Thr Thr His Tyr Gly Gly Val Tyr Tyr Gly Pro Tyr
Trp Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser Ala 115
120118125PRTArtificial SequenceNanobody Sequence 118Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Thr Met
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala
Ala Ile Ser Trp Ser Gly Gly
Arg Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser
Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Ala Tyr Arg
Arg Arg Arg Ala Ser Ser Asn Arg Gly Leu Trp Asp 100 105 110Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala 115 120
12511925PRTArtificial SequenceFR1 119Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Val Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys
Ala Ala Ser 20 2512025PRTArtificial SequenceFR1 120Asp Val Gln Leu
Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser 20 2512114PRTArtificial SequenceFR2 121Trp
Tyr Arg Arg Ala Pro Gly Lys Gln Arg Glu Leu Val Ala1 5
1012239PRTArtificial SequenceFR3 122Tyr Val Asp Ser Val Arg Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser1 5 10 15Lys Asn Thr Val Tyr Leu Gln
Met Asn Ser Leu Arg Pro Glu Asp Thr 20 25 30Ala Val Tyr Tyr Cys Asn
Val 3512339PRTArtificial SequenceFR3 123Tyr Val Asp Ser Val Arg Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser1 5 10 15Lys Asn Thr Val Tyr Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr 20 25 30Ala Leu Tyr Tyr Cys
Asn Val 3512439PRTArtificial SequenceFR3 124Tyr Ala Asp Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser1 5 10 15Lys Asn Thr Val Tyr
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr 20 25 30Ala Leu Tyr Tyr
Cys Ala Ala 351252415PRTHomo sapiens 125Met Thr Thr Leu Leu Trp Val
Phe Val Thr Leu Arg Val Ile Thr Ala1 5 10 15Ala Val Thr Val Glu Thr
Ser Asp His Asp Asn Ser Leu Ser Val Ser 20 25 30Ile Pro Gln Pro Ser
Pro Leu Arg Val Leu Leu Gly Thr Ser Leu Thr 35 40 45Ile Pro Cys Tyr
Phe Ile Asp Pro Met His Pro Val Thr Thr Ala Pro 50 55 60Ser Thr Ala
Pro Leu Ala Pro Arg Ile Lys Trp Ser Arg Val Ser Lys65 70 75 80Glu
Lys Glu Val Val Leu Leu Val Ala Thr Glu Gly Arg Val Arg Val 85 90
95Asn Ser Ala Tyr Gln Asp Lys Val Ser Leu Pro Asn Tyr Pro Ala Ile
100 105 110Pro Ser Asp Ala Thr Leu Glu Val Gln Ser Leu Arg Ser Asn
Asp Ser 115 120 125Gly Val Tyr Arg Cys Glu Val Met His Gly Ile Glu
Asp Ser Glu Ala 130 135 140Thr Leu Glu Val Val Val Lys Gly Ile Val
Phe His Tyr Arg Ala Ile145 150 155 160Ser Thr Arg Tyr Thr Leu Asp
Phe Asp Arg Ala Gln Arg Ala Cys Leu 165 170 175Gln Asn Ser Ala Ile
Ile Ala Thr Pro Glu Gln Leu Gln Ala Ala Tyr 180 185 190Glu Asp Gly
Phe His Gln Cys Asp Ala Gly Trp Leu Ala Asp Gln Thr 195 200 205Val
Arg Tyr Pro Ile His Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys 210 215
220Asp Glu Phe Pro Gly Val Arg Thr Tyr Gly Ile Arg Asp Thr Asn
Glu225 230 235 240Thr Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met Glu
Gly Glu Val Phe 245 250 255Tyr Ala Thr Ser Pro Glu Lys Phe Thr Phe
Gln Glu Ala Ala Asn Glu 260 265 270Cys Arg Arg Leu Gly Ala Arg Leu
Ala Thr Thr Gly His Val Tyr Leu 275 280 285Ala Trp Gln Ala Gly Met
Asp Met Cys Ser Ala Gly Trp Leu Ala Asp 290 295 300Arg Ser Val Arg
Tyr Pro Ile Ser Lys Ala Arg Pro Asn Cys Gly Gly305 310 315 320Asn
Leu Leu Gly Val Arg Thr Val Tyr Val His Ala Asn Gln Thr Gly 325 330
335Tyr Pro Asp Pro Ser Ser Arg Tyr Asp Ala Ile Cys Tyr Thr Gly Glu
340 345 350Asp Phe Val Asp Ile Pro Glu Asn Phe Phe Gly Val Gly Gly
Glu Glu 355 360 365Asp Ile Thr Val Gln Thr Val Thr Trp Pro Asp Met
Glu Leu Pro Leu 370 375 380Pro Arg Asn Ile Thr Glu Gly Glu Ala Arg
Gly Ser Val Ile Leu Thr385 390 395 400Val Lys Pro Ile Phe Glu Val
Ser Pro Ser Pro Leu Glu Pro Glu Glu 405 410 415Pro Phe Thr Phe Ala
Pro Glu Ile Gly Ala Thr Ala Phe Ala Glu Val 420 425 430Glu Asn Glu
Thr Gly Glu Ala Thr Arg Pro Trp Gly Phe Pro Thr Pro 435 440 445Gly
Leu Gly Pro Ala Thr Ala Phe Thr Ser Glu Asp Leu Val Val Gln 450 455
460Val Thr Ala Val Pro Gly Gln Pro His Leu Pro Gly Gly Val Val
Phe465 470 475 480His Tyr Arg Pro Gly Pro Thr Arg Tyr Ser Leu Thr
Phe Glu Glu Ala 485 490 495Gln Gln Ala Cys Pro Gly Thr Gly Ala Val
Ile Ala Ser Pro Glu Gln 500 505 510Leu Gln Ala Ala Tyr Glu Ala Gly
Tyr Glu Gln Cys Asp Ala Gly Trp 515 520 525Leu Arg Asp Gln Thr Val
Arg Tyr Pro Ile Val Ser Pro Arg Thr Pro 530 535 540Cys Val Gly Asp
Lys Asp Ser Ser Pro Gly Val Arg Thr Tyr Gly Val545 550 555 560Arg
Pro Ser Thr Glu Thr Tyr Asp Val Tyr Cys Phe Val Asp Arg Leu 565 570
575Glu Gly Glu Val Phe Phe Ala Thr Arg Leu Glu Gln Phe Thr Phe Gln
580 585 590Glu Ala Leu Glu Phe Cys Glu Ser His Asn Ala Thr Ala Thr
Thr Gly 595 600 605Gln Leu Tyr Ala Ala Trp Ser Arg Gly Leu Asp Lys
Cys Tyr Ala Gly 610 615 620Trp Leu Ala Asp Gly Ser Leu Arg Tyr Pro
Ile Val Thr Pro Arg Pro625 630 635 640Ala Cys Gly Gly Asp Lys Pro
Gly Val Arg Thr Val Tyr Leu Tyr Pro 645 650 655Asn Gln Thr Gly Leu
Pro Asp Pro Leu Ser Arg His His Ala Phe Cys 660 665 670Phe Arg Gly
Ile Ser Ala Val Pro Ser Pro Gly Glu Glu Glu Gly Gly 675 680 685Thr
Pro Thr Ser Pro Ser Gly Val Glu Glu Trp Ile Val Thr Gln Val 690 695
700Val Pro Gly Val Ala Ala Val Pro Val Glu Glu Glu Thr Thr Ala
Val705 710 715 720Pro Ser Gly Glu Thr Thr Ala Ile Leu Glu Phe Thr
Thr Glu Pro Glu 725 730 735Asn Gln Thr Glu Trp Glu Pro Ala Tyr Thr
Pro Val Gly Thr Ser Pro 740 745 750Leu Pro Gly Ile Leu Pro Thr Trp
Pro Pro Thr Gly Ala Glu Thr Glu 755 760 765Glu Ser Thr Glu Gly Pro
Ser Ala Thr Glu Val Pro Ser Ala Ser Glu 770 775 780Glu Pro Ser Pro
Ser Glu Val Pro Phe Pro Ser Glu Glu Pro Ser Pro785 790 795 800Ser
Glu Glu Pro Phe Pro Ser Val Arg Pro Phe Pro Ser Val Glu Leu 805 810
815Phe Pro Ser Glu Glu Pro Phe Pro Ser Lys Glu Pro Ser Pro Ser Glu
820 825 830Glu Pro Ser Ala Ser Glu Glu Pro Tyr Thr Pro Ser Pro Pro
Glu Pro 835 840 845Ser Trp Thr Glu Leu Pro Ser Ser Gly Glu Glu Ser
Gly Ala Pro Asp 850 855 860Val Ser Gly Asp Phe Thr Gly Ser Gly Asp
Val Ser Gly His Leu Asp865 870 875 880Phe Ser Gly Gln Leu Ser Gly
Asp Arg Ala Ser Gly Leu Pro Ser Gly 885 890 895Asp Leu Asp Ser Ser
Gly Leu Thr Ser Thr Val Gly Ser Gly Leu Thr 900 905 910Val Glu Ser
Gly Leu Pro Ser Gly Asp Glu Glu Arg Ile Glu Trp Pro 915 920 925Ser
Thr Pro Thr Val Gly Glu Leu Pro Ser Gly Ala Glu Ile Leu Glu 930 935
940Gly Ser Ala Ser Gly Val Gly Asp Leu Ser Gly Leu Pro Ser Gly
Glu945 950 955 960Val Leu Glu Thr Ser Ala Ser Gly Val Gly Asp Leu
Ser Gly Leu Pro 965 970 975Ser Gly Glu Val Leu Glu Thr Thr Ala Pro
Gly Val Glu Asp Ile Ser 980 985 990Gly Leu Pro Ser Gly Glu Val Leu
Glu Thr Thr Ala Pro Gly Val Glu 995 1000 1005Asp Ile Ser Gly Leu
Pro Ser Gly Glu Val Leu Glu Thr Thr Ala 1010 1015 1020Pro Gly Val
Glu Asp Ile Ser Gly Leu Pro Ser Gly Glu Val Leu 1025 1030 1035Glu
Thr Thr Ala Pro Gly Val Glu Asp Ile Ser Gly Leu Pro Ser 1040 1045
1050Gly Glu Val Leu Glu Thr Thr Ala Pro Gly Val Glu Asp Ile Ser
1055 1060 1065Gly Leu Pro Ser Gly Glu Val Leu Glu Thr Ala Ala Pro
Gly Val 1070 1075 1080Glu Asp Ile Ser Gly Leu Pro Ser Gly Glu Val
Leu Glu Thr Ala 1085 1090 1095Ala Pro Gly Val Glu Asp Ile Ser Gly
Leu Pro Ser Gly Glu Val 1100 1105 1110Leu Glu Thr Ala Ala Pro Gly
Val Glu Asp Ile Ser Gly Leu Pro 1115 1120 1125Ser Gly Glu Val Leu
Glu Thr Ala Ala Pro Gly Val Glu Asp Ile 1130 1135 1140Ser Gly Leu
Pro Ser Gly Glu Val Leu Glu Thr Ala Ala Pro Gly 1145 1150 1155Val
Glu Asp Ile Ser Gly Leu Pro Ser Gly Glu Val Leu Glu Thr 1160 1165
1170Ala Ala Pro Gly Val Glu Asp Ile Ser Gly Leu Pro Ser Gly Glu
1175 1180 1185Val Leu Glu Thr Ala Ala Pro Gly Val Glu Asp Ile Ser
Gly Leu 1190 1195 1200Pro Ser Gly Glu Val Leu Glu Thr Ala Ala Pro
Gly Val Glu Asp 1205 1210 1215Ile Ser Gly Leu Pro Ser Gly Glu Val
Leu Glu Thr Ala Ala Pro 1220 1225 1230Gly Val Glu Asp Ile Ser Gly
Leu Pro Ser Gly Glu Val Leu Glu 1235 1240 1245Thr Ala Ala Pro Gly
Val Glu Asp Ile Ser Gly Leu Pro Ser Gly 1250 1255 1260Glu Val Leu
Glu Thr Ala Ala Pro Gly Val Glu Asp Ile Ser Gly 1265 1270 1275Leu
Pro Ser Gly Glu Val Leu Glu Thr Thr Ala Pro Gly Val Glu 1280 1285
1290Glu Ile Ser Gly Leu Pro Ser Gly Glu Val Leu Glu Thr Thr Ala
1295 1300 1305Pro Gly Val Asp Glu Ile Ser Gly Leu Pro Ser Gly Glu
Val Leu 1310 1315 1320Glu Thr Thr Ala Pro Gly Val Glu Glu Ile Ser
Gly Leu Pro Ser 1325 1330 1335Gly Glu Val Leu Glu Thr Ser Thr Ser
Ala Val Gly Asp Leu Ser 1340 1345 1350Gly Leu Pro Ser Gly Gly Glu
Val Leu Glu Ile Ser Val Ser Gly 1355 1360 1365Val Glu Asp Ile Ser
Gly Leu Pro Ser Gly Glu Val Val Glu Thr 1370 1375 1380Ser Ala Ser
Gly Ile Glu Asp Val Ser Glu Leu Pro Ser Gly Glu 1385 1390 1395Gly
Leu Glu Thr Ser Ala Ser Gly Val Glu Asp Leu Ser Arg Leu 1400 1405
1410Pro Ser Gly Glu Glu Val Leu Glu Ile Ser Ala Ser Gly Phe Gly
1415 1420 1425Asp Leu Ser Gly Val Pro Ser Gly Gly Glu Gly Leu Glu
Thr Ser 1430 1435 1440Ala Ser Glu Val Gly Thr Asp Leu Ser Gly Leu
Pro Ser Gly Arg 1445 1450 1455Glu Gly Leu Glu Thr Ser Ala Ser Gly
Ala Glu Asp Leu Ser Gly 1460 1465 1470Leu Pro Ser Gly Lys Glu Asp
Leu Val Gly Ser Ala Ser Gly Asp 1475 1480 1485Leu Asp Leu Gly Lys
Leu Pro Ser Gly Thr Leu Gly Ser Gly Gln 1490 1495 1500Ala Pro Glu
Thr Ser Gly Leu Pro Ser Gly Phe Ser Gly Glu Tyr 1505 1510 1515Ser
Gly Val Asp Leu Gly Ser Gly Pro Pro Ser Gly Leu Pro Asp 1520 1525
1530Phe Ser Gly Leu Pro Ser Gly Phe Pro Thr Val Ser Leu Val Asp
1535 1540 1545Ser Thr Leu Val Glu Val Val Thr Ala Ser Thr Ala Ser
Glu Leu 1550 1555 1560Glu Gly Arg Gly Thr Ile Gly Ile Ser Gly Ala
Gly Glu Ile Ser 1565 1570 1575Gly Leu Pro Ser Ser Glu Leu Asp Ile
Ser Gly Arg Ala Ser Gly 1580 1585 1590Leu Pro Ser Gly Thr Glu Leu
Ser Gly Gln Ala Ser Gly Ser Pro 1595 1600 1605Asp Val Ser Gly Glu
Ile Pro Gly Leu Phe Gly Val Ser Gly Gln 1610 1615 1620Pro Ser Gly
Phe Pro Asp Thr Ser Gly Glu Thr Ser Gly Val Thr 1625 1630 1635Glu
Leu Ser Gly Leu Ser Ser Gly Gln Pro Gly Val Ser Gly Glu 1640 1645
1650Ala Ser Gly Val Leu Tyr Gly Thr Ser Gln Pro Phe Gly Ile Thr
1655 1660 1665Asp Leu Ser Gly Glu Thr Ser Gly Val Pro Asp Leu Ser
Gly Gln 1670 1675 1680Pro Ser Gly Leu Pro Gly Phe Ser Gly Ala Thr
Ser Gly Val Pro 1685 1690 1695Asp Leu Val Ser Gly Thr Thr Ser Gly
Ser Gly Glu Ser Ser Gly 1700 1705 1710Ile Thr Phe Val Asp Thr Ser
Leu Val Glu Val Ala Pro Thr Thr 1715 1720 1725Phe Lys Glu Glu Glu
Gly Leu Gly Ser Val Glu Leu Ser Gly Leu 1730 1735 1740Pro Ser Gly
Glu Ala Asp Leu Ser Gly Lys Ser Gly Met Val Asp 1745 1750 1755Val
Ser Gly Gln Phe Ser Gly Thr Val Asp Ser Ser Gly Phe Thr 1760 1765
1770Ser Gln Thr Pro Glu Phe Ser Gly Leu Pro Ser Gly Ile Ala Glu
1775 1780 1785Val Ser Gly Glu Ser Ser Arg Ala Glu Ile Gly Ser Ser
Leu Pro 1790 1795 1800Ser Gly Ala Tyr Tyr Gly Ser Gly Thr Pro Ser
Ser Phe Pro Thr 1805 1810 1815Val Ser Leu Val Asp Arg Thr Leu Val
Glu Ser Val Thr Gln Ala 1820 1825 1830Pro Thr Ala Gln Glu Ala Gly
Glu Gly Pro Ser Gly Ile Leu Glu 1835 1840 1845Leu Ser Gly Ala His
Ser Gly Ala Pro Asp Met Ser Gly Glu His 1850 1855 1860Ser Gly Phe
Leu Asp Leu Ser Gly Leu Gln Ser Gly Leu Ile Glu 1865 1870 1875Pro
Ser Gly Glu Pro Pro Gly Thr Pro Tyr Phe Ser Gly Asp Phe 1880 1885
1890Ala Ser Thr Thr Asn Val Ser Gly Glu Ser Ser Val Ala Met Gly
1895 1900 1905Thr Ser Gly Glu Ala Ser Gly Leu Pro Glu Val Thr Leu
Ile Thr 1910 1915 1920Ser Glu Phe Val Glu Gly Val Thr Glu Pro Thr
Ile Ser Gln Glu 1925 1930 1935Leu Gly Gln Arg Pro Pro Val Thr His
Thr Pro Gln Leu Phe Glu 1940 1945 1950Ser Ser Gly Lys Val Ser Thr
Ala Gly Asp Ile Ser Gly Ala Thr 1955 1960 1965Pro Val Leu Pro Gly
Ser Gly Val Glu Val Ser Ser Val Pro Glu 1970 1975 1980Ser Ser Ser
Glu Thr Ser Ala Tyr Pro Glu Ala Gly Phe Gly Ala 1985 1990 1995Ser
Ala Ala Pro Glu Ala Ser Arg Glu Asp Ser Gly Ser Pro Asp 2000 2005
2010Leu Ser Glu Thr Thr Ser Ala Phe His Glu Ala Asn Leu Glu Arg
2015 2020 2025Ser Ser Gly Leu Gly Val Ser Gly Ser Thr Leu Thr Phe
Gln Glu 2030 2035 2040Gly Glu Ala Ser Ala Ala Pro Glu Val Ser Gly
Glu Ser Thr Thr 2045 2050 2055Thr Ser Asp Val Gly Thr Glu Ala Pro
Gly Leu Pro Ser Ala Thr 2060 2065 2070Pro Thr Ala Ser Gly Asp Arg
Thr Glu Ile Ser Gly Asp Leu Ser 2075 2080 2085Gly His Thr Ser Gln
Leu Gly Val Val Ile Ser Thr Ser Ile Pro 2090 2095 2100Glu Ser Glu
Trp Thr Gln Gln Thr Gln Arg Pro Ala Glu Thr His 2105 2110 2115Leu
Glu Ile Glu Ser Ser Ser Leu Leu Tyr Ser Gly Glu Glu Thr 2120 2125
2130His Thr Val Glu Thr Ala Thr Ser Pro Thr Asp Ala Ser Ile Pro
2135 2140 2145Ala Ser Pro Glu Trp Lys Arg Glu Ser Glu Ser Thr Ala
Ala Ala 2150 2155 2160Pro Ala Arg Ser Cys Ala Glu Glu Pro Cys Gly
Ala Gly Thr Cys
2165 2170 2175Lys Glu Thr Glu Gly His Val Ile Cys Leu Cys Pro Pro
Gly Tyr 2180 2185 2190Thr Gly Glu His Cys Asn Ile Asp Gln Glu Val
Cys Glu Glu Gly 2195 2200 2205Trp Asn Lys Tyr Gln Gly His Cys Tyr
Arg His Phe Pro Asp Arg 2210 2215 2220Glu Thr Trp Val Asp Ala Glu
Arg Arg Cys Arg Glu Gln Gln Ser 2225 2230 2235His Leu Ser Ser Ile
Val Thr Pro Glu Glu Gln Glu Phe Val Asn 2240 2245 2250Asn Asn Ala
Gln Asp Tyr Gln Trp Ile Gly Leu Asn Asp Arg Thr 2255 2260 2265Ile
Glu Gly Asp Phe Arg Trp Ser Asp Gly His Pro Met Gln Phe 2270 2275
2280Glu Asn Trp Arg Pro Asn Gln Pro Asp Asn Phe Phe Ala Ala Gly
2285 2290 2295Glu Asp Cys Val Val Met Ile Trp His Glu Lys Gly Glu
Trp Asn 2300 2305 2310Asp Val Pro Cys Asn Tyr His Leu Pro Phe Thr
Cys Lys Lys Gly 2315 2320 2325Thr Val Ala Cys Gly Glu Pro Pro Val
Val Glu His Ala Arg Thr 2330 2335 2340Phe Gly Gln Lys Lys Asp Arg
Tyr Glu Ile Asn Ser Leu Val Arg 2345 2350 2355Tyr Gln Cys Thr Glu
Gly Phe Val Gln Arg His Met Pro Thr Ile 2360 2365 2370Arg Cys Gln
Pro Ser Gly His Trp Glu Glu Pro Arg Ile Thr Cys 2375 2380 2385Thr
Asp Ala Thr Thr Tyr Lys Arg Arg Leu Gln Lys Arg Ser Ser 2390 2395
2400Arg His Pro Arg Arg Ser Arg Pro Ser Thr Ala His 2405 2410
24151262333PRTCanis lupus 126Met Thr Thr Leu Leu Trp Val Phe Val
Thr Leu Arg Val Ile Thr Ala1 5 10 15Ala Ser Ser Glu Glu Thr Ser Asp
His Asp Asn Ser Leu Ser Val Ser 20 25 30Ile Pro Glu Pro Ser Pro Met
Arg Val Leu Leu Gly Ser Ser Leu Thr 35 40 45Ile Pro Cys Tyr Phe Ile
Asp Pro Met His Pro Val Thr Thr Ala Pro 50 55 60Ser Thr Ala Pro Leu
Ala Pro Arg Ile Lys Trp Ser Arg Ile Thr Lys65 70 75 80Glu Lys Glu
Val Val Leu Leu Val Ala Thr Glu Gly Gln Val Arg Ile 85 90 95Asn Ser
Ala Tyr Gln Asp Lys Val Ser Leu Pro Asn Tyr Pro Ala Ile 100 105
110Pro Ser Asp Ala Thr Leu Glu Ile Gln Asn Leu Arg Ser Asn Asp Ser
115 120 125Gly Ile Tyr Arg Cys Glu Val Met His Gly Ile Glu Asp Ser
Glu Ala 130 135 140Thr Leu Glu Val Val Val Lys Gly Ile Val Phe His
Tyr Arg Ala Ile145 150 155 160Ser Thr Arg Tyr Thr Leu Asp Phe Asp
Arg Ala Gln Arg Ala Cys Leu 165 170 175Gln Asn Ser Ala Ile Ile Ala
Thr Pro Glu Gln Leu Gln Ala Ala Tyr 180 185 190Glu Asp Gly Phe His
Gln Cys Asp Ala Gly Trp Leu Ala Asp Gln Thr 195 200 205Val Arg Tyr
Pro Ile His Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys 210 215 220Asp
Glu Phe Pro Gly Val Arg Thr Tyr Gly Ile Arg Asp Thr Asn Glu225 230
235 240Thr Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met Glu Gly Glu Val
Leu 245 250 255Tyr Ala Thr Ser Pro Glu Lys Phe Thr Phe Gln Glu Ala
Ala Asn Glu 260 265 270Cys Arg Arg Leu Gly Ala Arg Leu Ala Thr Thr
Gly Gln Leu Tyr Leu 275 280 285Ala Trp Gln Gly Gly Met Asp Met Cys
Ser Ala Gly Trp Leu Ala Asp 290 295 300Arg Ser Val Arg Tyr Pro Ile
Ser Lys Ala Arg Pro Asn Cys Gly Gly305 310 315 320Asn Leu Leu Gly
Val Arg Thr Val Tyr Leu His Ala Asn Gln Thr Gly 325 330 335Tyr Pro
Asp Pro Ser Ser Arg Tyr Asp Ala Ile Cys Tyr Thr Gly Glu 340 345
350Asp Phe Val Asp Ile Pro Glu Asn Phe Phe Gly Val Gly Gly Glu Glu
355 360 365Asp Ile Thr Ile Gln Thr Val Thr Trp Pro Asp Val Glu Leu
Pro Leu 370 375 380Pro Arg Asn Ile Thr Glu Gly Glu Ala Arg Gly Asn
Val Ile Leu Thr385 390 395 400Val Lys Pro Ile Phe Asp Leu Ser Pro
Thr Ala Pro Glu Pro Glu Glu 405 410 415Pro Phe Thr Phe Val Pro Glu
Pro Glu Lys Pro Phe Thr Phe Ala Thr 420 425 430Asp Val Gly Val Thr
Ala Phe Pro Glu Ala Glu Asn Arg Thr Gly Glu 435 440 445Ala Thr Arg
Pro Trp Gly Val Pro Glu Glu Ser Thr Pro Gly Pro Ala 450 455 460Phe
Thr Ala Phe Thr Ser Glu Asp His Val Val Gln Val Thr Ala Val465 470
475 480Pro Gly Ala Ala Glu Val Pro Gly Gln Pro Arg Leu Pro Gly Gly
Val 485 490 495Val Phe His Tyr Arg Pro Gly Ser Ala Arg Tyr Ser Leu
Thr Phe Glu 500 505 510Glu Ala Gln Gln Ala Cys Leu Arg Thr Gly Ala
Val Ile Ala Ser Pro 515 520 525Glu Gln Leu Gln Ala Ala Tyr Glu Ala
Gly Tyr Glu Gln Cys Asp Ala 530 535 540Gly Trp Leu Gln Asp Gln Thr
Val Arg Tyr Pro Ile Val Ser Pro Arg545 550 555 560Thr Pro Cys Val
Gly Asp Lys Asp Ser Ser Pro Gly Val Arg Thr Tyr 565 570 575Gly Val
Arg Pro Pro Ser Glu Thr Tyr Asp Val Tyr Cys Tyr Val Asp 580 585
590Lys Leu Glu Gly Glu Val Phe Phe Ile Thr Arg Leu Glu Gln Phe Thr
595 600 605Phe Gln Glu Ala Leu Ala Phe Cys Glu Ser His Asn Ala Thr
Leu Ala 610 615 620Ser Thr Gly Gln Leu Tyr Ala Ala Trp Arg Gln Gly
Leu Asp Lys Cys625 630 635 640Tyr Ala Gly Trp Leu Ser Asp Gly Ser
Leu Arg Tyr Pro Ile Val Thr 645 650 655Pro Arg Pro Ser Cys Gly Gly
Asp Lys Pro Gly Val Arg Thr Val Tyr 660 665 670Leu Tyr Pro Asn Gln
Thr Gly Leu Pro Asp Pro Leu Ser Arg His His 675 680 685Val Phe Cys
Phe Arg Gly Val Ser Gly Val Pro Ser Pro Gly Glu Glu 690 695 700Glu
Gly Gly Thr Pro Thr Pro Ser Val Val Glu Asp Trp Ile Pro Thr705 710
715 720Gln Val Gly Pro Val Val Pro Ser Val Pro Met Gly Glu Glu Thr
Thr 725 730 735Ala Ile Leu Asp Phe Thr Ile Glu Pro Glu Asn Gln Thr
Glu Trp Glu 740 745 750Pro Ala Tyr Ser Pro Ala Gly Thr Ser Pro Leu
Pro Gly Ile Pro Pro 755 760 765Thr Trp Pro Pro Thr Ser Thr Ala Thr
Glu Glu Ser Thr Glu Gly Pro 770 775 780Ser Gly Thr Glu Val Pro Ser
Val Ser Glu Glu Pro Ser Pro Ser Glu785 790 795 800Glu Pro Phe Pro
Trp Glu Glu Leu Ser Thr Leu Ser Pro Pro Gly Pro 805 810 815Ser Gly
Thr Glu Leu Pro Gly Ser Gly Glu Ala Ser Gly Val Pro Glu 820 825
830Val Ser Gly Asp Phe Thr Gly Ser Gly Glu Val Ser Gly His Pro Asp
835 840 845Ser Ser Gly Gln Leu Ser Gly Glu Ser Ala Ser Gly Leu Pro
Ser Glu 850 855 860Asp Leu Asp Ser Ser Gly Leu Thr Ser Ala Val Gly
Ser Gly Leu Ala865 870 875 880Ser Gly Asp Glu Asp Arg Ile Thr Leu
Ser Ser Ile Pro Lys Val Glu 885 890 895Gly Glu Gly Leu Glu Thr Ser
Ala Ser Gly Val Glu Asp Leu Ser Gly 900 905 910Leu Pro Ser Gly Arg
Glu Gly Leu Glu Thr Ser Thr Ser Gly Val Gly 915 920 925Asp Leu Ser
Gly Leu Pro Ser Gly Glu Gly Leu Glu Val Ser Ala Ser 930 935 940Gly
Val Glu Asp Leu Ser Gly Leu Pro Ser Gly Glu Gly Pro Glu Thr945 950
955 960Ser Thr Ser Gly Val Gly Asp Leu Ser Arg Leu Pro Ser Gly Glu
Gly 965 970 975Pro Glu Val Ser Ala Ser Gly Val Gly Asp Leu Ser Gly
Leu Pro Ser 980 985 990Gly Arg Glu Gly Leu Glu Thr Ser Thr Ser Gly
Val Glu Asp Leu Ser 995 1000 1005Gly Leu Pro Ser Gly Glu Gly Pro
Glu Ala Ser Thr Ser Gly Val 1010 1015 1020Gly Asp Leu Ser Arg Leu
Pro Ser Gly Glu Gly Pro Glu Val Ser 1025 1030 1035Ala Ser Gly Val
Glu Asp Leu Ser Gly Leu Pro Ser Gly Glu Gly 1040 1045 1050Leu Glu
Ala Ser Ala Ser Gly Val Gly Asp Leu Ser Gly Leu Pro 1055 1060
1065Ser Gly Glu Gly Pro Glu Ala Ser Ala Ser Gly Val Gly Asp Leu
1070 1075 1080Ser Arg Leu Pro Ser Gly Glu Gly Pro Glu Val Ser Ala
Ser Gly 1085 1090 1095Val Glu Asp Leu Ser Gly Leu Ser Ser Gly Glu
Ser Pro Glu Ala 1100 1105 1110Ser Ala Ser Gly Val Gly Asp Leu Ser
Gly Leu Pro Ser Gly Arg 1115 1120 1125Glu Gly Leu Glu Thr Ser Ala
Ser Gly Val Gly Asp Leu Ser Gly 1130 1135 1140Leu Pro Ser Gly Glu
Gly Gln Glu Ala Ser Ala Ser Gly Val Glu 1145 1150 1155Asp Leu Ser
Arg Leu Pro Ser Gly Glu Gly Pro Glu Ala Ser Ala 1160 1165 1170Ser
Gly Val Gly Glu Leu Ser Gly Leu Pro Ser Gly Arg Glu Gly 1175 1180
1185Leu Glu Thr Ser Ala Ser Gly Val Gly Asp Leu Ser Gly Leu Pro
1190 1195 1200Ser Gly Glu Gly Pro Glu Ala Phe Ala Ser Gly Val Glu
Asp Leu 1205 1210 1215Ser Ile Leu Pro Ser Gly Glu Gly Pro Glu Ala
Ser Ala Ser Gly 1220 1225 1230Val Gly Asp Leu Ser Gly Leu Pro Ser
Gly Arg Glu Gly Leu Glu 1235 1240 1245Thr Ser Thr Ser Gly Val Gly
Asp Leu Ser Gly Leu Pro Ser Gly 1250 1255 1260Arg Glu Gly Leu Glu
Thr Ser Thr Ser Gly Val Gly Asp Leu Ser 1265 1270 1275Gly Leu Pro
Ser Gly Glu Gly Pro Glu Ala Ser Ala Ser Gly Ile 1280 1285 1290Gly
Asp Ile Ser Gly Leu Pro Ser Gly Arg Glu Gly Leu Glu Thr 1295 1300
1305Ser Ser Ser Gly Val Glu Asp His Pro Glu Thr Ser Ala Ser Gly
1310 1315 1320Val Glu Asp Leu Ser Gly Leu Pro Ser Gly Val Glu Gly
His Pro 1325 1330 1335Glu Thr Ser Ala Ser Gly Val Glu Asp Leu Ser
Asp Leu Ser Ser 1340 1345 1350Gly Gly Glu Gly Leu Glu Thr Ser Ala
Ser Gly Ala Glu Asp Leu 1355 1360 1365Ser Gly Phe Pro Ser Gly Lys
Glu Asp Leu Ile Gly Ser Ala Ser 1370 1375 1380Gly Ala Leu Asp Phe
Gly Arg Ile Pro Ser Gly Thr Leu Gly Ser 1385 1390 1395Gly Gln Ala
Pro Glu Ala Ser Ser Leu Pro Ser Gly Phe Ser Gly 1400 1405 1410Glu
Tyr Ser Gly Val Asp Phe Gly Ser Gly Pro Ile Ser Gly Leu 1415 1420
1425Pro Asp Phe Ser Gly Leu Pro Ser Gly Phe Pro Thr Ile Ser Leu
1430 1435 1440Val Asp Thr Thr Leu Val Glu Val Ile Thr Thr Thr Ser
Ala Ser 1445 1450 1455Glu Leu Glu Gly Arg Gly Thr Ile Gly Ile Ser
Gly Ala Gly Glu 1460 1465 1470Thr Ser Gly Leu Pro Val Ser Glu Leu
Asp Ile Ser Gly Ala Val 1475 1480 1485Ser Gly Leu Pro Ser Gly Ala
Glu Leu Ser Gly Gln Ala Ser Gly 1490 1495 1500Ser Pro Asp Met Ser
Gly Glu Thr Ser Gly Phe Phe Gly Val Ser 1505 1510 1515Gly Gln Pro
Ser Gly Phe Pro Asp Ile Ser Gly Gly Thr Ser Gly 1520 1525 1530Leu
Phe Glu Val Ser Gly Gln Pro Ser Gly Phe Ser Gly Glu Thr 1535 1540
1545Ser Gly Val Thr Glu Leu Ser Gly Leu Tyr Ser Gly Gln Pro Asp
1550 1555 1560Val Ser Gly Glu Ala Ser Gly Val Pro Ser Gly Ser Gly
Gln Pro 1565 1570 1575Phe Gly Met Thr Asp Leu Ser Gly Glu Thr Ser
Gly Val Pro Asp 1580 1585 1590Ile Ser Gly Gln Pro Ser Gly Leu Pro
Glu Phe Ser Gly Thr Thr 1595 1600 1605Ser Gly Ile Pro Asp Leu Val
Ser Ser Thr Met Ser Gly Ser Gly 1610 1615 1620Glu Ser Ser Gly Ile
Thr Phe Val Asp Thr Ser Leu Val Glu Val 1625 1630 1635Thr Pro Thr
Thr Phe Lys Glu Lys Lys Arg Leu Gly Ser Val Glu 1640 1645 1650Leu
Ser Gly Leu Pro Ser Gly Glu Val Asp Leu Ser Gly Ala Ser 1655 1660
1665Gly Thr Met Asp Ile Ser Gly Gln Ser Ser Gly Ala Thr Asp Ser
1670 1675 1680Ser Gly Leu Thr Ser His Leu Pro Lys Phe Ser Gly Leu
Pro Ser 1685 1690 1695Gly Ala Ala Glu Val Ser Gly Glu Ser Ser Gly
Ala Glu Val Gly 1700 1705 1710Ser Ser Leu Pro Ser Gly Thr Tyr Glu
Gly Ser Gly Asn Phe His 1715 1720 1725Pro Ala Phe Pro Thr Val Phe
Leu Val Asp Arg Thr Leu Val Glu 1730 1735 1740Ser Val Thr Gln Ala
Pro Thr Ala Gln Glu Ala Gly Glu Gly Pro 1745 1750 1755Ser Gly Ile
Leu Glu Leu Ser Gly Ala His Ser Gly Ala Pro Asp 1760 1765 1770Val
Ser Gly Asp His Ser Gly Ser Leu Asp Leu Ser Gly Met Gln 1775 1780
1785Ser Gly Leu Val Glu Pro Ser Gly Glu Pro Ser Ser Thr Pro Tyr
1790 1795 1800Phe Ser Gly Asp Phe Ser Gly Thr Met Asp Val Thr Gly
Glu Pro 1805 1810 1815Ser Thr Ala Met Ser Ala Ser Gly Glu Ala Ser
Gly Leu Leu Glu 1820 1825 1830Val Thr Leu Ile Thr Ser Glu Phe Val
Glu Gly Val Thr Glu Pro 1835 1840 1845Thr Val Ser Gln Glu Leu Ala
Gln Arg Pro Pro Val Thr His Thr 1850 1855 1860Pro Gln Leu Phe Glu
Ser Ser Gly Glu Ala Ser Ala Ser Gly Glu 1865 1870 1875Ile Ser Gly
Ala Thr Pro Ala Phe Pro Gly Ser Gly Leu Glu Ala 1880 1885 1890Ser
Ser Val Pro Glu Ser Ser Ser Glu Thr Ser Asp Phe Pro Glu 1895 1900
1905Arg Ala Val Gly Val Ser Ala Ala Pro Glu Ala Ser Gly Gly Ala
1910 1915 1920Ser Gly Ala Pro Asp Val Ser Glu Ala Thr Ser Thr Phe
Pro Glu 1925 1930 1935Ala Asp Val Glu Gly Ala Ser Gly Leu Gly Val
Ser Gly Gly Thr 1940 1945 1950Ser Ala Phe Pro Glu Ala Pro Arg Glu
Gly Ser Ala Thr Pro Glu 1955 1960 1965Val Gln Glu Glu Pro Thr Thr
Ser Tyr Asp Val Gly Arg Glu Ala 1970 1975 1980Leu Gly Trp Pro Ser
Ala Thr Pro Thr Ala Ser Gly Asp Arg Ile 1985 1990 1995Glu Val Ser
Gly Asp Leu Ser Gly His Thr Ser Gly Leu Asp Val 2000 2005 2010Val
Ile Ser Thr Ser Val Pro Glu Ser Glu Trp Ile Gln Gln Thr 2015 2020
2025Gln Arg Pro Ala Glu Ala His Leu Glu Ile Glu Ala Ser Ser Pro
2030 2035 2040Leu His Ser Gly Glu Glu Thr Gln Thr Ala Glu Thr Ala
Thr Ser 2045 2050 2055Pro Thr Asp Asp Ala Ser Ile Pro Thr Ser Pro
Ser Gly Thr Asp 2060 2065 2070Glu Ser Ala Pro Ala Ile Pro Asp Ile
Asp Glu Cys Leu Ser Ser 2075 2080 2085Pro Cys Leu Asn Gly Ala Thr
Cys Val Asp Ala Ile Asp Ser Phe 2090 2095 2100Thr Cys Leu Cys Leu
Pro Ser Tyr Arg Gly Asp Leu Cys Glu Ile 2105 2110 2115Asp Gln Glu
Leu Cys Glu Glu Gly Trp Thr Lys Phe Gln Gly His 2120 2125 2130Cys
Tyr Arg Tyr Phe Pro Asp Arg Glu Ser Trp Val Asp Ala Glu 2135 2140
2145Ser Arg Cys Arg Ala Gln Gln Ser His Leu Ser Ser Ile Val Thr
2150 2155 2160Pro Glu Glu Gln Glu Phe Val Asn Asn Asn Ala Gln Asp
Tyr Gln 2165 2170 2175Trp Ile Gly Leu Asn Asp Arg Thr Ile Glu Gly
Asp Phe Arg Trp 2180 2185 2190Ser Asp Gly His Ser Leu Gln Phe Glu
Asn Trp Arg Pro Asn Gln 2195
2200 2205Pro Asp Asn Phe Phe Val Ser Gly Glu Asp Cys Val Val Met
Ile 2210 2215 2220Trp His Glu Lys Gly Glu Trp Asn Asp Val Pro Cys
Asn Tyr Tyr 2225 2230 2235Leu Pro Phe Thr Cys Lys Lys Gly Thr Val
Ala Cys Gly Asp Pro 2240 2245 2250Pro Val Val Glu His Ala Arg Thr
Phe Gly Gln Lys Lys Asp Arg 2255 2260 2265Tyr Glu Ile Asn Ser Leu
Val Arg Tyr Gln Cys Thr Glu Gly Phe 2270 2275 2280Val Gln Arg His
Val Pro Thr Ile Arg Cys Gln Pro Ser Gly His 2285 2290 2295Trp Glu
Lys Pro Arg Ile Thr Cys Thr Asp Pro Ser Thr Tyr Lys 2300 2305
2310Arg Arg Leu Gln Lys Arg Ser Ser Arg Ala Pro Arg Arg Ser Arg
2315 2320 2325Pro Ser Thr Ala His 23301272364PRTBos taurus 127Met
Thr Thr Leu Leu Leu Val Phe Val Thr Leu Arg Val Ile Thr Ala1 5 10
15Ala Ile Ser Val Glu Val Ser Glu Pro Asp Asn Ser Leu Ser Val Ser
20 25 30Ile Pro Glu Pro Ser Pro Leu Arg Val Leu Leu Gly Ser Ser Leu
Thr 35 40 45Ile Pro Cys Tyr Phe Ile Asp Pro Met His Pro Val Thr Thr
Ala Pro 50 55 60Ser Thr Ala Pro Leu Ala Pro Arg Ile Lys Trp Ser Arg
Ile Ser Lys65 70 75 80Glu Lys Glu Val Val Leu Leu Val Ala Thr Glu
Gly Arg Val Arg Val 85 90 95Asn Ser Ala Tyr Gln Asp Lys Val Thr Leu
Pro Asn Tyr Pro Ala Ile 100 105 110Pro Ser Asp Ala Thr Leu Glu Ile
Gln Asn Met Arg Ser Asn Asp Ser 115 120 125Gly Ile Leu Arg Cys Glu
Val Met His Gly Ile Glu Asp Ser Gln Ala 130 135 140Thr Leu Glu Val
Val Val Lys Gly Ile Val Phe His Tyr Arg Ala Ile145 150 155 160Ser
Thr Arg Tyr Thr Leu Asp Phe Asp Arg Ala Gln Arg Ala Cys Leu 165 170
175Gln Asn Ser Ala Ile Ile Ala Thr Pro Glu Gln Leu Gln Ala Ala Tyr
180 185 190Glu Asp Gly Phe His Gln Cys Asp Ala Gly Trp Leu Ala Asp
Gln Thr 195 200 205Val Arg Tyr Pro Ile His Thr Pro Arg Glu Gly Cys
Tyr Gly Asp Lys 210 215 220Asp Glu Phe Pro Gly Val Arg Thr Tyr Gly
Ile Arg Asp Thr Asn Glu225 230 235 240Thr Tyr Asp Val Tyr Cys Phe
Ala Glu Glu Met Glu Gly Glu Val Phe 245 250 255Tyr Ala Thr Ser Pro
Glu Lys Phe Thr Phe Gln Glu Ala Ala Asn Glu 260 265 270Cys Arg Arg
Leu Gly Ala Arg Leu Ala Thr Thr Gly Gln Leu Tyr Leu 275 280 285Ala
Trp Gln Gly Gly Met Asp Met Cys Ser Ala Gly Trp Leu Ala Asp 290 295
300Arg Ser Val Arg Tyr Pro Ile Ser Lys Ala Arg Pro Asn Cys Gly
Gly305 310 315 320Asn Leu Leu Gly Val Arg Thr Val Tyr Leu His Ala
Asn Gln Thr Gly 325 330 335Tyr Pro Asp Pro Ser Ser Arg Tyr Asp Ala
Ile Cys Tyr Thr Gly Glu 340 345 350Asp Phe Val Asp Ile Pro Glu Ser
Phe Phe Gly Val Gly Gly Glu Glu 355 360 365Asp Ile Thr Ile Gln Thr
Val Thr Trp Pro Asp Val Glu Leu Pro Leu 370 375 380Pro Arg Asn Ile
Thr Glu Gly Glu Ala Arg Gly Ser Val Ile Leu Thr385 390 395 400Ala
Lys Pro Asp Phe Glu Val Ser Pro Thr Ala Pro Glu Pro Glu Glu 405 410
415Pro Phe Thr Phe Val Pro Glu Val Arg Ala Thr Ala Phe Pro Glu Val
420 425 430Glu Asn Arg Thr Glu Glu Ala Thr Arg Pro Trp Ala Phe Pro
Arg Glu 435 440 445Ser Thr Pro Gly Leu Gly Ala Pro Thr Ala Phe Thr
Ser Glu Asp Leu 450 455 460Val Val Gln Val Thr Leu Ala Pro Gly Ala
Ala Glu Val Pro Gly Gln465 470 475 480Pro Arg Leu Pro Gly Gly Val
Val Phe His Tyr Arg Pro Gly Ser Ser 485 490 495Arg Tyr Ser Leu Thr
Phe Glu Glu Ala Lys Gln Ala Cys Leu Arg Thr 500 505 510Gly Ala Ile
Ile Ala Ser Pro Glu Gln Leu Gln Ala Ala Tyr Glu Ala 515 520 525Gly
Tyr Glu Gln Cys Asp Ala Gly Trp Leu Gln Asp Gln Thr Val Arg 530 535
540Tyr Pro Ile Val Ser Pro Arg Thr Pro Cys Val Gly Asp Lys Asp
Ser545 550 555 560Ser Pro Gly Val Arg Thr Tyr Gly Val Arg Pro Pro
Ser Glu Thr Tyr 565 570 575Asp Val Tyr Cys Tyr Val Asp Arg Leu Glu
Gly Glu Val Phe Phe Ala 580 585 590Thr Arg Leu Glu Gln Phe Thr Phe
Trp Glu Ala Gln Glu Phe Cys Glu 595 600 605Ser Gln Asn Ala Thr Leu
Ala Thr Thr Gly Gln Leu Tyr Ala Ala Trp 610 615 620Ser Arg Gly Leu
Asp Lys Cys Tyr Ala Gly Trp Leu Ala Asp Gly Ser625 630 635 640Leu
Arg Tyr Pro Ile Val Thr Pro Arg Pro Ala Cys Gly Gly Asp Lys 645 650
655Pro Gly Val Arg Thr Val Tyr Leu Tyr Pro Asn Gln Thr Gly Leu Leu
660 665 670Asp Pro Leu Ser Arg His His Ala Phe Cys Phe Arg Gly Val
Ser Ala 675 680 685Ala Pro Ser Pro Glu Glu Glu Glu Gly Ser Ala Pro
Thr Ala Gly Pro 690 695 700Asp Val Glu Glu Trp Met Val Thr Gln Val
Gly Pro Gly Val Ala Ala705 710 715 720Val Pro Ile Gly Glu Glu Thr
Thr Ala Ile Pro Gly Phe Thr Val Glu 725 730 735Pro Glu Asn Lys Thr
Glu Trp Glu Leu Ala Tyr Thr Pro Ala Gly Thr 740 745 750Leu Pro Leu
Pro Gly Ile Pro Pro Thr Trp Pro Pro Thr Gly Glu Ala 755 760 765Thr
Glu Glu His Thr Glu Gly Pro Ser Ala Thr Glu Val Pro Ser Ala 770 775
780Ser Glu Lys Pro Phe Pro Ser Glu Glu Pro Phe Pro Pro Glu Glu
Pro785 790 795 800Phe Pro Ser Glu Lys Pro Phe Pro Pro Glu Glu Leu
Phe Pro Ser Glu 805 810 815Lys Pro Phe Pro Ser Glu Lys Pro Phe Pro
Ser Glu Glu Pro Phe Pro 820 825 830Ser Glu Lys Pro Phe Pro Pro Glu
Glu Leu Phe Pro Ser Glu Lys Pro 835 840 845Ile Pro Ser Glu Glu Pro
Phe Pro Ser Glu Glu Pro Phe Pro Ser Glu 850 855 860Lys Pro Phe Pro
Pro Glu Glu Pro Phe Pro Ser Glu Lys Pro Ile Pro865 870 875 880Ser
Glu Glu Pro Phe Pro Ser Glu Lys Pro Phe Pro Ser Glu Glu Pro 885 890
895Phe Pro Ser Glu Glu Pro Ser Thr Leu Ser Ala Pro Val Pro Ser Arg
900 905 910Thr Glu Leu Pro Ser Ser Gly Glu Val Ser Gly Val Pro Glu
Ile Ser 915 920 925Gly Asp Phe Thr Gly Ser Gly Glu Ile Ser Gly His
Leu Asp Phe Ser 930 935 940Gly Gln Pro Ser Gly Glu Ser Ala Ser Gly
Leu Pro Ser Glu Asp Leu945 950 955 960Asp Ser Ser Gly Leu Thr Ser
Thr Val Gly Ser Gly Leu Pro Val Glu 965 970 975Ser Gly Leu Pro Ser
Gly Glu Glu Glu Arg Ile Thr Trp Thr Ser Ala 980 985 990Pro Lys Val
Asp Arg Leu Pro Ser Gly Gly Glu Gly Pro Glu Val Ser 995 1000
1005Gly Val Glu Asp Ile Ser Gly Leu Pro Ser Gly Gly Glu Val His
1010 1015 1020Leu Glu Ile Ser Ala Ser Gly Val Glu Asp Ile Ser Gly
Leu Pro 1025 1030 1035Ser Gly Gly Glu Val His Leu Glu Ile Ser Ala
Ser Gly Val Glu 1040 1045 1050Asp Leu Ser Arg Ile Pro Ser Gly Glu
Gly Pro Glu Ile Ser Ala 1055 1060 1065Ser Gly Val Glu Asp Ile Ser
Gly Leu Pro Ser Gly Glu Glu Gly 1070 1075 1080His Leu Glu Ile Ser
Ala Ser Gly Val Glu Asp Leu Ser Gly Ile 1085 1090 1095Pro Ser Gly
Glu Gly Pro Glu Val Ser Ala Ser Gly Val Glu Asp 1100 1105 1110Leu
Ile Gly Leu Pro Ser Gly Glu Gly Pro Glu Val Ser Ala Ser 1115 1120
1125Gly Val Glu Asp Leu Ser Arg Leu Pro Ser Gly Glu Gly Pro Glu
1130 1135 1140Val Ser Ala Ser Gly Val Glu Asp Leu Ser Gly Leu Pro
Ser Gly 1145 1150 1155Glu Gly Pro Glu Val Ser Val Ser Gly Val Glu
Asp Leu Ser Arg 1160 1165 1170Leu Pro Ser Gly Glu Gly Pro Glu Val
Ser Ala Ser Gly Val Glu 1175 1180 1185Asp Leu Ser Arg Leu Pro Ser
Gly Glu Gly Pro Glu Ile Ser Val 1190 1195 1200Ser Gly Val Glu Asp
Ile Ser Ile Leu Pro Ser Gly Glu Gly Pro 1205 1210 1215Glu Val Ser
Ala Ser Gly Val Glu Asp Leu Ser Val Leu Pro Ser 1220 1225 1230Gly
Glu Gly His Leu Glu Ile Ser Thr Ser Gly Val Glu Asp Leu 1235 1240
1245Ser Val Leu Pro Ser Gly Glu Gly His Leu Glu Thr Ser Ser Gly
1250 1255 1260Val Glu Asp Ile Ser Arg Leu Pro Ser Gly Glu Gly Pro
Glu Val 1265 1270 1275Ser Ala Ser Gly Val Glu Asp Leu Ser Val Leu
Pro Ser Gly Glu 1280 1285 1290Asp His Leu Glu Ile Ser Ala Ser Gly
Val Glu Asp Leu Gly Val 1295 1300 1305Leu Pro Ser Gly Glu Asp His
Leu Glu Ile Ser Ala Ser Gly Val 1310 1315 1320Glu Asp Ile Ser Arg
Leu Pro Ser Gly Glu Gly Pro Glu Val Ser 1325 1330 1335Ala Ser Gly
Val Glu Asp Leu Ser Val Leu Pro Ser Gly Glu Gly 1340 1345 1350His
Leu Glu Ile Ser Ala Ser Gly Val Glu Asp Leu Ser Arg Leu 1355 1360
1365Pro Ser Gly Gly Glu Asp His Leu Glu Thr Ser Ala Ser Gly Val
1370 1375 1380Gly Asp Leu Ser Gly Leu Pro Ser Gly Arg Glu Gly Leu
Glu Ile 1385 1390 1395Ser Ala Ser Gly Ala Gly Asp Leu Ser Gly Leu
Thr Ser Gly Lys 1400 1405 1410Glu Asp Leu Thr Gly Ser Ala Ser Gly
Ala Leu Asp Leu Gly Arg 1415 1420 1425Ile Pro Ser Val Thr Leu Gly
Ser Gly Gln Ala Pro Glu Ala Ser 1430 1435 1440Gly Leu Pro Ser Gly
Phe Ser Gly Glu Tyr Ser Gly Val Asp Leu 1445 1450 1455Glu Ser Gly
Pro Ser Ser Gly Leu Pro Asp Phe Ser Gly Leu Pro 1460 1465 1470Ser
Gly Phe Pro Thr Val Ser Leu Val Asp Thr Thr Leu Val Glu 1475 1480
1485Val Val Thr Ala Thr Thr Ala Gly Glu Leu Glu Gly Arg Gly Thr
1490 1495 1500Ile Asp Ile Ser Gly Ala Gly Glu Thr Ser Gly Leu Pro
Phe Ser 1505 1510 1515Glu Leu Asp Ile Ser Gly Gly Ala Ser Gly Leu
Ser Ser Gly Ala 1520 1525 1530Glu Leu Ser Gly Gln Ala Ser Gly Ser
Pro Asp Ile Ser Gly Glu 1535 1540 1545Thr Ser Gly Leu Phe Gly Val
Ser Gly Gln Pro Ser Gly Phe Pro 1550 1555 1560Asp Ile Ser Gly Glu
Thr Ser Gly Leu Leu Glu Val Ser Gly Gln 1565 1570 1575Pro Ser Gly
Phe Tyr Gly Glu Ile Ser Gly Val Thr Glu Leu Ser 1580 1585 1590Gly
Leu Ala Ser Gly Gln Pro Glu Ile Ser Gly Glu Ala Ser Gly 1595 1600
1605Ile Leu Ser Gly Leu Gly Pro Pro Phe Gly Ile Thr Asp Leu Ser
1610 1615 1620Gly Glu Ala Pro Gly Ile Pro Asp Leu Ser Gly Gln Pro
Ser Gly 1625 1630 1635Leu Pro Glu Phe Ser Gly Thr Ala Ser Gly Ile
Pro Asp Leu Val 1640 1645 1650Ser Ser Ala Val Ser Gly Ser Gly Glu
Ser Ser Gly Ile Thr Phe 1655 1660 1665Val Asp Thr Ser Leu Val Glu
Val Thr Pro Thr Thr Phe Lys Glu 1670 1675 1680Glu Glu Gly Leu Gly
Ser Val Glu Leu Ser Gly Leu Pro Ser Gly 1685 1690 1695Glu Leu Gly
Val Ser Gly Thr Ser Gly Leu Ala Asp Val Ser Gly 1700 1705 1710Leu
Ser Ser Gly Ala Ile Asp Ser Ser Gly Phe Thr Ser Gln Pro 1715 1720
1725Pro Glu Phe Ser Gly Leu Pro Ser Gly Val Thr Glu Val Ser Gly
1730 1735 1740Glu Ala Ser Gly Ala Glu Ser Gly Ser Ser Leu Pro Ser
Gly Ala 1745 1750 1755Tyr Asp Ser Ser Gly Leu Pro Ser Gly Phe Pro
Thr Val Ser Phe 1760 1765 1770Val Asp Arg Thr Leu Val Glu Ser Val
Thr Gln Ala Pro Thr Ala 1775 1780 1785Gln Glu Ala Gly Glu Gly Pro
Ser Gly Ile Leu Glu Leu Ser Gly 1790 1795 1800Ala Pro Ser Gly Ala
Pro Asp Met Ser Gly Asp His Leu Gly Ser 1805 1810 1815Leu Asp Gln
Ser Gly Leu Gln Ser Gly Leu Val Glu Pro Ser Gly 1820 1825 1830Glu
Pro Ala Ser Thr Pro Tyr Phe Ser Gly Asp Phe Ser Gly Thr 1835 1840
1845Thr Asp Val Ser Gly Glu Ser Ser Ala Ala Thr Ser Thr Ser Gly
1850 1855 1860Glu Ala Ser Gly Leu Pro Glu Val Thr Leu Ile Thr Ser
Glu Leu 1865 1870 1875Val Glu Gly Val Thr Glu Pro Thr Val Ser Gln
Glu Leu Gly Gln 1880 1885 1890Arg Pro Pro Val Thr Tyr Thr Pro Gln
Leu Phe Glu Ser Ser Gly 1895 1900 1905Glu Ala Ser Ala Ser Gly Asp
Val Pro Arg Phe Pro Gly Ser Gly 1910 1915 1920Val Glu Val Ser Ser
Val Pro Glu Ser Ser Gly Glu Thr Ser Ala 1925 1930 1935Tyr Pro Glu
Ala Glu Val Gly Ala Ser Ala Ala Pro Glu Ala Ser 1940 1945 1950Gly
Gly Ala Ser Gly Ser Pro Asn Leu Ser Glu Thr Thr Ser Thr 1955 1960
1965Phe His Glu Ala Asp Leu Glu Gly Thr Ser Gly Leu Gly Val Ser
1970 1975 1980Gly Ser Pro Ser Ala Phe Pro Glu Gly Pro Thr Glu Gly
Leu Ala 1985 1990 1995Thr Pro Glu Val Ser Gly Glu Ser Thr Thr Ala
Phe Asp Val Ser 2000 2005 2010Val Glu Ala Ser Gly Ser Pro Ser Ala
Thr Pro Leu Ala Ser Gly 2015 2020 2025Asp Arg Thr Asp Thr Ser Gly
Asp Leu Ser Gly His Thr Ser Gly 2030 2035 2040Leu Asp Ile Val Ile
Ser Thr Thr Ile Pro Glu Ser Glu Trp Thr 2045 2050 2055Gln Gln Thr
Gln Arg Pro Ala Glu Ala Arg Leu Glu Ile Glu Ser 2060 2065 2070Ser
Ser Pro Val His Ser Gly Glu Glu Ser Gln Thr Ala Asp Thr 2075 2080
2085Ala Thr Ser Pro Thr Asp Ala Ser Ile Pro Ala Ser Ala Gly Gly
2090 2095 2100Thr Asp Asp Ser Glu Ala Thr Thr Thr Asp Ile Asp Glu
Cys Leu 2105 2110 2115Ser Ser Pro Cys Leu Asn Gly Ala Thr Cys Val
Asp Ala Ile Asp 2120 2125 2130Ser Phe Thr Cys Leu Cys Leu Pro Ser
Tyr Gln Gly Asp Val Cys 2135 2140 2145Glu Ile Gln Lys Leu Cys Glu
Glu Gly Trp Thr Lys Phe Gln Gly 2150 2155 2160His Cys Tyr Arg His
Phe Pro Asp Arg Ala Thr Trp Val Asp Ala 2165 2170 2175Glu Ser Gln
Cys Arg Lys Gln Gln Ser His Leu Ser Ser Ile Val 2180 2185 2190Thr
Pro Glu Glu Gln Glu Phe Val Asn Asn Asn Ala Gln Asp Tyr 2195 2200
2205Gln Trp Ile Gly Leu Asn Asp Lys Thr Ile Glu Gly Asp Phe Arg
2210 2215 2220Trp Ser Asp Gly His Ser Leu Gln Phe Glu Asn Trp Arg
Pro Asn 2225 2230 2235Gln Pro Asp Asn Phe Phe Ala Thr Gly Glu Asp
Cys Val Val Met 2240 2245 2250Ile Trp His Glu Lys Gly Glu Trp Asn
Asp Val Pro Cys Asn Tyr 2255 2260 2265Gln Leu Pro Phe Thr Cys Lys
Lys Gly Thr Val Ala Cys Gly Glu 2270 2275 2280Pro Pro Val Val Glu
His Ala Arg Ile Phe Gly Gln Lys Lys Asp 2285 2290 2295Arg Tyr Glu
Ile Asn Ala Leu Val Arg Tyr Gln Cys Thr Glu Gly 2300 2305 2310Phe
Ile Gln Gly His Val Pro Thr Ile Arg Cys Gln Pro
Ser Gly 2315 2320 2325His Trp Glu Glu Pro Arg Ile Thr Cys Thr Asp
Pro Ala Thr Tyr 2330 2335 2340Lys Arg Arg Leu Gln Lys Arg Ser Ser
Arg Pro Leu Arg Arg Ser 2345 2350 2355His Pro Ser Thr Ala His
23601282124PRTRattus norvegicus 128Met Thr Thr Leu Leu Leu Val Phe
Val Thr Leu Arg Val Ile Ala Ala1 5 10 15Val Ile Ser Glu Glu Val Pro
Asp His Asp Asn Ser Leu Ser Val Ser 20 25 30Ile Pro Gln Pro Ser Pro
Leu Lys Ala Leu Leu Gly Thr Ser Leu Thr 35 40 45Ile Pro Cys Tyr Phe
Ile Asp Pro Met His Pro Val Thr Thr Ala Pro 50 55 60Ser Thr Ala Pro
Leu Thr Pro Arg Ile Lys Trp Ser Arg Val Ser Lys65 70 75 80Glu Lys
Glu Val Val Leu Leu Val Ala Thr Glu Gly Gln Val Arg Val 85 90 95Asn
Ser Ile Tyr Gln Asp Lys Val Ser Leu Pro Asn Tyr Pro Ala Ile 100 105
110Pro Ser Asp Ala Thr Leu Glu Ile Gln Asn Leu Arg Ser Asn Asp Ser
115 120 125Gly Ile Tyr Arg Cys Glu Val Met His Gly Ile Glu Asp Ser
Glu Ala 130 135 140Thr Leu Glu Val Ile Val Lys Gly Ile Val Phe His
Tyr Arg Ala Ile145 150 155 160Ser Thr Arg Tyr Thr Leu Asp Phe Asp
Arg Ala Gln Arg Ala Cys Leu 165 170 175Gln Asn Ser Ala Ile Ile Ala
Thr Pro Glu Gln Leu Gln Ala Ala Tyr 180 185 190Glu Asp Gly Phe His
Gln Cys Asp Ala Gly Trp Leu Ala Asp Gln Thr 195 200 205Val Arg Tyr
Pro Ile His Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys 210 215 220Asp
Glu Phe Pro Gly Val Arg Thr Tyr Gly Ile Arg Asp Thr Asn Glu225 230
235 240Thr Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met Glu Gly Glu Val
Phe 245 250 255Tyr Ala Thr Ser Pro Glu Lys Phe Thr Phe Gln Glu Ala
Ala Asn Glu 260 265 270Cys Arg Thr Val Gly Ala Arg Leu Ala Thr Thr
Gly Gln Leu Tyr Leu 275 280 285Ala Trp Gln Gly Gly Met Asp Met Cys
Ser Ala Gly Trp Leu Ala Asp 290 295 300Arg Ser Val Arg Tyr Pro Ile
Ser Lys Ala Arg Pro Asn Cys Gly Gly305 310 315 320Asn Leu Leu Gly
Val Arg Thr Val Tyr Leu His Ala Asn Gln Thr Gly 325 330 335Tyr Pro
Asp Pro Ser Ser Arg Tyr Asp Ala Ile Cys Tyr Thr Gly Glu 340 345
350Asp Phe Val Asp Ile Pro Glu Asn Phe Phe Gly Val Gly Gly Glu Glu
355 360 365Asp Ile Thr Ile Gln Thr Val Thr Trp Pro Asp Leu Glu Leu
Pro Leu 370 375 380Pro Arg Asn Ile Thr Glu Gly Glu Ala Arg Gly Asn
Val Ile Leu Thr385 390 395 400Ala Lys Pro Ile Phe Asp Met Ser Pro
Thr Val Ser Glu Pro Gly Glu 405 410 415Ala Leu Thr Leu Ala Pro Glu
Val Gly Thr Thr Val Phe Pro Glu Ala 420 425 430Gly Glu Arg Thr Glu
Lys Thr Thr Arg Pro Trp Gly Phe Pro Glu Glu 435 440 445Ala Thr Arg
Gly Pro Asp Ser Ala Thr Ala Phe Ala Ser Glu Asp Leu 450 455 460Val
Val Arg Val Thr Ile Ser Pro Gly Ala Val Glu Val Pro Gly Gln465 470
475 480Pro Arg Leu Pro Gly Gly Val Val Phe His Tyr Arg Pro Gly Ser
Thr 485 490 495Arg Tyr Ser Leu Thr Phe Glu Glu Ala Gln Gln Ala Cys
Ile Arg Thr 500 505 510Gly Ala Ala Ile Ala Ser Pro Glu Gln Leu Gln
Ala Ala Tyr Glu Ala 515 520 525Gly Tyr Glu Gln Cys Asp Ala Gly Trp
Leu Gln Asp Gln Thr Val Arg 530 535 540Tyr Pro Ile Val Ser Pro Arg
Thr Pro Cys Val Gly Asp Lys Asp Ser545 550 555 560Ser Pro Gly Val
Arg Thr Tyr Gly Val Arg Pro Ser Ser Glu Thr Tyr 565 570 575Asp Val
Tyr Cys Tyr Val Asp Lys Leu Glu Gly Glu Val Phe Phe Ala 580 585
590Thr Gln Met Glu Gln Phe Thr Phe Gln Glu Ala Gln Ala Phe Cys Ala
595 600 605Ala Gln Asn Ala Thr Leu Ala Ser Thr Gly Gln Leu Tyr Ala
Ala Trp 610 615 620Ser Gln Gly Leu Asp Lys Cys Tyr Ala Gly Trp Leu
Ala Asp Gly Thr625 630 635 640Leu Arg Tyr Pro Ile Val Asn Pro Arg
Pro Ala Cys Gly Gly Asp Lys 645 650 655Pro Gly Val Arg Thr Val Tyr
Leu Tyr Pro Asn Gln Thr Gly Leu Pro 660 665 670Asp Pro Leu Ser Lys
His His Ala Phe Cys Phe Arg Gly Val Ser Val 675 680 685Val Pro Ser
Pro Gly Gly Thr Pro Thr Ser Pro Ser Asp Ile Glu Asp 690 695 700Trp
Ile Val Thr Arg Val Glu Pro Gly Val Asp Ala Val Pro Leu Glu705 710
715 720Pro Glu Thr Thr Glu Val Pro Tyr Phe Thr Thr Glu Pro Glu Lys
Gln 725 730 735Thr Glu Trp Glu Pro Ala Tyr Thr Pro Val Gly Thr Ser
Pro Leu Pro 740 745 750Gly Ile Pro Pro Thr Trp Leu Pro Thr Val Pro
Ala Ala Glu Glu His 755 760 765Thr Glu Ser Pro Ser Ala Ser Gln Glu
Pro Ser Ala Ser Gln Val Pro 770 775 780Ser Thr Ser Glu Glu Pro Tyr
Thr Pro Ser Leu Ala Val Pro Ser Gly785 790 795 800Thr Glu Leu Pro
Ser Ser Gly Asp Thr Ser Gly Ala Pro Asp Leu Ser 805 810 815Gly Asp
Phe Thr Gly Ser Thr Asp Thr Ser Gly Arg Leu Asp Ser Ser 820 825
830Gly Glu Pro Ser Gly Gly Ser Glu Ser Gly Leu Pro Ser Gly Asp Leu
835 840 845Asp Ser Ser Gly Leu Gly Pro Thr Val Ser Ser Gly Leu Pro
Val Glu 850 855 860Ser Gly Ser Ala Ser Gly Asp Gly Glu Ile Pro Trp
Ser Ser Thr Pro865 870 875 880Thr Val Asp Arg Leu Pro Ser Gly Gly
Glu Ser Leu Glu Gly Ser Ala 885 890 895Ser Ala Ser Gly Thr Gly Asp
Leu Ser Gly Leu Pro Ser Gly Gly Glu 900 905 910Ile Thr Glu Thr Ser
Ala Ser Gly Thr Glu Glu Ile Ser Gly Leu Pro 915 920 925Ser Gly Gly
Asp Asp Leu Glu Thr Ser Thr Ser Gly Ile Asp Gly Ala 930 935 940Ser
Val Leu Pro Thr Gly Arg Gly Gly Leu Glu Thr Ser Ala Ser Gly945 950
955 960Val Glu Asp Leu Ser Gly Leu Pro Ser Gly Glu Glu Gly Ser Glu
Thr 965 970 975Ser Thr Ser Gly Ile Glu Asp Ile Ser Val Leu Pro Thr
Gly Glu Ser 980 985 990Pro Glu Thr Ser Ala Ser Gly Val Gly Asp Leu
Ser Gly Leu Pro Ser 995 1000 1005Gly Gly Glu Ser Leu Glu Thr Ser
Ala Ser Gly Val Glu Asp Val 1010 1015 1020Thr Gln Leu Pro Thr Glu
Arg Gly Gly Leu Glu Thr Ser Ala Ser 1025 1030 1035Gly Ile Glu Asp
Ile Thr Val Leu Pro Thr Gly Arg Glu Asn Leu 1040 1045 1050Glu Thr
Ser Ala Ser Gly Val Glu Asp Val Ser Gly Leu Pro Ser 1055 1060
1065Gly Lys Glu Gly Leu Glu Thr Ser Ala Ser Gly Ile Glu Asp Ile
1070 1075 1080Ser Val Phe Pro Thr Glu Ala Glu Gly Leu Glu Thr Ser
Ala Ser 1085 1090 1095Gly Gly Tyr Val Ser Gly Ile Pro Ser Gly Glu
Asp Gly Thr Glu 1100 1105 1110Thr Ser Thr Ser Gly Val Glu Gly Val
Ser Gly Leu Pro Ser Gly 1115 1120 1125Gly Glu Gly Leu Glu Thr Ser
Ala Ser Gly Val Glu Asp Leu Gly 1130 1135 1140Leu Pro Thr Arg Asp
Ser Leu Glu Thr Ser Ala Ser Gly Val Asp 1145 1150 1155Val Thr Gly
Tyr Pro Ser Gly Arg Glu Asp Thr Glu Thr Ser Val 1160 1165 1170Pro
Gly Val Gly Asp Asp Leu Ser Gly Leu Pro Ser Gly Gln Glu 1175 1180
1185Gly Leu Glu Thr Ser Ala Ser Gly Ala Glu Asp Leu Gly Gly Leu
1190 1195 1200Pro Ser Gly Lys Glu Asp Leu Val Gly Ser Ala Ser Gly
Ala Leu 1205 1210 1215Asp Phe Gly Lys Leu Pro Ser Gly Thr Leu Gly
Ser Gly Gln Thr 1220 1225 1230Pro Glu Ala Ser Gly Leu Pro Ser Gly
Phe Ser Gly Glu Tyr Ser 1235 1240 1245Gly Val Asp Ile Gly Ser Gly
Pro Ser Ser Gly Leu Pro Asp Phe 1250 1255 1260Ser Gly Leu Pro Ser
Gly Phe Pro Thr Val Ser Leu Val Asp Ser 1265 1270 1275Thr Leu Val
Glu Val Ile Thr Ala Thr Thr Ala Ser Glu Leu Glu 1280 1285 1290Gly
Arg Gly Thr Ile Ser Val Ser Gly Ser Gly Glu Glu Ser Gly 1295 1300
1305Pro Pro Leu Ser Glu Leu Asp Ser Ser Ala Asp Ile Ser Gly Leu
1310 1315 1320Pro Ser Gly Thr Glu Leu Ser Gly Gln Thr Ser Gly Ser
Leu Asp 1325 1330 1335Val Ser Gly Glu Thr Ser Gly Phe Phe Asp Val
Ser Gly Gln Pro 1340 1345 1350Phe Gly Ser Ser Gly Thr Gly Glu Gly
Thr Ser Gly Ile Pro Glu 1355 1360 1365Val Ser Gly Gln Ala Val Arg
Ser Pro Asp Thr Thr Glu Ile Ser 1370 1375 1380Glu Leu Ser Gly Leu
Ser Ser Gly Gln Pro Asp Val Ser Gly Glu 1385 1390 1395Gly Ser Gly
Ile Leu Phe Gly Ser Gly Gln Ser Ser Gly Ile Thr 1400 1405 1410Ser
Val Ser Gly Glu Thr Ser Gly Ile Ser Asp Leu Ser Gly Gln 1415 1420
1425Pro Ser Gly Phe Pro Val Leu Ser Gly Thr Thr Pro Gly Thr Pro
1430 1435 1440Asp Leu Ala Ser Gly Ala Met Ser Gly Ser Gly Asp Ser
Ser Gly 1445 1450 1455Ile Thr Phe Val Asp Thr Ser Leu Ile Glu Val
Thr Pro Thr Thr 1460 1465 1470Phe Arg Glu Glu Glu Gly Leu Gly Ser
Val Glu Leu Ser Gly Leu 1475 1480 1485Pro Ser Gly Glu Thr Asp Leu
Ser Gly Thr Ser Gly Met Val Asp 1490 1495 1500Val Ser Gly Gln Ser
Ser Gly Ala Ile Asp Ser Ser Gly Leu Ile 1505 1510 1515Ser Pro Thr
Pro Glu Phe Ser Gly Leu Pro Ser Gly Val Ala Glu 1520 1525 1530Val
Ser Gly Glu Val Ser Gly Val Glu Thr Gly Ser Ser Leu Ser 1535 1540
1545Ser Gly Ala Phe Asp Gly Ser Gly Leu Val Ser Gly Phe Pro Thr
1550 1555 1560Val Ser Leu Val Asp Arg Thr Leu Val Glu Ser Ile Thr
Leu Ala 1565 1570 1575Pro Thr Ala Gln Glu Ala Gly Glu Gly Pro Ser
Ser Ile Leu Glu 1580 1585 1590Phe Ser Gly Ala His Ser Gly Thr Pro
Asp Ile Ser Gly Asp Leu 1595 1600 1605Ser Gly Ser Leu Asp Gln Ser
Thr Trp Gln Pro Gly Trp Thr Glu 1610 1615 1620Ala Ser Thr Glu Pro
Pro Ser Ser Pro Tyr Phe Ser Gly Asp Phe 1625 1630 1635Ser Ser Thr
Thr Asp Ala Ser Gly Glu Ser Ile Thr Ala Pro Thr 1640 1645 1650Gly
Ser Gly Glu Thr Ser Gly Leu Pro Glu Val Thr Leu Ile Thr 1655 1660
1665Ser Glu Leu Val Glu Gly Val Thr Glu Pro Thr Val Ser Gln Glu
1670 1675 1680Leu Gly His Gly Pro Ser Met Thr Tyr Thr Pro Arg Leu
Phe Glu 1685 1690 1695Ala Ser Gly Glu Ala Ser Ala Ser Gly Asp Leu
Gly Gly Pro Val 1700 1705 1710Thr Ile Phe Pro Gly Ser Gly Val Glu
Ala Ser Val Pro Glu Gly 1715 1720 1725Ser Ser Asp Pro Ser Ala Tyr
Pro Glu Ala Gly Val Gly Val Ser 1730 1735 1740Ala Ala Pro Glu Ala
Ser Ser Gln Leu Ser Glu Phe Pro Asp Leu 1745 1750 1755His Gly Ile
Thr Ser Ala Ser Arg Glu Thr Asp Leu Glu Met Thr 1760 1765 1770Thr
Pro Gly Thr Glu Val Ser Ser Asn Pro Trp Thr Phe Gln Glu 1775 1780
1785Gly Thr Arg Glu Gly Ser Ala Ala Pro Glu Val Ser Gly Glu Ser
1790 1795 1800Ser Thr Thr Ser Asp Ile Asp Ala Gly Thr Ser Gly Val
Pro Phe 1805 1810 1815Ala Thr Pro Met Thr Ser Gly Asp Arg Thr Glu
Ile Ser Gly Glu 1820 1825 1830Trp Ser Asp His Thr Ser Glu Val Asn
Val Thr Val Ser Thr Thr 1835 1840 1845Val Pro Glu Ser Arg Trp Ala
Gln Ser Thr Gln His Pro Thr Glu 1850 1855 1860Thr Leu Gln Glu Ile
Gly Ser Pro Asn Pro Ser Tyr Ser Gly Glu 1865 1870 1875Glu Thr Gln
Thr Ala Glu Thr Ala Lys Ser Leu Thr Asp Thr Pro 1880 1885 1890Thr
Leu Ala Ser Pro Glu Gly Ser Gly Glu Thr Glu Ser Thr Ala 1895 1900
1905Ala Asp Gln Glu Gln Cys Glu Glu Gly Trp Thr Lys Phe Gln Gly
1910 1915 1920His Cys Tyr Arg His Phe Pro Asp Arg Glu Thr Trp Val
Asp Ala 1925 1930 1935Glu Arg Arg Cys Arg Glu Gln Gln Ser His Leu
Ser Ser Ile Val 1940 1945 1950Thr Pro Glu Glu Gln Glu Phe Val Asn
Lys Asn Ala Gln Asp Tyr 1955 1960 1965Gln Trp Ile Gly Leu Asn Asp
Arg Thr Ile Glu Gly Asp Phe Arg 1970 1975 1980Trp Ser Asp Gly His
Ser Leu Gln Phe Glu Lys Trp Arg Pro Asn 1985 1990 1995Gln Pro Asp
Asn Phe Phe Ala Thr Gly Glu Asp Cys Val Val Met 2000 2005 2010Ile
Trp His Glu Arg Gly Glu Trp Asn Asp Val Pro Cys Asn Tyr 2015 2020
2025Gln Leu Pro Phe Thr Cys Lys Lys Gly Thr Val Ala Cys Gly Glu
2030 2035 2040Pro Pro Ala Val Glu His Ala Arg Thr Leu Gly Gln Lys
Lys Asp 2045 2050 2055Arg Tyr Glu Ile Ser Ser Leu Val Arg Tyr Gln
Cys Thr Glu Gly 2060 2065 2070Phe Val Gln Arg His Val Pro Thr Ile
Arg Cys Gln Pro Ser Ala 2075 2080 2085Asp Trp Glu Glu Pro Arg Ile
Thr Cys Thr Asp Pro Asn Thr Tyr 2090 2095 2100Lys His Arg Leu Gln
Lys Arg Thr Met Arg Pro Thr Arg Arg Ser 2105 2110 2115Arg Pro Ser
Met Ala His 2120129537PRTSus scrofaVARIANT(45)..(45)Xaa can be any
naturally occurring amino acidVARIANT(49)..(49)Xaa can be any
naturally occurring amino acidVARIANT(146)..(146)Xaa can be any
naturally occurring amino acid 129Ala Ile Ser Val Glu Val Ser Glu
Pro Asp Asn Ser Leu Ser Val Ser1 5 10 15Ile Pro Gln Pro Ser Pro Leu
Arg Val Leu Leu Gly Gly Ser Leu Thr 20 25 30Ile Pro Cys Tyr Phe Ile
Asp Pro Met His Pro Val Xaa Thr Ala Pro 35 40 45Xaa Thr Ala Pro Leu
Ala Pro Arg Ile Lys Trp Ser Arg Val Ser Lys 50 55 60Glu Lys Glu Val
Val Leu Leu Val Ala Thr Glu Gly Gln Val Arg Val65 70 75 80Asn Ser
Ala Tyr Gln Asp Arg Val Thr Leu Pro Asn Tyr Pro Ala Ile 85 90 95Pro
Ser Asp Ala Thr Leu Glu Ile Gln Asn Leu Arg Ser Asn Asp Ser 100 105
110Gly Ile Tyr Arg Cys Glu Val Met His Gly Ile Glu Asp Ser Glu Ala
115 120 125Thr Leu Glu Val Val Val Lys Gly Ile Val Phe His Tyr Arg
Ala Ile 130 135 140Ser Xaa Arg Tyr Thr Leu Asp Phe Asp Arg Ala Gln
Arg Ala Cys Leu145 150 155 160Gln Asn Ser Ala Ile Ile Ala Thr Pro
Glu Gln Leu Gln Ala Ala Tyr 165 170 175Glu Asp Gly Phe His Gln Cys
Asp Ala Gly Trp Leu Ala Asp Gln Thr 180 185 190Val Arg Tyr Pro Ile
His Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys 195 200 205Asp Glu Phe
Pro Gly Val Ile Thr Tyr Gly Ile Arg Asp Thr Asn Glu 210 215 220Thr
Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met Glu Gly Glu Val Phe225 230
235 240Tyr Ala Thr Ser Pro Glu Lys Phe Thr Phe Gln Glu Ala Ala Asn
Glu 245 250
255Cys Arg Arg Leu Gly Ala Arg Leu Ala Thr Thr Gly Gln Leu Tyr Leu
260 265 270Ala Trp Arg Gly Gly Met Asp Met Cys Ser Ala Gly Trp Leu
Ala Asp 275 280 285Arg Ser Val Arg Tyr Pro Ile Ser Lys Ala Arg Pro
Asn Cys Gly Gly 290 295 300Asn Leu Leu Gly Val Arg Thr Val Tyr Leu
His Ala Asn Gln Thr Gly305 310 315 320Tyr Pro Asp Pro Ser Ser Arg
Tyr Asp Ala Ile Cys Tyr Thr Gly Glu 325 330 335Asp Phe Val Asp Ile
Pro Glu Asn Phe Phe Gly Val Gly Gly Glu Glu 340 345 350Asp Ile Thr
Ile Gln Thr Val Thr Trp Pro Asp Val Glu Leu Pro Leu 355 360 365Pro
Arg Asn Ile Thr Glu Gly Glu Ala Arg Gly Thr Val Ile Leu Thr 370 375
380Val Lys Pro Val Phe Glu Phe Ser Pro Thr Ala Pro Glu Pro Glu
Glu385 390 395 400Pro Phe Thr Phe Ala Pro Gly Thr Gly Ala Thr Ala
Phe Pro Glu Ala 405 410 415Glu Asn Arg Thr Gly Glu Ala Thr Arg Pro
Trp Ala Phe Pro Glu Glu 420 425 430Ser Thr Pro Gly Leu Gly Ala Pro
Thr Ala Phe Thr Ser Glu Asp Leu 435 440 445Val Val Gln Val Thr Ser
Ala Ala Thr Glu Glu Gly Thr Glu Gly Pro 450 455 460Ser Ala Thr Glu
Ala Pro Ser Thr Ser Glu Glu Pro Phe Pro Ser Glu465 470 475 480Lys
Pro Phe Pro Ser Glu Glu Pro Phe Pro Ser Glu Glu Pro Phe Pro 485 490
495Ser Glu Lys Pro Ser Ala Ser Glu Glu Pro Phe Pro Ser Glu Gln Pro
500 505 510Ser Thr Leu Ser Ala Pro Val Pro Ser Arg Thr Glu Leu Pro
Gly Ser 515 520 525Gly Glu Val Ser Gly Ala Pro Glu Val 530
5351302132PRTMus musculus 130Met Thr Thr Leu Leu Leu Val Phe Val
Thr Leu Arg Val Ile Ala Ala1 5 10 15Val Ile Ser Glu Glu Val Pro Asp
His Asp Asn Ser Leu Ser Val Ser 20 25 30Ile Pro Gln Pro Ser Pro Leu
Lys Val Leu Leu Gly Ser Ser Leu Thr 35 40 45Ile Pro Cys Tyr Phe Ile
Asp Pro Met His Pro Val Thr Thr Ala Pro 50 55 60Ser Thr Ala Pro Leu
Thr Pro Arg Ile Lys Trp Ser Arg Val Ser Lys65 70 75 80Glu Lys Glu
Val Val Leu Leu Val Ala Thr Glu Gly Gln Val Arg Val 85 90 95Asn Ser
Ile Tyr Gln Asp Lys Val Ser Leu Pro Asn Tyr Pro Ala Ile 100 105
110Pro Ser Asp Ala Thr Leu Glu Ile Gln Asn Leu Arg Ser Asn Asp Ser
115 120 125Gly Ile Tyr Arg Cys Glu Val Met His Gly Ile Glu Asp Ser
Glu Ala 130 135 140Thr Leu Glu Val Ile Val Lys Gly Ile Val Phe His
Tyr Arg Ala Ile145 150 155 160Ser Thr Arg Tyr Thr Leu Asp Phe Asp
Arg Ala Gln Arg Ala Cys Leu 165 170 175Gln Asn Ser Ala Ile Ile Ala
Thr Pro Glu Gln Leu Gln Ala Ala Tyr 180 185 190Glu Asp Gly Phe His
Gln Cys Asp Ala Gly Trp Leu Ala Asp Gln Thr 195 200 205Val Arg Tyr
Pro Ile His Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys 210 215 220Asp
Glu Phe Pro Gly Val Arg Thr Tyr Gly Ile Arg Asp Thr Asn Glu225 230
235 240Thr Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met Glu Gly Glu Val
Phe 245 250 255Tyr Ala Thr Ser Pro Glu Lys Phe Thr Phe Gln Glu Ala
Ala Asn Glu 260 265 270Cys Arg Arg Leu Gly Ala Arg Leu Ala Thr Thr
Gly Gln Leu Tyr Leu 275 280 285Ala Trp Gln Gly Gly Met Asp Met Cys
Ser Ala Gly Trp Leu Ala Asp 290 295 300Arg Ser Val Arg Tyr Pro Ile
Ser Lys Ala Arg Pro Asn Cys Gly Gly305 310 315 320Asn Leu Leu Gly
Val Arg Thr Val Tyr Leu His Ala Asn Gln Thr Gly 325 330 335Tyr Pro
Asp Pro Ser Ser Arg Tyr Asp Ala Ile Cys Tyr Thr Gly Glu 340 345
350Asp Phe Val Asp Ile Pro Glu Asn Phe Phe Gly Val Gly Gly Glu Asp
355 360 365Asp Ile Thr Ile Gln Thr Val Thr Trp Pro Asp Leu Glu Leu
Pro Leu 370 375 380Pro Arg Asn Val Thr Glu Gly Glu Ala Leu Gly Ser
Val Ile Leu Thr385 390 395 400Ala Lys Pro Ile Phe Asp Leu Ser Pro
Thr Ile Ser Glu Pro Gly Glu 405 410 415Ala Leu Thr Leu Ala Pro Glu
Val Gly Ser Thr Ala Phe Pro Glu Ala 420 425 430Glu Glu Arg Thr Gly
Glu Ala Thr Arg Pro Trp Gly Phe Pro Ala Glu 435 440 445Val Thr Arg
Gly Pro Asp Ser Ala Thr Ala Phe Ala Ser Glu Asp Leu 450 455 460Val
Val Arg Val Thr Ile Ser Pro Gly Ala Ala Glu Val Pro Gly Gln465 470
475 480Pro Arg Leu Pro Gly Gly Val Val Phe His Tyr Arg Pro Gly Ser
Thr 485 490 495Arg Tyr Ser Leu Thr Phe Glu Glu Ala Gln Gln Ala Cys
Met His Thr 500 505 510Gly Ala Val Ile Ala Ser Pro Glu Gln Leu Gln
Ala Ala Tyr Glu Ala 515 520 525Gly Tyr Glu Gln Cys Asp Ala Gly Trp
Leu Gln Asp Gln Thr Val Arg 530 535 540Tyr Pro Ile Val Ser Pro Arg
Thr Pro Cys Val Gly Asp Lys Asp Ser545 550 555 560Ser Pro Gly Val
Arg Thr Tyr Gly Val Arg Pro Ser Ser Glu Thr Tyr 565 570 575Asp Val
Tyr Cys Tyr Val Asp Lys Leu Glu Gly Glu Val Phe Phe Ala 580 585
590Thr Arg Leu Glu Gln Phe Thr Phe Gln Glu Ala Arg Ala Phe Cys Ala
595 600 605Ala Gln Asn Ala Thr Leu Ala Ser Thr Gly Gln Leu Tyr Ala
Ala Trp 610 615 620Ser Gln Gly Leu Asp Lys Cys Tyr Ala Gly Trp Leu
Ala Asp Gly Thr625 630 635 640Leu Arg Tyr Pro Ile Ile Thr Pro Arg
Pro Ala Cys Gly Gly Asp Lys 645 650 655Pro Gly Val Arg Thr Val Tyr
Leu Tyr Pro Asn Gln Thr Gly Leu Pro 660 665 670Asp Pro Leu Ser Lys
His His Ala Phe Cys Phe Arg Gly Val Ser Val 675 680 685Ala Pro Ser
Pro Gly Glu Glu Gly Gly Ser Thr Pro Thr Ser Pro Ser 690 695 700Asp
Ile Glu Asp Trp Ile Val Thr Gln Val Gly Pro Gly Val Asp Ala705 710
715 720Val Pro Leu Glu Pro Lys Thr Thr Glu Val Pro Tyr Phe Thr Thr
Glu 725 730 735Pro Arg Lys Gln Thr Glu Trp Glu Pro Ala Tyr Thr Pro
Val Gly Thr 740 745 750Ser Pro Gln Pro Gly Ile Pro Pro Thr Trp Leu
Pro Thr Leu Pro Ala 755 760 765Ala Glu Glu His Thr Glu Ser Pro Ser
Ala Ser Glu Glu Pro Ser Ala 770 775 780Ser Ala Val Pro Ser Thr Ser
Glu Glu Pro Tyr Thr Ser Ser Phe Ala785 790 795 800Val Pro Ser Met
Thr Glu Leu Pro Gly Ser Gly Glu Ala Ser Gly Ala 805 810 815Pro Asp
Leu Ser Gly Asp Phe Thr Gly Ser Gly Asp Ala Ser Gly Arg 820 825
830Leu Asp Ser Ser Gly Gln Pro Ser Gly Gly Ile Glu Ser Gly Leu Pro
835 840 845Ser Gly Asp Leu Asp Ser Ser Gly Leu Ser Pro Thr Val Ser
Ser Gly 850 855 860Leu Pro Val Glu Ser Gly Ser Ala Ser Gly Asp Gly
Glu Val Pro Trp865 870 875 880Ser His Thr Pro Thr Val Gly Arg Leu
Pro Ser Gly Gly Glu Ser Pro 885 890 895Glu Gly Ser Ala Ser Ala Ser
Gly Thr Gly Asp Leu Ser Gly Leu Pro 900 905 910Ser Gly Gly Glu Ile
Thr Glu Thr Ser Thr Ser Gly Ala Glu Glu Thr 915 920 925Ser Gly Leu
Pro Ser Gly Gly Asp Gly Leu Glu Thr Ser Thr Ser Gly 930 935 940Val
Asp Asp Val Ser Gly Ile Pro Thr Gly Arg Glu Gly Leu Glu Thr945 950
955 960Ser Ala Ser Gly Val Glu Asp Leu Ser Gly Leu Pro Ser Gly Glu
Glu 965 970 975Gly Ser Glu Thr Ser Thr Ser Gly Ile Glu Asp Ile Ser
Val Leu Pro 980 985 990Thr Gly Gly Glu Ser Leu Glu Thr Ser Ala Ser
Gly Val Gly Asp Leu 995 1000 1005Ser Gly Leu Pro Ser Gly Gly Glu
Ser Leu Glu Thr Ser Ala Ser 1010 1015 1020Gly Ala Glu Asp Val Thr
Gln Leu Pro Thr Glu Arg Gly Gly Leu 1025 1030 1035Glu Thr Ser Ala
Ser Gly Val Glu Asp Ile Thr Val Leu Pro Thr 1040 1045 1050Gly Arg
Glu Ser Leu Glu Thr Ser Ala Ser Gly Val Glu Asp Val 1055 1060
1065Ser Gly Leu Pro Ser Gly Arg Glu Gly Leu Glu Thr Ser Ala Ser
1070 1075 1080Gly Ile Glu Asp Ile Ser Val Phe Pro Thr Glu Ala Glu
Gly Leu 1085 1090 1095Asp Thr Ser Ala Ser Gly Gly Tyr Val Ser Gly
Ile Pro Ser Gly 1100 1105 1110Gly Asp Gly Thr Glu Thr Ser Ala Ser
Gly Val Glu Asp Val Ser 1115 1120 1125Gly Leu Pro Ser Gly Gly Glu
Gly Leu Glu Thr Ser Ala Ser Gly 1130 1135 1140Val Glu Asp Leu Gly
Pro Ser Thr Arg Asp Ser Leu Glu Thr Ser 1145 1150 1155Ala Ser Gly
Val Asp Val Thr Gly Phe Pro Ser Gly Arg Gly Asp 1160 1165 1170Pro
Glu Thr Ser Val Ser Gly Val Gly Asp Asp Phe Ser Gly Leu 1175 1180
1185Pro Ser Gly Lys Glu Gly Leu Glu Thr Ser Ala Ser Gly Ala Glu
1190 1195 1200Asp Leu Ser Gly Leu Pro Ser Gly Lys Glu Asp Leu Val
Gly Ser 1205 1210 1215Ala Ser Gly Ala Leu Asp Phe Gly Lys Leu Pro
Pro Gly Thr Leu 1220 1225 1230Gly Ser Gly Gln Thr Pro Glu Val Asn
Gly Phe Pro Ser Gly Phe 1235 1240 1245Ser Gly Glu Tyr Ser Gly Ala
Asp Ile Gly Ser Gly Pro Ser Ser 1250 1255 1260Gly Leu Pro Asp Phe
Ser Gly Leu Pro Ser Gly Phe Pro Thr Val 1265 1270 1275Ser Leu Val
Asp Ser Thr Leu Val Glu Val Ile Thr Ala Thr Thr 1280 1285 1290Ser
Ser Glu Leu Glu Gly Arg Gly Thr Ile Gly Ile Ser Gly Ser 1295 1300
1305Gly Glu Val Ser Gly Leu Pro Leu Gly Glu Leu Asp Ser Ser Ala
1310 1315 1320Asp Ile Ser Gly Leu Pro Ser Gly Thr Glu Leu Ser Gly
Gln Ala 1325 1330 1335Ser Gly Ser Pro Asp Ser Ser Gly Glu Thr Ser
Gly Phe Phe Asp 1340 1345 1350Val Ser Gly Gln Pro Phe Gly Ser Ser
Gly Val Ser Glu Glu Thr 1355 1360 1365Ser Gly Ile Pro Glu Ile Ser
Gly Gln Pro Ser Gly Thr Pro Asp 1370 1375 1380Thr Thr Ala Thr Ser
Gly Val Thr Glu Leu Asn Glu Leu Ser Ser 1385 1390 1395Gly Gln Pro
Asp Val Ser Gly Asp Gly Ser Gly Ile Leu Phe Gly 1400 1405 1410Ser
Gly Gln Ser Ser Gly Ile Thr Ser Val Ser Gly Glu Thr Ser 1415 1420
1425Gly Ile Ser Asp Leu Ser Gly Gln Pro Ser Gly Phe Pro Val Phe
1430 1435 1440Ser Gly Thr Ala Thr Arg Thr Pro Asp Leu Ala Ser Gly
Thr Ile 1445 1450 1455Ser Gly Ser Gly Glu Ser Ser Gly Ile Thr Phe
Val Asp Thr Ser 1460 1465 1470Phe Val Glu Val Thr Pro Thr Thr Phe
Arg Glu Glu Glu Gly Leu 1475 1480 1485Gly Ser Val Glu Leu Ser Gly
Phe Pro Ser Gly Glu Thr Glu Leu 1490 1495 1500Ser Gly Thr Ser Gly
Thr Val Asp Val Ser Glu Gln Ser Ser Gly 1505 1510 1515Ala Ile Asp
Ser Ser Gly Leu Thr Ser Pro Thr Pro Glu Phe Ser 1520 1525 1530Gly
Leu Pro Ser Gly Val Ala Glu Val Ser Gly Glu Phe Ser Gly 1535 1540
1545Val Glu Thr Gly Ser Ser Leu Pro Ser Gly Ala Phe Asp Gly Ser
1550 1555 1560Gly Leu Val Ser Gly Phe Pro Thr Val Ser Leu Val Asp
Arg Thr 1565 1570 1575Leu Val Glu Ser Ile Thr Gln Ala Pro Thr Ala
Gln Glu Ala Gly 1580 1585 1590Glu Gly Pro Ser Gly Ile Leu Glu Phe
Ser Gly Ala His Ser Gly 1595 1600 1605Thr Pro Asp Ile Ser Gly Glu
Leu Ser Gly Ser Leu Asp Leu Ser 1610 1615 1620Thr Leu Gln Ser Gly
Gln Met Glu Thr Ser Thr Glu Thr Pro Ser 1625 1630 1635Ser Pro Tyr
Phe Ser Gly Asp Phe Ser Ser Thr Thr Asp Val Ser 1640 1645 1650Gly
Glu Ser Ile Ala Ala Thr Thr Gly Ser Gly Glu Ser Ser Gly 1655 1660
1665Leu Pro Glu Val Thr Leu Asn Thr Ser Glu Leu Val Glu Gly Val
1670 1675 1680Thr Glu Pro Thr Val Ser Gln Glu Leu Gly His Gly Pro
Ser Met 1685 1690 1695Thr Tyr Thr Pro Arg Leu Phe Glu Ala Ser Gly
Asp Ala Ser Ala 1700 1705 1710Ser Gly Asp Leu Gly Gly Ala Val Thr
Asn Phe Pro Gly Ser Gly 1715 1720 1725Ile Glu Ala Ser Val Pro Glu
Ala Ser Ser Asp Leu Ser Ala Tyr 1730 1735 1740Pro Glu Ala Gly Val
Gly Val Ser Ala Ala Pro Glu Ala Ser Ser 1745 1750 1755Lys Leu Ser
Glu Phe Pro Asp Leu His Gly Ile Thr Ser Ala Phe 1760 1765 1770His
Glu Thr Asp Leu Glu Met Thr Thr Pro Ser Thr Glu Val Asn 1775 1780
1785Ser Asn Pro Trp Thr Phe Gln Glu Gly Thr Arg Glu Gly Ser Ala
1790 1795 1800Ala Pro Glu Val Ser Gly Glu Ser Ser Thr Thr Ser Asp
Ile Asp 1805 1810 1815Thr Gly Thr Ser Gly Val Pro Ser Ala Thr Pro
Met Ala Ser Gly 1820 1825 1830Asp Arg Thr Glu Ile Ser Gly Glu Trp
Ser Asp His Thr Ser Glu 1835 1840 1845Val Asn Val Ala Ile Ser Ser
Thr Ile Thr Glu Ser Glu Trp Ala 1850 1855 1860Gln Pro Thr Arg Tyr
Pro Thr Glu Thr Leu Gln Glu Ile Glu Ser 1865 1870 1875Pro Asn Pro
Ser Tyr Ser Gly Glu Glu Thr Gln Thr Ala Glu Thr 1880 1885 1890Thr
Met Ser Leu Thr Asp Ala Pro Thr Leu Ser Ser Ser Glu Gly 1895 1900
1905Ser Gly Glu Thr Glu Ser Thr Val Ala Asp Gln Glu Gln Cys Glu
1910 1915 1920Glu Gly Trp Thr Lys Phe Gln Gly His Cys Tyr Arg His
Phe His 1925 1930 1935Asp Arg Glu Thr Trp Val Asp Ala Glu Arg Arg
Cys Arg Glu Gln 1940 1945 1950Gln Ser His Leu Ser Ser Ile Val Thr
Pro Glu Glu Gln Glu Phe 1955 1960 1965Val Asn Lys Asn Ala Gln Asp
Tyr Gln Trp Ile Gly Leu Asn Asp 1970 1975 1980Arg Thr Ile Glu Gly
Asp Phe Arg Trp Ser Asp Gly His Ser Leu 1985 1990 1995Gln Phe Glu
Lys Trp Arg Pro Asn Gln Pro Asp Asn Phe Phe Ala 2000 2005 2010Thr
Gly Glu Asp Cys Val Val Met Ile Trp His Glu Arg Gly Glu 2015 2020
2025Trp Asn Asp Val Pro Cys Asn Tyr Gln Leu Pro Phe Thr Cys Lys
2030 2035 2040Lys Gly Thr Val Ala Cys Gly Asp Pro Pro Val Val Glu
His Ala 2045 2050 2055Arg Thr Leu Gly Gln Lys Lys Asp Arg Tyr Glu
Ile Ser Ser Leu 2060 2065 2070Val Arg Tyr Gln Cys Thr Glu Gly Phe
Val Gln Arg His Val Pro 2075 2080 2085Thr Ile Arg Cys Gln Pro Ser
Gly His Trp Glu Glu Pro Arg Ile 2090 2095 2100Thr Cys Thr Asp Pro
Asn Thr Tyr Lys His Arg Leu Gln Lys Arg 2105 2110 2115Ser Met Arg
Pro Thr Arg Arg Ser Arg Pro Ser Met Ala His 2120 2125
21301312167PRTOryctolagus cuniculus 131Met Thr Thr Leu Leu Leu Val
Leu Val Ala Leu Arg Val Ile Ala Ala1 5 10 15Ala Ile Ser Gly Asp Val
Ser Asp Leu Asp Asn Ala Leu Ser Val Ser 20 25 30Ile Pro
Gln Pro Ser Pro Val Arg Ala Leu Leu Gly Thr Ser Leu Thr 35 40 45Ile
Pro Cys Tyr Phe Ile Asp Pro Val His Pro Val Thr Thr Ala Pro 50 55
60Ser Thr Ala Pro Leu Thr Pro Arg Ile Lys Trp Ser Arg Ile Ser Lys65
70 75 80Asp Lys Glu Val Val Leu Leu Val Ala Asn Glu Gly Arg Val Arg
Ile 85 90 95Asn Ser Ala Tyr Gln Asp Lys Val Ser Leu Pro Asn Tyr Pro
Ala Ile 100 105 110Pro Ser Asp Ala Thr Leu Glu Ile Gln Ser Leu Arg
Ser Asn Asp Ser 115 120 125Gly Ile Tyr Arg Cys Glu Val Met His Gly
Leu Glu Asp Ser Glu Ala 130 135 140Thr Leu Glu Val Val Val Lys Gly
Val Val Phe His Tyr Arg Ala Ile145 150 155 160Ser Thr Arg Tyr Thr
Leu Asp Phe Asp Arg Ala Gln Arg Ala Cys Leu 165 170 175Gln Asn Ser
Ala Ile Ile Ala Thr Pro Glu Gln Leu Gln Ala Ala Tyr 180 185 190Glu
Asp Gly Phe His Gln Cys Asp Ala Gly Trp Leu Ala Asp Gln Thr 195 200
205Val Arg Tyr Pro Ile His Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys
210 215 220Asp Glu Phe Pro Gly Val Arg Thr Tyr Gly Ile Arg Asp Thr
Asn Glu225 230 235 240Thr Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met
Glu Gly Glu Val Phe 245 250 255Tyr Ala Thr Ser Pro Glu Lys Phe Thr
Phe Gln Glu Ala Ala Ser Glu 260 265 270Cys Arg Arg Leu Gly Ala Arg
Leu Ala Thr Thr Gly Gln Leu Tyr Leu 275 280 285Ala Trp Gln Ala Gly
Met Asp Met Cys Ser Ala Gly Trp Leu Ala Asp 290 295 300Arg Ser Val
Arg Tyr Pro Ile Ser Lys Ala Arg Pro Asn Cys Gly Gly305 310 315
320Asn Leu Leu Gly Val Arg Thr Val Tyr Val His Ala Asn Gln Thr Gly
325 330 335Tyr Pro Asp Pro Ser Ser Arg Tyr Asp Ala Ile Cys Tyr Thr
Gly Glu 340 345 350Asp Phe Met Asp Ile Pro Glu Asn Phe Phe Gly Val
Gly Gly Glu Glu 355 360 365Asp Ile Thr Val Gln Thr Val Thr Trp Pro
Asp Val Glu Leu Pro Val 370 375 380Pro Arg Asn Ile Thr Glu Gly Glu
Ala Arg Gly Ser Val Val Leu Thr385 390 395 400Ala Lys Pro Val Leu
Asp Val Ser Pro Thr Ala Pro Gln Pro Glu Glu 405 410 415Thr Phe Ala
Pro Gly Val Gly Ala Thr Ala Phe Pro Gly Val Glu Asn 420 425 430Gly
Thr Glu Glu Ala Thr Arg Pro Arg Gly Phe Ala Asp Glu Ala Thr 435 440
445Leu Gly Pro Ser Ser Ala Thr Ala Phe Thr Ser Ala Asp Leu Val Val
450 455 460Gln Val Thr Ala Ala Pro Gly Val Ala Glu Val Pro Gly Gln
Pro Arg465 470 475 480Leu Pro Gly Gly Val Val Phe His Tyr Arg Pro
Gly Pro Thr Arg Tyr 485 490 495Ser Leu Thr Phe Glu Glu Ala Gln Gln
Ala Cys Leu Arg Thr Gly Ala 500 505 510Ala Met Ala Ser Ala Glu Gln
Leu Gln Ala Ala Tyr Glu Ala Gly Tyr 515 520 525Glu Gln Cys Asp Ala
Gly Trp Leu Gln Asp Gln Thr Val Arg Tyr Pro 530 535 540Ile Val Ser
Pro Arg Thr Pro Cys Val Gly Asp Lys Asp Ser Ser Pro545 550 555
560Gly Val Arg Thr Tyr Gly Val Arg Pro Pro Ser Glu Thr Tyr Asp Val
565 570 575Tyr Cys Tyr Val Asp Arg Leu Glu Gly Glu Val Phe Phe Ala
Thr Arg 580 585 590Leu Glu Gln Phe Thr Phe Gln Glu Ala Leu Glu Phe
Cys Glu Ser His 595 600 605Asn Ala Thr Leu Ala Ser Thr Gly Gln Leu
Tyr Ala Ala Trp Ser Arg 610 615 620Gly Leu Asp Arg Cys Tyr Ala Gly
Trp Leu Ala Asp Gly Ser Leu Arg625 630 635 640Tyr Pro Ile Val Thr
Pro Arg Pro Ala Cys Gly Gly Asp Lys Pro Gly 645 650 655Val Arg Thr
Val Tyr Leu Tyr Pro Asn Gln Thr Gly Leu Pro Asp Pro 660 665 670Leu
Ser Arg His His Ala Phe Cys Phe Arg Gly Thr Ser Glu Ala Pro 675 680
685Ser Pro Gly Pro Glu Glu Gly Gly Thr Ala Thr Pro Ala Ser Gly Leu
690 695 700Glu Asp Trp Ile Val Thr Gln Val Gly Pro Gly Val Ala Ala
Thr Pro705 710 715 720Arg Ala Glu Glu Arg Thr Ala Val Pro Ser Phe
Ala Thr Glu Pro Gly 725 730 735Asn Gln Thr Gly Trp Glu Ala Ala Ser
Ser Pro Val Gly Thr Ser Leu 740 745 750Leu Pro Gly Ile Pro Pro Thr
Trp Pro Pro Thr Gly Thr Ala Ala Glu 755 760 765Gly Thr Thr Glu Gly
Leu Ser Thr Ala Ala Met Pro Ser Ala Ser Glu 770 775 780Gly Pro Tyr
Thr Pro Ser Ser Leu Val Ala Arg Glu Thr Glu Leu Pro785 790 795
800Gly Leu Gly Val Thr Ser Val Pro Pro Asp Ile Ser Gly Asp Leu Thr
805 810 815Ser Ser Gly Glu Ala Ser Gly Leu Phe Gly Pro Thr Gly Gln
Pro Leu 820 825 830Gly Gly Ser Ala Ser Gly Leu Pro Ser Gly Glu Leu
Asp Ser Gly Ser 835 840 845Leu Thr Pro Thr Val Gly Ser Gly Leu Pro
Ile Gly Ser Gly Leu Ala 850 855 860Ser Gly Asp Glu Asp Arg Ile Gln
Trp Ser Ser Ser Thr Glu Val Gly865 870 875 880Gly Val Thr Ser Gly
Ala Glu Ile Pro Glu Thr Ser Ala Ser Gly Val 885 890 895Gly Thr Asp
Leu Ser Gly Leu Pro Ser Gly Ala Glu Ile Pro Glu Thr 900 905 910Phe
Ala Ser Gly Val Gly Thr Asp Leu Ser Gly Leu Pro Ser Gly Ala 915 920
925Glu Ile Pro Glu Thr Phe Ala Ser Gly Val Gly Thr Asp Leu Ser Gly
930 935 940Leu Pro Ser Gly Ala Glu Ile Leu Glu Thr Ser Ala Ser Gly
Val Gly945 950 955 960Thr Asp Leu Ser Gly Leu Pro Ser Gly Ala Glu
Ile Leu Glu Thr Ser 965 970 975Ala Ser Gly Val Gly Thr Asp Leu Ser
Gly Leu Pro Ser Gly Ala Glu 980 985 990Ile Leu Glu Thr Ser Ala Ser
Gly Val Gly Thr Asp Leu Ser Gly Leu 995 1000 1005Pro Ser Gly Ala
Glu Ile Pro Glu Thr Phe Ala Ser Gly Val Gly 1010 1015 1020Thr Asp
Leu Ser Gly Leu Pro Ser Gly Ala Glu Ile Leu Glu Thr 1025 1030
1035Ser Ala Ser Gly Val Gly Thr Asp Leu Ser Gly Leu Pro Ser Gly
1040 1045 1050Ala Glu Ile Pro Glu Thr Ser Ala Ser Gly Val Gly Thr
Asp Leu 1055 1060 1065Ser Gly Leu Pro Ser Gly Ala Glu Ile Leu Glu
Thr Ser Ala Ser 1070 1075 1080Gly Val Gly Thr Asp Leu Ser Gly Leu
Pro Ser Gly Ala Glu Ile 1085 1090 1095Leu Glu Thr Ser Ala Ser Gly
Val Gly Thr Asp Leu Ser Gly Leu 1100 1105 1110Pro Ser Gly Ala Glu
Ile Leu Glu Thr Ser Ala Ser Gly Val Gly 1115 1120 1125Thr Asp Leu
Ser Gly Leu Pro Ser Gly Ala Glu Ile Leu Glu Thr 1130 1135 1140Ser
Ala Ser Gly Val Gly Thr Asp Leu Ser Gly Leu Pro Ser Gly 1145 1150
1155Ala Glu Ile Leu Glu Thr Ser Ala Ser Gly Val Gly Thr Asp Leu
1160 1165 1170Ser Gly Leu Pro Ser Gly Gly Glu Ile Pro Glu Thr Phe
Ala Ser 1175 1180 1185Gly Val Gly Asp Leu Ser Gly Leu Pro Pro Gly
Arg Glu Asp Leu 1190 1195 1200Glu Thr Leu Thr Ser Gly Val Gly Asp
Leu Ser Gly Leu Ser Ser 1205 1210 1215Gly Lys Asp Gly Leu Val Gly
Ser Ala Ser Gly Ala Leu Asp Phe 1220 1225 1230Gly Gly Thr Leu Gly
Ser Gly Gln Ile Pro Glu Thr Ser Gly Leu 1235 1240 1245Pro Ser Gly
Tyr Ser Gly Glu Tyr Ser Glu Val Asp Leu Gly Ser 1250 1255 1260Gly
Pro Ser Ser Gly Leu Pro Asp Phe Ser Gly Leu Pro Ser Gly 1265 1270
1275Phe Pro Thr Val Ser Leu Val Asp Thr Pro Leu Val Glu Val Val
1280 1285 1290Thr Ala Thr Thr Ala Arg Glu Leu Glu Gly Arg Gly Thr
Ile Gly 1295 1300 1305Ile Ser Gly Ala Gly Glu Ile Ser Gly Leu Pro
Ser Ser Glu Leu 1310 1315 1320Asp Val Ser Gly Gly Thr Ser Gly Ala
Asp Ile Ser Gly Glu Ala 1325 1330 1335Asp Val Gly Gly Glu Ala Ser
Gly Leu Ile Val Arg Gly Gln Pro 1340 1345 1350Ser Gly Phe Pro Asp
Thr Ser Gly Glu Ala Phe Gly Val Thr Glu 1355 1360 1365Val Ser Gly
Leu Ser Ser Gly Gln Pro Asp Leu Ser Gly Glu Ala 1370 1375 1380Ser
Gly Val Leu Phe Gly Ser Gly Pro Pro Phe Gly Ile Thr Asp 1385 1390
1395Leu Ser Gly Glu Pro Ser Gly Gln Pro Ser Gly Leu Pro Glu Phe
1400 1405 1410Ser Gly Thr Thr His Arg Ile Pro Asp Leu Val Ser Gly
Ala Thr 1415 1420 1425Ser Gly Ser Gly Glu Ser Ser Gly Ile Ala Phe
Val Asp Thr Ser 1430 1435 1440Val Val Glu Val Thr Pro Thr Thr Leu
Arg Glu Glu Glu Gly Leu 1445 1450 1455Gly Ser Val Glu Phe Ser Gly
Phe Pro Ser Gly Glu Thr Gly Leu 1460 1465 1470Ser Gly Thr Pro Glu
Thr Ile Asp Val Ser Gly Gln Ser Ser Gly 1475 1480 1485Thr Ile Asp
Ser Ser Gly Phe Thr Ser Leu Ala Pro Glu Val Ser 1490 1495 1500Gly
Ser Pro Ser Gly Val Ala Glu Val Ser Gly Glu Ala Ser Gly 1505 1510
1515Thr Glu Ile Thr Ser Gly Leu Pro Ser Gly Val Phe Asp Ser Ser
1520 1525 1530Gly Leu Pro Ser Gly Phe Pro Thr Val Ser Leu Val Asp
Arg Thr 1535 1540 1545Leu Val Glu Ser Val Thr Gln Ala Pro Thr Ala
Gln Glu Ala Glu 1550 1555 1560Gly Pro Ser Asp Ile Leu Glu Leu Ser
Gly Val His Ser Gly Leu 1565 1570 1575Pro Asp Val Ser Gly Ala His
Ser Gly Phe Leu Asp Pro Ser Gly 1580 1585 1590Leu Gln Ser Gly Leu
Val Glu Pro Ser Gly Glu Pro Pro Arg Thr 1595 1600 1605Pro Tyr Phe
Ser Gly Asp Phe Pro Ser Thr Pro Asp Val Ser Gly 1610 1615 1620Glu
Ala Ser Ala Ala Thr Ser Ser Ser Gly Asp Ile Ser Gly Leu 1625 1630
1635Pro Glu Val Thr Leu Val Thr Ser Glu Phe Met Glu Gly Val Thr
1640 1645 1650Arg Pro Thr Val Ser Gln Glu Leu Gly Gln Gly Pro Pro
Met Thr 1655 1660 1665His Val Pro Lys Leu Phe Glu Ser Ser Gly Glu
Ala Leu Ala Ser 1670 1675 1680Gly Asp Thr Ser Gly Ala Ala Pro Ala
Phe Pro Gly Ser Gly Leu 1685 1690 1695Glu Ala Ser Ser Val Pro Glu
Ser His Gly Glu Thr Ser Ala Tyr 1700 1705 1710Ala Glu Pro Gly Thr
Lys Ala Ala Ala Ala Pro Asp Ala Ser Gly 1715 1720 1725Glu Ala Ser
Gly Ser Pro Asp Ser Gly Glu Ile Thr Ser Val Phe 1730 1735 1740Arg
Glu Ala Ala Gly Glu Gly Ala Ser Gly Leu Glu Val Ser Ser 1745 1750
1755Ser Ser Leu Ala Ser Gln Gln Gly Pro Arg Glu Gly Ser Ala Ser
1760 1765 1770Pro Glu Val Ser Gly Glu Ser Thr Thr Ser Tyr Glu Ile
Gly Thr 1775 1780 1785Glu Thr Ser Gly Leu Pro Leu Ala Thr Pro Ala
Ala Ser Glu Asp 1790 1795 1800Arg Ala Glu Val Ser Gly Asp Leu Ser
Gly Arg Thr Pro Val Pro 1805 1810 1815Val Asp Val Val Thr Asn Val
Pro Glu Ala Glu Trp Ile Gln His 1820 1825 1830Ser Gln Arg Pro Ala
Glu Met Trp Pro Glu Thr Lys Ser Ser Ser 1835 1840 1845Pro Ser Tyr
Ser Gly Glu Asp Thr Ala Gly Thr Ala Ala Ser Pro 1850 1855 1860Ala
Ser Ala Asp Thr Pro Gly Glu Pro Gly Pro Thr Thr Ala Ala 1865 1870
1875Pro Arg Ser Cys Ala Glu Glu Pro Cys Gly Pro Gly Thr Cys Gln
1880 1885 1890Glu Thr Glu Gly Arg Val Thr Cys Leu Cys Pro Pro Gly
His Thr 1895 1900 1905Gly Glu Tyr Cys Asp Ile Asp Ile Asp Glu Cys
Leu Ser Ser Pro 1910 1915 1920Cys Val Asn Gly Ala Thr Cys Val Asp
Ala Ser Asp Ser Phe Thr 1925 1930 1935Cys Leu Cys Leu Pro Ser Tyr
Gly Gly Asp Leu Cys Glu Thr Asp 1940 1945 1950Gln Glu Val Cys Glu
Glu Gly Trp Thr Lys Phe Gln Gly His Cys 1955 1960 1965Tyr Arg His
Phe Pro Asp Arg Glu Thr Trp Val Asp Ala Glu Gly 1970 1975 1980Arg
Cys Arg Glu Gln Gln Ser His Leu Ser Ser Ile Val Thr Pro 1985 1990
1995Glu Glu Gln Glu Phe Val Asn Asn Asn Ala Gln Asp Tyr Gln Trp
2000 2005 2010Ile Gly Leu Asn Asp Arg Thr Ile Glu Gly Asp Phe Arg
Trp Ser 2015 2020 2025Asp Gly His Pro Leu Gln Phe Glu Asn Trp Arg
Pro Asn Gln Pro 2030 2035 2040Asp Asn Phe Phe Ala Thr Gly Glu Asp
Cys Val Val Met Ile Trp 2045 2050 2055His Glu Lys Gly Glu Trp Asn
Asp Val Pro Cys Asn Tyr His Leu 2060 2065 2070Pro Phe Thr Cys Lys
Lys Gly Thr Val Ala Cys Gly Asp Pro Pro 2075 2080 2085Val Val Glu
His Ala Arg Thr Phe Gly Gln Lys Lys Asp Arg Tyr 2090 2095 2100Glu
Ile Asn Ser Leu Val Arg Tyr Gln Cys Ala Glu Gly Phe Thr 2105 2110
2115Gln Arg His Val Pro Thr Ile Arg Cys Gln Pro Ser Gly His Trp
2120 2125 2130Glu Glu Pro Arg Ile Thr Cys Thr His Pro Thr Thr Tyr
Lys Arg 2135 2140 2145Arg Val Gln Lys Arg Ser Ser Arg Thr Leu Gln
Arg Ser Gln Ala 2150 2155 2160Ser Ser Ala Pro 21651322266PRTMacaca
fascicularis 132Met Thr Thr Leu Leu Trp Val Phe Val Thr Leu Arg Val
Ile Ala Ala1 5 10 15Ala Val Thr Val Glu Thr Ser Asp His Asp Asn Ser
Leu Ser Val Ser 20 25 30Ile Pro Gln Pro Ser Pro Leu Arg Val Leu Leu
Gly Thr Ser Leu Thr 35 40 45Ile Pro Cys Tyr Phe Ile Asp Pro Met His
Pro Val Thr Thr Ala Pro 50 55 60Ser Thr Ala Pro Leu Ala Pro Arg Ile
Lys Trp Ser Arg Val Ser Lys65 70 75 80Glu Lys Glu Val Val Leu Leu
Val Ala Thr Glu Gly Arg Val Arg Val 85 90 95Asn Ser Ala Tyr Gln Asp
Lys Val Ser Leu Pro Asn Tyr Pro Ala Ile 100 105 110Pro Ser Asp Ala
Thr Leu Glu Ile Gln Ser Leu Arg Ser Asn Asp Ser 115 120 125Gly Val
Tyr Arg Cys Glu Val Met His Gly Ile Glu Asp Ser Glu Ala 130 135
140Thr Leu Glu Val Val Val Lys Gly Ile Val Phe His Tyr Arg Ala
Ile145 150 155 160Ser Thr Arg Tyr Thr Leu Asp Phe Asp Arg Ala Gln
Arg Ala Cys Leu 165 170 175Gln Asn Ser Ala Ile Ile Ala Thr Pro Glu
Gln Leu Gln Ala Ala Tyr 180 185 190Glu Asp Gly Phe His Gln Cys Asp
Ala Gly Trp Leu Ala Asp Gln Thr 195 200 205Val Arg Tyr Pro Ile His
Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys 210 215 220Asp Glu Phe Pro
Gly Val Arg Thr Tyr Gly Ile Arg Asp Thr Asn Glu225 230 235 240Thr
Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met Glu Gly Glu Val Phe 245 250
255Tyr Ala Thr Ser Pro Glu Lys Phe Thr Phe Gln Glu Ala Ala Asn Glu
260 265 270Cys Arg Arg Leu Gly Ala Arg Leu Ala Thr Thr Gly Gln Leu
Tyr Leu 275 280 285Ala Trp Gln Ala Gly Met Asp Met Cys Ser Ala Gly
Trp Leu Ala Asp 290 295 300Arg Ser Val Arg Tyr Pro Ile Ser Lys Ala
Arg Pro Asn Cys Gly Gly305 310 315
320Asn Leu Leu Gly Val Arg Thr Val Tyr Leu His Ala Asn Gln Thr Gly
325 330 335Tyr Pro Asp Pro Ser Ser Arg Tyr Asp Ala Ile Cys Tyr Thr
Gly Glu 340 345 350Asp Phe Val Asp Ile Pro Glu Asn Phe Phe Gly Val
Gly Gly Glu Glu 355 360 365Asp Ile Thr Val Gln Thr Val Thr Trp Pro
Asp Met Glu Leu Pro Leu 370 375 380Pro Arg Asn Ile Thr Glu Gly Glu
Ala Arg Gly Ser Val Ile Leu Thr385 390 395 400Val Lys Pro Ile Phe
Asp Val Ser Pro Ser Pro Leu Glu Pro Glu Glu 405 410 415Pro Phe Thr
Phe Ala Pro Glu Ile Gly Ala Thr Ala Phe Pro Glu Val 420 425 430Glu
Asn Glu Thr Gly Glu Ala Thr Arg Pro Trp Gly Phe Pro Thr Pro 435 440
445Gly Leu Gly Pro Ala Thr Ala Phe Thr Ser Glu Asp Leu Val Val Gln
450 455 460Val Thr Ala Val Pro Gly Gln Pro His Leu Pro Gly Gly Val
Val Phe465 470 475 480His Tyr Arg Pro Gly Ser Thr Arg Tyr Ser Leu
Thr Phe Glu Glu Ala 485 490 495Gln Gln Ala Cys Leu Arg Thr Gly Ala
Val Ile Ala Ser Pro Glu Gln 500 505 510Leu Gln Ala Ala Tyr Glu Ala
Gly Tyr Glu Gln Cys Asp Ala Gly Trp 515 520 525Leu Arg Asp Gln Thr
Val Arg Tyr Pro Ile Val Ser Pro Arg Thr Pro 530 535 540Cys Val Gly
Asp Lys Asp Ser Ser Pro Gly Val Arg Thr Tyr Gly Val545 550 555
560Arg Pro Ser Thr Glu Thr Tyr Asp Val Tyr Cys Tyr Val Asp Arg Leu
565 570 575Glu Gly Glu Val Phe Phe Ala Thr Arg Leu Glu Gln Phe Thr
Phe Gln 580 585 590Glu Ala Leu Glu Phe Cys Glu Ser His Asn Ala Thr
Leu Ala Thr Thr 595 600 605Gly Gln Leu Tyr Ala Ala Trp Ser Arg Gly
Leu Asp Lys Cys Tyr Ala 610 615 620Gly Trp Leu Ala Asp Gly Ser Leu
Arg Tyr Pro Ile Val Thr Pro Arg625 630 635 640Pro Ala Cys Gly Gly
Asp Lys Pro Gly Val Arg Thr Val Tyr Leu Tyr 645 650 655Pro Asn Gln
Thr Gly Leu Pro Asp Pro Leu Ser Arg His His Ala Phe 660 665 670Cys
Phe Arg Gly Val Ser Ala Val Pro Ser Pro Gly Glu Glu Glu Gly 675 680
685Gly Thr Pro Thr Ser Pro Ser Gly Val Glu Asp Trp Ile Ala Thr Gln
690 695 700Val Val Pro Gly Val Ala Ala Val Pro Val Glu Glu Glu Thr
Thr Ala705 710 715 720Val Pro Leu Gly Glu Thr Thr Ala Ile Leu Glu
Phe Thr Thr Glu Pro 725 730 735Glu Asn Gln Thr Glu Trp Glu Pro Ala
Tyr Thr Pro Met Gly Thr Ser 740 745 750Pro Leu Pro Gly Ile Leu Pro
Thr Trp Pro Pro Thr Gly Thr Ala Thr 755 760 765Glu Glu Ser Thr Glu
Gly Pro Ser Ala Thr Glu Val Leu Thr Ala Ser 770 775 780Lys Glu Pro
Ser Pro Pro Glu Val Pro Phe Pro Ser Glu Glu Pro Ser785 790 795
800Pro Ser Glu Glu Pro Phe Pro Ser Val Arg Pro Phe Pro Ser Val Glu
805 810 815Pro Ser Pro Ser Glu Glu Pro Phe Pro Ser Val Glu Pro Ser
Pro Ser 820 825 830Glu Glu Pro Ser Ala Ser Glu Glu Pro Tyr Thr Pro
Ser Pro Pro Val 835 840 845Pro Ser Trp Thr Glu Leu Pro Gly Ser Gly
Glu Glu Ser Gly Ala Pro 850 855 860Asp Val Ser Gly Asp Phe Ile Gly
Ser Gly Asp Val Ser Gly His Leu865 870 875 880Asp Phe Ser Gly Gln
Leu Ser Gly Asp Arg Ile Ser Gly Leu Pro Ser 885 890 895Gly Asp Leu
Asp Ser Ser Gly Leu Thr Ser Thr Val Gly Ser Gly Leu 900 905 910Pro
Val Asp Ser Gly Leu Ala Ser Gly Asp Glu Glu Arg Ile Glu Trp 915 920
925Ser Ser Thr Pro Thr Val Gly Glu Leu Pro Ser Gly Ala Glu Ile Leu
930 935 940Glu Gly Ser Ala Ser Glu Val Gly Asp Leu Ser Gly Leu Pro
Ser Gly945 950 955 960Asp Val Leu Glu Thr Ser Ala Ser Gly Val Gly
Asp Leu Ser Gly Leu 965 970 975Pro Ser Gly Glu Val Leu Glu Thr Ser
Ala Ser Gly Val Gly Asp Leu 980 985 990Ser Gly Leu Pro Ser Gly Glu
Val Leu Glu Thr Ser Thr Ser Gly Val 995 1000 1005Gly Asp Leu Ser
Gly Leu Pro Ser Gly Glu Val Leu Glu Thr Ser 1010 1015 1020Thr Ser
Gly Val Gly Asp Leu Ser Gly Leu Pro Ser Ala Gly Glu 1025 1030
1035Val Leu Glu Thr Thr Ala Ser Gly Val Glu Asp Ile Ser Gly Leu
1040 1045 1050Pro Ser Gly Glu Val Leu Glu Thr Thr Ala Ser Gly Val
Glu Asp 1055 1060 1065Ile Ser Gly Phe Pro Ser Gly Glu Val Leu Glu
Thr Thr Ala Ser 1070 1075 1080Gly Val Glu Asp Ile Ser Gly Leu Pro
Ser Gly Glu Val Leu Glu 1085 1090 1095Thr Thr Ala Ser Gly Val Glu
Asp Ile Ser Gly Leu Pro Ser Gly 1100 1105 1110Glu Val Leu Glu Thr
Thr Ala Ser Gly Val Gly Asp Leu Gly Gly 1115 1120 1125Leu Pro Ser
Gly Glu Val Leu Glu Thr Ser Thr Ser Gly Val Gly 1130 1135 1140Asp
Leu Ser Gly Leu Pro Ser Gly Glu Val Val Glu Thr Ser Thr 1145 1150
1155Ser Gly Val Glu Asp Leu Ser Gly Leu Pro Ser Gly Gly Glu Val
1160 1165 1170Leu Glu Thr Ser Thr Ser Gly Val Glu Asp Ile Ser Gly
Leu Pro 1175 1180 1185Ser Gly Glu Val Leu Glu Thr Thr Ala Ser Gly
Ile Glu Asp Val 1190 1195 1200Ser Glu Leu Pro Ser Gly Glu Gly Leu
Glu Thr Ser Ala Ser Gly 1205 1210 1215Val Glu Asp Leu Ser Arg Leu
Pro Ser Gly Glu Val Leu Glu Thr 1220 1225 1230Ser Ala Ser Gly Val
Gly Asp Ile Ser Gly Leu Pro Ser Gly Gly 1235 1240 1245Glu Val Leu
Glu Ile Ser Ala Ser Gly Val Gly Asp Leu Ser Gly 1250 1255 1260Leu
Pro Ser Gly Gly Glu Gly Leu Glu Thr Ser Ala Ser Gly Val 1265 1270
1275Gly Thr Asp Leu Ser Gly Leu Pro Ser Gly Arg Glu Gly Leu Glu
1280 1285 1290Thr Ser Ala Ser Gly Ala Glu Asp Leu Ser Gly Leu Pro
Ser Gly 1295 1300 1305Lys Glu Asp Leu Val Gly Pro Ala Ser Gly Asp
Leu Asp Leu Gly 1310 1315 1320Lys Leu Pro Ser Gly Thr Leu Arg Ser
Gly Gln Ala Pro Glu Thr 1325 1330 1335Ser Gly Leu Pro Ser Gly Phe
Ser Gly Glu Tyr Ser Gly Val Asp 1340 1345 1350Leu Gly Ser Gly Pro
Pro Ser Gly Leu Pro Asp Phe Ser Gly Leu 1355 1360 1365Pro Ser Gly
Phe Pro Thr Val Ser Leu Val Asp Ser Thr Leu Val 1370 1375 1380Glu
Val Val Thr Ala Ser Thr Ala Ser Glu Leu Glu Gly Arg Gly 1385 1390
1395Thr Ile Gly Ile Ser Gly Ala Gly Glu Ile Ser Gly Leu Pro Ser
1400 1405 1410Ser Glu Leu Asp Ile Ser Gly Glu Ala Ser Gly Leu Pro
Ser Gly 1415 1420 1425Thr Glu Leu Ser Gly Gln Ala Ser Gly Ser Pro
Asp Val Ser Arg 1430 1435 1440Glu Thr Pro Gly Leu Phe Asp Val Ser
Gly Gln Pro Ser Gly Phe 1445 1450 1455Pro Asp Ile Ser Gly Gly Thr
Ser Gly Ile Ser Glu Val Ser Gly 1460 1465 1470Gln Pro Ser Gly Phe
Pro Asp Thr Ser Gly Glu Thr Ser Gly Val 1475 1480 1485Thr Glu Leu
Ser Gly Leu Pro Ser Gly Gln Pro Gly Val Ser Gly 1490 1495 1500Glu
Ala Ser Gly Val Pro Tyr Gly Ser Ser Gln Pro Phe Gly Ile 1505 1510
1515Thr Asp Leu Ser Gly Glu Thr Ser Gly Val Pro Asp Leu Ser Gly
1520 1525 1530Gln Pro Ser Gly Leu Pro Gly Phe Ser Gly Ala Thr Ser
Gly Val 1535 1540 1545Pro Asp Leu Val Ser Gly Ala Thr Ser Gly Ser
Gly Glu Ser Ser 1550 1555 1560Gly Ile Thr Phe Val Asp Thr Ser Leu
Val Glu Val Thr Pro Thr 1565 1570 1575Thr Phe Lys Glu Glu Glu Gly
Leu Gly Ser Val Glu Leu Ser Gly 1580 1585 1590Leu Pro Ser Gly Glu
Ala Asp Leu Ser Gly Arg Ser Gly Met Val 1595 1600 1605Asp Val Ser
Gly Gln Phe Ser Gly Thr Val Asp Ser Ser Gly Phe 1610 1615 1620Thr
Ser Gln Thr Pro Glu Phe Ser Gly Leu Pro Ile Gly Ile Ala 1625 1630
1635Glu Val Ser Gly Glu Ser Ser Gly Ala Glu Thr Gly Ser Ser Leu
1640 1645 1650Pro Ser Gly Ala Tyr Tyr Gly Ser Gly Leu Pro Ser Gly
Phe Pro 1655 1660 1665Thr Val Ser Leu Val Asp Arg Thr Leu Val Glu
Ser Val Thr Gln 1670 1675 1680Ala Pro Thr Ala Gln Glu Ala Gly Glu
Gly Pro Pro Gly Ile Leu 1685 1690 1695Glu Leu Ser Gly Thr His Ser
Gly Ala Pro Asp Met Ser Gly Asp 1700 1705 1710His Ser Gly Phe Leu
Asp Val Ser Gly Leu Gln Phe Gly Leu Val 1715 1720 1725Glu Pro Ser
Gly Glu Pro Pro Ser Thr Pro Tyr Phe Ser Gly Asp 1730 1735 1740Phe
Ala Ser Thr Thr Asp Val Ser Gly Glu Ser Ser Ala Ala Met 1745 1750
1755Gly Thr Ser Gly Glu Ala Ser Gly Leu Pro Gly Val Thr Leu Ile
1760 1765 1770Thr Ser Glu Phe Met Glu Gly Val Thr Glu Pro Thr Val
Ser Gln 1775 1780 1785Glu Leu Gly Gln Arg Pro Pro Val Thr His Thr
Pro Gln Leu Phe 1790 1795 1800Glu Ser Ser Gly Glu Ala Ser Ala Ala
Gly Asp Ile Ser Gly Ala 1805 1810 1815Thr Pro Val Leu Pro Gly Ser
Gly Val Glu Val Ser Ser Val Pro 1820 1825 1830Glu Ser Ser Ser Glu
Thr Ser Ala Tyr Pro Glu Ala Gly Val Gly 1835 1840 1845Ala Ser Ala
Ala Pro Glu Thr Ser Gly Glu Asp Ser Gly Ser Pro 1850 1855 1860Asp
Leu Ser Glu Thr Thr Ser Ala Phe His Glu Ala Asp Leu Glu 1865 1870
1875Arg Ser Ser Gly Leu Gly Val Ser Gly Ser Thr Leu Thr Phe Gln
1880 1885 1890Glu Gly Glu Pro Ser Ala Ser Pro Glu Val Ser Gly Glu
Ser Thr 1895 1900 1905Thr Thr Gly Asp Val Gly Thr Glu Ala Pro Gly
Leu Pro Ser Ala 1910 1915 1920Thr Pro Thr Ala Ser Gly Asp Arg Thr
Glu Ile Ser Gly Asp Leu 1925 1930 1935Ser Gly His Thr Ser Gly Leu
Gly Val Val Ile Ser Thr Ser Ile 1940 1945 1950Pro Glu Ser Glu Trp
Thr Gln Gln Thr Gln Arg Pro Ala Glu Ala 1955 1960 1965His Leu Glu
Thr Glu Ser Ser Ser Leu Leu Tyr Ser Gly Glu Glu 1970 1975 1980Thr
His Thr Ala Glu Thr Ala Thr Ser Pro Thr Asp Ala Ser Ile 1985 1990
1995Pro Ala Ser Pro Glu Trp Thr Gly Glu Ser Glu Ser Thr Val Ala
2000 2005 2010Asp Ile Asp Glu Cys Leu Ser Ser Pro Cys Leu Asn Gly
Ala Thr 2015 2020 2025Cys Val Asp Ala Ile Asp Ser Phe Thr Cys Leu
Cys Leu Pro Ser 2030 2035 2040Tyr Gly Gly Asp Leu Cys Glu Ile Asp
Gln Glu Val Cys Glu Glu 2045 2050 2055Gly Trp Thr Lys Tyr Gln Gly
His Cys Tyr Arg His Phe Pro Asp 2060 2065 2070Arg Glu Thr Trp Val
Asp Ala Glu Arg Arg Cys Arg Glu Gln Gln 2075 2080 2085Ser His Leu
Ser Ser Ile Val Thr Pro Glu Glu Gln Glu Phe Val 2090 2095 2100Asn
Asn Asn Ala Gln Asp Tyr Gln Trp Ile Gly Leu Asn Asp Arg 2105 2110
2115Thr Ile Glu Gly Asp Phe Arg Trp Ser Asp Gly His Pro Met Gln
2120 2125 2130Phe Glu Asn Trp Arg Pro Asn Gln Pro Asp Asn Phe Phe
Ala Ala 2135 2140 2145Gly Glu Asp Cys Val Val Met Ile Trp His Glu
Lys Gly Glu Trp 2150 2155 2160Asn Asp Val Pro Cys Asn Tyr His Leu
Pro Phe Thr Cys Lys Lys 2165 2170 2175Gly Thr Val Ala Cys Gly Glu
Pro Pro Met Val Gln His Ala Arg 2180 2185 2190Thr Phe Gly Gln Lys
Lys Asp Arg Tyr Glu Ile Asn Ser Leu Val 2195 2200 2205Arg Tyr Gln
Cys Thr Glu Gly Phe Val Gln Arg His Val Pro Thr 2210 2215 2220Ile
Arg Cys Gln Pro Ser Gly His Trp Glu Glu Pro Arg Ile Thr 2225 2230
2235Cys Thr Asp Ala Thr Ala Tyr Lys Arg Arg Leu Gln Lys Arg Ser
2240 2245 2250Ser Arg His Pro Arg Arg Ser Arg Pro Ser Thr Ala His
2255 2260 22651332167PRTMacaca mulattaVARIANT(1910)..(1915)Xaa can
be any naturally occurring amino acid 133Met Thr Thr Leu Leu Trp
Val Phe Val Thr Leu Arg Val Ile Ala Ala1 5 10 15Ala Val Thr Val Glu
Thr Ser Asp His Asp Asn Ser Leu Ser Val Ser 20 25 30Ile Pro Gln Pro
Ser Pro Leu Arg Val Leu Leu Gly Thr Ser Leu Thr 35 40 45Ile Pro Cys
Tyr Phe Ile Asp Pro Met His Pro Val Thr Thr Ala Pro 50 55 60Ser Thr
Ala Pro Leu Ala Pro Arg Ile Lys Trp Ser Arg Val Ser Lys65 70 75
80Glu Lys Glu Val Val Leu Leu Val Ala Thr Glu Gly Arg Val Arg Val
85 90 95Asn Ser Ala Tyr Gln Asp Lys Val Ser Leu Pro Asn Tyr Pro Ala
Ile 100 105 110Pro Ser Asp Ala Thr Leu Glu Ile Gln Ser Leu Arg Ser
Asn Asp Ser 115 120 125Gly Val Tyr Arg Cys Glu Val Met His Gly Ile
Glu Asp Ser Glu Ala 130 135 140Thr Leu Glu Val Val Val Lys Gly Ile
Val Phe His Tyr Arg Ala Ile145 150 155 160Ser Thr Arg Tyr Thr Leu
Asp Phe Asp Arg Ala Gln Arg Ala Cys Leu 165 170 175Gln Asn Ser Ala
Ile Ile Ala Thr Pro Glu Gln Leu Gln Ala Ala Tyr 180 185 190Glu Asp
Gly Phe His Gln Cys Asp Ala Gly Trp Leu Ala Asp Gln Thr 195 200
205Val Arg Tyr Pro Ile His Thr Pro Arg Glu Gly Cys Tyr Gly Asp Lys
210 215 220Asp Glu Phe Pro Gly Val Arg Thr Tyr Gly Ile Arg Asp Thr
Asn Glu225 230 235 240Thr Tyr Asp Val Tyr Cys Phe Ala Glu Glu Met
Glu Gly Glu Val Phe 245 250 255Tyr Ala Thr Ser Pro Glu Lys Phe Thr
Phe Gln Glu Ala Ala Asn Glu 260 265 270Cys Arg Arg Leu Gly Ala Arg
Leu Ala Thr Thr Gly Gln Leu Tyr Leu 275 280 285Ala Trp Gln Ala Gly
Met Asp Met Cys Ser Ala Gly Trp Leu Ala Asp 290 295 300Arg Ser Val
Arg Tyr Pro Ile Ser Lys Ala Arg Pro Asn Cys Gly Gly305 310 315
320Asn Leu Leu Gly Val Arg Thr Val Tyr Leu His Ala Asn Gln Thr Gly
325 330 335Tyr Pro Asp Pro Ser Ser Arg Tyr Asp Ala Ile Cys Tyr Thr
Gly Glu 340 345 350Asp Phe Val Asp Ile Pro Glu Asn Phe Phe Gly Val
Gly Gly Glu Glu 355 360 365Asp Ile Thr Val Gln Thr Val Thr Trp Pro
Asp Met Glu Leu Pro Leu 370 375 380Pro Arg Asn Ile Thr Glu Gly Glu
Ala Arg Gly Ser Val Ile Leu Thr385 390 395 400Val Lys Pro Ile Phe
Asp Val Ser Pro Ser Pro Leu Glu Pro Glu Glu 405 410 415Pro Phe Thr
Phe Ala Pro Glu Ile Gly Ala Thr Ala Phe Pro Glu Val 420 425 430Glu
Asn Glu Thr Gly Glu Ala Thr Arg Pro Trp Gly Phe Pro Thr Pro 435 440
445Gly Leu Gly Pro Ala Thr Ala Phe Thr Ser Glu Asp Leu Val Val Gln
450 455 460Val Thr Ala Val Pro Gly Gln Pro His Leu Pro Gly Gly Val
Val Phe465 470 475 480His Tyr Arg Pro Gly Ser Thr Arg Tyr Ser Leu
Thr Phe Glu Glu Ala
485 490 495Gln Gln Ala Cys Leu Arg Thr Gly Ala Val Ile Ala Ser Pro
Glu Gln 500 505 510Leu Gln Ala Ala Tyr Glu Ala Gly Tyr Glu Gln Cys
Asp Ala Gly Trp 515 520 525Leu Arg Asp Gln Thr Val Arg Tyr Pro Ile
Val Ser Pro Arg Thr Pro 530 535 540Cys Val Gly Asp Lys Asp Ser Ser
Pro Gly Val Arg Thr Tyr Gly Val545 550 555 560Arg Pro Ser Thr Glu
Thr Tyr Asp Val Tyr Cys Tyr Val Asp Arg Leu 565 570 575Glu Gly Glu
Val Phe Phe Ala Thr Arg Leu Glu Gln Phe Thr Phe Gln 580 585 590Glu
Ala Leu Glu Phe Cys Glu Ser His Asn Ala Thr Leu Ala Thr Thr 595 600
605Gly Gln Leu Tyr Ala Ala Trp Ser Arg Gly Leu Asp Lys Cys Tyr Ala
610 615 620Gly Trp Leu Ala Asp Gly Ser Leu Arg Tyr Pro Ile Val Thr
Pro Arg625 630 635 640Pro Ala Cys Gly Gly Asp Lys Pro Gly Val Arg
Thr Val Tyr Leu Tyr 645 650 655Pro Asn Gln Thr Gly Leu Pro Asp Pro
Leu Ser Arg His His Ala Phe 660 665 670Cys Phe Arg Gly Val Ser Ala
Val Pro Ser Pro Gly Glu Glu Glu Gly 675 680 685Gly Thr Pro Thr Ser
Pro Ser Gly Val Glu Asp Trp Ile Ala Thr Gln 690 695 700Val Val Pro
Gly Val Ala Ala Val Pro Val Glu Glu Glu Thr Thr Ala705 710 715
720Val Pro Leu Gly Glu Thr Thr Ala Ile Leu Glu Phe Thr Thr Glu Pro
725 730 735Glu Asn Gln Thr Glu Trp Glu Pro Ala Tyr Thr Pro Met Gly
Thr Ser 740 745 750Pro Leu Pro Gly Ile Leu Pro Thr Trp Pro Pro Thr
Gly Thr Ala Thr 755 760 765Glu Glu Ser Thr Glu Gly Pro Ser Ala Thr
Glu Val Leu Thr Ala Ser 770 775 780Lys Glu Pro Ser Pro Pro Glu Val
Pro Phe Pro Ser Glu Glu Pro Ser785 790 795 800Pro Ser Glu Glu Pro
Phe Pro Ser Val Arg Pro Phe Pro Ser Val Glu 805 810 815Pro Ser Pro
Ser Glu Glu Pro Phe Pro Ser Val Glu Pro Ser Pro Ser 820 825 830Glu
Glu Pro Ser Ala Ser Glu Glu Pro Tyr Thr Pro Ser Pro Pro Val 835 840
845Pro Ser Trp Thr Glu Leu Pro Gly Ser Gly Glu Glu Ser Gly Ala Pro
850 855 860Asp Val Ser Gly Asp Phe Ile Gly Ser Gly Asp Val Ser Gly
His Leu865 870 875 880Asp Phe Ser Gly Gln Leu Ser Gly Asp Arg Ile
Ser Gly Leu Pro Ser 885 890 895Gly Asp Leu Asp Ser Ser Gly Leu Thr
Ser Thr Val Gly Ser Gly Leu 900 905 910Pro Val Asp Ser Gly Leu Ala
Ser Gly Asp Glu Glu Arg Ile Glu Trp 915 920 925Ser Ser Thr Pro Thr
Val Gly Glu Leu Pro Ser Gly Ala Glu Ile Leu 930 935 940Glu Gly Ser
Ala Ser Glu Val Gly Asp Leu Ser Gly Leu Pro Ser Gly945 950 955
960Asp Val Leu Glu Thr Ser Ala Ser Gly Val Gly Asp Leu Ser Gly Leu
965 970 975Pro Ser Gly Glu Val Leu Glu Thr Ser Val Ser Gly Val Gly
Asp Leu 980 985 990Ser Gly Leu Pro Ser Gly Glu Val Leu Glu Thr Ser
Thr Ser Gly Val 995 1000 1005Gly Asp Leu Ser Gly Leu Pro Ser Gly
Glu Val Leu Glu Thr Ser 1010 1015 1020Thr Ser Gly Val Gly Asp Leu
Ser Gly Leu Pro Ser Ala Gly Glu 1025 1030 1035Val Leu Glu Thr Thr
Ala Ser Gly Val Glu Asp Ile Ser Gly Leu 1040 1045 1050Pro Ser Gly
Glu Val Leu Glu Thr Thr Ala Ser Gly Val Glu Asp 1055 1060 1065Ile
Ser Gly Phe Pro Ser Gly Glu Val Leu Glu Thr Thr Ala Ser 1070 1075
1080Gly Val Glu Asp Ile Ser Gly Leu Pro Ser Gly Glu Val Leu Glu
1085 1090 1095Thr Thr Ala Ser Gly Val Glu Asp Ile Ser Gly Leu Pro
Ser Gly 1100 1105 1110Glu Val Leu Glu Thr Thr Ala Ser Gly Val Gly
Asp Leu Gly Gly 1115 1120 1125Leu Pro Ser Gly Glu Val Leu Glu Thr
Ser Thr Ser Gly Val Gly 1130 1135 1140Asp Leu Ser Gly Leu Pro Ser
Gly Glu Val Val Glu Thr Ser Thr 1145 1150 1155Ser Gly Val Glu Asp
Leu Ser Gly Leu Pro Ser Gly Gly Glu Val 1160 1165 1170Leu Glu Thr
Ser Thr Ser Gly Val Glu Asp Ile Ser Gly Leu Pro 1175 1180 1185Ser
Gly Glu Val Leu Glu Thr Thr Ala Ser Gly Ile Glu Asp Val 1190 1195
1200Ser Glu Leu Pro Ser Gly Glu Gly Leu Glu Thr Ser Ala Ser Gly
1205 1210 1215Val Glu Asp Leu Ser Arg Leu Pro Ser Gly Glu Val Leu
Glu Thr 1220 1225 1230Ser Ala Ser Gly Val Gly Asp Ile Ser Gly Leu
Pro Ser Gly Gly 1235 1240 1245Glu Val Leu Glu Ile Ser Ala Ser Gly
Val Gly Asp Leu Ser Gly 1250 1255 1260Leu Pro Ser Gly Gly Glu Gly
Leu Glu Thr Ser Ala Ser Gly Val 1265 1270 1275Gly Thr Asp Leu Ser
Gly Leu Pro Ser Gly Arg Glu Gly Leu Glu 1280 1285 1290Thr Ser Ala
Ser Gly Ala Glu Asp Leu Ser Gly Leu Pro Ser Gly 1295 1300 1305Lys
Glu Asp Leu Val Gly Pro Ala Ser Gly Asp Leu Asp Leu Gly 1310 1315
1320Lys Leu Pro Ser Gly Thr Leu Gly Ser Gly Gln Ala Pro Glu Thr
1325 1330 1335Ser Gly Leu Pro Ser Gly Phe Ser Gly Glu Tyr Ser Gly
Val Asp 1340 1345 1350Leu Gly Ser Gly Pro Pro Ser Gly Leu Pro Asp
Phe Ser Gly Leu 1355 1360 1365Pro Ser Gly Phe Pro Thr Val Ser Leu
Val Asp Ser Thr Leu Val 1370 1375 1380Glu Val Val Thr Ala Ser Thr
Ala Ser Glu Leu Glu Gly Arg Gly 1385 1390 1395Thr Ile Gly Ile Ser
Gly Ala Gly Glu Ile Ser Gly Leu Pro Ser 1400 1405 1410Ser Glu Leu
Asp Ile Ser Gly Glu Ala Ser Gly Leu Pro Ser Gly 1415 1420 1425Thr
Glu Leu Ser Gly Gln Ala Ser Gly Ser Pro Asp Val Ser Arg 1430 1435
1440Glu Thr Ser Gly Leu Phe Asp Val Ser Gly Gln Pro Ser Gly Phe
1445 1450 1455Pro Asp Thr Ser Gly Glu Thr Ser Gly Val Thr Glu Leu
Ser Gly 1460 1465 1470Leu Pro Ser Gly Gln Pro Gly Val Ser Gly Glu
Ala Ser Gly Val 1475 1480 1485Pro Tyr Gly Ser Ser Gln Pro Phe Gly
Ile Thr Asp Leu Ser Gly 1490 1495 1500Glu Thr Ser Gly Val Pro Asp
Leu Ser Gly Gln Pro Ser Gly Leu 1505 1510 1515Pro Gly Phe Ser Gly
Ala Thr Ser Gly Val Pro Asp Leu Val Ser 1520 1525 1530Gly Ala Thr
Ser Gly Ser Gly Glu Ser Ser Asp Ile Thr Phe Val 1535 1540 1545Asp
Thr Ser Leu Val Glu Val Thr Pro Thr Thr Phe Lys Glu Glu 1550 1555
1560Glu Gly Leu Gly Ser Val Glu Leu Ser Gly Leu Pro Ser Gly Glu
1565 1570 1575Ala Asp Leu Ser Gly Arg Ser Gly Met Val Asp Val Ser
Gly Gln 1580 1585 1590Phe Ser Gly Thr Val Asp Ser Ser Gly Phe Thr
Ser Gln Thr Pro 1595 1600 1605Glu Phe Ser Gly Leu Pro Ile Gly Ile
Ala Glu Val Ser Gly Glu 1610 1615 1620Ser Ser Gly Ala Glu Thr Gly
Ser Ser Leu Pro Ser Gly Ala Tyr 1625 1630 1635Tyr Gly Ser Glu Leu
Pro Ser Gly Phe Pro Thr Val Ser Leu Val 1640 1645 1650Asp Arg Thr
Leu Val Glu Ser Val Thr Gln Ala Pro Thr Ala Gln 1655 1660 1665Glu
Ala Gly Glu Gly Pro Pro Gly Ile Leu Glu Leu Ser Gly Thr 1670 1675
1680His Ser Gly Ala Pro Asp Met Ser Gly Asp His Ser Gly Phe Leu
1685 1690 1695Asp Val Ser Gly Leu Gln Phe Gly Leu Val Glu Pro Ser
Gly Glu 1700 1705 1710Pro Pro Ser Thr Pro Tyr Phe Ser Gly Asp Phe
Ala Ser Thr Thr 1715 1720 1725Asp Val Ser Gly Glu Ser Ser Ala Ala
Met Gly Thr Asn Gly Glu 1730 1735 1740Ala Ser Gly Leu Pro Glu Val
Thr Leu Ile Thr Ser Glu Phe Met 1745 1750 1755Glu Gly Val Thr Glu
Pro Thr Val Ser Gln Glu Leu Gly Gln Arg 1760 1765 1770Pro Pro Val
Thr His Thr Pro Gln Leu Phe Glu Ser Ser Gly Glu 1775 1780 1785Ala
Ser Ala Ala Gly Asp Ile Ser Gly Ala Thr Pro Val Leu Pro 1790 1795
1800Gly Ser Gly Val Glu Val Ser Ser Val Pro Glu Ser Ser Ser Glu
1805 1810 1815Thr Ser Ala Tyr Pro Glu Ala Gly Val Gly Ala Ser Ala
Ala Pro 1820 1825 1830Glu Thr Ser Gly Glu Asp Ser Gly Ser Pro Asp
Leu Ser Glu Thr 1835 1840 1845Thr Ser Ala Phe His Glu Ala Asp Leu
Glu Arg Ser Ser Gly Leu 1850 1855 1860Gly Val Ser Gly Ser Thr Leu
Thr Phe Gln Glu Gly Glu Pro Ser 1865 1870 1875Ala Ser Pro Glu Val
Ser Gly Glu Ser Thr Thr Thr Gly Asp Val 1880 1885 1890Gly Thr Glu
Ala Pro Gly Leu Pro Ser Ala Thr Pro Thr Ala Ser 1895 1900 1905Gly
Xaa Xaa Xaa Xaa Xaa Xaa Pro Thr Arg Ser Cys Ala Glu Glu 1910 1915
1920Pro Cys Gly Ala Gly Thr Cys Lys Glu Thr Glu Gly His Val Ile
1925 1930 1935Cys Leu Cys Pro Pro Gly Tyr Thr Gly Glu His Cys Asn
Ile Asp 1940 1945 1950Gln Glu Val Cys Glu Glu Gly Trp Thr Lys Tyr
Gln Gly His Cys 1955 1960 1965Tyr Arg His Phe Pro Asp Arg Glu Thr
Trp Val Asp Ala Glu Arg 1970 1975 1980Arg Cys Arg Glu Gln Gln Ser
His Leu Ser Ser Ile Val Thr Pro 1985 1990 1995Glu Glu Gln Glu Phe
Val Asn Asn Asn Ala Gln Asp Tyr Gln Trp 2000 2005 2010Ile Gly Leu
Asn Asp Arg Thr Ile Glu Gly Asp Phe Arg Trp Ser 2015 2020 2025Asp
Gly His Pro Met Gln Phe Glu Asn Trp Arg Pro Asn Gln Pro 2030 2035
2040Asp Asn Phe Phe Ala Ala Gly Glu Asp Cys Val Val Met Ile Trp
2045 2050 2055His Glu Lys Gly Glu Trp Asn Asp Val Pro Cys Asn Tyr
His Leu 2060 2065 2070Pro Phe Thr Cys Lys Lys Gly Thr Val Ala Cys
Gly Glu Pro Pro 2075 2080 2085Met Val Gln His Ala Arg Thr Phe Gly
Gln Lys Lys Asp Arg Tyr 2090 2095 2100Glu Ile Asn Ser Leu Val Arg
Tyr Gln Cys Thr Glu Gly Phe Val 2105 2110 2115Gln Arg His Val Pro
Thr Ile Arg Cys Gln Pro Ser Gly His Trp 2120 2125 2130Glu Glu Pro
Arg Ile Thr Cys Thr Asp Ala Thr Ala Tyr Lys Arg 2135 2140 2145Arg
Leu Gln Lys Arg Ser Ser Arg His Pro Arg Arg Ser Arg Pro 2150 2155
2160Ser Thr Ala His 21651341321PRTHomo sapiens 134Met Gly Ala Pro
Phe Val Trp Ala Leu Gly Leu Leu Met Leu Gln Met1 5 10 15Leu Leu Phe
Val Ala Gly Glu Gln Gly Thr Gln Asp Ile Thr Asp Ala 20 25 30Ser Glu
Arg Gly Leu His Met Gln Lys Leu Gly Ser Gly Ser Val Gln 35 40 45Ala
Ala Leu Ala Glu Leu Val Ala Leu Pro Cys Leu Phe Thr Leu Gln 50 55
60Pro Arg Pro Ser Ala Ala Arg Asp Ala Pro Arg Ile Lys Trp Thr Lys65
70 75 80Val Arg Thr Ala Ser Gly Gln Arg Gln Asp Leu Pro Ile Leu Val
Ala 85 90 95Lys Asp Asn Val Val Arg Val Ala Lys Ser Trp Gln Gly Arg
Val Ser 100 105 110Leu Pro Ser Tyr Pro Arg Arg Arg Ala Asn Ala Thr
Leu Leu Leu Gly 115 120 125Pro Leu Arg Ala Ser Asp Ser Gly Leu Tyr
Arg Cys Gln Val Val Arg 130 135 140Gly Ile Glu Asp Glu Gln Asp Leu
Val Pro Leu Glu Val Thr Gly Val145 150 155 160Val Phe His Tyr Arg
Ser Ala Arg Asp Arg Tyr Ala Leu Thr Phe Ala 165 170 175Glu Ala Gln
Glu Ala Cys Arg Leu Ser Ser Ala Ile Ile Ala Ala Pro 180 185 190Arg
His Leu Gln Ala Ala Phe Glu Asp Gly Phe Asp Asn Cys Asp Ala 195 200
205Gly Trp Leu Ser Asp Arg Thr Val Arg Tyr Pro Ile Thr Gln Ser Arg
210 215 220Pro Gly Cys Tyr Gly Asp Arg Ser Ser Leu Pro Gly Val Arg
Ser Tyr225 230 235 240Gly Arg Arg Asn Pro Gln Glu Leu Tyr Asp Val
Tyr Cys Phe Ala Arg 245 250 255Glu Leu Gly Gly Glu Val Phe Tyr Val
Gly Pro Ala Arg Arg Leu Thr 260 265 270Leu Ala Gly Ala Arg Ala Gln
Cys Arg Arg Gln Gly Ala Ala Leu Ala 275 280 285Ser Val Gly Gln Leu
His Leu Ala Trp His Glu Gly Leu Asp Gln Cys 290 295 300Asp Pro Gly
Trp Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile Gln Thr305 310 315
320Pro Arg Arg Arg Cys Gly Gly Pro Ala Pro Gly Val Arg Thr Val Tyr
325 330 335Arg Phe Ala Asn Arg Thr Gly Phe Pro Ser Pro Ala Glu Arg
Phe Asp 340 345 350Ala Tyr Cys Phe Arg Ala His His Pro Thr Ser Gln
His Gly Asp Leu 355 360 365Glu Thr Pro Ser Ser Gly Asp Glu Gly Glu
Ile Leu Ser Ala Glu Gly 370 375 380Pro Pro Val Arg Glu Leu Glu Pro
Thr Leu Glu Glu Glu Glu Val Val385 390 395 400Thr Pro Asp Phe Gln
Glu Pro Leu Val Ser Ser Gly Glu Glu Glu Thr 405 410 415Leu Ile Leu
Glu Glu Lys Gln Glu Ser Gln Gln Thr Leu Ser Pro Thr 420 425 430Pro
Gly Asp Pro Met Leu Ala Ser Trp Pro Thr Gly Glu Val Trp Leu 435 440
445Ser Thr Val Ala Pro Ser Pro Ser Asp Met Gly Ala Gly Thr Ala Ala
450 455 460Ser Ser His Thr Glu Val Ala Pro Thr Asp Pro Met Pro Arg
Arg Arg465 470 475 480Gly Arg Phe Lys Gly Leu Asn Gly Arg Tyr Phe
Gln Gln Gln Glu Pro 485 490 495Glu Pro Gly Leu Gln Gly Gly Met Glu
Ala Ser Ala Gln Pro Pro Thr 500 505 510Ser Glu Ala Ala Val Asn Gln
Met Glu Pro Pro Leu Ala Met Ala Val 515 520 525Thr Glu Met Leu Gly
Ser Gly Gln Ser Arg Ser Pro Trp Ala Asp Leu 530 535 540Thr Asn Glu
Val Asp Met Pro Gly Ala Gly Ser Ala Gly Gly Lys Ser545 550 555
560Ser Pro Glu Pro Trp Leu Trp Pro Pro Thr Met Val Pro Pro Ser Ile
565 570 575Ser Gly His Ser Arg Ala Pro Val Leu Glu Leu Glu Lys Ala
Glu Gly 580 585 590Pro Ser Ala Arg Pro Ala Thr Pro Asp Leu Phe Trp
Ser Pro Leu Glu 595 600 605Ala Thr Val Ser Ala Pro Ser Pro Ala Pro
Trp Glu Ala Phe Pro Val 610 615 620Ala Thr Ser Pro Asp Leu Pro Met
Met Ala Met Leu Arg Gly Pro Lys625 630 635 640Glu Trp Met Leu Pro
His Pro Thr Pro Ile Ser Thr Glu Ala Asn Arg 645 650 655Val Glu Ala
His Gly Glu Ala Thr Ala Thr Ala Pro Pro Ser Pro Ala 660 665 670Ala
Glu Thr Lys Val Tyr Ser Leu Pro Leu Ser Leu Thr Pro Thr Gly 675 680
685Gln Gly Gly Glu Ala Met Pro Thr Thr Pro Glu Ser Pro Arg Ala Asp
690 695 700Phe Arg Glu Thr Gly Glu Thr Ser Pro Ala Gln Val Asn Lys
Ala Glu705 710 715 720His Ser Ser Ser Ser Pro Trp Pro Ser Val Asn
Arg Asn Val Ala Val 725 730 735Gly Phe Val Pro Thr Glu Thr Ala Thr
Glu Pro Thr Gly Leu Arg Gly 740 745 750Ile Pro Gly Ser Glu Ser Gly
Val Phe Asp Thr Ala Glu Ser Pro Thr 755 760 765Ser Gly Leu Gln Ala
Thr Val Asp Glu Val Gln Asp Pro Trp
Pro Ser 770 775 780Val Tyr Ser Lys Gly Leu Asp Ala Ser Ser Pro Ser
Ala Pro Leu Gly785 790 795 800Ser Pro Gly Val Phe Leu Val Pro Lys
Val Thr Pro Asn Leu Glu Pro 805 810 815Trp Val Ala Thr Asp Glu Gly
Pro Thr Val Asn Pro Met Asp Ser Thr 820 825 830Val Thr Pro Ala Pro
Ser Asp Ala Ser Gly Ile Trp Glu Pro Gly Ser 835 840 845Gln Val Phe
Glu Glu Ala Glu Ser Thr Thr Leu Ser Pro Gln Val Ala 850 855 860Leu
Asp Thr Ser Ile Val Thr Pro Leu Thr Thr Leu Glu Gln Gly Asp865 870
875 880Lys Val Gly Val Pro Ala Met Ser Thr Leu Gly Ser Ser Ser Ser
Gln 885 890 895Pro His Pro Glu Pro Glu Asp Gln Val Glu Thr Gln Gly
Thr Ser Gly 900 905 910Ala Ser Val Pro Pro His Gln Ser Ser Pro Leu
Gly Lys Pro Ala Val 915 920 925Pro Pro Gly Thr Pro Thr Ala Ala Ser
Val Gly Glu Ser Ala Ser Val 930 935 940Ser Ser Gly Glu Pro Thr Val
Pro Trp Asp Pro Ser Ser Thr Leu Leu945 950 955 960Pro Val Thr Leu
Gly Ile Glu Asp Phe Glu Leu Glu Val Leu Ala Gly 965 970 975Ser Pro
Gly Val Glu Ser Phe Trp Glu Glu Val Ala Ser Gly Glu Glu 980 985
990Pro Ala Leu Pro Gly Thr Pro Met Asn Ala Gly Ala Glu Glu Val His
995 1000 1005Ser Asp Pro Cys Glu Asn Asn Pro Cys Leu His Gly Gly
Thr Cys 1010 1015 1020Asn Ala Asn Gly Thr Met Tyr Gly Cys Ser Cys
Asp Gln Gly Phe 1025 1030 1035Ala Gly Glu Asn Cys Glu Ile Asp Ile
Asp Asp Cys Leu Cys Ser 1040 1045 1050Pro Cys Glu Asn Gly Gly Thr
Cys Ile Asp Glu Val Asn Gly Phe 1055 1060 1065Val Cys Leu Cys Leu
Pro Ser Tyr Gly Gly Ser Phe Cys Glu Lys 1070 1075 1080Asp Thr Glu
Gly Cys Asp Arg Gly Trp His Lys Phe Gln Gly His 1085 1090 1095Cys
Tyr Arg Tyr Phe Ala His Arg Arg Ala Trp Glu Asp Ala Glu 1100 1105
1110Lys Asp Cys Arg Arg Arg Ser Gly His Leu Thr Ser Val His Ser
1115 1120 1125Pro Glu Glu His Ser Phe Ile Asn Ser Phe Gly His Glu
Asn Thr 1130 1135 1140Trp Ile Gly Leu Asn Asp Arg Ile Val Glu Arg
Asp Phe Gln Trp 1145 1150 1155Thr Asp Asn Thr Gly Leu Gln Phe Glu
Asn Trp Arg Glu Asn Gln 1160 1165 1170Pro Asp Asn Phe Phe Ala Gly
Gly Glu Asp Cys Val Val Met Val 1175 1180 1185Ala His Glu Ser Gly
Arg Trp Asn Asp Val Pro Cys Asn Tyr Asn 1190 1195 1200Leu Pro Tyr
Val Cys Lys Lys Gly Thr Val Leu Cys Gly Pro Pro 1205 1210 1215Pro
Ala Val Glu Asn Ala Ser Leu Ile Gly Ala Arg Lys Ala Lys 1220 1225
1230Tyr Asn Val His Ala Thr Val Arg Tyr Gln Cys Asn Glu Gly Phe
1235 1240 1245Ala Gln His His Val Ala Thr Ile Arg Cys Arg Ser Asn
Gly Lys 1250 1255 1260Trp Asp Arg Pro Gln Ile Val Cys Thr Lys Pro
Arg Arg Ser His 1265 1270 1275Arg Met Arg Arg His His His His His
Gln His His His Gln His 1280 1285 1290His His His Lys Ser Arg Lys
Glu Arg Arg Lys His Lys Lys His 1295 1300 1305Pro Thr Glu Asp Trp
Glu Lys Asp Glu Gly Asn Phe Cys 1310 1315 1320135911PRTHomo sapiens
135Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala Gln1
5 10 15Ala Pro Ala Ala Leu Ala Asp Val Leu Glu Gly Asp Ser Ser Glu
Asp 20 25 30Arg Ala Phe Arg Val Arg Ile Ala Gly Asp Ala Pro Leu Gln
Gly Val 35 40 45Leu Gly Gly Ala Leu Thr Ile Pro Cys His Val His Tyr
Leu Arg Pro 50 55 60Pro Pro Ser Arg Arg Ala Val Leu Gly Ser Pro Arg
Val Lys Trp Thr65 70 75 80Phe Leu Ser Arg Gly Arg Glu Ala Glu Val
Leu Val Ala Arg Gly Val 85 90 95Arg Val Lys Val Asn Glu Ala Tyr Arg
Phe Arg Val Ala Leu Pro Ala 100 105 110Tyr Pro Ala Ser Leu Thr Asp
Val Ser Leu Ala Leu Ser Glu Leu Arg 115 120 125Pro Asn Asp Ser Gly
Ile Tyr Arg Cys Glu Val Gln His Gly Ile Asp 130 135 140Asp Ser Ser
Asp Ala Val Glu Val Lys Val Lys Gly Val Val Phe Leu145 150 155
160Tyr Arg Glu Gly Ser Ala Arg Tyr Ala Phe Ser Phe Ser Gly Ala Gln
165 170 175Glu Ala Cys Ala Arg Ile Gly Ala His Ile Ala Thr Pro Glu
Gln Leu 180 185 190Tyr Ala Ala Tyr Leu Gly Gly Tyr Glu Gln Cys Asp
Ala Gly Trp Leu 195 200 205Ser Asp Gln Thr Val Arg Tyr Pro Ile Gln
Thr Pro Arg Glu Ala Cys 210 215 220Tyr Gly Asp Met Asp Gly Phe Pro
Gly Val Arg Asn Tyr Gly Val Val225 230 235 240Asp Pro Asp Asp Leu
Tyr Asp Val Tyr Cys Tyr Ala Glu Asp Leu Asn 245 250 255Gly Glu Leu
Phe Leu Gly Asp Pro Pro Glu Lys Leu Thr Leu Glu Glu 260 265 270Ala
Arg Ala Tyr Cys Gln Glu Arg Gly Ala Glu Ile Ala Thr Thr Gly 275 280
285Gln Leu Tyr Ala Ala Trp Asp Gly Gly Leu Asp His Cys Ser Pro Gly
290 295 300Trp Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile Val Thr Pro
Ser Gln305 310 315 320Arg Cys Gly Gly Gly Leu Pro Gly Val Lys Thr
Leu Phe Leu Phe Pro 325 330 335Asn Gln Thr Gly Phe Pro Asn Lys His
Ser Arg Phe Asn Val Tyr Cys 340 345 350Phe Arg Asp Ser Ala Gln Pro
Ser Ala Ile Pro Glu Ala Ser Asn Pro 355 360 365Ala Ser Asn Pro Ala
Ser Asp Gly Leu Glu Ala Ile Val Thr Val Thr 370 375 380Glu Thr Leu
Glu Glu Leu Gln Leu Pro Gln Glu Ala Thr Glu Ser Glu385 390 395
400Ser Arg Gly Ala Ile Tyr Ser Ile Pro Ile Met Glu Asp Gly Gly Gly
405 410 415Gly Ser Ser Thr Pro Glu Asp Pro Ala Glu Ala Pro Arg Thr
Leu Leu 420 425 430Glu Phe Glu Thr Gln Ser Met Val Pro Pro Thr Gly
Phe Ser Glu Glu 435 440 445Glu Gly Lys Ala Leu Glu Glu Glu Glu Lys
Tyr Glu Asp Glu Glu Glu 450 455 460Lys Glu Glu Glu Glu Glu Glu Glu
Glu Val Glu Asp Glu Ala Leu Trp465 470 475 480Ala Trp Pro Ser Glu
Leu Ser Ser Pro Gly Pro Glu Ala Ser Leu Pro 485 490 495Thr Glu Pro
Ala Ala Gln Glu Glu Ser Leu Ser Gln Ala Pro Ala Arg 500 505 510Ala
Val Leu Gln Pro Gly Ala Ser Pro Leu Pro Asp Gly Glu Ser Glu 515 520
525Ala Ser Arg Pro Pro Arg Val His Gly Pro Pro Thr Glu Thr Leu Pro
530 535 540Thr Pro Arg Glu Arg Asn Leu Ala Ser Pro Ser Pro Ser Thr
Leu Val545 550 555 560Glu Ala Arg Glu Val Gly Glu Ala Thr Gly Gly
Pro Glu Leu Ser Gly 565 570 575Val Pro Arg Gly Glu Ser Glu Glu Thr
Gly Ser Ser Glu Gly Ala Pro 580 585 590Ser Leu Leu Pro Ala Thr Arg
Ala Pro Glu Gly Thr Arg Glu Leu Glu 595 600 605Ala Pro Ser Glu Asp
Asn Ser Gly Arg Thr Ala Pro Ala Gly Thr Ser 610 615 620Val Gln Ala
Gln Pro Val Leu Pro Thr Asp Ser Ala Ser Arg Gly Gly625 630 635
640Val Ala Val Val Pro Ala Ser Gly Asp Cys Val Pro Ser Pro Cys His
645 650 655Asn Gly Gly Thr Cys Leu Glu Glu Glu Glu Gly Val Arg Cys
Leu Cys 660 665 670Leu Pro Gly Tyr Gly Gly Asp Leu Cys Asp Val Gly
Leu Arg Phe Cys 675 680 685Asn Pro Gly Trp Asp Ala Phe Gln Gly Ala
Cys Tyr Lys His Phe Ser 690 695 700Thr Arg Arg Ser Trp Glu Glu Ala
Glu Thr Gln Cys Arg Met Tyr Gly705 710 715 720Ala His Leu Ala Ser
Ile Ser Thr Pro Glu Glu Gln Asp Phe Ile Asn 725 730 735Asn Arg Tyr
Arg Glu Tyr Gln Trp Ile Gly Leu Asn Asp Arg Thr Ile 740 745 750Glu
Gly Asp Phe Leu Trp Ser Asp Gly Val Pro Leu Leu Tyr Glu Asn 755 760
765Trp Asn Pro Gly Gln Pro Asp Ser Tyr Phe Leu Ser Gly Glu Asn Cys
770 775 780Val Val Met Val Trp His Asp Gln Gly Gln Trp Ser Asp Val
Pro Cys785 790 795 800Asn Tyr His Leu Ser Tyr Thr Cys Lys Met Gly
Leu Val Ser Cys Gly 805 810 815Pro Pro Pro Glu Leu Pro Leu Ala Gln
Val Phe Gly Arg Pro Arg Leu 820 825 830Arg Tyr Glu Val Asp Thr Val
Leu Arg Tyr Arg Cys Arg Glu Gly Leu 835 840 845Ala Gln Arg Asn Leu
Pro Leu Ile Arg Cys Gln Glu Asn Gly Arg Trp 850 855 860Glu Ala Pro
Gln Ile Ser Cys Val Pro Arg Arg Pro Ala Arg Ala Leu865 870 875
880His Pro Glu Glu Asp Pro Glu Gly Arg Gln Gly Arg Leu Leu Gly Arg
885 890 895Trp Lys Ala Leu Leu Ile Pro Pro Ser Ser Pro Met Pro Gly
Pro 900 905 910136115PRTArtificial SequenceNanobody Sequence 136Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr
Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser
Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser
115137115PRTArtificial SequenceNanobody Sequence 137Glu Val Gln Leu
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20 25 30Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45Ser
Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser 115138116PRTArtificial
SequenceNanobody Sequence 138Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Val Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser
Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65 70 75 80Leu Gln Met
Asn Ser Leu Arg Pro Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105
110Val Ser Ser Ala 115139116PRTArtificial SequenceNanobody Sequence
139Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser
Phe 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu
Trp Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Thr Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser
Ser Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser Ala
115140115PRTArtificial SequenceNanobody Sequence 140Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser
Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser 115141116PRTArtificial
SequenceNanobody Sequence 141Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser
Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65 70 75 80Leu Gln Met
Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Lys 100 105
110Val Ser Ser Ala 115142115PRTArtificial SequenceNanobody Sequence
142Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Asn1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Phe 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
Thr Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Leu Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser
Ser Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser
115143116PRTArtificial SequenceNanobody Sequence 143Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser
Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr
Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser Ala 115144117PRTArtificial
SequenceNanobody Sequence 144Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Val Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser
Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr
Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser Ala Ala 115145118PRTArtificial
SequenceNanobody Sequence 145Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Val Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser
Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65 70 75 80Leu Gln Met
Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105
110Val Ser Ser Ala Ala Ala 115146116PRTArtificial SequenceNanobody
Sequence 146Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro
Gly Asn1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Ser Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala Lys Thr Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser Gly
115147117PRTArtificial SequenceNanobody Sequence 147Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser
Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr
Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser Gly Gly 115148118PRTArtificial
SequenceNanobody Sequence 148Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Val Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser
Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65 70 75 80Leu Gln Met
Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105
110Val Ser Ser Gly Gly Gly 115149115PRTArtificial SequenceNanobody
Sequence 149Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Arg Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
Pro Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser
115150116PRTArtificial SequenceNanobody Sequence 150Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20 25 30Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45Ser
Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr
Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser Ala 1151515PRTArtificial
SequenceNanobody Sequence 151Ser Phe Gly Met Ser1
515217PRTArtificial SequenceNanobody Sequence 152Ser Ile Ser Gly
Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys1 5 10
15Gly1536PRTArtificial SequenceNanobody Sequence 153Gly Gly Ser Leu
Ser Arg1 51543PRTArtificial SequenceLinker Sequence 154Ala Ala
Ala11555PRTArtificial SequenceLinker Sequence 155Gly Gly Gly Gly
Ser1 51567PRTArtificial SequenceLinker Sequence 156Ser Gly Gly Ser
Gly Gly Ser1 51578PRTArtificial SequenceLinker Sequence 157Gly Gly
Gly Gly Gly Gly Gly Ser1 51589PRTArtificial SequenceLinker Sequence
158Gly Gly Gly Gly Ser Gly Gly Gly Ser1 515910PRTArtificial
SequenceLinker Sequence 159Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1
5 1016015PRTArtificial SequenceLinker Sequence 160Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1 5 10
1516118PRTArtificial SequenceLinker Sequence 161Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly1 5 10 15Gly
Ser16220PRTArtificial SequenceLinker Sequence 162Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly
Ser 2016325PRTArtificial SequenceLinker Sequence 163Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly
Ser Gly Gly Gly Gly Ser 20 2516430PRTArtificial SequenceLinker
Sequence 164Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser 20 25 3016535PRTArtificial SequenceLinker Sequence 165Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25
30Gly Gly Ser 3516640PRTArtificial SequenceLinker Sequence 166Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10
15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30Gly Gly Ser Gly Gly Gly Gly Ser 35 4016715PRTArtificial
SequenceLinker Sequence 167Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys Pro1 5 10 1516824PRTArtificial SequenceLinker
Sequence 168Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Pro Lys Ser Cys
Asp Lys1 5 10 15Thr His Thr Cys Pro Pro Cys Pro
2016912PRTArtificial SequenceLinker Sequence 169Glu Pro Lys Thr Pro
Lys Pro Gln Pro Ala Ala Ala1 5 1017062PRTArtificial SequenceLinker
Sequence 170Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro
Arg Cys1 5 10 15Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro
Arg Cys Pro 20 25 30Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro
Arg Cys Pro Glu 35 40 45Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro
Arg Cys Pro 50 55 60171116PRTArtificial SequenceNanobody Sequence
171Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Phe 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
Thr Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser
Ser Gln Gly Thr Leu Val Thr 100 105 110Val Lys Ser Ala
11517217PRTArtificial Sequencemyc tag 172Ala Ala Ala Glu Gln Lys
Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala1 5 10 15Ala
* * * * *